Gene,Gene ID,Category,Detail,Target,Forbidden,Reproductive RNA (nTPM),Maximum RNA (nTPM),IHC measurements,Positive IHC measurements,IHC coverage,Normal protein positive,Normal RNA above ceiling,Normal donor RNA above ceiling,Reproductive positive control,Previous CTA screen,Previous expression group,Disposable expression,Below-threshold subgroup,Donor review,Donor findings,Clinical evidence,Previous reason,Reason,RNA evidence,IHC evidence,Coverage gaps,Policy,Cell RNA review,Cell RNA findings,HPA cell RNA measured,Immune RNA review,Immune RNA findings,DICE measured,HPA immune measured,Corneal RNA review,Corneal RNA findings,Corneal measured,Antibody review,Antibody findings,Additional reproductive protein,Primary IHC measured,Cell evidence assessed,Previous category,Previous detail,Baseline policy,Publication support,Published normal protein,Publication sources,Change,Normal RNA assessed,Normal RNA measured,High normal RNA,Normal RNA maximum (TPM),Normal RNA maximum (nTPM),High normal RNA findings,Before cell review category,Previous policy,Highest normal TPM context,Highest normal nTPM context,Cancer RNA at >=5 pTPM,Cancer IHC Medium/High,Cancer RNA cohorts,Cancer IHC groups,UniProt entries,Biology sources,Biological function,Curated tissue biology,Disease biology,Biology caveats,Protein location,Function PubMed IDs,Tissue PubMed IDs,Shared UniProt entry,Biology coverage,Trial evidence,Trial sources,Reviewed literature,Reviewed literature sources,Reviewed evidence types,Nomination sources,Nomination scope,Review question,Reconsideration evidence,Limitations,Boundary review,Literature conflict priority,Literature conflict,Literature follow-up,Literature conflict source
ABCC12,ENSG00000140798,Neither,Antibody,False,False,2.8,2.8,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,cerebral cortex: 1.4 nTPM; continuous selectivity; hippocampal formation: 0.8 nTPM; continuous selectivity; skeletal muscle: 1.4 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bone marrow/Hematopoietic cells: Low, HPA043100; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA043100; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA043100; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA043100; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA043100; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: High, HPA043100; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA043100; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA043100; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA043100; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA043100; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA043100; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA043100; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA043100; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA043100; conflicting or uncurated primary profile; Liver/Cholangiocytes: High, HPA043100; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA043100; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA043100; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA043100; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA043100; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA043100; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA043100; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA043100; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA043100; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA043100; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA043100; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA043100; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA043100; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.3,10.0,,Neither,oncoref.target-sets.2026-10-23.2,0.3 TPM; blood/basophil; hpa_immune_monaco; vital,10 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 11/50 (22.0%); Glioblastoma Multiforme (validation): 1/58 (1.7%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%),prostate cancer: 9/11 (81.8%); stomach cancer: 8/12 (66.7%),31,20,Q96J65,https://www.uniprot.org/uniprotkb/Q96J65/entry,"Probable transporter, its substrate specificity is unknown","Expressed in testis (at protein level). Widely expressed at low level (PubMed:11483364, PubMed:11688999, PubMed:12011458, PubMed:17472575). Isoform 5 is specifically expressed in brain, testis and breast cancer cells (PubMed:11483364, PubMed:11688999, PubMed:12011458)",,"Does not transport any of the organic anions transported by the other multidrug resistance-associated proteins (MRPs) in vesicular transport assays, nor does it confer resistance to cytotoxic agents in intact cell assays",Endoplasmic reticulum membrane,17472575,11483364|11688999|12011458|17472575,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ACP4,ENSG00000142513,Neither,Low,False,False,3.6,3.6,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,4.34219910335,1.3,,Neither,oncoref.target-sets.2026-10-23.2,4.342 TPM; blood/CD8_STIM; dice_cd8_stim; vital,1.3 nTPM; small intestine/intestinal goblet cells; hpa_single_cell_tissue; vital,Liver Hepatocellular Carcinoma (TCGA): 9/362 (2.5%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Bladder Urothelial Carcinoma (TCGA): 2/169 (1.2%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q9BZG2,https://www.uniprot.org/uniprotkb/Q9BZG2/entry,"Protein tyrosine phosphatase that dephosphorylates the receptor tyrosine-protein kinase ERBB4, thereby inhibiting its ligand-induced proteolytic cleavage (PubMed:15219672). Involved in odontogenesis (PubMed:27843125). Regulates odontoblast cell fate via its extracellular catalytic domain by inhibiting proliferation and promoting differentiation (By similarity)","Expressed mainly in the testis. Also expressed in the brain where they are enriched at the postsynaptic sites. Expressed at lower levels in the trachea, prostate, bone marrow, spinal cord, colon, fetal brain, heart, thymus, fetal liver, spleen, leukocytes, ovary, small intestine, pancreas and skeletal muscle. Expression is significantly lower in testicular cancer tissues than in normal testicular tissues. Isoform 3 is expressed in the testis, trachea, prostate and bone marrow","Amelogenesis imperfecta 1J: A form of amelogenesis imperfecta, a disorder characterized by defective enamel formation. The enamel may be hypoplastic, hypomineralized or both, and affected teeth may be discolored, sensitive or prone to disintegration. AI1J is an autosomal recessive form characterized by hypoplastic enamel, enamel discolorization ranging from yellow to black, and normal dentin.",,Membrane,15219672|27843125,11414767,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ACSM4,ENSG00000215009,Neither,Antibody,False,False,0.8,0.8,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,retina: 0.4 nTPM; continuous selectivity; spleen: 0.5 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA049895; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA049895; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA049895; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA049895; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA049895; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: High, HPA049895; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: High, HPA049895; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA049895; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA049895; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA049895; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA049895; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA049895; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA049895; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA049895; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA049895; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA049895; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA049895; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA049895; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA049895; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA049895; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA049895; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA049895; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA049895; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA049895; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA049895; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA049895; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.983904636702,4.5,,Neither,oncoref.target-sets.2026-10-23.2,0.9839 TPM; blood/MONOCYTES; dice_monocytes; vital,4.5 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Colon Adenocarcinoma (validation): 1/486 (0.2%),prostate cancer: 12/12 (100.0%); glioma: 10/11 (90.9%),31,20,P0C7M7,https://www.uniprot.org/uniprotkb/P0C7M7/entry,"Catalyzes the activation of fatty acids by CoA to produce an acyl-CoA, the first step in fatty acid metabolism (By similarity). Capable of activating medium-chain fatty acids with a preference for C6-12 fatty acids (By similarity)",,,,Mitochondrion,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
ACTL9,ENSG00000181786,Neither,Antibody,False,False,108.6,108.6,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA019231; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA019231; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA019231; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA019231; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA019231; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA019231; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA019231; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: High, HPA019231; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA019231; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA019231; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA019231; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA019231; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA019231; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA019231; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA019231; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA019231; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA019231; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA019231; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA019231; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA019231; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA019231; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA019231; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA019231; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA019231; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA019231; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA019231; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA019231; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA019231; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA019231; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA019231; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA019231; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA019231; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA019231; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA019231; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA019231; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA019231; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: Medium, HPA026693; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA026693; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA026693; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA026693; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA026693; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA026693; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: High, HPA026693; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA026693; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA026693; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA026693; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA026693; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA026693; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA026693; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA026693; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA026693; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA026693; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA026693; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA026693; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA026693; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA026693; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA026693; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA026693; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA026693; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA026693; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA026693; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA026693; conflicting or uncurated primary profile; Lymph node/Germinal center cells: High, HPA026693; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA026693; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA026693; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA026693; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA026693; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: High, HPA026693; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA026693; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA026693; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA026693; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA026693; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA026693; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA026693; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA026693; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA026693; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA026693; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA026693; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA026693; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA026693; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA026693; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA026693; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA026693; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.1278241771,6.2,,CTA,oncoref.target-sets.2026-10-23.2,1.128 TPM; blood/NK; dice_nk; vital,6.2 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%),breast cancer: 11/11 (100.0%); ovarian cancer: 11/11 (100.0%),31,20,Q8TC94,https://www.uniprot.org/uniprotkb/Q8TC94/entry,Testis-specic protein that plays an important role in fusion of proacrosomal vesicles and perinuclear theca formation,Testis-specific,"Spermatogenic failure 53: An autosomal recessive infertility disorder characterized by impaired oocyte fertilization due to oocyte activation failure, in association with structural anomalies in sperm heads.",,"Cytoplasmic vesicle, secretory vesicle, acrosome Cytoplasm, cytoskeleton, perinuclear theca",33626338,33626338,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ADAM30,ENSG00000134249,Neither,Antibody,False,False,25.2,25.2,79,1,Positive somewhere,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bronchus/Respiratory epithelial cells: Low, HPA026080; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA026080; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA026080; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA026080; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA026080; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA026080; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA026080; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA026080; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA026080; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA026080; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA026080; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA026080; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.452322329998,1.6,,CTA,oncoref.target-sets.2026-10-23.2,0.4523 TPM; blood/NK; dice_nk; vital,1.6 nTPM; skeletal muscle/fibroblasts; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),colorectal cancer: 3/11 (27.3%); ovarian cancer: 3/12 (25.0%),31,20,Q9UKF2,https://www.uniprot.org/uniprotkb/Q9UKF2/entry,Plays a role in lysosomal amyloid precursor protein (APP) processing by cleaving and activating CTSD/cathepsin D which leads to APP degradation (PubMed:27333034),Expressed in brain neurons (at protein level) (PubMed:27333034). Expressed in testis (PubMed:10512762),,,Late endosome membrane,27333034,10512762|27333034,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ADIG,ENSG00000182035,Neither,Antibody,False,False,52.0,52.0,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA041124; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA041124; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA041124; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA041124; conflicting or uncurated primary profile; Caudate/Glial cells: High, HPA041124; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA041124; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: High, HPA041124; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: High, HPA041124; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA041124; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA041124; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: High, HPA041124; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA041124; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA041124; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA041124; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA041124; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA041124; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA041124; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA041124; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA041124; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA041124; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: High, HPA041124; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA041124; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA041124; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA041124; conflicting or uncurated primary profile; Lung/Alveolar cells: High, HPA041124; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA041124; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA041124; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA041124; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA041124; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA041124; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA041124; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA041124; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA041124; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA041124; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA041124; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA041124; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA041124; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA041124; conflicting or uncurated primary profile; Skin 1/Langerhans: High, HPA041124; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA041124; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA041124; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA041124; conflicting or uncurated primary profile; Spleen/Cells in red pulp: High, HPA041124; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA041124; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA041124; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA041124; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA041124; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.13195166476,5.1,,CTA,oncoref.target-sets.2026-10-23.2,1.132 TPM; blood/TFH; dice_tfh; vital,5.1 nTPM; kidney/proximal tubular cells; hpa_single_cell_tissue; vital,Thyroid Carcinoma (TCGA): 22/495 (4.4%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Kidney Renal Clear Cell Carcinoma (validation): 1/100 (1.0%),breast cancer: 12/12 (100.0%); lung cancer: 11/11 (100.0%),31,20,Q0VDE8,https://www.uniprot.org/uniprotkb/Q0VDE8/entry,"Key regulator of lipid storage that promotes the expansion of lipid droplets during the formation of mature adipocytes. Acts by forming a dodecameric complex with seipin (BSCL2) when adipocytes have differentiated and are undergoing maturation. In the dodecameric complex, ADIG antagonizes the activity of BSCL2 by reducing BSCL2-mediated triacylglycerol nucleation and relieving BSCL2's inhibition of GPAT3 and GPAT4. GPAT3 and GPAT4 then translocate to lipid droplets, promoting the synthesis of triacylglycerols and the expansion of lipid droplets",,,,Endoplasmic reticulum membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
AKNAD1,ENSG00000162641,Neither,Antibody,False,False,4.7,4.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Kidney/Cells in tubules: Low, HPA030270; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA030270; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA030270; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: Low, HPA030271; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Low, HPA030271; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA030271; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA030271; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA030271; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA030271; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA030271; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA030271; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA030271; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA030271; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA030271; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA030271; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA030271; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA030271; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA030271; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA030271; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA030271; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA030271; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA030271; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA030271; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA030271; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA030271; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA030271; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA030271; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA030271; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA030271; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA030271; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA030271; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA030271; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA030271; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA030271; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA030272; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA030272; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA030272; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA030272; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA030272; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA030272; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA030272; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA030272; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA030272; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA030272; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA030272; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA030272; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA030272; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA030272; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA030272; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA030272; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA030272; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA030272; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA030272; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA030272; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA030272; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA030272; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA030272; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA030272; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA030272; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA030272; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA030272; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA030272; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA030272; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA030272; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.42448873059,24.0,,Neither,oncoref.target-sets.2026-10-23.2,0.4245 TPM; blood/CD8_STIM; dice_cd8_stim; vital,24 nTPM; esophagus/schwann cells; hpa_single_cell_tissue; protected,Glioblastoma Multiforme (validation): 13/58 (22.4%); Bladder Urothelial Carcinoma (TCGA): 2/169 (1.2%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%),colorectal cancer: 6/12 (50.0%); breast cancer: 5/11 (45.5%),31,20,Q5T1N1,https://www.uniprot.org/uniprotkb/Q5T1N1/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Loriot2025_S2,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
AMELY,ENSG00000099721,Neither,Low,False,False,0.1,0.3,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,pancreas: 0.1 nTPM; reproductive not higher; thyroid gland: 0.3 nTPM; continuous selectivity;reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,1.3,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1.3 nTPM; tongue/suprabasal keratinocytes; hpa_single_cell_tissue; protected,Kidney Chromophobe (TCGA): 1/64 (1.6%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q99218,https://www.uniprot.org/uniprotkb/Q99218/entry,Plays a role in biomineralization. Seems to regulate the formation of crystallites during the secretory stage of tooth enamel development. Thought to play a major role in the structural organization and mineralization of developing enamel,,,,"Secreted, extracellular space, extracellular matrix",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
ANHX,ENSG00000227059,Neither,Low,False,False,4.8,4.8,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.16556084082,0.6,,Neither,oncoref.target-sets.2026-10-23.2,0.1656 TPM; blood/TREG_MEM; dice_treg_mem; vital,0.6 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 73/133 (54.9%); Ovary Serous Cystadenocarcinoma (TCGA): 5/349 (1.4%); Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,E9PGG2,https://www.uniprot.org/uniprotkb/E9PGG2/entry,,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ANKRD60,ENSG00000124227,Neither,Antibody,False,False,3.5,3.5,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Liver/Hepatocytes: High, HPA060561; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA060561; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.9778,1.3735,,Neither,oncoref.target-sets.2026-10-23.2,0.9778 TPM; blood/neutrophil; hpa_immune_cell_samples; vital,1.373 nTPM; blood/neutrophil; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),liver cancer: 4/9 (44.4%); stomach cancer: 1/11 (9.1%),29,20,Q9BZ19,https://www.uniprot.org/uniprotkb/Q9BZ19/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
ANTXRL,ENSG00000274209,Neither,Screening,False,False,12.4,12.4,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.3043,3.2368,,Neither,oncoref.target-sets.2026-10-23.2,2.304 TPM; blood/neutrophil; hpa_immune_cell_samples; vital,3.237 nTPM; blood/neutrophil; hpa_immune_cell_samples; vital,Ovary Serous Cystadenocarcinoma (TCGA): 6/349 (1.7%); Kidney Renal Clear Cell Carcinoma (validation): 1/100 (1.0%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%),No exact-ID IHC coverage in the HPA cancer snapshot,28,0,A6NF34,https://www.uniprot.org/uniprotkb/A6NF34/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ARGFX,ENSG00000186103,Neither,Antibody,False,False,0.3,1.0,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 1 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 0.2 nTPM; continuous selectivity; duodenum: 0.2 nTPM; continuous selectivity; lymph node: 0.3 nTPM; continuous selectivity;reproductive not higher; pancreas: 0.3 nTPM; continuous selectivity;reproductive not higher; retina: 0.5 nTPM; continuous selectivity;reproductive not higher; salivary gland: 0.3 nTPM; continuous selectivity;reproductive not higher; skeletal muscle: 0.4 nTPM; continuous selectivity;reproductive not higher; skin: 0.7 nTPM; continuous selectivity;reproductive not higher; small intestine: 0.2 nTPM; continuous selectivity; spleen: 0.3 nTPM; continuous selectivity;reproductive not higher; stomach: 0.4 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA043049; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA043049; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA043049; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA043049; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA043049; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA043049; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA043049; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA043049; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA043049; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA043049; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA043049; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA043049; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA043049; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA043049; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,3.8,6.3,,Neither,oncoref.target-sets.2026-10-23.2,3.8 TPM; blood/basophil; hpa_immune_monaco; vital,6.3 nTPM; heart muscle/endothelial cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 29/133 (21.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 15/176 (8.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 16/283 (5.7%),breast cancer: 1/12 (8.3%); cervical cancer: 0/11 (0.0%),31,20,A6NJG6,https://www.uniprot.org/uniprotkb/A6NJG6/entry,Transcription factor that acts as activator,Expressed at low level in testis and undifferentiated embryonic stem cells,,,Nucleus,27412763,17005330,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
ARL13A,ENSG00000174225,Neither,Antibody,False,False,5.0,5.0,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 18/91 values ≥5 TPM, max 9.15082; DICE TREG_MEM (unstimulated): 3/89 values ≥5 TPM, max 6.15185; DICE CD4_NAIVE (unstimulated): 28/88 values ≥5 TPM, max 7.86248; DICE TREG_NAIVE (unstimulated): 28/89 values ≥5 TPM, max 8.12582; DICE TFH (unstimulated): 3/89 values ≥5 TPM, max 6.03433; DICE THSTAR (unstimulated): 5/88 values ≥5 TPM, max 7.25708; DICE CD8_NAIVE (unstimulated): 19/89 values ≥5 TPM, max 7.09977",True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA037377; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA037377; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA037377; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA037377; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA037377; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA037377; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA037377; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA037377; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA037377; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA037377; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA037377; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA037377; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA037377; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA037377; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA037377; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA037377; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA037377; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA037377; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA037377; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA037377; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA037377; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA037377; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA037377; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA037377; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA037377; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA037377; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA037377; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA037377; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA037377; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA037377; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA037377; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA037377; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA037377; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA037377; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA037377; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA037377; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA037377; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA037377; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA037377; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA037377; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA037377; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA037377; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA037377; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA037377; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA037378; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA037378; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA037378; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA037378; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA037378; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA037378; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA037378; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA037378; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA037378; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA037378; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA037378; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA037378; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA037378; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA037378; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA037378; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA037378; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA037378; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA037378; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA037378; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA037378; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA037378; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA037378; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA037378; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA037378; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA037378; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA037378; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA037378; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA037378; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA037378; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA037378; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA037378; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA037378; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA037378; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA037378; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA037378; conflicting or uncurated primary profile; Skin 1/Fibroblasts: High, HPA037378; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA037378; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA037378; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA037378; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA037378; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA037378; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA037378; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA037378; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA037378; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA037378; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA037378; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA037378; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,9.15082163056,2.4,,CTA,oncoref.target-sets.2026-10-23.2,9.151 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,2.4 nTPM; eye/muller glia cells; hpa_single_cell_tissue; vital,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 4/283 (1.4%); Rectum Adenocarcinoma (validation): 2/207 (1.0%); Colon Adenocarcinoma (validation): 4/486 (0.8%),breast cancer: 12/12 (100.0%); liver cancer: 12/12 (100.0%),31,20,Q5H913,https://www.uniprot.org/uniprotkb/Q5H913/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Carter2023_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ARL14EPL,ENSG00000268223,Neither,Cellular,False,False,0.2,0.3,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,existing nomination or manual review; nomination unresolved; bone marrow: 0.3 nTPM; continuous selectivity;reproductive not higher; lung: 0.2 nTPM; continuous selectivity;reproductive not higher; lymph node: 0.2 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,True,"colon/undifferentiated cells cluster c-8: 7.4 nTPM, 35 reads; reproductive-cell max 4.8",True,False,,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.08735041557,7.4,,Neither,oncoref.target-sets.2026-10-23.2,2.087 TPM; blood/M2; dice_m2; vital,7.4 nTPM; colon/undifferentiated cells; hpa_single_cell_tissue; protected,Glioblastoma Multiforme (validation): 1/58 (1.7%); Uterine Corpus Endometrial Carcinoma (TCGA): 3/176 (1.7%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P0DKL9,https://www.uniprot.org/uniprotkb/P0DKL9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
ARMH2,ENSG00000260286,Neither,Cellular,False,False,13.0,13.0,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 31/91 values ≥5 TPM, max 10.9245; DICE TREG_MEM (unstimulated): 4/89 values ≥5 TPM, max 5.87256; DICE CD4_NAIVE (unstimulated): 27/88 values ≥5 TPM, max 9.19957; DICE TREG_NAIVE (unstimulated): 5/89 values ≥5 TPM, max 7.19294; DICE TH1 (unstimulated): 11/81 values ≥5 TPM, max 7.94433; DICE THSTAR (unstimulated): 7/88 values ≥5 TPM, max 6.42101; DICE TH17 (unstimulated): 11/89 values ≥5 TPM, max 6.58756; DICE TH2 (unstimulated): 14/89 values ≥5 TPM, max 6.78963; DICE CD8_NAIVE (unstimulated): 20/89 values ≥5 TPM, max 8.16728",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,16.589296291900002,4.4,,CTA,oncoref.target-sets.2026-10-23.2,16.59 TPM; blood/NK; dice_nk; vital,4.4 nTPM; lung/ciliated cells; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,H3BNL8,https://www.uniprot.org/uniprotkb/H3BNL8/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ATXN3L,ENSG00000123594,Neither,Antibody,False,False,3.9,3.9,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA024123; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA024123; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: High, HPA024123; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA024123; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA024123; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA024123; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA024123; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA024123; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA024123; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: High, HPA024123; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA024123; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA024123; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA024123; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA024123; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA024123; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA024123; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA024123; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA024123; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA024123; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA024123; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA024123; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA024123; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA024123; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA024123; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA024123; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA024123; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA024123; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA024123; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA024123; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA024123; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA024123; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA024123; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA024123; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA024123; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: Low, HPA027539; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA027539; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA027539; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA027539; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA027539; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA027539; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA027539; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA027539; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA027539; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA027539; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA027539; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA027539; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA027539; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA027539; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA027539; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA027539; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA027539; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA027539; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA027539; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA027539; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA027539; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA027539; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA027539; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA027539; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA027539; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA027539; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA027539; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA027539; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA027539; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA027539; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA027539; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA027539; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA027539; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.800500352889,1.2,,Neither,oncoref.target-sets.2026-10-23.2,0.8005 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1.2 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),colorectal cancer: 10/12 (83.3%); breast cancer: 9/11 (81.8%),31,20,Q9H3M9,https://www.uniprot.org/uniprotkb/Q9H3M9/entry,"Deubiquitinating enzyme that cleaves both 'Lys-48'-linked and 'Lys-63'-linked poly-ubiquitin chains (in vitro) (PubMed:21118805). Acts as a deubiquitinating enzyme for the transcription factor KLF5, playing a role in the regulation of KLF5 stability (PubMed:26079537)",Widely expressed,,,Nucleus,21118805|26079537,11450850,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
BHLHE23,ENSG00000125533,Neither,Antibody,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,thymus: 0.2 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA030575; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA030575; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA030575; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA030575; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA030575; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA030575; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA030575; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA030575; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: High, HPA030575; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA030575; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA030575; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA030575; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA030575; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA030575; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA030575; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA030575; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA030575; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA030575; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA030575; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA030575; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA030575; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA030575; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA030575; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA030575; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA030575; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA030575; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA030575; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA030575; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA030575; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA030575; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA030575; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA030575; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA030575; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA030575; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA030575; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA030575; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA030575; conflicting or uncurated primary profile; Spleen/Cells in red pulp: High, HPA030575; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA030575; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA030575; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA030575; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA030575; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.234777360249,0.4,,Neither,oncoref.target-sets.2026-10-23.2,0.2348 TPM; blood/TH1; dice_th1; vital,0.4 nTPM; eye/rod photoreceptor cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),cervical cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,Q8NDY6,https://www.uniprot.org/uniprotkb/Q8NDY6/entry,May function as transcriptional repressor. May modulate the expression of genes required for the differentiation and/or maintenance of pancreatic and neuronal cell types. May be important for rod bipolar cell maturation (By similarity),,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
BLID,ENSG00000259571,Neither,Low,False,False,0.1,0.2,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,choroid plexus: 0.2 nTPM; continuous selectivity;reproductive not higher; heart muscle: 0.1 nTPM; reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.84285989278,3.1,,Neither,oncoref.target-sets.2026-10-23.2,1.843 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,3.1 nTPM; skeletal muscle/fibroblasts; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 39/58 (67.2%); Kidney Chromophobe (TCGA): 1/64 (1.6%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IZY5,https://www.uniprot.org/uniprotkb/Q8IZY5/entry,Functions as a proapoptotic molecule through the caspase-dependent mitochondrial pathway of cell death,Ubiquitously expressed,,,Cytoplasm Mitochondrion,15069058,15069058,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
BMP15,ENSG00000130385,Neither,Low,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.278379321704,0.2,,Neither,oncoref.target-sets.2026-10-23.2,0.2784 TPM; blood/TH1; dice_th1; vital,0.2 nTPM; lung/ciliated cells; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O95972,https://www.uniprot.org/uniprotkb/O95972/entry,May be involved in follicular development. Oocyte-specific growth/differentiation factor that stimulates folliculogenesis and granulosa cell (GC) growth,,"Ovarian dysgenesis 2: A disorder characterized by lack of spontaneous pubertal development, primary amenorrhea, uterine hypoplasia, and hypergonadotropic hypogonadism as a result of streak gonads. Premature ovarian failure 4: An ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol.",,Secreted,18227435,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
BPIFB3,ENSG00000186190,Neither,Antibody,False,False,0.4,0.5,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,pituitary gland: 0.5 nTPM; continuous selectivity;reproductive not higher; salivary gland: 0.5 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA045741; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA045741; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA045741; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA045741; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA045741; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA045741; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA045741; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA045741; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA045741; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA045741; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA045741; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA045741; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA045741; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA045741; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA045741; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA045741; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA045741; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA045741; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA045741; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA045741; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA045741; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA045741; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA045741; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA045741; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA045741; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA045741; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA045741; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA045741; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA045741; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA045741; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA045741; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA045741; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA045741; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA045741; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA045741; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA045741; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA045741; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.2025,9.5,,Neither,oncoref.target-sets.2026-10-23.2,0.2025 TPM; blood/neutrophil; hpa_immune_cell_samples; vital,9.5 nTPM; pbmc/platelets; hpa_single_cell_tissue; vital,Ovary Serous Cystadenocarcinoma (TCGA): 22/349 (6.3%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%),breast cancer: 5/12 (41.7%); prostate cancer: 4/10 (40.0%),29,20,P59826,https://www.uniprot.org/uniprotkb/P59826/entry,"May have the capacity to recognize and bind specific classes of odorants. May act as a carrier molecule, transporting odorants across the mucus layer to access receptor sites. May serve as a primary defense mechanism by recognizing and removing potentially harmful odorants or pathogenic microorganisms from the mucosa or clearing excess odorant from mucus to enable new odorant stimuli to be received (By similarity)",Detected in nasal septal epithelium,,,Secreted Cytoplasm,,11971875,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
BPY2,ENSG00000183753,Neither,Low,False,False,1.1,1.1,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.2,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.2 nTPM; kidney/bulk; hpa_rna_consensus; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O14599,https://www.uniprot.org/uniprotkb/O14599/entry,,"Expressed exclusively in testis. Expressed in ejaculated spermatozoa of germ cell. Expressed in the nuclei of spermatogonia, spermatocytes, and round spermatids, except elongated spermatids (at protein level)",,,,,12207887|12724276|14627543,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
BPY2B,ENSG00000183795,Neither,Low,False,False,1.1,1.1,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.2,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.2 nTPM; kidney/bulk; hpa_rna_consensus; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,O14599,https://www.uniprot.org/uniprotkb/O14599/entry,,"Expressed exclusively in testis. Expressed in ejaculated spermatozoa of germ cell. Expressed in the nuclei of spermatogonia, spermatocytes, and round spermatids, except elongated spermatids (at protein level)",,,,,12207887|12724276|14627543,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
BPY2C,ENSG00000185894,Neither,Low,False,False,1.1,1.1,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.1173906186879999,0.2,,Neither,oncoref.target-sets.2026-10-23.2,0.1174 TPM; blood/CD4_STIM; dice_cd4_stim; vital,0.2 nTPM; kidney/bulk; hpa_rna_consensus; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,O14599,https://www.uniprot.org/uniprotkb/O14599/entry,,"Expressed exclusively in testis. Expressed in ejaculated spermatozoa of germ cell. Expressed in the nuclei of spermatogonia, spermatocytes, and round spermatids, except elongated spermatids (at protein level)",,,,,12207887|12724276|14627543,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
BRDT,ENSG00000137948,Neither,Cellular,False,False,127.6,127.6,75,1,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_monaco basophil: 5 TPM; hpa_immune_monaco Effector memory CD8 T-cell: 6 TPM,True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,6.0,17.7,,CTA,oncoref.target-sets.2026-10-23.2,6 TPM; blood/Effector memory CD8 T-cell; hpa_immune_monaco; vital,17.7 nTPM; bronchus/smooth muscle cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 103/133 (77.4%); Lung Adenocarcinoma (validation): 29/105 (27.6%); Lung Adenocarcinoma (TCGA): 107/497 (21.5%),cervical cancer: 12/12 (100.0%); glioma: 12/12 (100.0%),31,20,Q58F21,https://www.uniprot.org/uniprotkb/Q58F21/entry,"Testis-specific chromatin protein that specifically binds histone H4 acetylated at 'Lys-5' and 'Lys-8' (H4K5ac and H4K8ac, respectively) and plays a key role in spermatogenesis (PubMed:22464331, PubMed:22901802). Required in late pachytene spermatocytes: plays a role in meiotic and post-meiotic cells by binding to acetylated histones at the promoter of specific meiotic and post-meiotic genes, facilitating their activation at the appropriate time (PubMed:22901802). In the post-meiotic phase of spermatogenesis, binds to hyperacetylated histones and participates in their general removal from DNA (PubMed:22901802). Also recognizes and binds a subset of butyrylated histones: able to bind histone H4 butyrylated at 'Lys-8' (H4K8ac), while it is not able to bind H4 butyrylated at 'Lys-5' (H4K5ac) (By similarity). Also acts as a component of the splicing machinery in pachytene spermatocytes and round spermatids and participates in 3'-UTR truncation of specific mRNAs in post-meiotic spermatids (By similarity). Required for chromocenter organization, a structure comprised of peri-centromeric heterochromatin","Testis-specific. A 3-fold higher expression is seen in adult testis than in embryo testis. Expression seems to be correlated with histone H4 hyperacetylation during the haploid phase of spermatogenesis (spermiogenesis). No expression, or very low expression is seen in patients' testes with abnormal spermatogenesis. Expressed in cancers such as non-small cell lung cancer and squamous cell carcinomas of the head and neck as well as of esophagus, but not in melanoma or in cancers of the colon, breast, kidney and bladder",Spermatogenic failure 21: An infertility disorder caused by spermatogenesis defects and characterized by acephalic spermatozoa in the semen of affected individuals. SPGF21 inheritance is autosomal recessive.,,Nucleus,15647849|22464331|22901802|9367677,10704737|15647849|9367677,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S1 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,Does the Monaco-only borderline signal reflect genuine immune expression?,Reconcile Monaco CD8/basophil RNA with the much lower DICE values and obtain relevant protein evidence.,Monaco summary values 5 and 6 TPM are weaker evidence than recurrent high original-sample RNA; DICE does not sample basophils.,,,,,
BSX,ENSG00000188909,Neither,Antibody,False,False,0.2,0.9,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,hypothalamus: 0.9 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA015654; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA015654; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA015654; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA015654; conflicting or uncurated primary profile; Caudate/Glial cells: High, HPA015654; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA015654; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA015654; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: High, HPA015654; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA015654; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: High, HPA015654; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA015654; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA015654; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA015654; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA015654; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA015654; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA015654; conflicting or uncurated primary profile; Hippocampus/Glial cells: High, HPA015654; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA015654; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA015654; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA015654; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA015654; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA015654; conflicting or uncurated primary profile; Lung/Alveolar cells: High, HPA015654; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA015654; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA015654; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA015654; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA015654; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA015654; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA015654; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA015654; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA015654; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA015654; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA015654; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA015654; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA015654; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA015654; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA015654; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA015654; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA015654; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA015654; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA015654; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA015654; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA015654; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA015654; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA015654; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA015654; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.399830158813,0.9,,Neither,oncoref.target-sets.2026-10-23.2,0.3998 TPM; blood/TREG_MEM; dice_treg_mem; vital,0.9 nTPM; hypothalamus/bulk; hpa_rna_consensus; vital,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 2/283 (0.7%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),breast cancer: 12/12 (100.0%); glioma: 11/11 (100.0%),31,20,Q3C1V8,https://www.uniprot.org/uniprotkb/Q3C1V8/entry,DNA binding protein that function as transcriptional activator. Is essential for normal postnatal growth and nursing. Is an essential factor for neuronal neuropeptide Y and agouti-related peptide function and locomotory behavior in the control of energy balance (By similarity),,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
BTBD18,ENSG00000233436,Neither,Antibody,False,False,2.1,2.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA049325; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA049325; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA049325; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA049325; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: High, HPA049325; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA049325; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA049325; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA049325; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA049325; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA049325; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA049325; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA049325; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA049325; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA049325; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA049325; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA049325; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA049325; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA049325; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA049325; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA049325; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA049325; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA049325; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA049325; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA049325; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA049325; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA049325; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA049325; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA049325; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA049325; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.29313919066,3.8,,Neither,oncoref.target-sets.2026-10-23.2,2.293 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,3.8 nTPM; eye/rod photoreceptor cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 6/207 (2.9%); Colon Adenocarcinoma (validation): 11/486 (2.3%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%),glioma: 6/11 (54.5%); melanoma: 3/10 (30.0%),31,20,B2RXH4,https://www.uniprot.org/uniprotkb/B2RXH4/entry,"Specifically required during spermatogenesis to promote expression of piRNA precursors. The piRNA metabolic process mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and governs the methylation and subsequent repression of transposons, which is essential for the germline integrity. Acts by facilitating transcription elongation at piRNA loci during pachytene",,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
C11orf91,ENSG00000205177,Neither,Antibody,False,False,9.3,9.3,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,adipose tissue: 4.6 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bone marrow/Hematopoietic cells: Low, HPA050487; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA050487; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA050487; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA050487; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA050487; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA050487; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA050487; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA050487; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA050487; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA050487; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA050487; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA050487; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA050487; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA050487; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA050487; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA050487; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA050487; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.21166572935,4.6,,Neither,oncoref.target-sets.2026-10-23.2,2.212 TPM; blood/TREG_MEM; dice_treg_mem; vital,4.6 nTPM; adipose tissue/bulk; hpa_rna_consensus; manageable,Kidney Chromophobe (TCGA): 6/64 (9.4%); Pancreatic Adenocarcinoma (TCGA): 6/176 (3.4%); Liver Hepatocellular Carcinoma (validation): 5/231 (2.2%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),30,20,Q3C1V1,https://www.uniprot.org/uniprotkb/Q3C1V1/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
C1QL4,ENSG00000186897,Neither,Low,False,False,4.1,4.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.230116803318,5.7,,Neither,oncoref.target-sets.2026-10-23.2,0.2301 TPM; blood/TH17; dice_th17; vital,5.7 nTPM; unsited/Horizontal cells; hpa_single_cell; unresolved,Glioblastoma Multiforme (validation): 19/58 (32.8%); Kidney Renal Clear Cell Carcinoma (TCGA): 164/521 (31.5%); Glioblastoma Multiforme (TCGA): 37/141 (26.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q86Z23,https://www.uniprot.org/uniprotkb/Q86Z23/entry,May regulate the number of excitatory synapses that are formed on hippocampus neurons. Has no effect on inhibitory synapses (By similarity). May inhibit adipocyte differentiation at an early stage of the process (By similarity),"Highest expression levels in testis and adipose tissue, lower levels in skeletal muscle and kidney",,,Secreted,,23449976,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
C1orf146,ENSG00000203910,Neither,Screening,False,False,7.3,7.3,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,retina: 2 nTPM; continuous selectivity,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,6.389760721830001,2.4,,Neither,oncoref.target-sets.2026-10-23.2,6.39 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,2.4 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%); Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 3/283 (1.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5VVC0,https://www.uniprot.org/uniprotkb/Q5VVC0/entry,"Plays a key role in reinforcing the integrity of the central element of the synaptonemal complex (SC) thereby stabilizing SC, ensuring progression of meiotic prophase I in male and female germ cells (By similarity). Promotes homologous recombination and crossing-over in meiotic prophase I via its association with SHOC1 (By similarity). Required for the localization of TEX11 and MSH4 to recombination intermediates (By similarity)",,,,Chromosome,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
C1orf202,ENSG00000284188,Neither,Screening,False,False,8.6,8.6,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.96465216732,6.1,,Neither,oncoref.target-sets.2026-10-23.2,1.965 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,6.1 nTPM; unsited/Distal tubular cells; hpa_single_cell; unresolved,Glioblastoma Multiforme (TCGA): 1/141 (0.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,A0A1W2PPE3,https://www.uniprot.org/uniprotkb/A0A1W2PPE3/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
C3orf20,ENSG00000131379,Neither,Antibody,False,False,6.4,6.4,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,True,"Adipose tissue/Adipocytes: Low, HPA039584; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA039584; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA039584; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA039584; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA039584; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA039584; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA039584; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA039584; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA039584; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA039584; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA039584; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA039584; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA039584; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA039584; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA039584; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA039584; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA039584; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA039584; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA039584; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA039584; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA039584; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA039584; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA039584; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA039584; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA039584; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA039584; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA039584; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA039584; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA039584; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA039584; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA039584; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA039584; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA039584; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA039584; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA039584; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA039584; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA039584; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA039584; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA039584; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,5.726898118459999,12.1,,CTA,oncoref.target-sets.2026-10-23.2,5.727 TPM; blood/TH2; dice_th2; vital,12.1 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 4/58 (6.9%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),melanoma: 8/12 (66.7%); prostate cancer: 8/12 (66.7%),31,20,Q8ND61,https://www.uniprot.org/uniprotkb/Q8ND61/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Carter2023_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
C4orf17,ENSG00000138813,Neither,Antibody,False,False,19.5,19.5,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA060374; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA060374; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA060374; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA060374; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA060564; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.697013890272,1.2,,CTA,oncoref.target-sets.2026-10-23.2,0.697 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1.2 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Lung Squamous Cell Carcinoma (TCGA): 3/489 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),31,20,Q53FE4,https://www.uniprot.org/uniprotkb/Q53FE4/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
C7orf33,ENSG00000170279,Neither,Low,False,False,0.2,1.3,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,retina: 1.3 nTPM; continuous selectivity;reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.20904078075,10.2,,Neither,oncoref.target-sets.2026-10-23.2,1.209 TPM; blood/MONOCYTES; dice_monocytes; vital,10.2 nTPM; unsited/Cone photoreceptor cells; hpa_single_cell; unresolved,Lung Squamous Cell Carcinoma (validation): 2/68 (2.9%); Bladder Urothelial Carcinoma (TCGA): 4/169 (2.4%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8WU49,https://www.uniprot.org/uniprotkb/Q8WU49/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
C8orf74,ENSG00000171060,Neither,Antibody,False,False,16.6,16.6,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bronchus/Respiratory epithelial cells: Low, HPA027986; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA027986; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA027986; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA027986; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.2053,0.6,,CTA,oncoref.target-sets.2026-10-23.2,0.2053 TPM; blood/NK-cell; hpa_immune_cell_samples; vital,0.6 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q6P047,https://www.uniprot.org/uniprotkb/Q6P047/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
C9orf43,ENSG00000157653,Neither,Cellular,False,False,44.3,44.3,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_monaco Progenitor cell: 18.3 TPM,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,18.3,14.5,,CTA,oncoref.target-sets.2026-10-23.2,18.3 TPM; blood/Progenitor cell; hpa_immune_monaco; vital,14.5 nTPM; liver/b-cells; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 8/50 (16.0%); Glioblastoma Multiforme (validation): 3/58 (5.2%); Kidney Renal Papillary Cell Carcinoma (TCGA): 7/282 (2.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8TAL5,https://www.uniprot.org/uniprotkb/Q8TAL5/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CAGE1,ENSG00000164304,Neither,Antibody,False,False,4.9,4.9,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA029832; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA029832; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA029832; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA029832; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA029832; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA029832; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA029832; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA029832; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA029832; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA029832; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA029832; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA029832; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA029832; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA029832; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA029832; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA029832; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA029832; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA029832; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA029832; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA029832; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA029832; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA029832; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA029832; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA029832; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA029832; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA029832; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA029832; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA029832; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA029832; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA029832; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA029832; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA029832; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA029832; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA029832; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA029832; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA029832; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA029832; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA029832; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.27707364248,9.1,,Neither,oncoref.target-sets.2026-10-23.2,1.277 TPM; blood/CD4_STIM; dice_cd4_stim; vital,9.1 nTPM; breast/macrophages; hpa_single_cell_tissue; vital,Liver Hepatocellular Carcinoma (validation): 4/231 (1.7%); Uterine Corpus Endometrial Carcinoma (TCGA): 3/176 (1.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),colorectal cancer: 12/12 (100.0%); breast cancer: 11/11 (100.0%),31,20,Q8TC20,https://www.uniprot.org/uniprotkb/Q8TC20/entry,,"Testis-specific expression in normal tissues, but wide expression among cancer tissues and cell lines",,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CAPN11,ENSG00000137225,Neither,Cellular,False,False,29.5,29.5,85,6,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE TREG_MEM (unstimulated): 4/89 values ≥5 TPM, max 7.18971; DICE TFH (unstimulated): 4/89 values ≥5 TPM, max 7.72887",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,7.72887429293,19.0,,CTA,oncoref.target-sets.2026-10-23.2,7.729 TPM; blood/TFH; dice_tfh; vital,19 nTPM; pbmc/platelets; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 27/50 (54.0%); Kidney Renal Clear Cell Carcinoma (validation): 4/100 (4.0%); Skin Cuteneous Melanoma (TCGA): 2/99 (2.0%),urothelial cancer: 2/11 (18.2%); ovarian cancer: 2/12 (16.7%),31,20,Q9UMQ6,https://www.uniprot.org/uniprotkb/Q9UMQ6/entry,Calcium-regulated non-lysosomal thiol-protease which catalyzes limited proteolysis of substrates involved in cytoskeletal remodeling and signal transduction,Highest expression in testis,,,"Cytoplasmic vesicle, secretory vesicle, acrosome",,10409436,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CCDC166,ENSG00000255181,Neither,Antibody,False,False,4.0,4.0,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA025058; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA025058; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA025058; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA025058; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA025058; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA025058; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA025058; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA025058; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA025058; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA025058; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA025058; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA025058; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA025058; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA025058; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA025058; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA025058; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA025058; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA025058; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA025058; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA025058; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA025058; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA025058; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA025058; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA025058; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA025058; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA025058; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA025058; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA025058; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA025058; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA025058; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA025058; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA025058; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA025058; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA025058; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA025058; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.493392395241,0.8,,Neither,oncoref.target-sets.2026-10-23.2,0.4934 TPM; blood/TFH; dice_tfh; vital,0.8 nTPM; eye/rod photoreceptor cells; hpa_single_cell_tissue; vital,Stomach Adenocarcinoma (TCGA): 1/346 (0.3%); Lung Squamous Cell Carcinoma (TCGA): 1/489 (0.2%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),testis cancer: 12/12 (100.0%); pancreatic cancer: 7/10 (70.0%),30,20,P0CW27,https://www.uniprot.org/uniprotkb/P0CW27/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CCDC168,ENSG00000175820,Neither,Antibody,False,False,8.6,8.6,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,True,"Adrenal gland/Glandular cells: Low, HPA048184; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA048184; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA048184; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA048184; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA048184; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA048184; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA048184; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA048184; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA048184; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA048184; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA048184; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA048184; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA048184; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA048184; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA048184; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA048184; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA048184; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA048184; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA048184; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA048184; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA048184; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA058793; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA058793; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA058793; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA058793; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA058793; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA058793; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA058793; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA058793; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.16222268437,13.0,,CTA,oncoref.target-sets.2026-10-23.2,1.162 TPM; blood/CD4_STIM; dice_cd4_stim; vital,13 nTPM; heart muscle/cardiomyocytes; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),29,20,Q8NDH2,https://www.uniprot.org/uniprotkb/Q8NDH2/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
CCDC169-SOHLH2,ENSG00000250709,Neither,Screening,False,False,9.9,9.9,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.3,1.7,,Neither,oncoref.target-sets.2026-10-23.2,1.3 TPM; blood/Progenitor cell; hpa_immune_monaco; vital,1.7 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%); Kidney Renal Papillary Cell Carcinoma (TCGA): 2/282 (0.7%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q9NX45,https://www.uniprot.org/uniprotkb/Q9NX45/entry,"Transcription regulator of both male and female germline differentiation. Suppresses genes involved in spermatogonial stem cells maintenance, and induces genes important for spermatogonial differentiation. Coordinates oocyte differentiation without affecting meiosis I (By similarity)",,,,Nucleus Cytoplasm,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
CCDC182,ENSG00000166329,Neither,Antibody,False,False,27.7,27.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA023446; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA023446; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA023446; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA023446; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA023446; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA023446; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA023446; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: High, HPA023446; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA023446; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA023446; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA023446; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA023446; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: High, HPA023446; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA023446; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA023446; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA023446; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA023446; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA023446; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA023446; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA023446; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA023446; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA023446; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA023446; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA023446; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA023446; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA023446; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA023446; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA023446; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA023446; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA023446; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA023446; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: High, HPA023446; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA023446; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA023446; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA023446; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA023446; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA023446; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA023446; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA023446; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA023446; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA023446; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA023446; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA023446; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA023446; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA023446; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA023446; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA023446; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA023446; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.28465900587,3.7,,CTA,oncoref.target-sets.2026-10-23.2,1.285 TPM; blood/TFH; dice_tfh; vital,3.7 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),prostate cancer: 12/12 (100.0%); colorectal cancer: 11/12 (91.7%),29,20,A6NF36,https://www.uniprot.org/uniprotkb/A6NF36/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Carter2023_CT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CCDC183,ENSG00000213213,Neither,Antibody,False,False,21.4,21.4,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA043812; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA043812; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA043812; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA043812; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA043812; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA043812; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA043812; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA043812; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA043812; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA043812; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA043812; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA043812; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA043812; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA043812; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA043812; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA043812; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA043812; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA043812; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA043812; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA043812; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA043812; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA043812; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA043812; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA043812; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA043812; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA043812; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA043812; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA043812; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA043812; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA043812; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA043812; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA043812; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA043812; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA043812; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA043812; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA043812; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA043812; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA043812; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA043812; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,4.80455157461,30.0,,CTA,oncoref.target-sets.2026-10-23.2,4.805 TPM; blood/TFH; dice_tfh; vital,30 nTPM; adipose tissue/dendritic cells; hpa_single_cell_tissue; vital,Pancreatic Adenocarcinoma (validation): 31/80 (38.8%); Ovary Serous Cystadenocarcinoma (validation): 2/81 (2.5%); Rectum Adenocarcinoma (validation): 5/207 (2.4%),colorectal cancer: 5/10 (50.0%); breast cancer: 5/11 (45.5%),29,20,Q5T5S1,https://www.uniprot.org/uniprotkb/Q5T5S1/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CCDC197,ENSG00000175699,Neither,Screening,False,False,7.8,7.8,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.6932192051980001,1.1,,Neither,oncoref.target-sets.2026-10-23.2,0.6932 TPM; blood/TREG_MEM; dice_treg_mem; vital,1.1 nTPM; skin/macrophages; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q8NCU1,https://www.uniprot.org/uniprotkb/Q8NCU1/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CCDC62,ENSG00000130783,Neither,Cellular,False,False,68.0,68.0,87,1,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 74/91 values ≥5 TPM, max 10.9628",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,10.9627928607,19.0,,CTA,oncoref.target-sets.2026-10-23.2,10.96 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,19 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 16/58 (27.6%); Testicular Germ Cell Tumor (TCGA): 5/133 (3.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 5/176 (2.8%),colorectal cancer: 1/12 (8.3%); breast cancer: 0/10 (0.0%),31,20,Q6P9F0,https://www.uniprot.org/uniprotkb/Q6P9F0/entry,"Nuclear receptor coactivator that can enhance preferentially estrogen receptors ESR1 and ESR2 transactivation. Also modulates progesterone/PGR, glucocorticoid/NR3C1 and androgen/AR receptors transactivation, although at lower level; little effect on vitamin D receptor/VDR. Required for normal spermiogenesis. It probably plays a role in acrosome formation (By similarity)","Highly expressed in adult testis. Expressed in both prostate epithelial and stromal cells, with predominant expression in epithelial cells (at protein level) (PubMed:19126643). Not detected in prostate by RT-PCR (PubMed:19165854). Overexpressed in various cancers","Spermatogenic failure 67: An autosomal recessive male infertility disorder characterized by globozoospermia. Affected individuals have a normal sperm count, but spermatozoa are round-headed and lack the acrosome. In addition to pure globozoospermia, some patients have a mixture of acrosomeless spermatozoa and spermatozoa with small or detached acrosomes, which is defined as acrosomal hypoplasia.",,"Cytoplasm Nucleus Cytoplasmic vesicle, secretory vesicle, acrosome",19126643,19126643|19165854,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CCDC73,ENSG00000186714,Neither,Antibody,False,False,3.7,3.7,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA038668; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA038668; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA038668; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA038668; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA038668; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA038668; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA038668; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA038668; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA038668; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA038668; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA038668; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA038668; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA038668; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA038668; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA038668; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA038668; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA038668; conflicting or uncurated primary profile; Lymph node/Germinal center cells: High, HPA038668; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA038668; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA038668; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA038668; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA038668; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA038668; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA038668; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA038668; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA038668; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA038668; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA038668; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA038668; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA038668; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA038668; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA038668; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA038668; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA038668; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA038668; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA038669; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA038669; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA038669; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA038669; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA038669; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA038669; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA038669; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA038669; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA038669; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA038669; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA038669; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA038669; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA038669; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.8452,7.2,,Neither,oncoref.target-sets.2026-10-23.2,0.8452 TPM; blood/intermediate monocyte; hpa_immune_cell_samples; vital,7.2 nTPM; unsited/Microglial cells; hpa_single_cell; unresolved,Liver Hepatocellular Carcinoma (validation): 204/231 (88.3%); Uterine Corpus Endometrial Carcinoma (TCGA): 54/176 (30.7%); Breast Invasive Carcinoma (validation): 5/50 (10.0%),colorectal cancer: 12/12 (100.0%); liver cancer: 12/12 (100.0%),31,20,Q6ZRK6,https://www.uniprot.org/uniprotkb/Q6ZRK6/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CCIN,ENSG00000185972,Neither,Cellular,False,False,72.6,72.6,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE MONOCYTES (unstimulated): 61/91 values ≥5 TPM, max 11.7323",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,11.7323132104,6.2,,CTA,oncoref.target-sets.2026-10-23.2,11.73 TPM; blood/MONOCYTES; dice_monocytes; vital,6.2 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 3/58 (5.2%); Breast Invasive Carcinoma (validation): 1/50 (2.0%); Ovary Serous Cystadenocarcinoma (TCGA): 6/349 (1.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q13939,https://www.uniprot.org/uniprotkb/Q13939/entry,Required for both nuclear and acrosomal shaping during spermiogenesis,"Expressed in testis, in spermatozoa (at protein level)","Spermatogenic failure 91: An autosomal recessive, male infertility disorder due to globozoospermia and asthenoteratozoospermia. Patient sperm show defects of the head, including a misshapen rounded head and detachment of the acrosome, and the sperm fail to attach to the zona pellucida of the egg.",,"Cytoplasm, cytoskeleton, perinuclear theca, calyx",36546111,36527329|36546111,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CDC20B,ENSG00000164287,Neither,Antibody,False,False,2.5,2.5,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,kidney: 1.1 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA053900; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA053900; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA053900; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA053900; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA053900; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA053900; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA053900; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA053900; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA053900; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA053900; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA053900; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA053900; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA053900; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA053900; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA053900; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA053900; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA053900; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA053900; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA053900; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA053900; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA053900; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA053900; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA053900; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA053900; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA053900; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA053900; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA053900; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA053900; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA053900; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA053900; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA053900; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA053900; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA053900; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA053900; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.867440713292,27.5,,Neither,oncoref.target-sets.2026-10-23.2,0.8674 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,27.5 nTPM; bronchus/ciliated cells; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 12/50 (24.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 40/176 (22.7%); Ovary Serous Cystadenocarcinoma (TCGA): 53/349 (15.2%),colorectal cancer: 9/10 (90.0%); liver cancer: 9/11 (81.8%),31,20,Q86Y33,https://www.uniprot.org/uniprotkb/Q86Y33/entry,Protein regulator of centriole-deuterosome disengagement and subsequently participates in the ciliogenesis in multiciliated cells (MCCs),Expressed in multiciliated cells (MCCs),,,Cytoplasm,,30405130,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CDKL4,ENSG00000205111,Neither,Antibody,False,False,2.0,2.0,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,choroid plexus: 0.7 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE TREG_MEM (unstimulated): 15/89 values ≥5 TPM, max 9.02174",True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA067895; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA067895; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA067895; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA067895; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA067895; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA067895; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA067895; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA067895; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA067895; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA067895; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA067895; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA067895; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA067895; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA067895; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA067895; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA067895; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA067895; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA067895; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA067895; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA067895; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA067895; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA067895; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA067895; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA067895; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA067895; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA067895; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA067895; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,9.02174435222,7.7,,Neither,oncoref.target-sets.2026-10-23.2,9.022 TPM; blood/TREG_MEM; dice_treg_mem; vital,7.7 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 33/58 (56.9%); Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%),lung cancer: 1/8 (12.5%); breast cancer: 1/10 (10.0%),31,20,Q5MAI5,https://www.uniprot.org/uniprotkb/Q5MAI5/entry,,,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CDRT15,ENSG00000223510,Neither,Antibody,False,False,20.3,20.3,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 3/91 values ≥5 TPM, max 6.24683; DICE NK (unstimulated): 37/90 values ≥5 TPM, max 16.9055; DICE TREG_MEM (unstimulated): 89/89 values ≥5 TPM, max 18.8119; DICE CD4_NAIVE (unstimulated): 54/88 values ≥5 TPM, max 13.0333; DICE TREG_NAIVE (unstimulated): 63/89 values ≥5 TPM, max 15.1295; DICE TFH (unstimulated): 51/89 values ≥5 TPM, max 15.6692; DICE TH1 (unstimulated): 31/81 values ≥5 TPM, max 12.17; DICE THSTAR (unstimulated): 30/88 values ≥5 TPM, max 7.80653; DICE TH17 (unstimulated): 35/89 values ≥5 TPM, max 10.7032; DICE TH2 (unstimulated): 68/89 values ≥5 TPM, max 12.285; DICE CD8_NAIVE (unstimulated): 56/89 values ≥5 TPM, max 11.9432",True,True,False,,True,True,"Bone marrow/Hematopoietic cells: Low, HPA055952; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA055952; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA055952; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA055952; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA055952; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA055952; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA055952; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA055952; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA055952; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA055952; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,18.8119400907,3.2,,CTA,oncoref.target-sets.2026-10-23.2,18.81 TPM; blood/TREG_MEM; dice_treg_mem; vital,3.2 nTPM; skin/bulk; hpa_rna_consensus; manageable,Testicular Germ Cell Tumor (TCGA): 11/133 (8.3%); Bladder Urothelial Carcinoma (TCGA): 12/169 (7.1%); Skin Cuteneous Melanoma (TCGA): 7/99 (7.1%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q96T59,https://www.uniprot.org/uniprotkb/Q96T59/entry,,"Expressed in fetal heart, kidney, liver, lung and spleen",,,,,11381029,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S1 | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
CDY1,ENSG00000172288,Neither,Screening,False,False,1.3,1.3,77,1,Positive somewhere,False,False,False,True,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Breast Invasive Carcinoma (validation): 0/50 (0.0%),liver cancer: 4/11 (36.4%); breast cancer: 0/12 (0.0%),30,20,Q9Y6F8,https://www.uniprot.org/uniprotkb/Q9Y6F8/entry,"Has histone acetyltransferase activity, with a preference for histone H4",Testis-specific. Detected in spermatids (at protein level),,,Nucleus,12072557,12072557,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
CDY1B,ENSG00000172352,Neither,Screening,False,False,1.8,1.8,77,1,Positive somewhere,False,False,False,True,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Breast Invasive Carcinoma (validation): 0/50 (0.0%),liver cancer: 4/11 (36.4%); breast cancer: 0/12 (0.0%),30,20,Q9Y6F8,https://www.uniprot.org/uniprotkb/Q9Y6F8/entry,"Has histone acetyltransferase activity, with a preference for histone H4",Testis-specific. Detected in spermatids (at protein level),,,Nucleus,12072557,12072557,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
CEP295NL,ENSG00000178404,Neither,Antibody,False,False,27.6,27.6,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE MONOCYTES (unstimulated): 19/91 values ≥5 TPM, max 7.45263; DICE M2 (unstimulated): 13/90 values ≥5 TPM, max 7.65032; hpa_immune_cell memory B-cell: 5.5 nTPM",True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA023609; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA023609; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA023609; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA023609; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA023609; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA023609; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA023609; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA023609; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA023609; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA023609; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA023609; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA023609; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA023609; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA023609; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA023609; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA024619; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA024619; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA024619; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA024619; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA024619; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA024619; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA024619; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA024619; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA024619; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA024619; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA024619; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA024619; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA024619; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA024619; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA024619; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA024619; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA024619; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA024619; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA024619; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA024619; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA024619; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA024619; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA024619; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA024619; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA024619; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA024619; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA024619; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA024619; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA024619; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA024619; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA024619; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA024619; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: Medium, HPA025717; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Low, HPA025717; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA025717; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA025717; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA025717; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA025717; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA025717; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA025717; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA025717; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA025717; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA025717; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA025717; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA025717; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA025717; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA025717; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA025717; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA025717; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA025717; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA025717; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA025717; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA025717; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA025717; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA025717; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA025717; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA025717; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA025717; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA025717; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA025717; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA025717; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA025717; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA025717; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA025717; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA025717; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,7.65031902638,13.0481,,CTA,oncoref.target-sets.2026-10-23.2,7.65 TPM; blood/M2; dice_m2; vital,13.05 nTPM; blood/memory B-cell; hpa_immune_cell_samples; vital,Glioblastoma Multiforme (validation): 24/58 (41.4%); Pancreatic Adenocarcinoma (validation): 15/80 (18.8%); Rectum Adenocarcinoma (validation): 7/207 (3.4%),endometrial cancer: 9/12 (75.0%); colorectal cancer: 8/12 (66.7%),29,20,Q96MC4,https://www.uniprot.org/uniprotkb/Q96MC4/entry,,,,,"Cell projection, cilium",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CGB2,ENSG00000104818,Neither,Selectivity,False,False,1.5,1.5,87,3,Positive somewhere,False,False,False,True,Excluded,Normal,False,,Not assessed,,,basal ganglia: 0.6 nTPM; continuous selectivity,Fails reproductive selectivity without above-ceiling normal RNA or a normal-protein veto,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Selectivity,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.01245619182,1.5,,Neither,oncoref.target-sets.2026-10-23.2,1.012 TPM; blood/CD4_STIM; dice_cd4_stim; vital,1.5 nTPM; pancreas/mixed cell types; hpa_single_cell_tissue; vital,Ovary Serous Cystadenocarcinoma (TCGA): 37/349 (10.6%); Uterine Corpus Endometrial Carcinoma (TCGA): 10/176 (5.7%); Testicular Germ Cell Tumor (TCGA): 7/133 (5.3%),urothelial cancer: 1/10 (10.0%); breast cancer: 0/10 (0.0%),31,20,Q6NT52,https://www.uniprot.org/uniprotkb/Q6NT52/entry,,"Expressed in placenta, testis and pituitary",,,Secreted,,16123088|18048458,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
CIB3,ENSG00000141977,Neither,Antibody,False,False,0.7,1.2,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 1.2 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE NK (unstimulated): 8/90 values ≥5 TPM, max 7.16002",True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA043553; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA043553; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA043553; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA043553; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA043553; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA043553; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA043553; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA043553; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA043553; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA043553; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA043553; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA043553; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA043553; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA043553; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA043553; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA043553; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA043553; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA043553; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA043553; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA043553; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA043553; conflicting or uncurated primary profile; Lung/Alveolar cells: High, HPA043553; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA043553; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA043553; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA043553; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA043553; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA043553; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA043553; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA043553; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA043553; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA043553; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA043553; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA043553; conflicting or uncurated primary profile; Skin 1/Fibroblasts: High, HPA043553; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA043553; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA043553; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA043553; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA043553; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA043553; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA043553; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA043553; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA043553; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA043553; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA043553; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA043553; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,7.1600239654,8.9,,Neither,oncoref.target-sets.2026-10-23.2,7.16 TPM; blood/NK; dice_nk; vital,8.9 nTPM; colon/distal enterocytes; hpa_single_cell_tissue; protected,Breast Invasive Carcinoma (validation): 31/50 (62.0%); Breast Invasive Carcinoma (TCGA): 39/1022 (3.8%); Ovary Serous Cystadenocarcinoma (TCGA): 2/349 (0.6%),testis cancer: 12/12 (100.0%); colorectal cancer: 11/12 (91.7%),31,20,Q96Q77,https://www.uniprot.org/uniprotkb/Q96Q77/entry,Acts a an auxiliary subunit of the sensory mechanoelectrical transduction (MET) channel in hair cells (By similarity). Plays a role in regulating hair cell MET channel localization and function (By similarity),,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
CIB4,ENSG00000157884,Neither,Antibody,False,False,16.8,16.8,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA036130; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA036130; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA036130; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA036130; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA036130; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA036130; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA036130; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA036130; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA036130; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA036130; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA036130; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA036130; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA036130; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA036130; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA036130; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA036130; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA036130; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA036130; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA036130; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA036130; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA036130; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA036130; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA036130; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA036130; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA036130; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA036130; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA036130; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA036130; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA036130; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA036130; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA036130; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA036130; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA036131; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA036131; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA036131; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA036131; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA036131; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA036131; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA036131; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA036131; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA036131; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA036131; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA036131; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA036131; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA036131; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA036131; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA036131; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA036131; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA036131; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA036131; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA036131; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA036131; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA036131; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA036131; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA036131; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA036131; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA036131; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA036131; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA036131; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA036131; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA036131; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA036131; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA036131; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA036131; conflicting or uncurated primary profile; Skin 1/Keratinocytes: High, HPA036131; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA036131; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA036131; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA036131; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA036131; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA036131; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA036131; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA036131; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.201885357389,5.8,,CTA,oncoref.target-sets.2026-10-23.2,0.2019 TPM; blood/CD4_STIM; dice_cd4_stim; vital,5.8 nTPM; unsited/Collecting duct cells; hpa_single_cell; unresolved,Kidney Renal Clear Cell Carcinoma (validation): 22/100 (22.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 81/521 (15.5%); Thyroid Carcinoma (TCGA): 39/495 (7.9%),colorectal cancer: 10/11 (90.9%); liver cancer: 10/11 (90.9%),31,20,A0PJX0,https://www.uniprot.org/uniprotkb/A0PJX0/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CLDN34,ENSG00000234469,Neither,Low,False,False,1.6,1.6,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,retina: 0.5 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.841649075766,4.7,,Neither,oncoref.target-sets.2026-10-23.2,0.8416 TPM; blood/TREG_MEM; dice_treg_mem; vital,4.7 nTPM; liver/hepatocytes; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,H7C241,https://www.uniprot.org/uniprotkb/H7C241/entry,"Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity",,,,"Cell junction, tight junction Cell membrane",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CLEC20A,ENSG00000188585,Neither,Cellular,False,False,2.1,2.1,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,existing nomination or manual review; nomination unresolved; bone marrow: 0.8 nTPM; continuous selectivity; lymph node: 1.1 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_cell naive B-cell: 10.8 nTPM; hpa_immune_monaco naive B-cell: 15.5 TPM,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,15.8176,25.3,,Neither,oncoref.target-sets.2026-10-23.2,15.82 TPM; blood/naive B-cell; hpa_immune_cell_samples; vital,25.3 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Bladder Urothelial Carcinoma (TCGA): 4/169 (2.4%); Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%); Kidney Renal Papillary Cell Carcinoma (TCGA): 4/282 (1.4%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q6ZU45,https://www.uniprot.org/uniprotkb/Q6ZU45/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CLRN2,ENSG00000249581,Neither,Antibody,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; kidney: 0.1 nTPM; reproductive not higher; salivary gland: 0.1 nTPM; reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA042407; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA042407; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA042407; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA042407; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA042407; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA042407; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA042407; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA042407; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA042407; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA042407; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA042407; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA042407; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA042407; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA042407; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA042407; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA042407; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA042407; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA042407; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA042407; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA042407; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA042407; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA042407; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA042407; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA042407; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA042407; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA042407; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA042407; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA042407; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.764220280607,0.2,,Neither,oncoref.target-sets.2026-10-23.2,0.7642 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,0.2 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),liver cancer: 6/11 (54.5%); lung cancer: 4/10 (40.0%),31,20,A0PK11,https://www.uniprot.org/uniprotkb/A0PK11/entry,Plays a key role to hearing function. Required for normal organization and maintenance of the stereocilia bundle and for mechano-electrical transduction,,"Deafness, autosomal recessive, 117: A form of non-syndromic deafness characterized by prelingual, moderate-to-profound sensorineural hearing loss. Sensorineural hearing loss results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information.",,"Cell projection, stereocilium membrane",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
CNGA2,ENSG00000183862,Neither,Antibody,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA015065; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA015065; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA015065; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA015065; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA015065; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA015065; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA015065; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA015065; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA015065; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA015065; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA015065; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA015065; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA015065; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA015065; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA015065; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA015065; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA015065; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA015065; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA015065; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA015065; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA015065; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA015065; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA015065; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.101133099953,0.0409,,Neither,oncoref.target-sets.2026-10-23.2,0.1011 TPM; blood/TREG_MEM; dice_treg_mem; vital,0.0409 nTPM; blood/neutrophil; hpa_immune_cell_samples; vital,Breast Invasive Carcinoma (validation): 1/50 (2.0%); Breast Invasive Carcinoma (TCGA): 9/1022 (0.9%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),liver cancer: 3/12 (25.0%); pancreatic cancer: 2/9 (22.2%),31,20,Q16280,https://www.uniprot.org/uniprotkb/Q16280/entry,"Pore-forming subunit of the olfactory cyclic nucleotide-gated channel. Operates in the cilia of olfactory sensory neurons where chemical stimulation of the odorant is converted to an electrical signal. Mediates odorant-induced cAMP-dependent Ca(2+) influx triggering neuron depolarization. The rise of intracellular Ca(2+) levels potentiates the olfactory response by activating Ca(2+)-dependent Cl(-) channels, but it also serves as a negative feedback signal to desensitize the channel for rapid adaptation to odorants. Conducts cAMP- and cGMP-gated ion currents, with permeability for monovalent and divalent cations. Also expressed in a subpopulation of sensory neurons of the main olfactory epithelium (type B cells), where it mediates Ca(2+) influx in response to hydrogen sulfide, and is required for defensive behavioral responses to this stimulus (By similarity)",,,,"Cell projection, cilium membrane",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
CSAG1,ENSG00000198930,Neither,Low,False,False,1.3,1.9,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,existing nomination or manual review; nomination unresolved; amygdala: 1.7 nTPM; continuous selectivity;reproductive not higher; basal ganglia: 1.9 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 1.6 nTPM; continuous selectivity;reproductive not higher; hippocampal formation: 1.6 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 1 nTPM; continuous selectivity; midbrain: 1.6 nTPM; continuous selectivity;reproductive not higher; spinal cord: 0.6 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.303900212285,2.2,,Neither,oncoref.target-sets.2026-10-23.2,0.3039 TPM; blood/TREG_MEM; dice_treg_mem; vital,2.2 nTPM; eye/muller glia cells; hpa_single_cell_tissue; vital,Skin Cuteneous Melanoma (TCGA): 51/99 (51.5%); Stomach Adenocarcinoma (TCGA): 97/346 (28.0%); Lung Squamous Cell Carcinoma (TCGA): 134/489 (27.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6PB30,https://www.uniprot.org/uniprotkb/Q6PB30/entry,May play an important role in maintaining centrosome integrity during mitosis,"Expressed in chondrosarcoma, melanoma, cartilage and testis, but not in other normal tissues",,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, spindle pole",32295846,12039054,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
CSAG2,ENSG00000268902,Neither,Low,False,False,1.0,1.0,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,lymph node: 1 nTPM; continuous selectivity;reproductive not higher; skin: 0.7 nTPM; continuous selectivity; spleen: 0.6 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.3,1.0,,Neither,oncoref.target-sets.2026-10-23.2,0.3 TPM; blood/Progenitor cell; hpa_immune_monaco; vital,1 nTPM; lymph node/bulk; hpa_rna_consensus; protected,Head and Neck Squamous Cell Carcinoma (TCGA): 154/492 (31.3%); Lung Squamous Cell Carcinoma (TCGA): 153/489 (31.3%); Skin Cuteneous Melanoma (TCGA): 26/99 (26.3%),No exact-ID IHC coverage in the HPA cancer snapshot,28,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CSAG3,ENSG00000268916,Neither,Low,False,False,3.8,3.8,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,spleen: 2.2 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.1,2.2,,Neither,oncoref.target-sets.2026-10-23.2,1.1 TPM; blood/Progenitor cell; hpa_immune_monaco; vital,2.2 nTPM; spleen/bulk; hpa_rna_consensus; manageable,Skin Cuteneous Melanoma (TCGA): 38/99 (38.4%); Lung Squamous Cell Carcinoma (validation): 25/68 (36.8%); Lung Squamous Cell Carcinoma (TCGA): 165/489 (33.7%),No exact-ID IHC coverage in the HPA cancer snapshot,28,0,Q9Y5P2,https://www.uniprot.org/uniprotkb/Q9Y5P2/entry,"Drug-resistance related protein, its expression is associated with the chemotherapy resistant and neoplastic phenotype. May also be linked to the malignant phenotype","Weakly expressed in kidney. Expressed in various tumor cell lines including carcinomas, myeloid and lymphoid malignancies, melanomas and prostate cancer. Overexpressed in taxol-resistant breast cancer line MDA 435TR and the doxorubicin-resistant multiple myelanoma lines RPMI-8226/Dox40 and RPMI-8226/MDR10V",,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CSNK1A1L,ENSG00000180138,Neither,Cellular,False,False,3.4,3.4,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_cell neutrophil: 7.6 nTPM; hpa_immune_monaco neutrophil: 9.6 TPM,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,9.6,16.0,,Neither,oncoref.target-sets.2026-10-23.2,9.6 TPM; blood/neutrophil; hpa_immune_monaco; vital,16 nTPM; bronchus/smooth muscle cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8N752,https://www.uniprot.org/uniprotkb/Q8N752/entry,Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. It can phosphorylate a large number of proteins. Participates in Wnt signaling (By similarity),,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
CSNK2A2IP,ENSG00000283434,Neither,Screening,False,False,22.7,22.7,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.43636400851,1.9,,Neither,oncoref.target-sets.2026-10-23.2,0.4364 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,1.9 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Stomach Adenocarcinoma (TCGA): 1/346 (0.3%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,A0A1B0GTH6,https://www.uniprot.org/uniprotkb/A0A1B0GTH6/entry,May play a role in chromatin regulation of male germ cells,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CST9,ENSG00000173335,Neither,Antibody,False,False,1.9,1.9,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA029190; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA029190; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA029190; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA029190; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA029190; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: High, HPA029190; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA029190; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA029190; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA029190; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA029190; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA029190; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA029190; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA029190; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA029190; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA029190; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA029190; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA029190; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA029190; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA029190; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA029190; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA029190; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA029190; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA029190; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA029190; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA029190; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA029190; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA029190; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA029190; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA029190; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA029190; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA029190; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA029190; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA029190; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA029190; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA029190; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA029190; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA029190; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA029190; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA029190; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA029190; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA029190; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA029190; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA029190; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA029190; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.397970038016,0.3,,Neither,oncoref.target-sets.2026-10-23.2,0.398 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,0.3 nTPM; esophagus/fibroblasts; hpa_single_cell_tissue; protected,Breast Invasive Carcinoma (validation): 23/50 (46.0%); Breast Invasive Carcinoma (TCGA): 226/1022 (22.1%); Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%),prostate cancer: 12/12 (100.0%); liver cancer: 10/11 (90.9%),31,20,Q5W186,https://www.uniprot.org/uniprotkb/Q5W186/entry,"May be involved in testis development (By similarity). May play a role in hematopoietic differentiation or inflammation (PubMed:12535658). Has immunomodulatory and antimicrobial functions against Francisella tularensis, a Gram-negative bacteria (PubMed:23922243)","Expressed in heart, placenta, lung, liver, skeletal muscle and pancreas (PubMed:12535658). Not expressed in brain (PubMed:12535658). Expressed in epididymis, kidney, testis, spinal cord, and thymus with a strong expression in epididymis and kidney and a weak expression in the spinal cord and thymus (PubMed:20565543)",,,Secreted,12535658|23922243,12535658|20565543,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
CSTL1,ENSG00000125823,Neither,Low,False,False,1.7,1.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.31575749589,1.0,,Neither,oncoref.target-sets.2026-10-23.2,2.316 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1 nTPM; unsited/Skeletal myocytes; hpa_single_cell; unresolved,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 9/283 (3.2%); Breast Invasive Carcinoma (validation): 1/50 (2.0%); Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9H114,https://www.uniprot.org/uniprotkb/Q9H114/entry,,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S1 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CT45A8,ENSG00000278085,Neither,Unassessed,False,False,1.0,1.0,85,4,Positive somewhere,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,reviewed unreliable ihc; reviewed unreliable ihc,Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,heart muscle / cardiomyocytes: Low (Supported),reviewed_unreliable_ihc,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.1,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.1 nTPM; basal ganglia/bulk; hpa_rna_consensus; vital,Lung Squamous Cell Carcinoma (validation): 5/68 (7.4%); Lung Squamous Cell Carcinoma (TCGA): 15/489 (3.1%); Ovary Serous Cystadenocarcinoma (TCGA): 10/349 (2.9%),ovarian cancer: 4/10 (40.0%); testis cancer: 3/12 (25.0%),26,20,Q5DJT8 | P0DMV1 | P0DMV2,https://www.uniprot.org/uniprotkb/Q5DJT8/entry | https://www.uniprot.org/uniprotkb/P0DMV1/entry | https://www.uniprot.org/uniprotkb/P0DMV2/entry,,Testis specific. Expressed in cancer cell lines,,,,,15905330,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Loriot2025_S1,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
CT45A9,ENSG00000270946,Neither,Unassessed,False,False,0.8,0.8,85,4,Positive somewhere,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,reviewed unreliable ihc; reviewed unreliable ihc,Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,heart muscle / cardiomyocytes: Low (Supported),reviewed_unreliable_ihc,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.1,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.1 nTPM; basal ganglia/bulk; hpa_rna_consensus; vital,Lung Squamous Cell Carcinoma (validation): 10/68 (14.7%); Ovary Serous Cystadenocarcinoma (TCGA): 45/349 (12.9%); Lung Squamous Cell Carcinoma (TCGA): 50/489 (10.2%),ovarian cancer: 4/10 (40.0%); testis cancer: 3/12 (25.0%),26,20,Q5DJT8 | P0DMV1 | P0DMV2,https://www.uniprot.org/uniprotkb/Q5DJT8/entry | https://www.uniprot.org/uniprotkb/P0DMV1/entry | https://www.uniprot.org/uniprotkb/P0DMV2/entry,,Testis specific. Expressed in cancer cell lines,,,,,15905330,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Loriot2025_S1,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
CT47C1,ENSG00000277535,Neither,Screening,False,False,4.2,4.2,83,1,Positive somewhere,False,False,False,True,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,False,,False,True,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.293937102765,0.011,,Neither,oncoref.target-sets.2026-10-23.2,0.2939 TPM; blood/CD4_STIM; dice_cd4_stim; vital,0.011 nTPM; blood/MAIT T-cell; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),26,20,A0A0U1RQG5,https://www.uniprot.org/uniprotkb/A0A0U1RQG5/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CTAG2,ENSG00000126890,Neither,Variable,False,False,10.1,10.1,86,6,Positive somewhere,False,False,True,True,Variable,Reproductive,False,,Reviewed,149: 13.5 nTPM (fails); 150: 0 nTPM (passes); 151: 0 nTPM (passes); 152: 7.1 nTPM (fails),Shared target in a clinical study,individual vital-tissue RNA donors fail the same inclusion limits,Donor-variable vital RNA with negative local IHC; excluded from targets and forbidden background pending review,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Variable,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,5.07496579565,24.9,,Neither,oncoref.target-sets.2026-10-23.2,5.075 TPM; blood/TH1; dice_th1; vital,24.9 nTPM; bronchus/basal respiratory cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 35/133 (26.3%); Skin Cuteneous Melanoma (TCGA): 25/99 (25.3%); Bladder Urothelial Carcinoma (TCGA): 39/169 (23.1%),colorectal cancer: 5/11 (45.5%); lung cancer: 4/12 (33.3%),31,20,O75638,https://www.uniprot.org/uniprotkb/O75638/entry,,"Testis and very low level in placenta and in some uterus samples. Observed in 25-50% of tumor samples of melanomas, non-small-cell lung carcinomas, bladder, prostate and head and neck cancers",,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,Clinical shared-epitope target,https://aacrjournals.org/clincancerres/article-split/31/3/529/751208/Safety-and-Tolerability-of-Letetresgene-Autoleucel,"One durable response among 18 treated patients; cytopenias and CRS were common, without fatal treatment-related serious adverse events. Recognition includes a shared NY-ESO-1/LAGE-1A epitope; this is not proof of all-isoform CTAG2 safety. | Responses: 2/10 and 4/10 across two cohorts. A potentially related fatal cardiac arrest occurred on day 161 amid substantial competing illness/treatment. It does not establish CTAG2-mediated myocardial injury; the independent donor-expression hold remains.",https://pubmed.ncbi.nlm.nih.gov/39576208/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC12084024/,Clinical outcomes,daSilva2017_testis_biased | daSilva2017_CT | Seager2024_CTA | Loriot2025_S1 | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Member of the published 17-target CTA profiling panel; includes differentiation antigen MLANA | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,When and why do some normal heart specimens contain CTAG2 RNA?,Resolve donor variability and obtain paired RNA/protein information from the implicated cardiac context.,RNA donors and negative-IHC donors differ; neither absence of established target-mediated toxicity nor separate negative specimens clears the positive RNA donors.,,,,,
CTAGE1,ENSG00000212710,Neither,Antibody,False,False,10.0,10.0,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA000387; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA000387; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA000387; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA000387; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA000387; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA000387; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA000387; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA000387; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA000387; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA000387; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA000387; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA000387; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA000387; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA000387; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA000387; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA000387; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA000387; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA000387; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA000387; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA000387; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA000387; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA000387; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA000387; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA000387; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA000387; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA000387; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA000387; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA000387; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA000387; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA000387; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA000387; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Low, HPA000922; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA000922; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA000922; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA000922; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA000922; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA000922; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA000922; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA000922; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA000922; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA000922; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA000922; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA000922; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA000922; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA000922; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA000922; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA000922; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA000922; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA000922; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA000922; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA000922; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA000922; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA000922; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA000922; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Low, CAB016204; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, CAB016204; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, CAB016204; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, CAB016204; conflicting or uncurated primary profile; Colon/Glandular cells: Low, CAB016204; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, CAB016204; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, CAB016204; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, CAB016204; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, CAB016204; conflicting or uncurated primary profile; Liver/Hepatocytes: High, CAB016204; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, CAB016204; conflicting or uncurated primary profile; Lung/Macrophages: Low, CAB016204; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, CAB016204; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, CAB016204; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, CAB016204; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, CAB016204; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, CAB016204; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, CAB016204; conflicting or uncurated primary profile; Skin 1/Langerhans: High, CAB016204; conflicting or uncurated primary profile; Spleen/Cells in red pulp: High, CAB016204; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, CAB016204; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, CAB016204; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, CAB016204; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.388429633131,1.9,,CTA,oncoref.target-sets.2026-10-23.2,0.3884 TPM; blood/CD4_STIM; dice_cd4_stim; vital,1.9 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),stomach cancer: 11/11 (100.0%); endometrial cancer: 10/10 (100.0%),31,20,Q96RT6 | Q9HC47,https://www.uniprot.org/uniprotkb/Q96RT6/entry | https://www.uniprot.org/uniprotkb/Q9HC47/entry,,"Testis. Not found in tumor | Testis. Expressed in several cutaneous T-cell lymphoma (CTCL) cell lines, in head-neck carcinomas and carcinoma of ovarian tissues",,,Membrane,,11149944,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,Can the uncertain primary-antibody normal staining be resolved?,Use independently validated protein evidence to adjudicate primary staining conflicts.,An uncertain antibody is not reliable proof of either expression or absence.,,,,,
CTAGE6,ENSG00000271321,Neither,Antibody,False,False,14.0,14.0,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA000387; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA000387; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA000387; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA000387; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA000387; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA000387; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA000387; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA000387; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA000387; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA000387; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA000387; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA000387; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA000387; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA000387; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA000387; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA000387; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA000387; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA000387; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA000387; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA000387; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA000387; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA000387; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA000387; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA000387; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA000387; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA000387; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA000387; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA000387; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA000387; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA000387; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA000387; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Low, HPA000922; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA000922; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA000922; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA000922; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA000922; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA000922; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA000922; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA000922; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA000922; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA000922; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA000922; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA000922; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA000922; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA000922; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA000922; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA000922; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA000922; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA000922; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA000922; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA000922; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA000922; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA000922; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA000922; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.998306808385,2.2,,CTA,oncoref.target-sets.2026-10-23.2,0.9983 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,2.2 nTPM; pancreas/exocrine glandular cells; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 16/50 (32.0%); Glioblastoma Multiforme (validation): 1/58 (1.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),stomach cancer: 11/11 (100.0%); endometrial cancer: 10/10 (100.0%),28,20,Q86UF2,https://www.uniprot.org/uniprotkb/Q86UF2/entry,,,,,Membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CTAGE9,ENSG00000236761,Neither,Antibody,False,False,8.1,8.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA000387; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA000387; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA000387; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA000387; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA000387; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA000387; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA000387; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA000387; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA000387; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA000387; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA000387; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA000387; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA000387; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA000387; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA000387; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA000387; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA000387; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA000387; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA000387; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA000387; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA000387; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA000387; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA000387; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA000387; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA000387; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA000387; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA000387; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA000387; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA000387; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA000387; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA000387; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA000387; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Low, HPA000922; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA000922; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA000922; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA000922; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA000922; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA000922; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA000922; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA000922; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA000922; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA000922; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA000922; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA000922; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA000922; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA000922; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA000922; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA000922; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA000922; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA000922; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA000922; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA000922; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA000922; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA000922; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA000922; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,4.5,9.8,,CTA,oncoref.target-sets.2026-10-23.2,4.5 TPM; blood/basophil; hpa_immune_monaco; vital,9.8 nTPM; rectum/intestinal goblet cells; hpa_single_cell_tissue; protected,Breast Invasive Carcinoma (validation): 47/50 (94.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 6/521 (1.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%),stomach cancer: 11/11 (100.0%); endometrial cancer: 10/10 (100.0%),31,20,A4FU28,https://www.uniprot.org/uniprotkb/A4FU28/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Carter2023_CT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CXorf49,ENSG00000215115,Neither,Low,False,False,3.3,3.3,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Stomach Adenocarcinoma (TCGA): 7/346 (2.0%); Ovary Serous Cystadenocarcinoma (validation): 1/81 (1.2%); Liver Hepatocellular Carcinoma (TCGA): 3/362 (0.8%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,A8MYA2,https://www.uniprot.org/uniprotkb/A8MYA2/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Loriot2025_S1 | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
CXorf49B,ENSG00000215113,Neither,Low,False,False,4.6,4.6,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0068,1.9,,Neither,oncoref.target-sets.2026-10-23.2,0.0068 TPM; blood/myeloid DC; hpa_immune_cell_samples; vital,1.9 nTPM; placenta/mixed immune cells; hpa_single_cell_tissue; vital,Stomach Adenocarcinoma (TCGA): 7/346 (2.0%); Breast Invasive Carcinoma (validation): 1/50 (2.0%); Ovary Serous Cystadenocarcinoma (validation): 1/81 (1.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A8MYA2,https://www.uniprot.org/uniprotkb/A8MYA2/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Loriot2025_S1,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
CXorf51A,ENSG00000224440,Neither,Screening,False,False,50.7,50.7,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0408,0.0501,,Neither,oncoref.target-sets.2026-10-23.2,0.0408 TPM; blood/naive CD4 T-cell; hpa_immune_cell_samples; vital,0.0501 nTPM; blood/naive CD4 T-cell; hpa_immune_cell_samples; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 0/283 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A0A1B0GTR3 | P0DPH9,https://www.uniprot.org/uniprotkb/A0A1B0GTR3/entry | https://www.uniprot.org/uniprotkb/P0DPH9/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
CXorf58,ENSG00000165182,Neither,Antibody,False,False,3.8,3.8,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA031542; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA031542; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA031542; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA031542; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA031542; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA031542; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA031542; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA031542; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA031542; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA031542; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA031542; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA031542; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA031542; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA031542; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA031542; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA031542; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA031542; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA031542; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA031542; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA031542; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA031542; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA031542; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA031542; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA031542; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA031542; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA031542; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA031542; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA031542; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA031542; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA031542; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA031542; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA031542; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA031542; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA031542; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA031542; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA031542; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA031542; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA031542; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA031542; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA031542; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA031542; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA031542; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA031542; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA031542; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA031542; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA031543; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA031543; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA031543; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA031543; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA031543; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA031543; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA031543; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA031543; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA031543; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA031543; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA031543; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA031543; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA031543; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA031543; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA031543; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA031543; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA031543; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA031543; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA031543; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA031543; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA031544; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA031544; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA031544; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA031544; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA031544; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA031544; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: High, HPA031544; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA031544; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA031544; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA031544; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA031544; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA031544; conflicting or uncurated primary profile; Colon/Endothelial cells: High, HPA031544; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA031544; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA031544; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA031544; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA031544; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA031544; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA031544; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA031544; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA031544; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA031544; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA031544; conflicting or uncurated primary profile; Lung/Alveolar cells: High, HPA031544; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA031544; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA031544; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA031544; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA031544; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA031544; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA031544; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA031544; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA031544; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA031544; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA031544; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA031544; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA031544; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA031544; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA031544; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA031544; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA031544; conflicting or uncurated primary profile; Spleen/Cells in red pulp: High, HPA031544; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA031544; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA031544; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA031544; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA031544; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.7,6.5,,Neither,oncoref.target-sets.2026-10-23.2,2.7 TPM; blood/T-reg; hpa_immune_monaco; vital,6.5 nTPM; bronchus/ciliated cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 1/283 (0.4%),colorectal cancer: 12/12 (100.0%); renal cancer: 12/12 (100.0%),31,20,Q96LI9,https://www.uniprot.org/uniprotkb/Q96LI9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DAZ1,ENSG00000188120,Neither,Cellular,False,False,2.0,2.0,88,3,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,True,"stomach/gastric mucus-secreting cells cluster c-6: 22.4 nTPM, 38 reads; reproductive-cell max 0.3",True,False,,True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,22.4,,CTA,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,22.4 nTPM; unsited/Gastric mucus-secreting cells; hpa_single_cell; unresolved,Pancreatic Adenocarcinoma (validation): 10/80 (12.5%); Rectum Adenocarcinoma (validation): 2/207 (1.0%); Prostate Adenocarcinoma (TCGA): 2/480 (0.4%),liver cancer: 1/12 (8.3%); testis cancer: 1/12 (8.3%),31,20,Q86SG3 | Q9NQZ3,https://www.uniprot.org/uniprotkb/Q86SG3/entry | https://www.uniprot.org/uniprotkb/Q9NQZ3/entry,RNA-binding protein that plays an essential role in spermatogenesis. May act by binding to the 3'-UTR of mRNAs and regulating their translation | RNA-binding protein that plays an essential role in spermatogenesis. May act by binding to the 3'-UTR of mRNAs and regulating their translation. Promotes germ-cell progression to meiosis and formation of haploid germ cells,"Testis-specific. Expression restricted to premeiotic germ cells, particularly in spermatogonia (at protein level)","Spermatogenic failure Y-linked 2: A disorder resulting in the absence (azoospermia) or reduction (oligozoospermia) of sperm in the semen, leading to male infertility.",,Cytoplasm Nucleus,19865085,10936047|18385127|19223287,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
DAZ2,ENSG00000205944,Neither,Selectivity,False,False,2.9,5.2,88,3,Positive somewhere,False,False,False,True,Excluded,Normal,False,,Not assessed,,,stomach: 5.2 nTPM; continuous selectivity;reproductive not higher,Fails reproductive selectivity without above-ceiling normal RNA or a normal-protein veto,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Selectivity,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,5.2,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,5.2 nTPM; stomach/bulk; hpa_rna_consensus; protected,Stomach Adenocarcinoma (TCGA): 58/346 (16.8%); Pancreatic Adenocarcinoma (validation): 5/80 (6.2%); Glioblastoma Multiforme (TCGA): 8/141 (5.7%),liver cancer: 1/12 (8.3%); testis cancer: 1/12 (8.3%),31,20,Q13117,https://www.uniprot.org/uniprotkb/Q13117/entry,RNA-binding protein that plays an essential role in spermatogenesis. May act by binding to the 3'-UTR of mRNAs and regulating their translation,Testis specific,"Spermatogenic failure Y-linked 2: A disorder resulting in the absence (azoospermia) or reduction (oligozoospermia) of sperm in the semen, leading to male infertility.",,Cytoplasm Nucleus,,10936047,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
DAZL,ENSG00000092345,Neither,Cellular,False,False,77.3,77.3,82,6,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 16/91 values ≥5 TPM, max 8.91336; hpa_immune_monaco naive B-cell: 7.5 TPM",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,8.91336027204,2.7,,CTA,oncoref.target-sets.2026-10-23.2,8.913 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,2.7 nTPM; unsited/Lymphatic endothelial cells; hpa_single_cell; unresolved,Testicular Germ Cell Tumor (TCGA): 50/133 (37.6%); Lung Adenocarcinoma (validation): 1/105 (1.0%); Stomach Adenocarcinoma (TCGA): 2/346 (0.6%),testis cancer: 3/12 (25.0%); breast cancer: 0/11 (0.0%),31,20,Q92904,https://www.uniprot.org/uniprotkb/Q92904/entry,"RNA-binding protein, which is essential for gametogenesis in both males and females. Plays a central role during spermatogenesis. Acts by binding to the 3'-UTR of mRNA, specifically recognizing GUU triplets, and thereby regulating the translation of key transcripts (By similarity)",Testis specific,,,Cytoplasm Nucleus,,8896558|8968755|8968756,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT | Carter2023_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Normal reproductive-tissue enrichment; no tumor validation,Is the naive-B-cell RNA translated in normal B cells?,Review gene-specific mapping and reliable protein evidence in naive B cells.,Reproductive-positive Enhanced IHC does not establish absence in the particular sorted immune cells measured by RNA.,,,,,
DBX1,ENSG00000109851,Neither,Antibody,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA039802; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA039802; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA039802; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA039802; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA039802; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA039802; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA039802; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA039802; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA039802; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA039802; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA039802; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA039802; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA039802; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: High, HPA039802; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA039802; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA039802; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA039802; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA039802; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA039802; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA039802; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA039802; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA039802; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA039802; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA039802; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA039802; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA039802; conflicting or uncurated primary profile; Skin 1/Langerhans: High, HPA039802; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA039802; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA039802; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA039802; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA039802; conflicting or uncurated primary profile; Spleen/Cells in white pulp: High, HPA039802; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA039802; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA039802; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA039802; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.970195879378,1.2,,Neither,oncoref.target-sets.2026-10-23.2,0.9702 TPM; blood/TFH; dice_tfh; vital,1.2 nTPM; lymph node/t-cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Colon Adenocarcinoma (validation): 1/486 (0.2%),prostate cancer: 10/10 (100.0%); lymphoma: 5/12 (41.7%),31,20,A6NMT0,https://www.uniprot.org/uniprotkb/A6NMT0/entry,"Could have a role in patterning the central nervous system during embryogenesis. Has a key role in regulating the distinct phenotypic features that distinguish two major classes of ventral interneurons, V0 and V1 neurons. Regulates the transcription factor profile, neurotransmitter phenotype, intraspinal migratory path and axonal trajectory of V0 neurons, features that differentiate them from an adjacent set of V1 neurons (By similarity)",,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
DCAF4L2,ENSG00000176566,Neither,Antibody,False,False,20.7,20.7,79,2,Positive somewhere,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA067584; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA067584; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA067584; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA067584; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA067584; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA067584; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA067584; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA067584; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA067584; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA067584; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA067584; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA067584; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA067584; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA067584; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA067584; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA067584; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA067584; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA067584; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA067584; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA067584; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA067584; conflicting or uncurated primary profile; Spleen/Cells in white pulp: High, HPA067584; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA067584; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA067584; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA067584; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA067584; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0915861589801,3.7,,CTA,oncoref.target-sets.2026-10-23.2,0.09159 TPM; blood/TREG_MEM; dice_treg_mem; vital,3.7 nTPM; skin/smooth muscle cells; hpa_single_cell_tissue; manageable,Testicular Germ Cell Tumor (TCGA): 72/133 (54.1%); Liver Hepatocellular Carcinoma (validation): 59/231 (25.5%); Liver Hepatocellular Carcinoma (TCGA): 77/362 (21.3%),prostate cancer: 9/9 (100.0%); pancreatic cancer: 7/9 (77.8%),31,20,Q8NA75,https://www.uniprot.org/uniprotkb/Q8NA75/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT | Carter2023_CT | Loriot2025_S1 | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
DCDC2C,ENSG00000214866,Neither,Antibody,False,False,4.0,4.0,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,choroid plexus: 1.2 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA045848; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA045848; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA045848; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA045848; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA045848; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA045848; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA045848; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA045848; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA045848; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA045848; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA045848; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA045848; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA045848; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA045848; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA045848; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA045848; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA045848; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA045848; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA045848; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA045848; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA045848; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA045848; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA045848; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA045848; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA045848; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA045848; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA045848; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA045848; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA045848; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA045848; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA045848; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA045848; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.9,23.6,,Neither,oncoref.target-sets.2026-10-23.2,0.9 TPM; blood/Progenitor cell; hpa_immune_monaco; vital,23.6 nTPM; unsited/Lymphatic endothelial cells; hpa_single_cell; unresolved,Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%); Kidney Renal Clear Cell Carcinoma (validation): 1/100 (1.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),prostate cancer: 10/10 (100.0%); liver cancer: 7/11 (63.6%),29,20,A8MYV0,https://www.uniprot.org/uniprotkb/A8MYV0/entry,,Expressed in testis and spermatozoa (at protein level),,,"Cell projection, cilium, flagellum Cytoplasm",,28395323,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DEFB104A,ENSG00000176782,Neither,Screening,False,False,1270.3,1270.3,79,1,Positive somewhere,False,False,False,True,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,3.1,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,3.1 nTPM; unsited/Distal tubular cells; hpa_single_cell; unresolved,Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%); Ovary Serous Cystadenocarcinoma (TCGA): 3/349 (0.9%); Head and Neck Squamous Cell Carcinoma (TCGA): 4/492 (0.8%),melanoma: 2/10 (20.0%); breast cancer: 0/10 (0.0%),31,20,Q8WTQ1,https://www.uniprot.org/uniprotkb/Q8WTQ1/entry,Has antimicrobial activity. Synergistic effects with lysozyme and DEFB103,"High expression in the testis. Gastric antrum exhibited relatively high levels. A lower expression is observed in uterus and neutrophils thyroid gland, lung, and kidney. No detectable expression in other tissues tested",,,Secreted,11481241,11481241,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DEFB104B,ENSG00000177023,Neither,Unassessed,False,False,0.0,0.2,82,1,Positive somewhere,False,False,False,True,Excluded,Unassessed,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; unresolved reproductive selectivity; unresolved reproductive selectivity; incomplete tissue evidence,Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,unresolved_reproductive_selectivity,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.6,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.6 nTPM; esophagus/squamous epithelial cells; hpa_single_cell_tissue; protected,Head and Neck Squamous Cell Carcinoma (TCGA): 1/492 (0.2%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),melanoma: 2/10 (20.0%); breast cancer: 0/10 (0.0%),30,20,Q8WTQ1,https://www.uniprot.org/uniprotkb/Q8WTQ1/entry,Has antimicrobial activity. Synergistic effects with lysozyme and DEFB103,"High expression in the testis. Gastric antrum exhibited relatively high levels. A lower expression is observed in uterus and neutrophils thyroid gland, lung, and kidney. No detectable expression in other tissues tested",,,Secreted,11481241,11481241,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DEFB105A,ENSG00000186562,Neither,Screening,False,False,1205.6,1205.6,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,5.0668,6.2413,,Neither,oncoref.target-sets.2026-10-23.2,5.067 TPM; blood/NK-cell; hpa_immune_cell_samples; vital,6.241 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Ovary Serous Cystadenocarcinoma (validation): 1/81 (1.2%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,Q8NG35,https://www.uniprot.org/uniprotkb/Q8NG35/entry,Has antibacterial activity,Specifically expressed in testis,,,Secreted,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DEFB105B,ENSG00000186599,Neither,Screening,False,False,489.2,489.2,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Ovary Serous Cystadenocarcinoma (TCGA): 1/349 (0.3%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q8NG35,https://www.uniprot.org/uniprotkb/Q8NG35/entry,Has antibacterial activity,Specifically expressed in testis,,,Secreted,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DEFB106A,ENSG00000186579,Neither,Screening,False,False,2968.1,2968.1,82,1,Positive somewhere,False,False,False,True,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.1,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.1 nTPM; esophagus/bulk; hpa_rna_consensus; protected,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),cervical cancer: 1/12 (8.3%); breast cancer: 0/9 (0.0%),30,20,Q8N104,https://www.uniprot.org/uniprotkb/Q8N104/entry,Has antibacterial activity (PubMed:12600824). Acts as a ligand for C-C chemokine receptor CCR2 (PubMed:23938203),Expressed specifically in epididymis and lung,,,Secreted Membrane,12600824|23938203,12600824,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DEFB106B,ENSG00000187082,Neither,Screening,False,False,38.9,38.9,76,1,Positive somewhere,False,False,False,True,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.054,0.0562,,Neither,oncoref.target-sets.2026-10-23.2,0.054 TPM; blood/classical monocyte; hpa_immune_cell_samples; vital,0.0562 nTPM; blood/classical monocyte; hpa_immune_cell_samples; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 0/283 (0.0%),cervical cancer: 1/12 (8.3%); breast cancer: 0/9 (0.0%),29,20,Q8N104,https://www.uniprot.org/uniprotkb/Q8N104/entry,Has antibacterial activity (PubMed:12600824). Acts as a ligand for C-C chemokine receptor CCR2 (PubMed:23938203),Expressed specifically in epididymis and lung,,,Secreted Membrane,12600824|23938203,12600824,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DEFB107A,ENSG00000186572,Neither,Screening,False,False,136.3,136.3,79,1,Positive somewhere,False,False,False,True,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.2,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.2 nTPM; tongue/suprabasal keratinocytes; hpa_single_cell_tissue; protected,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),prostate cancer: 2/11 (18.2%); colorectal cancer: 1/12 (8.3%),30,20,Q8IZN7,https://www.uniprot.org/uniprotkb/Q8IZN7/entry,Has antibacterial activity,Specifically expressed in testis,,It is uncertain whether Met-1 or Met-5 is the initiator,Secreted,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DEFB107B,ENSG00000198129,Neither,Screening,False,False,518.4,518.4,79,1,Positive somewhere,False,False,False,True,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.2,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.2 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Lung Squamous Cell Carcinoma (TCGA): 1/489 (0.2%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),prostate cancer: 2/11 (18.2%); colorectal cancer: 1/12 (8.3%),29,20,Q8IZN7,https://www.uniprot.org/uniprotkb/Q8IZN7/entry,Has antibacterial activity,Specifically expressed in testis,,It is uncertain whether Met-1 or Met-5 is the initiator,Secreted,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DEFB110,ENSG00000203970,Neither,Screening,False,False,848.5,848.5,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,1.2,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1.2 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (TCGA): 1/141 (0.7%); Stomach Adenocarcinoma (TCGA): 2/346 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q30KQ9,https://www.uniprot.org/uniprotkb/Q30KQ9/entry,Has antibacterial activity,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DEFB112,ENSG00000180872,Neither,Unassessed,False,False,24.0,24.0,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"existing nomination or manual review; incomplete routine rna; nomination unresolved; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,1.4,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1.4 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DEFB114,ENSG00000177684,Neither,Screening,False,False,51.4,51.4,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,Q30KQ6,https://www.uniprot.org/uniprotkb/Q30KQ6/entry,"Has a salt-sensitive antimicrobial activity against Gram-negative bacteria, including E.coli, Gram-positive, including S.aureus, and fungi, including C.albicans. Binds to and neutralizes bacterial lipopolysaccharides (LPS), abolishing TNF production by macrophages challenged with LPS. Rescues the LPS-induced reduction of sperm motility in vitro and may protect from LPS-induced lethality","Expressed in epididymis, predominantly in the caput (at protein level)",,,Secreted,23482568,23482568,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DEFB118,ENSG00000131068,Neither,Screening,False,False,967.5,967.5,80,1,Positive somewhere,False,False,False,True,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.23306279099,1.0,,Neither,oncoref.target-sets.2026-10-23.2,0.2331 TPM; blood/TH2; dice_th2; vital,1 nTPM; heart muscle/cardiomyocytes; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 1/283 (0.4%); Head and Neck Squamous Cell Carcinoma (TCGA): 1/492 (0.2%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q96PH6,https://www.uniprot.org/uniprotkb/Q96PH6/entry,"Host defense peptide that exhibits antimicrobial activity against both Gram-negative bacteria, such as E.coli and S.typhimurium, and Gram-positive bacteria, such as S.aureus and B.subtilis (PubMed:15033915, PubMed:33224970). Inhibits cell adhesion of E.coli on intestinal epithelial enterocytes (PubMed:33224970). Causes rapid permeabilization of both the outer and inner membrane of E.coli, leading to morphological alterations on the bacterial surface (PubMed:15033915). Binds to bacterial lipopolysaccharides (LPS) with high affinity, and may thereby be involved in immunoregulation through LPS neutralization (PubMed:33181266). May contribute to epididymal innate immunity and protect the sperm against attack by microorganisms (PubMed:15033915)",High-level and epididymis-specific expression (PubMed:12600824). Most abundant in the epithelium of the caput and present in the epididymis lumen and bound to sperm (PubMed:12600824). Also expressed in pancreas (PubMed:12600824),,,Secreted,15033915|33181266|33224970,12600824,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DEFB121,ENSG00000204548,Neither,Screening,False,False,2536.7,2536.7,78,1,Positive somewhere,False,False,False,True,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.1,0.3,,Neither,oncoref.target-sets.2026-10-23.2,0.1 TPM; blood/total PBMC; hpa_immune_monaco; vital,0.3 nTPM; unsited/Astrocytes; hpa_single_cell; unresolved,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q5J5C9,https://www.uniprot.org/uniprotkb/Q5J5C9/entry,Has antibacterial activity,Abundant expression in the male reproductive tract only,,,Secreted,,15772680,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
DEFB125,ENSG00000178591,Neither,Low,False,False,1.5,1.5,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.14210974397,0.0,,Neither,oncoref.target-sets.2026-10-23.2,1.142 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Kidney Renal Papillary Cell Carcinoma (TCGA): 2/282 (0.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Clear Cell Carcinoma (TCGA): 1/521 (0.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8N687,https://www.uniprot.org/uniprotkb/Q8N687/entry,Has antibacterial activity,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DEFB127,ENSG00000088782,Neither,Screening,False,False,1050.8,1050.8,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,4.8,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,4.8 nTPM; skin/granulocytes; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9H1M4,https://www.uniprot.org/uniprotkb/Q9H1M4/entry,Has antibacterial activity,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DEFB128,ENSG00000185982,Neither,Screening,False,False,1163.1,1163.1,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.28028094119,0.0,,Neither,oncoref.target-sets.2026-10-23.2,1.28 TPM; blood/CD8_NAIVE; dice_cd8_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Glioblastoma Multiforme (validation): 1/58 (1.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,Q7Z7B8,https://www.uniprot.org/uniprotkb/Q7Z7B8/entry,Has antibacterial activity,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DEFB129,ENSG00000125903,Neither,Screening,False,False,1895.4,1895.4,80,1,Positive somewhere,False,False,False,True,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.5840826546,0.0,,Neither,oncoref.target-sets.2026-10-23.2,1.584 TPM; blood/CD4_STIM; dice_cd4_stim; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Ovary Serous Cystadenocarcinoma (TCGA): 1/349 (0.3%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),pancreatic cancer: 2/12 (16.7%); breast cancer: 0/11 (0.0%),31,20,Q9H1M3,https://www.uniprot.org/uniprotkb/Q9H1M3/entry,Has antibacterial activity,Expressed specifically in testis,,,Secreted,,12600824,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DEFB130A,ENSG00000232948,Neither,Low,False,False,2.5,2.5,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.3,0.1505,,Neither,oncoref.target-sets.2026-10-23.2,1.3 TPM; blood/Memory CD4 T-cell Th1/Th17; hpa_immune_monaco; vital,0.1505 nTPM; blood/naive CD4 T-cell; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P0DP73 | P0DP74,https://www.uniprot.org/uniprotkb/P0DP73/entry | https://www.uniprot.org/uniprotkb/P0DP74/entry,Antimicrobial host-defense peptide. Has an antiplasmodial activity,Expressed on differentiated macrophage phagocytizing plasmodium falciparum-parasitized erythrocytes,,,Secreted,28181499,28181499,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DEFB130B,ENSG00000233050,Neither,Low,False,False,2.5,2.5,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.3,0.1505,,Neither,oncoref.target-sets.2026-10-23.2,1.3 TPM; blood/Memory CD4 T-cell Th1/Th17; hpa_immune_monaco; vital,0.1505 nTPM; blood/naive CD4 T-cell; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P0DP73 | P0DP74,https://www.uniprot.org/uniprotkb/P0DP73/entry | https://www.uniprot.org/uniprotkb/P0DP74/entry,Antimicrobial host-defense peptide. Has an antiplasmodial activity,Expressed on differentiated macrophage phagocytizing plasmodium falciparum-parasitized erythrocytes,,,Secreted,28181499,28181499,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DEFB135,ENSG00000205883,Neither,Screening,False,False,55.3,55.3,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.21907060773,0.4,,Neither,oncoref.target-sets.2026-10-23.2,1.219 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,0.4 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Stomach Adenocarcinoma (TCGA): 1/346 (0.3%); Ovary Serous Cystadenocarcinoma (TCGA): 1/349 (0.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q30KP9,https://www.uniprot.org/uniprotkb/Q30KP9/entry,Has antibacterial activity,,,Was termed (Ref.2) DEFB136,Secreted,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DMBX1,ENSG00000197587,Neither,Low,False,False,0.9,0.9,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,midbrain: 0.4 nTPM; continuous selectivity; pituitary gland: 0.6 nTPM; continuous selectivity; retina: 0.7 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.30587251209,4.6,,Neither,oncoref.target-sets.2026-10-23.2,1.306 TPM; blood/TREG_MEM; dice_treg_mem; vital,4.6 nTPM; eye/bipolar cells; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 34/176 (19.3%); Bladder Urothelial Carcinoma (TCGA): 30/169 (17.8%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 38/283 (13.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NFW5,https://www.uniprot.org/uniprotkb/Q8NFW5/entry,Functions as a transcriptional repressor. May repress OTX2-mediated transactivation by forming a heterodimer with OTX2 on the P3C (5'-TAATCCGATTA-3') sequence. Required for brain development (By similarity),,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DMRTC2,ENSG00000142025,Neither,Antibody,False,False,39.7,39.7,79,2,Positive somewhere,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bronchus/Respiratory epithelial cells: Low, HPA045016; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA045016; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA045016; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA045016; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA045016; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA045016; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA045016; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA045016; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA045016; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA045016; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA045016; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA045016; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA045016; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA045016; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA045016; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA045016; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA045016; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA045016; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA045016; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.893720017691,2.8,,CTA,oncoref.target-sets.2026-10-23.2,0.8937 TPM; blood/M2; dice_m2; vital,2.8 nTPM; fallopian tube/neutrophils; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 2/50 (4.0%); Lung Adenocarcinoma (TCGA): 8/497 (1.6%); Kidney Chromophobe (TCGA): 1/64 (1.6%),prostate cancer: 9/10 (90.0%); colorectal cancer: 4/11 (36.4%),31,20,Q8IXT2,https://www.uniprot.org/uniprotkb/Q8IXT2/entry,May be involved in sexual development,Expressed in testis and pancreas,,,Nucleus,11863363,11863363,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Carter2023_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
DNAH8,ENSG00000124721,Neither,Antibody,False,False,7.6,7.6,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE TREG_NAIVE (unstimulated): 23/89 values ≥5 TPM, max 9.70027; hpa_immune_monaco Switched memory B-cell: 5.7 TPM",True,True,False,,True,True,"Adipose tissue/Adipocytes: High, HPA028447; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA028447; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA028447; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA028447; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA028447; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA028447; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: High, HPA028447; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: High, HPA028447; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA028447; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA028447; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA028447; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA028447; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: High, HPA028447; conflicting or uncurated primary profile; Colon/Endothelial cells: High, HPA028447; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA028447; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: High, HPA028447; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA028447; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA028447; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA028447; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA028447; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA028447; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA028447; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA028447; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA028447; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA028447; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA028447; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA028447; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA028447; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA028447; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA028447; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA028447; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA028447; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA028447; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA028447; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA028447; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA028447; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA028447; conflicting or uncurated primary profile; Skin 1/Fibroblasts: High, HPA028447; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA028447; conflicting or uncurated primary profile; Skin 1/Langerhans: High, HPA028447; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA028447; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA028447; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA028447; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA028447; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA028447; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA028447; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA028447; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA028447; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA028447; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,9.70026524545,14.3,,CTA,oncoref.target-sets.2026-10-23.2,9.7 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,14.3 nTPM; thymus/t-cells; hpa_single_cell_tissue; vital,Prostate Adenocarcinoma (TCGA): 119/480 (24.8%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Rectum Adenocarcinoma (validation): 2/207 (1.0%),colorectal cancer: 12/12 (100.0%); endometrial cancer: 12/12 (100.0%),31,20,Q96JB1,https://www.uniprot.org/uniprotkb/Q96JB1/entry,"Force generating protein component of the outer dynein arms (ODAs) in the sperm flagellum (PubMed:32619401). Produces force towards the minus ends of microtubules (PubMed:32619401). Key component of dynein, a family of motor proteins essential for movement along microtubules (By similarity). Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP (PubMed:32619401). Involved in sperm motility; implicated in sperm flagellar assembly (PubMed:32619401)",Expressed in spermatozoa (at protein level). Not detected in airway epithelial cells (at protein level),"Spermatogenic failure 46: An autosomal recessive infertility disorder caused by spermatogenesis defects resulting in asthenoteratozoospermia. SPGF46 is characterized by multiple morphologic abnormalities of sperm flagella with disorganization of axonemal and periaxonemal structures. Flagella are absent, short, coiled, angulated, and/or of irregular caliber.",,"Cytoplasm, cytoskeleton, flagellum axoneme Cytoplasm",32619401,31178125,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DPEP3,ENSG00000141096,Neither,Cellular,False,False,45.7,45.7,85,4,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 67/91 values ≥5 TPM, max 13.6335; DICE MONOCYTES (unstimulated): 3/91 values ≥5 TPM, max 7.31646; DICE M2 (unstimulated): 22/90 values ≥5 TPM, max 8.45554; DICE TREG_MEM (unstimulated): 4/89 values ≥5 TPM, max 6.18271; DICE TREG_NAIVE (unstimulated): 16/89 values ≥5 TPM, max 8.05176; DICE TH1 (unstimulated): 5/81 values ≥5 TPM, max 5.56941; DICE CD8_NAIVE (unstimulated): 6/89 values ≥5 TPM, max 7.32634; hpa_immune_cell neutrophil: 6.7 nTPM; hpa_immune_monaco naive CD4 T-cell: 7.2 TPM; hpa_immune_monaco naive CD8 T-cell: 8.9 TPM; hpa_immune_monaco neutrophil: 22.1 TPM; hpa_immune_monaco Progenitor cell: 20.9 TPM",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,22.1,12.3545,,CTA,oncoref.target-sets.2026-10-23.2,22.1 TPM; blood/neutrophil; hpa_immune_monaco; vital,12.35 nTPM; blood/neutrophil; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 63/133 (47.4%); Ovary Serous Cystadenocarcinoma (TCGA): 94/349 (26.9%); Ovary Serous Cystadenocarcinoma (validation): 16/81 (19.8%),testis cancer: 1/12 (8.3%); breast cancer: 0/12 (0.0%),31,20,Q9H4B8,https://www.uniprot.org/uniprotkb/Q9H4B8/entry,"Lacks dipeptidase activity and is unable to hydrolyze cystinyl-bis-glycine, leukotriene D4 and the beta-lactam antibiotic imipenem (PubMed:32325220). The absence of activity may be due to the inability of asparagine (instead of aspartate found in DPEP1/2) at position 359 to function as the acid/base catalyst and activate the nucleophilic water/hydroxide (PubMed:32325220). A tyrosine (instead of histidine) at position 269 reduces affinity for the beta zinc and may cause substrate steric hindrance (PubMed:32325220)",,,,Membrane,32325220,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
DPPA2,ENSG00000163530,Neither,Antibody,False,False,3.2,3.2,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA036134; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA036134; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA036134; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA036134; conflicting or uncurated primary profile; Caudate/Glial cells: High, HPA036134; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA036134; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: High, HPA036134; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: High, HPA036134; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA036134; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA036134; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: High, HPA036134; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA036134; conflicting or uncurated primary profile; Colon/Endothelial cells: High, HPA036134; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA036134; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: High, HPA036134; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA036134; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA036134; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA036134; conflicting or uncurated primary profile; Hippocampus/Glial cells: High, HPA036134; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA036134; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: High, HPA036134; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA036134; conflicting or uncurated primary profile; Liver/Cholangiocytes: High, HPA036134; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA036134; conflicting or uncurated primary profile; Lung/Alveolar cells: High, HPA036134; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA036134; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA036134; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA036134; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA036134; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA036134; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA036134; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA036134; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA036134; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA036134; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA036134; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA036134; conflicting or uncurated primary profile; Skin 1/Fibroblasts: High, HPA036134; conflicting or uncurated primary profile; Skin 1/Keratinocytes: High, HPA036134; conflicting or uncurated primary profile; Skin 1/Langerhans: High, HPA036134; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA036134; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA036134; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA036134; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA036134; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA036134; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA036134; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA036134; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA036134; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA036134; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.2585696622,0.9,,Neither,oncoref.target-sets.2026-10-23.2,1.259 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.9 nTPM; kidney/proximal tubular cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 105/133 (78.9%); Uterine Corpus Endometrial Carcinoma (TCGA): 12/176 (6.8%); Lung Squamous Cell Carcinoma (validation): 4/68 (5.9%),breast cancer: 12/12 (100.0%); liver cancer: 12/12 (100.0%),31,20,Q7Z7J5,https://www.uniprot.org/uniprotkb/Q7Z7J5/entry,"Binds to target gene promoters, including NKX2-5 and SYCE1, but not GATA4, and may be involved in the maintenance of the active epigenetic status of these genes","Expressed in embryonic stem cells. No expression is seen in 5 months embryo, mesenchymal stem cells, embryonic fibrocytes and adult tissues",,,Nucleus,,15583978,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Carter2023_CT | Loriot2025_S1 | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
DPPA3,ENSG00000187569,Neither,Low,False,False,3.1,3.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,4.0,2.7,,Neither,oncoref.target-sets.2026-10-23.2,4 TPM; blood/plasmacytoid DC; hpa_immune_monaco; vital,2.7 nTPM; unsited/Lymphatic endothelial cells; hpa_single_cell; unresolved,Testicular Germ Cell Tumor (TCGA): 122/133 (91.7%); Stomach Adenocarcinoma (TCGA): 8/346 (2.3%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6W0C5,https://www.uniprot.org/uniprotkb/Q6W0C5/entry,"Primordial germ cell (PGCs)-specific protein involved in epigenetic chromatin reprogramming in the zygote following fertilization (PubMed:35314832). In zygotes, DNA demethylation occurs selectively in the paternal pronucleus before the first cell division, while the adjacent maternal pronucleus and certain paternally-imprinted loci are protected from this process (By similarity). Participates in protection of DNA methylation in the maternal pronucleus by preventing conversion of 5mC to 5hmC: specifically recognizes and binds histone H3 dimethylated at 'Lys-9' (H3K9me2) on maternal genome, and protects maternal genome from TET3-mediated conversion to 5hmC and subsequent DNA demethylation (By similarity). Does not bind paternal chromatin, which is mainly packed into protamine and does not contain much H3K9me2 mark (By similarity). Also protects imprinted loci that are marked with H3K9me2 in mature sperm from DNA demethylation in early embryogenesis (By similarity). May be important for the totipotent/pluripotent states continuing through preimplantation development (By similarity). Also involved in chromatin condensation in oocytogenesis (By similarity)","Low expression in testis, ovary and thymus. Expressed in embryonic stem and carcinoma cells. Highly expressed in testicular germ cell tumors",,,Nucleus Cytoplasm,35314832,14654002|14684992|14990856,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
DPPA5,ENSG00000203909,Neither,Antibody,False,False,2.0,2.0,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA064505; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA064505; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA064505; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA064505; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA064505; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA064505; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA064505; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA064505; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA064505; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA064505; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA064505; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA064505; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA064505; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA064505; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA064505; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA064505; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA064505; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA064505; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA064505; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA064505; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA064505; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA064505; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA064505; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA064505; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA064505; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA064505; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.0678759259799997,5.2,,Neither,oncoref.target-sets.2026-10-23.2,2.068 TPM; blood/TFH; dice_tfh; vital,5.2 nTPM; ovary/mixed immune cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 112/133 (84.2%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Ovary Serous Cystadenocarcinoma (TCGA): 4/349 (1.1%),skin cancer: 5/8 (62.5%); glioma: 7/12 (58.3%),31,20,A6NC42,https://www.uniprot.org/uniprotkb/A6NC42/entry,Involved in the maintenance of embryonic stem (ES) cell pluripotency. Dispensable for self-renewal of pluripotent ES cells and establishment of germ cells. Associates with specific target mRNAs (By similarity),,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DUX4,ENSG00000260596,Neither,Low,False,False,0.9,0.9,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.5034665200289999,0.3,,Neither,oncoref.target-sets.2026-10-23.2,0.5035 TPM; blood/CD4_STIM; dice_cd4_stim; vital,0.3 nTPM; duodenum/bulk; hpa_rna_consensus; vital,Breast Invasive Carcinoma (TCGA): 25/1022 (2.4%); Stomach Adenocarcinoma (TCGA): 7/346 (2.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 3/176 (1.7%),No exact-ID IHC coverage in the HPA cancer snapshot,28,0,Q9UBX2,https://www.uniprot.org/uniprotkb/Q9UBX2/entry,"Transcription factor that is selectively and transiently expressed in cleavage-stage embryos (PubMed:28459457). Binds to double-stranded DNA elements with the consensus sequence 5'-TAATCTAATCA-3' (PubMed:28459454, PubMed:28459457, PubMed:29572508, PubMed:30315230, PubMed:30540931). Binds to chromatin containing histone H3 acetylated at 'Lys-27' (H3K27ac) and promotes deacetylation of H3K27ac. In parallel, binds to chromatin that lacks histone H3 acetylation at 'Lys-27' (H3K27ac) and recruits EP300 and CREBBP to promote acetylation of histone H3 at 'Lys-27' at new sites (PubMed:26951377). Involved in transcriptional regulation of numerous genes, primarily as transcriptional activator, but also mediates repression of a set of target genes (PubMed:17984056, PubMed:26951377, PubMed:27378237, PubMed:28459454, PubMed:28459457, PubMed:29572508, PubMed:29618456, PubMed:30540931). Promotes expression of ZSCAN4 and KDM4E, two proteins with essential roles during early embryogenesis (PubMed:26951377, PubMed:27378237, PubMed:28459457, PubMed:29618456). Promotes nuclear translocation of CTNNB1/beta-catenin and its subsequent activation of target genes (PubMed:36158201). Heterologous expression in cultured embryonic stem cells mediates transcription of HERVL retrotransposons and transcripts derived from ACRO1 and HSATII satellite repeats (PubMed:28459457). May activate expression of PITX1 (PubMed:17984056). May regulate microRNA (miRNA) expression (PubMed:24145033). Inappropriate expression can inhibit myogenesis and promote apoptosis (PubMed:26951377, PubMed:28935672, PubMed:29618456) Probably inactive as a transcriptional activator, due to the absence of the C-terminal region that is important for transcriptional activation. Can inhibit transcriptional activation mediated by isoform 1. Heterologous expression of isoform 2 has no deleterious effect on cell survival","Isoform 1: Does not seem to be expressed in normal muscle, but is detected in muscle of individuals with FSHD, and also in testis (at protein level) (PubMed:17984056, PubMed:21060811). Isoform 1: Does not seem to be expressed in normal muscle, but in muscle of individuals with FSHD, where it may be toxic to cells (PubMed:17984056, PubMed:21060811). Isoform 2: Detected in skeletal muscle, fibroblasts and testis from healthy individuals (PubMed:21060811)","Facioscapulohumeral muscular dystrophy 1: A degenerative muscle disease characterized by slowly progressive weakness of the muscles of the face, upper-arm, and shoulder girdle. The onset of symptoms usually occurs in the first or second decade of life. Affected individuals usually present with impairment of upper extremity elevation. This tends to be followed by facial weakness, primarily involving the orbicularis oris and orbicularis oculi muscles.",,Nucleus Cytoplasm,17984056|24145033|26951377|27378237|28459454|28459457|28935672|29572508|29618456|30315230|30540931|36158201,17984056|21060811,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
DYDC1,ENSG00000170788,Neither,Antibody,False,False,123.0,123.0,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA037790; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA037790; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA037790; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA037790; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA037790; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA037790; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA037790; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA037790; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA037790; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA037790; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA037790; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA037790; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA037790; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA037790; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA037790; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA037790; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA037790; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA037790; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA037790; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA037790; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA037790; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA037790; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA037790; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA037790; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA037790; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA037790; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA037790; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA037790; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA037790; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA037790; conflicting or uncurated primary profile; Skin 1/Keratinocytes: High, HPA037790; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA037790; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA037790; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA037790; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA037790; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA037790; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA037790; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA037790; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA037790; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA037790; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA037790; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA037791; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA037791; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA037791; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA037791; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA037791; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA037791; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA037791; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA037791; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA037791; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA037791; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA037791; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA037791; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA037791; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA037791; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA037791; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA037791; conflicting or uncurated primary profile; Lung/Alveolar cells: High, HPA037791; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA037791; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA037791; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA037791; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA037791; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA037791; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA037791; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA037791; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA037791; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA037791; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA037791; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA037791; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA037791; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA037791; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA037791; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA037791; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA037791; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA037791; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,4.62421192432,22.9,,CTA,oncoref.target-sets.2026-10-23.2,4.624 TPM; blood/NK; dice_nk; vital,22.9 nTPM; lung/ciliated cells; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 21/176 (11.9%); Testicular Germ Cell Tumor (TCGA): 7/133 (5.3%); Kidney Chromophobe (TCGA): 3/64 (4.7%),melanoma: 11/12 (91.7%); ovarian cancer: 11/12 (91.7%),31,20,Q8WWB3,https://www.uniprot.org/uniprotkb/Q8WWB3/entry,Functions as part of axonemal radial spoke complexes that play an important part in the motility of sperm and cilia (By similarity). Plays a crucial role during acrosome biogenesis (PubMed:19545932),Brain and testis. Accumulates during late stage of spermiogenesis,,Sequence AAQ84766 was incorrectly indicated as originating from mouse,"Cytoplasm, cytoskeleton, flagellum axoneme",19545932,19545932,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
EBLN1,ENSG00000223601,Neither,Low,False,False,2.7,2.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.2319647129400004,0.6,,Neither,oncoref.target-sets.2026-10-23.2,2.232 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,0.6 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Breast Invasive Carcinoma (TCGA): 3/1022 (0.3%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,P0CF75,https://www.uniprot.org/uniprotkb/P0CF75/entry,May act as an RNA-binding protein. Highly homologous to the bornavirus nucleocapsid N protein that binds viral RNA and oligomerizes (By similarity),"Expression detected by RT-PCR in a few cell lines, including OL, HEK293T and MOLT-4. Not observed in HeLa cells (PubMed:20054395)",,,,,20054395,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
EFCAB3,ENSG00000172421,Neither,Antibody,False,False,5.8,5.8,79,1,Positive somewhere,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA046862; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA046862; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA046862; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA046862; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA046862; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA046862; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA046862; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA046862; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA046862; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA046862; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA046862; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA046862; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA046862; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA046862; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA046862; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA046862; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA046862; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA046862; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA046862; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA046862; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA046862; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA046862; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA046862; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA046862; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,3.3808133114200003,3.8,,CTA,oncoref.target-sets.2026-10-23.2,3.381 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,3.8 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 10/176 (5.7%); Bladder Urothelial Carcinoma (TCGA): 7/169 (4.1%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 8/283 (2.8%),ovarian cancer: 4/10 (40.0%); glioma: 2/11 (18.2%),31,20,Q8N7B9,https://www.uniprot.org/uniprotkb/Q8N7B9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
EFCAB8,ENSG00000215529,Neither,Antibody,False,False,3.3,3.3,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE TH2 (unstimulated): 6/89 values ≥5 TPM, max 7.03409",True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, CAB034246; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, CAB034246; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, CAB034246; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, CAB034246; conflicting or uncurated primary profile; Caudate/Glial cells: Low, CAB034246; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, CAB034246; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, CAB034246; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, CAB034246; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, CAB034246; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, CAB034246; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, CAB034246; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, CAB034246; conflicting or uncurated primary profile; Colon/Glandular cells: Low, CAB034246; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, CAB034246; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, CAB034246; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, CAB034246; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, CAB034246; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, CAB034246; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, CAB034246; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, CAB034246; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, CAB034246; conflicting or uncurated primary profile; Lung/Macrophages: Medium, CAB034246; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, CAB034246; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, CAB034246; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, CAB034246; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, CAB034246; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, CAB034246; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, CAB034246; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, CAB034246; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, CAB034246; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, CAB034246; conflicting or uncurated primary profile; Skin 1/Keratinocytes: High, CAB034246; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, CAB034246; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, CAB034246; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, CAB034246; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, CAB034246; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, CAB034246; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, CAB034246; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, CAB034246; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA042751; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA042751; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA042751; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA042751; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA042751; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA042751; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA042751; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA042751; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: High, HPA042751; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA042751; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA042751; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA042751; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA042751; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA042751; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA042751; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA042751; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA042751; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA042751; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA042751; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA042751; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA042751; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA042751; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA042751; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA042751; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA042751; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA042751; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA042751; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA042751; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,7.034091055539999,7.3,,Neither,oncoref.target-sets.2026-10-23.2,7.034 TPM; blood/TH2; dice_th2; vital,7.3 nTPM; spleen/t-cells; hpa_single_cell_tissue; vital,Ovary Serous Cystadenocarcinoma (validation): 2/81 (2.5%); Stomach Adenocarcinoma (TCGA): 2/346 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),colorectal cancer: 12/12 (100.0%); pancreatic cancer: 12/12 (100.0%),29,20,A8MWE9,https://www.uniprot.org/uniprotkb/A8MWE9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Loriot2025_S2,Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
ENTHD1,ENSG00000176177,Neither,Antibody,False,False,10.7,10.7,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE CD4_STIM (activated): 11/88 values ≥5 TPM, max 9.93135",True,True,False,,True,True,"Adipose tissue/Adipocytes: High, HPA019800; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA019800; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA019800; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA019800; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA019800; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA019800; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA019800; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA019800; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA019800; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA019800; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA019800; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA019800; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA019800; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA019800; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA019800; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA019800; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA019800; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA019800; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA019800; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA019800; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA019800; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA019800; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA019800; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA019800; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA019800; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA019800; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA019800; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA019800; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA019800; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA019800; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA019800; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA019800; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA019800; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA019800; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA019800; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA019800; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA019800; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA019800; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA019800; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA019800; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA019800; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA019800; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA019800; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA019800; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA019800; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,9.93134666446,19.0,,CTA,oncoref.target-sets.2026-10-23.2,9.931 TPM; blood/CD4_STIM; dice_cd4_stim; vital,19 nTPM; pbmc/platelets; hpa_single_cell_tissue; vital,Skin Cuteneous Melanoma (TCGA): 40/99 (40.4%); Glioblastoma Multiforme (validation): 1/58 (1.7%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%),renal cancer: 9/10 (90.0%); prostate cancer: 10/12 (83.3%),31,20,Q8IYW4,https://www.uniprot.org/uniprotkb/Q8IYW4/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
EPPIN-WFDC6,ENSG00000249139,Neither,Screening,False,False,62.3,62.3,87,1,Positive somewhere,False,False,False,True,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.20786797818,0.4,,Neither,oncoref.target-sets.2026-10-23.2,0.2079 TPM; blood/M2; dice_m2; vital,0.4 nTPM; lung/ciliated cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 5/133 (3.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 4/176 (2.3%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),29,20,O95925,https://www.uniprot.org/uniprotkb/O95925/entry,"Serine protease inhibitor that plays an essential role in male reproduction and fertility. Modulates the hydrolysis of SEMG1 by KLK3/PSA (a serine protease), provides antimicrobial protection for spermatozoa in the ejaculate coagulum, and binds SEMG1 thereby inhibiting sperm motility","In testis, expressed and secreted by Sertoli cells, appearing on the surface of testicular and ejaculate spermatozoa. Expressed in the spermatogonia and the earliest preleptotene spermatocytes. In the epididymis, is expressed and secreted by epithelial cells and covers the surface of epididymal spermatozoa and ciliated epithelial cells (at protein level). Expressed specifically in epididymis and testis. Isoform 2 is expressed only in the epididymis. Weak expression is detected in myoid cells as well as spermatogenic cells",,,Secreted Cell surface,15229136|17644992,11404006|21461566,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
ERICH6,ENSG00000163645,Neither,Cellular,False,False,28.9,28.9,84,2,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_cell MAIT T-cell: 5.2 nTPM,True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,7.8223,7.9952,,CTA,oncoref.target-sets.2026-10-23.2,7.822 TPM; blood/MAIT T-cell; hpa_immune_cell_samples; vital,7.995 nTPM; blood/naive B-cell; hpa_immune_cell_samples; vital,Kidney Renal Papillary Cell Carcinoma (TCGA): 16/282 (5.7%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 9/283 (3.2%); Skin Cuteneous Melanoma (TCGA): 2/99 (2.0%),testis cancer: 2/12 (16.7%); lung cancer: 1/12 (8.3%),29,20,Q7L0X2,https://www.uniprot.org/uniprotkb/Q7L0X2/entry,,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ERICH6B,ENSG00000165837,Neither,Antibody,False,False,1.9,1.9,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA043559; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA043559; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA043559; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA043559; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA043559; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA043559; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA043559; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA043559; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA043559; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA043559; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA043559; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA043559; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA043559; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA043559; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA043559; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA043559; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA043559; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA043559; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA043559; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA043559; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA043559; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA043559; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA043559; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA043559; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA043559; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA043559; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA043559; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA043559; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA043559; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA043559; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA043559; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA043559; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA043559; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA043559; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA043559; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA043559; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA043559; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA043559; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA043559; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA043559; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.21845005572,1.9,,Neither,oncoref.target-sets.2026-10-23.2,2.218 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1.9 nTPM; pancreas/mixed immune cells; hpa_single_cell_tissue; vital,Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),testis cancer: 9/11 (81.8%); urothelial cancer: 8/10 (80.0%),29,20,Q5W0A0,https://www.uniprot.org/uniprotkb/Q5W0A0/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
ERVH48-1,ENSG00000233056,Neither,Cellular,False,False,148.0,148.0,0,0,Missing,False,False,False,False,Excluded,Unassessed,True,,Not assessed,,,"incomplete routine rna; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord",Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE CD4_NAIVE (unstimulated): 47/88 values ≥5 TPM, max 9.53495; DICE CD4_STIM (activated): 10/88 values ≥5 TPM, max 8.18025; DICE TREG_NAIVE (unstimulated): 6/89 values ≥5 TPM, max 6.71039; hpa_immune_cell neutrophil: 7.8 nTPM",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,9.53494978075,10.6413,,Neither,oncoref.target-sets.2026-10-23.2,9.535 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,10.64 nTPM; blood/neutrophil; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 109/133 (82.0%); Prostate Adenocarcinoma (TCGA): 114/480 (23.8%); Rectum Adenocarcinoma (validation): 32/207 (15.5%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,M5A8F1,https://www.uniprot.org/uniprotkb/M5A8F1/entry,"May play a role in trophoblasts syncytialization, the spontaneous fusion of their plasma membranes, an essential process in placental development. May negatively regulate cell-cell fusion by interacting with SLC1A5, the probable receptor on the cell surface of the fusogenic syncytin-1/ERVW-1",Specifically expressed in placenta by extravillous trophoblasts and syncytiotrophoblasts (at protein level),,,Secreted,23492904,23492904,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_ncRNA | Gong2021_reproductive_ncRNA,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ETDB,ENSG00000224107,Neither,Screening,False,False,11.2,11.2,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,4.82274542201,0.5,,Neither,oncoref.target-sets.2026-10-23.2,4.823 TPM; blood/NK; dice_nk; vital,0.5 nTPM; unsited/Ciliated cells; hpa_single_cell; unresolved,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Prostate Adenocarcinoma (TCGA): 1/480 (0.2%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P0DPP9 | Q3ZM63,https://www.uniprot.org/uniprotkb/P0DPP9/entry | https://www.uniprot.org/uniprotkb/Q3ZM63/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
EVX2,ENSG00000174279,Neither,Antibody,False,False,2.9,2.9,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA041576; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA041576; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA041576; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA041576; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA041576; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA041576; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA041576; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA041576; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: High, HPA041576; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA041576; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA041576; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA041576; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA041576; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA041576; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA041576; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA041576; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA041576; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA041576; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA041576; conflicting or uncurated primary profile; Liver/Cholangiocytes: High, HPA041576; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA041576; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA041576; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA041576; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA041576; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA041576; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA041576; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA041576; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA041576; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA041576; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA041576; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA041576; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA041576; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA041576; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA041576; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA041576; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA041576; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA041576; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA041576; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA041576; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA041576; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0079,11.7,,Neither,oncoref.target-sets.2026-10-23.2,0.0079 TPM; blood/MAIT T-cell; hpa_immune_cell_samples; vital,11.7 nTPM; rectum/enteroendocrine cells; hpa_single_cell_tissue; protected,Glioblastoma Multiforme (validation): 1/58 (1.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Prostate Adenocarcinoma (TCGA): 1/480 (0.2%),testis cancer: 11/11 (100.0%); stomach cancer: 10/10 (100.0%),31,20,Q03828,https://www.uniprot.org/uniprotkb/Q03828/entry,,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
FAM170B,ENSG00000172538,Neither,Antibody,False,False,6.3,6.3,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA043899; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA043899; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA043899; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA043899; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA043899; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA043899; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA043899; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA043899; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA043899; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA043899; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA043899; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA043899; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA043899; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA043899; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA043899; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA043899; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA043899; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA043899; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA043899; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA043899; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA043899; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA043899; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA043899; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA043899; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA043899; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA043899; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA043899; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA043899; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA043899; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA043899; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA043899; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA043899; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA043899; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA043899; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA043899; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA043899; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA043899; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA043899; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA043899; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA043899; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA050610; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA050610; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA050610; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA050610; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA050610; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA050610; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA050610; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA050610; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA050610; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA050610; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA050610; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA050610; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA050610; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA050610; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA050610; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA050610; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA050610; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA050610; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA050610; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA050610; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA050610; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,5.1328,6.0292,,CTA,oncoref.target-sets.2026-10-23.2,5.133 TPM; blood/eosinophil; hpa_immune_cell_samples; vital,6.029 nTPM; blood/eosinophil; hpa_immune_cell_samples; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 1/283 (0.4%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,A6NMN3,https://www.uniprot.org/uniprotkb/A6NMN3/entry,Plays a role in fertilization through the acrosome reaction,Exclusively expressed in adult testis,,,"Cytoplasmic vesicle, secretory vesicle, acrosome Cytoplasmic vesicle, secretory vesicle, acrosome outer membrane",,26179146,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FAM186A,ENSG00000185958,Neither,Antibody,False,False,13.8,13.8,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA047128; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA047128; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA047128; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA047128; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA047128; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA047128; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA047128; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA047128; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA047128; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA047128; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA047128; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA047128; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA047128; conflicting or uncurated primary profile; Colon/Endothelial cells: High, HPA047128; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA047128; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA047128; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA047128; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA047128; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA047128; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA047128; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA047128; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA047128; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA047128; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA047128; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA047128; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA047128; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA047128; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA047128; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA047128; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA047128; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA047128; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA047128; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: High, HPA047128; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA047128; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA047128; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA047128; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA047128; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA047128; conflicting or uncurated primary profile; Skin 1/Keratinocytes: High, HPA047128; conflicting or uncurated primary profile; Skin 1/Langerhans: High, HPA047128; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA047128; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA047128; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA047128; conflicting or uncurated primary profile; Spleen/Cells in red pulp: High, HPA047128; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA047128; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA047128; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA047128; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA047128; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA047128; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.547,3.9,,CTA,oncoref.target-sets.2026-10-23.2,1.547 TPM; blood/NK-cell; hpa_immune_cell_samples; vital,3.9 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 11/176 (6.2%); Kidney Renal Papillary Cell Carcinoma (TCGA): 4/282 (1.4%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%),cervical cancer: 12/12 (100.0%); endometrial cancer: 12/12 (100.0%),31,20,A6NE01,https://www.uniprot.org/uniprotkb/A6NE01/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FAM186B,ENSG00000135436,Neither,Antibody,False,False,44.7,44.7,77,0,Negative where measured,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA039736; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA039736; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA039736; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA039736; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA039736; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA039736; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA039736; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA039736; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA039736; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA039736; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA039736; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA039736; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA039736; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA039736; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA039736; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA039736; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA039736; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA039736; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA039736; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA039736; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA039736; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA039736; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA039736; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA039736; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA039736; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA039736; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA039736; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA039736; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA039736; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA039736; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA039736; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA039736; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA039736; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA040028; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA040028; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA040028; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA040028; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA040028; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA040028; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA040028; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA040028; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA040028; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA040028; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA040028; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA040028; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA040028; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA040028; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA040028; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA040028; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA040028; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA040028; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA040028; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA040028; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA040028; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA040028; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA040028; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA040028; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA040028; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA040028; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA040028; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA040028; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA040028; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA040028; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,4.4,4.2,,CTA,oncoref.target-sets.2026-10-23.2,4.4 TPM; blood/naive CD8 T-cell; hpa_immune_monaco; vital,4.2 nTPM; tongue/basal keratinocytes; hpa_single_cell_tissue; protected,Kidney Chromophobe (TCGA): 7/64 (10.9%); Testicular Germ Cell Tumor (TCGA): 10/133 (7.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 16/282 (5.7%),endometrial cancer: 6/12 (50.0%); liver cancer: 6/12 (50.0%),31,20,Q8IYM0,https://www.uniprot.org/uniprotkb/Q8IYM0/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FAM217A,ENSG00000145975,Neither,Antibody,False,False,14.5,14.5,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 39/91 values ≥5 TPM, max 8.57213; DICE NK (unstimulated): 13/90 values ≥5 TPM, max 7.66611; DICE TREG_MEM (unstimulated): 8/89 values ≥5 TPM, max 7.99456; DICE CD4_NAIVE (unstimulated): 3/88 values ≥5 TPM, max 6.3609; DICE TREG_NAIVE (unstimulated): 20/89 values ≥5 TPM, max 7.98358; DICE TH1 (unstimulated): 3/81 values ≥5 TPM, max 5.75255; DICE TH2 (unstimulated): 6/89 values ≥5 TPM, max 6.21663; DICE CD8_NAIVE (unstimulated): 6/89 values ≥5 TPM, max 6.04189",True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA035455; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA035455; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA035455; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA035455; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA035455; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA035455; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA035455; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA035455; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA035455; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA035455; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA035455; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA035455; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA035455; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA035455; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA035455; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA035455; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA035455; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA035455; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA035455; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA035455; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA035455; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA035455; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA035455; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA035455; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA035455; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA035455; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA035455; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,8.57212702986,3.1,,CTA,oncoref.target-sets.2026-10-23.2,8.572 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,3.1 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),pancreatic cancer: 8/11 (72.7%); cervical cancer: 8/12 (66.7%),29,20,Q8IXS0,https://www.uniprot.org/uniprotkb/Q8IXS0/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S1 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FAM236A,ENSG00000275520,Neither,Screening,False,False,150.9,150.9,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.0,1.9,,Neither,oncoref.target-sets.2026-10-23.2,1 TPM; blood/Memory CD4 T-cell Th17; hpa_immune_monaco; vital,1.9 nTPM; lymph node/bulk; hpa_rna_consensus; protected,Testicular Germ Cell Tumor (TCGA): 11/133 (8.3%); Ovary Serous Cystadenocarcinoma (TCGA): 1/349 (0.3%); Lung Squamous Cell Carcinoma (TCGA): 1/489 (0.2%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,A0A1B0GUQ0 | A0A1B0GV22,https://www.uniprot.org/uniprotkb/A0A1B0GUQ0/entry | https://www.uniprot.org/uniprotkb/A0A1B0GV22/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FAM236B,ENSG00000268994,Neither,Screening,False,False,95.5,95.5,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,1.2,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1.2 nTPM; retina/bulk; hpa_rna_consensus; vital,Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%); Colon Adenocarcinoma (validation): 5/486 (1.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,A0A1B0GUQ0 | A0A1B0GV22,https://www.uniprot.org/uniprotkb/A0A1B0GUQ0/entry | https://www.uniprot.org/uniprotkb/A0A1B0GV22/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
FAM236C,ENSG00000283594,Neither,Low,False,False,2.4,2.4,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.9311,1.0932,,Neither,oncoref.target-sets.2026-10-23.2,0.9311 TPM; blood/eosinophil; hpa_immune_cell_samples; vital,1.093 nTPM; blood/eosinophil; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Ovary Serous Cystadenocarcinoma (TCGA): 1/349 (0.3%); Head and Neck Squamous Cell Carcinoma (TCGA): 1/492 (0.2%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,A0A1B0GTK5 | P0DP71,https://www.uniprot.org/uniprotkb/A0A1B0GTK5/entry | https://www.uniprot.org/uniprotkb/P0DP71/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FAM47A,ENSG00000185448,Neither,Antibody,False,False,2.8,2.8,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Caudate/Neuronal cells: Low, HPA000610; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA000610; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA000610; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA000610; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA000610; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA000610; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA000610; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA000610; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA000610; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA000610; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),skin cancer: 12/12 (100.0%); endometrial cancer: 11/11 (100.0%),31,20,Q5JRC9,https://www.uniprot.org/uniprotkb/Q5JRC9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FAM47B,ENSG00000189132,Neither,Antibody,False,False,9.0,9.0,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA046829; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA046829; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA046829; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA046829; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA046829; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA046829; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA046829; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA046829; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA046829; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA046829; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA046829; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA046829; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA046829; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA046829; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: High, HPA046829; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA046829; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA046829; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA046829; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA046829; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA046829; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA046829; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA046829; conflicting or uncurated primary profile; Liver/Cholangiocytes: High, HPA046829; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA046829; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA046829; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA046829; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA046829; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA046829; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA046829; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA046829; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA046829; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA046829; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA046829; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA046829; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA046829; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA046829; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA046829; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA046829; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA046829; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA046829; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA046829; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA046829; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA046829; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA046829; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA046829; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA046829; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA046829; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA046829; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA050996; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA050996; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA050996; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.2,,CTA,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.2 nTPM; colon/distal enterocytes; hpa_single_cell_tissue; protected,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),cervical cancer: 12/12 (100.0%); endometrial cancer: 12/12 (100.0%),31,20,Q8NA70,https://www.uniprot.org/uniprotkb/Q8NA70/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FAM47C,ENSG00000198173,Neither,Low,False,False,2.8,2.8,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.155584457256,0.1,,Neither,oncoref.target-sets.2026-10-23.2,0.1556 TPM; blood/TH17; dice_th17; vital,0.1 nTPM; pituitary gland/bulk; hpa_rna_consensus; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5HY64,https://www.uniprot.org/uniprotkb/Q5HY64/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FAM9A,ENSG00000183304,Neither,Antibody,False,False,4.2,4.2,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bronchus/Respiratory epithelial cells: Medium, HPA056076; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA056076; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA056076; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA056076; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA056076; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA056076; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA056076; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA056076; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA056076; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA056076; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA056076; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA056076; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA056076; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA056076; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA056076; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA056076; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA056076; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA056076; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA056076; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA056076; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA056076; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA056076; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.3544,0.8,,Neither,oncoref.target-sets.2026-10-23.2,0.3544 TPM; blood/eosinophil; hpa_immune_cell_samples; vital,0.8 nTPM; retina/bulk; hpa_rna_consensus; vital,Liver Hepatocellular Carcinoma (validation): 5/231 (2.2%); Rectum Adenocarcinoma (validation): 2/207 (1.0%); Stomach Adenocarcinoma (TCGA): 3/346 (0.9%),testis cancer: 2/11 (18.2%); colorectal cancer: 2/12 (16.7%),31,20,Q8IZU1,https://www.uniprot.org/uniprotkb/Q8IZU1/entry,,Expressed exclusively in testis,,,"Nucleus, nucleolus",,12213195,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FANCD2OS,ENSG00000163705,Neither,Cellular,False,False,59.9,59.9,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_cell neutrophil: 5.3 nTPM,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,5.2847,7.4234,,CTA,oncoref.target-sets.2026-10-23.2,5.285 TPM; blood/neutrophil; hpa_immune_cell_samples; vital,7.423 nTPM; blood/neutrophil; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q96PS1,https://www.uniprot.org/uniprotkb/Q96PS1/entry,Reduces testosterone levels by inhibiting steroidogenic enzymes and by promoting apoptosis in Leydig cells,,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FBXO43,ENSG00000156509,Neither,Antibody,False,False,3.5,3.5,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Duodenum/Glandular cells: Low, HPA024292; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA024292; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA024292; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA024292; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA024295; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA024295; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA024295; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA024295; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA024295; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA024295; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA024295; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA024295; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA024295; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA024295; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA024295; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA024295; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA024295; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA024295; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA024295; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA024295; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA024295; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA024295; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA024295; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA024295; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA024295; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA024295; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA024295; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA024295; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA024295; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA024295; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA024295; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA024295; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA024295; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA024295; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA024295; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA024295; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA024295; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA024295; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA024295; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA024295; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA024824; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA024824; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA024824; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA024824; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA024824; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA024824; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA024824; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA024824; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA024824; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA024824; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA024824; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA024824; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA024824; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA024824; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA024824; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA024824; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA024824; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA024824; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA024824; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA024824; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA024824; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA024824; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.5149813526599996,19.6,,Neither,oncoref.target-sets.2026-10-23.2,2.515 TPM; blood/CD4_STIM; dice_cd4_stim; vital,19.6 nTPM; adipose tissue/t-cells; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 12/50 (24.0%); Glioblastoma Multiforme (validation): 4/58 (6.9%); Liver Hepatocellular Carcinoma (validation): 6/231 (2.6%),ovarian cancer: 2/11 (18.2%); liver cancer: 1/12 (8.3%),31,20,Q4G163,https://www.uniprot.org/uniprotkb/Q4G163/entry,"Required to establish and maintain the arrest of oocytes at the second meiotic metaphase until fertilization. Acts by inhibiting the anaphase-promoting complex/cyclosome (APC/C) ubiquitin ligase. Probably recognizes and binds to some phosphorylated proteins and promotes their ubiquitination and degradation (PubMed:34052850, PubMed:34595750). Plays a vital role in modulating the ubiquitilation of CCNB1 and CDK1 during gametogenesis",Expressed in the testis,Oocyte/zygote/embryo maturation arrest 12: An autosomal recessive disorder characterized by infertility due to early embryonic arrest. Spermatogenic failure 64: An autosomal recessive male infertility disorder characterized by oligoasthenoteratozoospermia or non-obstructive azoospermia. Some patients have absent sperm due to meiotic arrest at the diplotene stage. Others show low sperm counts and reduced progressive motility.,,,34052850|34595750,34595750,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
FBXO47,ENSG00000204952,Neither,Antibody,False,False,3.8,3.8,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bronchus/Respiratory epithelial cells: Low, HPA057438; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA057438; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA057438; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA057438; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA057438; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA057438; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA057438; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA057438; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA057438; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.869615311938,1.7,,Neither,oncoref.target-sets.2026-10-23.2,0.8696 TPM; blood/CD4_STIM; dice_cd4_stim; vital,1.7 nTPM; stomach/plasma cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (TCGA): 1/88 (1.1%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Colon Adenocarcinoma (validation): 1/486 (0.2%),pancreatic cancer: 1/11 (9.1%); breast cancer: 1/12 (8.3%),31,20,Q5MNV8,https://www.uniprot.org/uniprotkb/Q5MNV8/entry,Probably recognizes and binds to some phosphorylated proteins and promotes their ubiquitination and degradation,"Widely expressed, with highest levels in kidney, liver and pancreas. Down-regulated in tumors",,,,,15723337,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FGF4,ENSG00000075388,Neither,Antibody,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA011209; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA011209; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA011209; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA011209; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: High, HPA011209; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA011209; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA011209; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA011209; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA011209; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA011209; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.2,1.0,,Neither,oncoref.target-sets.2026-10-23.2,0.2 TPM; blood/Progenitor cell; hpa_immune_monaco; vital,1 nTPM; vascular/schwann cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 48/133 (36.1%); Uterine Corpus Endometrial Carcinoma (TCGA): 5/176 (2.8%); Bladder Urothelial Carcinoma (TCGA): 4/169 (2.4%),liver cancer: 3/10 (30.0%); endometrial cancer: 3/12 (25.0%),31,20,P08620,https://www.uniprot.org/uniprotkb/P08620/entry,"Plays an important role in the regulation of embryonic development, cell proliferation, and cell differentiation. Required for normal limb and cardiac valve development during embryogenesis. May play a role in embryonic molar tooth bud development via inducing the expression of MSX1, MSX2 and MSX1-mediated expression of SDC1 in dental mesenchyme cells (By similarity)",,"Short-rib thoracic dysplasia 22 without polydactyly: A form of short-rib thoracic dysplasia, a group of autosomal recessive ciliopathies that are characterized by a constricted thoracic cage, short ribs, shortened tubular bones, and a 'trident' appearance of the acetabular roof. Polydactyly is variably present. Non-skeletal involvement can include cleft lip/palate as well as anomalies of major organs such as the brain, eye, heart, kidneys, liver, pancreas, intestines, and genitalia. Some forms of the disease are lethal in the neonatal period due to respiratory insufficiency secondary to a severely restricted thoracic cage, whereas others are compatible with life. Disease spectrum encompasses Ellis-van Creveld syndrome, asphyxiating thoracic dystrophy (Jeune syndrome), Mainzer-Saldino syndrome, and short rib-polydactyly syndrome. SRTD22 is a form characterized by short ribs, abnormally narrow chest, and respiratory insufficiency, without other diagnostic clinical or radiological signs.",,Secreted,8663044,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
FNDC7,ENSG00000143107,Neither,Selectivity,False,False,1.1,1.1,84,2,Positive somewhere,False,False,False,True,Excluded,Normal,False,,Not assessed,,,retina: 0.4 nTPM; continuous selectivity,Fails reproductive selectivity without above-ceiling normal RNA or a normal-protein veto,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Selectivity,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.86916512717,3.3,,Neither,oncoref.target-sets.2026-10-23.2,2.869 TPM; blood/CD8_NAIVE; dice_cd8_naive; vital,3.3 nTPM; unsited/Oligodendrocyte precursor cells; hpa_single_cell; unresolved,Glioblastoma Multiforme (validation): 6/58 (10.3%); Glioblastoma Multiforme (TCGA): 2/141 (1.4%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),melanoma: 1/12 (8.3%); ovarian cancer: 1/12 (8.3%),31,20,Q5VTL7,https://www.uniprot.org/uniprotkb/Q5VTL7/entry,,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
FOXE3,ENSG00000186790,Neither,Low,False,False,0.8,0.8,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,basal ganglia: 0.7 nTPM; continuous selectivity; cerebellum: 0.4 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.736973681686,1.6,,Neither,oncoref.target-sets.2026-10-23.2,0.737 TPM; blood/NK; dice_nk; vital,1.6 nTPM; colon/undifferentiated cells; hpa_single_cell_tissue; protected,Testicular Germ Cell Tumor (TCGA): 21/133 (15.8%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 23/283 (8.1%); Uterine Corpus Endometrial Carcinoma (TCGA): 4/176 (2.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q13461,https://www.uniprot.org/uniprotkb/Q13461/entry,"Transcription factor that controls lens epithelial cell growth through regulation of proliferation, apoptosis and cell cycle (PubMed:22527307, PubMed:25504734). During lens development, controls the ratio of the lens fiber cells to the cells of the anterior lens epithelium by regulating the rate of proliferation and differentiation (By similarity). Controls lens vesicle closure and subsequent separation of the lens vesicle from ectoderm (By similarity). Controls the expression of DNAJB1 in a pathway that is crucial for the development of the anterior segment of the eye (PubMed:27218149)",,"Anterior segment dysgenesis 2: A form of anterior segment dysgenesis, a group of defects affecting anterior structures of the eye including cornea, iris, lens, trabecular meshwork, and Schlemm canal. Anterior segment dysgeneses result from abnormal migration or differentiation of the neural crest derived mesenchymal cells that give rise to components of the anterior chamber during eye development. Different anterior segment anomalies may exist alone or in combination, including iris hypoplasia, enlarged or reduced corneal diameter, corneal vascularization and opacity, posterior embryotoxon, corectopia, polycoria, abnormal iridocorneal angle, ectopia lentis, and anterior synechiae between the iris and posterior corneal surface. Clinical conditions falling within the phenotypic spectrum of anterior segment dysgeneses include aniridia, Axenfeld anomaly, Reiger anomaly/syndrome, Peters anomaly, and iridogoniodysgenesis. Some ASGD2 patients show congenital primary aphakia, a defect caused by eye development arrest around the 4th-5th week of gestation. This prevents the formation of any lens structure and leads to severe secondary ocular anomalies, including a complete aplasia of the anterior segment of the eye. In contrast, in secondary aphakic eyes, lens induction has occurred, and the lens vesicle has developed to some degree but finally has progressively resorbed perinatally, leading, therefore, to less severe ocular defects. ASGD2 inheritance is autosomal recessive. Cataract 34, multiple types: An opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. Aortic aneurysm, familial thoracic 11: A form of thoracic aortic aneurysm, a disease characterized by permanent dilation of the thoracic aorta usually due to degenerative changes in the aortic wall. It is primarily associated with a characteristic histologic appearance known as 'medial necrosis' or 'Erdheim cystic medial necrosis' in which there is degeneration and fragmentation of elastic fibers, loss of smooth muscle cells, and an accumulation of basophilic ground substance.",,Nucleus,22527307|25504734|27218149,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
FOXL3,ENSG00000248767,Neither,Low,False,False,2.7,2.7,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,10.4,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,10.4 nTPM; small intestine/paneth cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Pancreatic Adenocarcinoma (TCGA): 1/176 (0.6%); Lung Squamous Cell Carcinoma (TCGA): 1/489 (0.2%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A0A1W2PRP0,https://www.uniprot.org/uniprotkb/A0A1W2PRP0/entry,Probable transcriptional regulator,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FOXN4,ENSG00000139445,Neither,Antibody,False,False,11.1,11.1,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,True,"bronchus/ciliated cells cluster c-12: 11.5 nTPM, 28 reads; reproductive-cell max 6.5",True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA050018; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA050018; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA050018; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA050018; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA050018; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA050018; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA050018; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA050018; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA050018; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA050018; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA050018; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA050018; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA050018; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA050018; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA050018; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA050018; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA050018; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA050018; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA050018; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.5291414846720001,11.5,,CTA,oncoref.target-sets.2026-10-23.2,0.5291 TPM; blood/TFH; dice_tfh; vital,11.5 nTPM; bronchus/ciliated cells; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 31/176 (17.6%); Liver Hepatocellular Carcinoma (validation): 33/231 (14.3%); Breast Invasive Carcinoma (validation): 6/50 (12.0%),pancreatic cancer: 6/10 (60.0%); stomach cancer: 4/10 (40.0%),31,20,Q96NZ1,https://www.uniprot.org/uniprotkb/Q96NZ1/entry,"Transcription factor essential for neural and some non-neural tissues development, such as retina and lung respectively. Binds to an 11-bp consensus sequence containing the invariant tetranucleotide 5'-ACGC-3'. During development of the central nervous system, is required to specify the amacrine and horizontal cell fates from multipotent retinal progenitors while suppressing the alternative photoreceptor cell fates through activating DLL4-NOTCH signaling. Also acts synergistically with ASCL1/MASH1 to activate DLL4-NOTCH signaling and drive commitment of p2 progenitors to the V2b interneuron fates during spinal cord neurogenesis. In development of non-neural tissues, plays an essential role in the specification of the atrioventricular canal and is indirectly required for patterning the distal airway during lung development (By similarity)",,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
FOXR1,ENSG00000176302,Neither,Low,False,False,4.1,4.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.65246040883,4.5,,Neither,oncoref.target-sets.2026-10-23.2,1.652 TPM; blood/TFH; dice_tfh; vital,4.5 nTPM; vascular/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 24/133 (18.0%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6PIV2,https://www.uniprot.org/uniprotkb/Q6PIV2/entry,Transcription factor which acts as both an activator and a repressor (PubMed:34723967). Activates transcription of a number of genes including the heat shock chaperones HSPA1A and HSPA6 and the antioxidant NADPH-dependent reductase DHRS2 which are involved in protection against oxidative stress (PubMed:34723967). Required for normal brain development (By similarity),Expressed in testis (at protein level),,,"Nucleus Cytoplasm Cytoplasm, perinuclear region",34723967,25609838,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Carter2023_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FOXR2,ENSG00000189299,Neither,Antibody,False,False,1.2,1.2,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Cerebral cortex/Endothelial cells: Low, HPA034487; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA034487; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA034487; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA034487; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA034487; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA034487; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA034487; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA034487; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: Medium, HPA057358; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA057358; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA057358; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA057358; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA057358; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA057358; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA057358; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA057358; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA057358; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA057358; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA057358; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA057358; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA057358; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA057358; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA057358; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA057358; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA057358; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA057358; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,True,False,https://pmc.ncbi.nlm.nih.gov/articles/PMC9437574/,Unchanged,True,True,False,0.51265540946,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0.5127 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Testicular Germ Cell Tumor (TCGA): 8/133 (6.0%); Skin Cuteneous Melanoma (TCGA): 2/99 (2.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%),melanoma: 3/8 (37.5%); endometrial cancer: 4/11 (36.4%),31,20,Q6PJQ5,https://www.uniprot.org/uniprotkb/Q6PJQ5/entry,,Expressed in breast cancer cell lines and primary cancer,,,Nucleus,,15202009,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,"Activation occurred in 8% of individual tumors across 70% of cancer types; experimental work supports ETS-circuit-driven growth. Testis restriction supports reconsideration, but the antibody conflict still needs resolution. No therapeutic outcome is established here.",https://pubmed.ncbi.nlm.nih.gov/35802025/,Cancer mechanism,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,Which primary antibody staining is specific to FOXR2?,Resolve discordance between HPA034487 and HPA057358 using independently validated protein evidence.,Both profiles are Uncertain; reproductive/tumor publication support does not validate normal-organ staining or waive counterevidence.,,,,,
FTHL17,ENSG00000132446,Neither,Low,False,False,3.8,3.8,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.1,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.1 nTPM; skin/bulk; hpa_rna_consensus; manageable,Testicular Germ Cell Tumor (TCGA): 39/133 (29.3%); Lung Squamous Cell Carcinoma (TCGA): 30/489 (6.1%); Bladder Urothelial Carcinoma (TCGA): 10/169 (5.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9BXU8,https://www.uniprot.org/uniprotkb/Q9BXU8/entry,,Testis specific. Also expressed in several cancers,,,,,12704671,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Carter2023_CT | Loriot2025_S1 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FUT5,ENSG00000130383,Neither,Antibody,False,False,0.2,0.5,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,bone marrow: 0.5 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bronchus/Respiratory epithelial cells: Low, HPA046966; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA046966; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA046966; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA046966; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA046966; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA046966; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA046966; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA046966; conflicting or uncurated primary profile; Colon/Endocrine cells: Medium, HPA046966; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA046966; conflicting or uncurated primary profile; Colon/Enterocytes: Medium, HPA046966; conflicting or uncurated primary profile; Colon/Enterocytes - Microvilli: Medium, HPA046966; conflicting or uncurated primary profile; Colon/Goblet cells: Medium, HPA046966; conflicting or uncurated primary profile; Colon/Mucosal lymphoid cells: Low, HPA046966; conflicting or uncurated primary profile; Duodenum/Endocrine cells: Medium, HPA046966; conflicting or uncurated primary profile; Duodenum/Enterocytes: Medium, HPA046966; conflicting or uncurated primary profile; Duodenum/Enterocytes - Microvilli: High, HPA046966; conflicting or uncurated primary profile; Duodenum/Goblet cells: Medium, HPA046966; conflicting or uncurated primary profile; Duodenum/Paneth cells: High, HPA046966; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA046966; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA046966; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA046966; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA046966; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA046966; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA046966; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA046966; conflicting or uncurated primary profile; Rectum/Endocrine cells: Medium, HPA046966; conflicting or uncurated primary profile; Rectum/Endothelial cells: Low, HPA046966; conflicting or uncurated primary profile; Rectum/Enterocytes: Medium, HPA046966; conflicting or uncurated primary profile; Rectum/Goblet cells: Medium, HPA046966; conflicting or uncurated primary profile; Rectum/Mucosal lymphoid cells: Low, HPA046966; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA046966; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA046966; conflicting or uncurated primary profile; Small intestine/Enterocytes: Medium, HPA046966; conflicting or uncurated primary profile; Small intestine/Enterocytes - Microvilli: Medium, HPA046966; conflicting or uncurated primary profile; Small intestine/Goblet cells: Medium, HPA046966; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA046966; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA046966; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA046966; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA046966; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA046966; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA046966; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.03789869555,0.7,,Neither,oncoref.target-sets.2026-10-23.2,1.038 TPM; blood/TH17; dice_th17; vital,0.7 nTPM; eye/bipolar cells; hpa_single_cell_tissue; vital,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 2/283 (0.7%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),colorectal cancer: 5/12 (41.7%); urothelial cancer: 4/10 (40.0%),31,20,Q11128,https://www.uniprot.org/uniprotkb/Q11128/entry,"Catalyzes preferentially the transfer of L-fucose, from a guanosine diphosphate-beta-L-fucose, to the N-acetyl-beta-D-glucosamine (GlcNAc) of an N-acetyllactosamine unit (type 2 chain) of an oligosaccharide, or a glycoprotein- and a glycolipid-linked N-acetyllactosamine unit via an alpha (1,3) linkage and participates in the surface expression of VIM-2, Lewis X/SSEA-1 and sialyl Lewis X antigens (PubMed:14718375, PubMed:1740457, PubMed:17604274, PubMed:29593094, PubMed:7721776, PubMed:9737988, PubMed:9737989). Preferentially transfers fucose to the GlcNAc of an internal N-acetyllactosamine unit of a poly-N-acetyllactosamine chain acceptor substrate (PubMed:17604274, PubMed:7721776). Also catalyzes to a lesser extend the transfer of L-fucose to the GlcNAc of a type 1 (beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl) or H-type 1 (alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-D-GlcNAc) chain oligosaccharide via an alpha (1,4) linkage (PubMed:14718375, PubMed:1740457, PubMed:17604274, PubMed:7721776, PubMed:9737988). Preferentially catalyzes sialylated type 2 oligosaccharide acceptors over neutral type 2 or H type 2 (alpha-L-Fuc-(1->2)-beta-D-Gal-(1->4)-D-GlcNAc) oligosaccharide acceptors (PubMed:1740457, PubMed:9737989). Lactose-based structures are also acceptor substrates (PubMed:1740457, PubMed:7721776)","Liver, colon and testis and trace amounts in T-cells and brain",,,"Golgi apparatus, Golgi stack membrane",14718375|1740457|17604274|7721776|9737988|9737989,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
GAB4,ENSG00000215568,Neither,Antibody,False,False,2.0,2.0,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA044621; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA044621; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA044621; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA044621; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA044621; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA044621; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA044621; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA044621; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA044621; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA044621; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA044621; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA044621; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA044621; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA044621; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA044621; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA044621; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA044621; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA044621; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA044621; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA044621; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA044621; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA044621; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA044621; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA044621; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.1,1.0,,Neither,oncoref.target-sets.2026-10-23.2,0.1 TPM; blood/Progenitor cell; hpa_immune_monaco; vital,1 nTPM; vascular/schwann cells; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 3/176 (1.7%); Ovary Serous Cystadenocarcinoma (validation): 1/81 (1.2%); Lung Adenocarcinoma (validation): 1/105 (1.0%),colorectal cancer: 6/10 (60.0%); melanoma: 6/12 (50.0%),31,20,Q2WGN9,https://www.uniprot.org/uniprotkb/Q2WGN9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
GAGE10,ENSG00000215274,Neither,Selectivity,False,False,1.6,1.6,83,3,Positive somewhere,False,False,False,True,Excluded,Normal,False,,Not assessed,,,basal ganglia: 0.5 nTPM; continuous selectivity; pituitary gland: 0.8 nTPM; continuous selectivity; retina: 0.5 nTPM; continuous selectivity,Fails reproductive selectivity without above-ceiling normal RNA or a normal-protein veto,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Selectivity,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,5.1779700129,1.6,,Neither,oncoref.target-sets.2026-10-23.2,5.178 TPM; blood/TREG_MEM; dice_treg_mem; vital,1.6 nTPM; skin/fibroblasts; hpa_single_cell_tissue; manageable,Lung Squamous Cell Carcinoma (TCGA): 36/489 (7.4%); Skin Cuteneous Melanoma (TCGA): 7/99 (7.1%); Liver Hepatocellular Carcinoma (TCGA): 19/362 (5.2%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),31,20,A6NGK3,https://www.uniprot.org/uniprotkb/A6NGK3/entry,,,,"The first GAGE nomenclature was based on identified mRNA sequences, but the high identity of the GAGE members made impossible to separate products of paralogous genes from polymorph products. PubMed:18179644 presented a new GAGE gene nomenclature based on the identified genes and their products",,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Seager2024_CTA,Member of the published 17-target CTA profiling panel; includes differentiation antigen MLANA,,,,,,,,
GDPD4,ENSG00000178795,Neither,Low,False,False,3.6,3.6,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,retina: 1.4 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.33382933462,1.7,,Neither,oncoref.target-sets.2026-10-23.2,1.334 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1.7 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 20/133 (15.0%); Liver Hepatocellular Carcinoma (validation): 10/231 (4.3%); Pancreatic Adenocarcinoma (TCGA): 1/176 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6W3E5,https://www.uniprot.org/uniprotkb/Q6W3E5/entry,"Ecto-phospholipase that cleaves the phosphodiester bond in the glycosylphosphatidylinositol (GPI) anchor of TRABD2A and TRABD2B, releasing them from the plasma membrane. The release in the extracellular space inactivates these metalloproteases involved in the negative regulation of Wnt signaling",,,It is still unclear whether it cleaves GPI-anchors via a phospholipase C (PLC)-like or phospholipase D (PLD)-like mechanism,Cell membrane,35182431,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GFY,ENSG00000261949,Neither,Low,False,False,1.3,1.3,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,cerebellum: 0.5 nTPM; continuous selectivity; retina: 0.6 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.360180475532,3.1,,Neither,oncoref.target-sets.2026-10-23.2,0.3602 TPM; blood/THSTAR; dice_thstar; vital,3.1 nTPM; pbmc/b-cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 11/133 (8.3%); Uterine Corpus Endometrial Carcinoma (TCGA): 9/176 (5.1%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 14/283 (4.9%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,I3L273,https://www.uniprot.org/uniprotkb/I3L273/entry,Required for proper function of the olfactory system. May be involved in establishing the acuity of olfactory sensory signaling (By similarity),,,,Golgi apparatus membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Loriot2025_S1,Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
GJA10,ENSG00000135355,Neither,Antibody,False,False,0.3,0.7,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,retina: 0.7 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,True,"eye/horizontal cells cluster c-5: 16.4 nTPM, 26 reads; reproductive-cell max 4.8",True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA021145; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA021145; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA021145; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA021145; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA021145; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA021145; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA021145; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA021145; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA021145; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA021145; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA021145; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA021145; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA021145; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA021145; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA021145; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA021145; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA021145; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA021145; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA021145; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA021145; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA021145; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA021145; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA021145; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA021145; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA021145; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA021145; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA021145; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA021145; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.629905474,16.4,,Neither,oncoref.target-sets.2026-10-23.2,0.6299 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,16.4 nTPM; unsited/Horizontal cells; hpa_single_cell; unresolved,Testicular Germ Cell Tumor (TCGA): 9/133 (6.8%); Liver Hepatocellular Carcinoma (validation): 6/231 (2.6%); Liver Hepatocellular Carcinoma (TCGA): 1/362 (0.3%),testis cancer: 9/11 (81.8%); glioma: 7/12 (58.3%),31,20,Q969M2,https://www.uniprot.org/uniprotkb/Q969M2/entry,"One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. Involved in tracer coupling between horizontal cells of the retina. May play a role in the regulation of horizontal cell patterning (By similarity)",Expressed in skeletal muscle and heart,,,"Cell membrane Cell junction, gap junction",,12881038,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
GK2,ENSG00000196475,Neither,Antibody,False,False,86.9,86.9,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA060687; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA060687; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA060687; conflicting or uncurated primary profile; Colon/Mucosal lymphoid cells: Medium, HPA060687; conflicting or uncurated primary profile; Duodenum/Endocrine cells: High, HPA060687; conflicting or uncurated primary profile; Duodenum/Enterocytes: High, HPA060687; conflicting or uncurated primary profile; Duodenum/Goblet cells: High, HPA060687; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA060687; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA060687; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA060687; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA060687; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA060687; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA060687; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA060687; conflicting or uncurated primary profile; Rectum/Mucosal lymphoid cells: Medium, HPA060687; conflicting or uncurated primary profile; Small intestine/Enterocytes: Low, HPA060687; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA060687; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA060687; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA060687; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA060687; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0523,1.2,,CTA,oncoref.target-sets.2026-10-23.2,0.0523 TPM; blood/neutrophil; hpa_immune_cell_samples; vital,1.2 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),liver cancer: 8/11 (72.7%); endometrial cancer: 5/11 (45.5%),31,20,Q14410,https://www.uniprot.org/uniprotkb/Q14410/entry,Key enzyme in the regulation of glycerol uptake and metabolism. Essential for male fertility and sperm mitochondrial sheath formation (By similarity). Required for proper arrangement of crescent-like mitochondria to form the mitochondrial sheath during spermatogenesis (By similarity). Can induce mitochondrial clustering through interactions with PLD6 and up-regulation of phosphatidic acid synthesis in the mitochondria (PubMed:28852571),Testis-specific (PubMed:33536340). Expressed in the midpiece of spermatozoa (PubMed:28852571),,,Mitochondrion outer membrane Cytoplasm,28852571,28852571|33536340,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GK3,ENSG00000229894,Neither,Antibody,False,False,12.7,12.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA060687; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA060687; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA060687; conflicting or uncurated primary profile; Colon/Mucosal lymphoid cells: Medium, HPA060687; conflicting or uncurated primary profile; Duodenum/Endocrine cells: High, HPA060687; conflicting or uncurated primary profile; Duodenum/Enterocytes: High, HPA060687; conflicting or uncurated primary profile; Duodenum/Goblet cells: High, HPA060687; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA060687; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA060687; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA060687; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA060687; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA060687; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA060687; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA060687; conflicting or uncurated primary profile; Rectum/Mucosal lymphoid cells: Medium, HPA060687; conflicting or uncurated primary profile; Small intestine/Enterocytes: Low, HPA060687; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA060687; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA060687; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA060687; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA060687; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.22197792577,5.9,,CTA,oncoref.target-sets.2026-10-23.2,2.222 TPM; blood/MONOCYTES; dice_monocytes; vital,5.9 nTPM; esophagus/b-cells; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 1/50 (2.0%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%),liver cancer: 8/11 (72.7%); endometrial cancer: 5/11 (45.5%),31,20,Q14409,https://www.uniprot.org/uniprotkb/Q14409/entry,May be involved in the regulation of glycerol uptake and metabolism,,,,"Mitochondrion outer membrane Cytoplasm, cytosol",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT | Carter2023_CT | Gong2021_reproductive_PC,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GLT6D1,ENSG00000204007,Neither,Antibody,False,False,4.6,4.6,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA023424; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA023424; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA023424; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA023424; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA023424; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA023424; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA023424; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: High, HPA023424; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA023424; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA023424; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA023424; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA023424; conflicting or uncurated primary profile; Colon/Endothelial cells: High, HPA023424; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA023424; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA023424; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA023424; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA023424; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA023424; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA023424; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA023424; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: High, HPA023424; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA023424; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA023424; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA023424; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA023424; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA023424; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA023424; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA023424; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA023424; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA023424; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA023424; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA023424; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA023424; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA023424; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA023424; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA023424; conflicting or uncurated primary profile; Skin 1/Fibroblasts: High, HPA023424; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA023424; conflicting or uncurated primary profile; Skin 1/Langerhans: High, HPA023424; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA023424; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA023424; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA023424; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA023424; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA023424; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA023424; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA023424; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA023424; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA023424; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.7,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.7 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),urothelial cancer: 12/12 (100.0%); testis cancer: 10/10 (100.0%),31,20,Q7Z4J2,https://www.uniprot.org/uniprotkb/Q7Z4J2/entry,,"Expressed in both healthy and inflamed gingival tissue samples at similar levels, with higher expression in the gingival connective tissue compared to gingival epithelium. Strongest expression in testis, followed by leukocytes",,Could be the product of a pseudogene,Membrane,,19897590,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GOLGA6B,ENSG00000215186,Neither,Selectivity,False,False,7.0,7.0,87,3,Positive somewhere,False,False,False,True,Excluded,Normal,False,,Not assessed,,,liver: 4.2 nTPM; continuous selectivity,Fails reproductive selectivity without above-ceiling normal RNA or a normal-protein veto,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Selectivity,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.5489116449570001,4.2,,Neither,oncoref.target-sets.2026-10-23.2,0.5489 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,4.2 nTPM; liver/bulk; hpa_rna_consensus; vital,Breast Invasive Carcinoma (validation): 1/50 (2.0%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),melanoma: 1/11 (9.1%); cervical cancer: 1/12 (8.3%),31,20,A6NDN3,https://www.uniprot.org/uniprotkb/A6NDN3/entry,,,,Maps to a duplicated region on chromosome 15; the gene is present in at least 4 almost identical copies,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
GOLGA6L1,ENSG00000273976,Neither,Antibody,False,False,27.6,27.6,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA047733; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA047733; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA047733; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA047733; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA047733; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA047733; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA047733; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA047733; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA047733; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA047733; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.1,1.1,,CTA,oncoref.target-sets.2026-10-23.2,0.1 TPM; blood/Effector memory CD8 T-cell; hpa_immune_monaco; vital,1.1 nTPM; eye/muller glia cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),melanoma: 2/10 (20.0%); skin cancer: 1/10 (10.0%),28,20,Q8N7Z2,https://www.uniprot.org/uniprotkb/Q8N7Z2/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GOLGA6L22,ENSG00000277865,Neither,Antibody,False,False,8.2,8.2,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA047733; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA047733; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA047733; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA047733; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA047733; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA047733; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA047733; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA047733; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA047733; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA047733; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.905726619343,1.5,,Neither,oncoref.target-sets.2026-10-23.2,0.9057 TPM; blood/NK; dice_nk; vital,1.5 nTPM; bone marrow/plasma cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),melanoma: 2/10 (20.0%); skin cancer: 1/10 (10.0%),26,20,H0YM25,https://www.uniprot.org/uniprotkb/H0YM25/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GOLGA6L6,ENSG00000277322,Neither,Antibody,False,False,5.0,5.0,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA047733; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA047733; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA047733; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA047733; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA047733; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA047733; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA047733; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA047733; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA047733; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA047733; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA047733; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.161451730854,12.0,,CTA,oncoref.target-sets.2026-10-23.2,0.1615 TPM; blood/TREG_MEM; dice_treg_mem; vital,12 nTPM; esophagus/schwann cells; hpa_single_cell_tissue; protected,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 1/283 (0.4%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),melanoma: 2/10 (20.0%); skin cancer: 1/10 (10.0%),28,20,A8MZA4,https://www.uniprot.org/uniprotkb/A8MZA4/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
GOLGA8F,ENSG00000153684,Neither,Screening,False,False,12.2,12.2,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.110240047112,0.1,,Neither,oncoref.target-sets.2026-10-23.2,0.1102 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.1 nTPM; basal ganglia/bulk; hpa_rna_consensus; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Breast Invasive Carcinoma (validation): 0/50 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P0DX52,https://www.uniprot.org/uniprotkb/P0DX52/entry,,,,"A family of highly similar proteins (GOLGA8A, GOLGA8B, GOLGA8C, GOLGA8D, GOLGA8E, GOLGA8F, GOLGA8G) are encoded by a repeated region on chromosome 15q11-15q13. Our sequences are in agreement with HGNC nomenclature",,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GOLGA8S,ENSG00000261739,Neither,Cellular,False,False,3.3,3.3,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE MONOCYTES (unstimulated): 3/91 values ≥5 TPM, max 5.83563; DICE NK (unstimulated): 82/90 values ≥5 TPM, max 26.5027; DICE CD4_NAIVE (unstimulated): 15/88 values ≥5 TPM, max 7.51251; DICE TREG_NAIVE (unstimulated): 8/89 values ≥5 TPM, max 7.45226; DICE CD8_NAIVE (unstimulated): 12/89 values ≥5 TPM, max 10.2482",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,26.5026696155,1.9,,Neither,oncoref.target-sets.2026-10-23.2,26.5 TPM; blood/NK; dice_nk; vital,1.9 nTPM; heart muscle/cardiomyocytes; hpa_single_cell_tissue; vital,Kidney Renal Papillary Cell Carcinoma (TCGA): 2/282 (0.7%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,H3BPF8,https://www.uniprot.org/uniprotkb/H3BPF8/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GOT1L1,ENSG00000169154,Neither,Antibody,False,False,13.7,13.7,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA028778; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA028778; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA028778; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA028778; conflicting or uncurated primary profile; Caudate/Glial cells: High, HPA028778; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA028778; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: High, HPA028778; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA028778; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA028778; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA028778; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA028778; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA028778; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA028778; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA028778; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA028778; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA028778; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA028778; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA028778; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA028778; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA028778; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA028778; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA028778; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA028778; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA028778; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA028778; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA028778; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA028778; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA028778; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA028778; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA028778; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA028778; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA028778; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA028778; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA028778; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA028778; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA028778; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA028778; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA028778; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA028778; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA028778; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA028778; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA028778; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA028778; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA028778; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA028778; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA028778; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA028778; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA028778; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.648548610482,2.0,,CTA,oncoref.target-sets.2026-10-23.2,0.6485 TPM; blood/CD4_STIM; dice_cd4_stim; vital,2 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,Q8NHS2,https://www.uniprot.org/uniprotkb/Q8NHS2/entry,"Catalyzes the conversion of L-aspartate and 2-oxoglutarate to L-glutamate and oxaloacetate (PubMed:25287256). It has been proposed to exhibit aspartate racemase activity, but this function remains debated and lacks strong experimental support (PubMed:25287256)",,,"Was reported to exhibit Asp racemase activity (By similarity). However, one study in humans did not confirm this activity (PubMed:25287256). Similarly, a study in mice also failed to demonstrate aspartate racemase activity (By similarity) The residues that bind the substrate in other aspartate aminotransferases are not conserved",Cytoplasm,25287256,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GPHB5,ENSG00000179600,Neither,Low,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; retina: 0.1 nTPM; reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.78649282635,1.0,,Neither,oncoref.target-sets.2026-10-23.2,1.786 TPM; blood/NK; dice_nk; vital,1 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Lung Squamous Cell Carcinoma (validation): 3/68 (4.4%); Lung Squamous Cell Carcinoma (TCGA): 6/489 (1.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q86YW7,https://www.uniprot.org/uniprotkb/Q86YW7/entry,"Functions as a heterodimeric glycoprotein hormone with GPHA2 able to bind and activate the thyroid-stimulating hormone receptor (TSHR), leading to increased cAMP production. Plays a central role in controlling thyroid cell metabolism","Highly expressed in brain and at low levels in pituitary. Also found in retina, testis and skin but not in pancreas, parotid, kidney, stomach, liver, colon, small intestine, thyroid, brain or adrenal gland. In pituitary, colocalizes with ACTH, suggesting that it is located in corticotrophs",,,Secreted,12045258|16210345,12089349|16210345,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
GPR139,ENSG00000180269,Neither,Antibody,False,False,0.1,0.4,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,basal ganglia: 0.4 nTPM; continuous selectivity;reproductive not higher; bone marrow: 0.4 nTPM; continuous selectivity;reproductive not higher; choroid plexus: 0.1 nTPM; reproductive not higher; hypothalamus: 0.2 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA046596; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA046596; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA046596; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA046596; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA046596; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA046596; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: High, HPA046596; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA046596; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA046596; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA046596; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA046596; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA046596; conflicting or uncurated primary profile; Colon/Endothelial cells: High, HPA046596; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA046596; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: High, HPA046596; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA046596; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA046596; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA046596; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA046596; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA046596; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: High, HPA046596; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA046596; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA046596; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA046596; conflicting or uncurated primary profile; Lung/Alveolar cells: High, HPA046596; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA046596; conflicting or uncurated primary profile; Lymph node/Germinal center cells: High, HPA046596; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA046596; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA046596; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA046596; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA046596; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA046596; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA046596; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA046596; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA046596; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA046596; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA046596; conflicting or uncurated primary profile; Skin 1/Keratinocytes: High, HPA046596; conflicting or uncurated primary profile; Skin 1/Langerhans: High, HPA046596; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA046596; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA046596; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA046596; conflicting or uncurated primary profile; Spleen/Cells in red pulp: High, HPA046596; conflicting or uncurated primary profile; Spleen/Cells in white pulp: High, HPA046596; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA046596; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA046596; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA046596; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA046596; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.198935520462,1.2,,Neither,oncoref.target-sets.2026-10-23.2,0.1989 TPM; blood/TH1; dice_th1; vital,1.2 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 9/58 (15.5%); Breast Invasive Carcinoma (validation): 6/50 (12.0%); Breast Invasive Carcinoma (TCGA): 31/1022 (3.0%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),31,20,Q6DWJ6,https://www.uniprot.org/uniprotkb/Q6DWJ6/entry,Orphan receptor. Seems to act through a G(q/11)-mediated pathway,Expressed almost exclusively in the brain. Detected at very low levels in the peripheral tissues,,,Cell membrane,,15845401,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
GPR21,ENSG00000188394,Neither,Antibody,False,False,0.9,1.6,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 0.9 nTPM; continuous selectivity;reproductive not higher; amygdala: 0.4 nTPM; continuous selectivity; basal ganglia: 0.5 nTPM; continuous selectivity; cerebral cortex: 1.6 nTPM; continuous selectivity;reproductive not higher; esophagus: 0.5 nTPM; continuous selectivity; lymph node: 0.9 nTPM; continuous selectivity;reproductive not higher; rectum: 0.5 nTPM; continuous selectivity; retina: 0.4 nTPM; continuous selectivity; smooth muscle: 0.9 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_monaco Progenitor cell: 7.2 TPM,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA041651; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA041651; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA041651; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA041651; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA041651; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA041651; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA041651; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA041651; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA041651; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA041651; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA041651; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA041651; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA041651; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA041651; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA041651; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA041651; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA041651; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA041651; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA041651; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA041651; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA041651; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA041651; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA041651; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA041651; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA041651; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA041651; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA041651; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA041651; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA041651; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA041651; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA041651; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA041651; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA041651; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA041651; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA041651; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA041651; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA041651; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA041651; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA041651; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA041651; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,7.2,8.4,,Neither,oncoref.target-sets.2026-10-23.2,7.2 TPM; blood/Progenitor cell; hpa_immune_monaco; vital,8.4 nTPM; esophagus/smooth muscle cells; hpa_single_cell_tissue; protected,Glioblastoma Multiforme (validation): 23/58 (39.7%); Breast Invasive Carcinoma (validation): 2/50 (4.0%); Rectum Adenocarcinoma (validation): 7/207 (3.4%),ovarian cancer: 12/12 (100.0%); cervical cancer: 11/12 (91.7%),31,20,Q99679,https://www.uniprot.org/uniprotkb/Q99679/entry,Orphan receptor,"Not detected in the brain regions thalamus, putamen, caudate, frontal cortex, pons, hypothalamus, hippocampus",,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GPR31,ENSG00000120436,Neither,Antibody,False,False,0.7,1.4,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,lymph node: 1.4 nTPM; continuous selectivity;reproductive not higher; spleen: 0.6 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,True,"adipose tissue/schwann cells cluster c-19: 14.8 nTPM, 38 reads; reproductive-cell max 1.3",True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA014014; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA014014; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA014014; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA014014; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA014014; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA014014; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA014014; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA014014; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA014014; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA014014; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA014014; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA014014; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA014014; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA014014; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA014014; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA014014; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA014014; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA014014; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA014014; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA014014; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA014014; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA014014; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA014014; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA014014; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA014014; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA014014; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA014014; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA014014; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA014014; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA014014; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA014014; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA014014; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA014014; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA014014; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA014014; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA014014; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA014014; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA014014; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA014014; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA014014; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA014014; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA014014; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA014014; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA014014; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA014014; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA014014; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA014014; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA014014; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA014014; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: Medium, HPA027108; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA027108; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA027108; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA027108; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA027108; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA027108; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA027108; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA027108; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA027108; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA027108; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA027108; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA027108; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA027108; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA027108; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA027108; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA027108; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA027108; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA027108; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA027108; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA027108; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA027108; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA027108; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA027108; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA027108; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA027108; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA027108; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA027108; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA027108; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA027108; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA027108; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA027108; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA027108; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA027108; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA027108; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA027108; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA027108; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA027108; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA027108; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA027108; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA027108; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA027108; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA027108; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA027108; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA027108; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.41360640417,14.8,,Neither,oncoref.target-sets.2026-10-23.2,2.414 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,14.8 nTPM; adipose tissue/schwann cells; hpa_single_cell_tissue; manageable,Breast Invasive Carcinoma (validation): 1/50 (2.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),cervical cancer: 10/12 (83.3%); colorectal cancer: 10/12 (83.3%),31,20,O00270,https://www.uniprot.org/uniprotkb/O00270/entry,"High-affinity receptor for 12-(S)-hydroxy-5,8,10,14-eicosatetraenoic acid (12-S-HETE), with much lower affinities for other HETE isomers (PubMed:21712392, PubMed:29227475). 12-S-HETE is a eicosanoid, a 12-lipoxygenase (ALOX12) metabolite of arachidonic acid, involved in many physiologic and pathologic processes (PubMed:26965684, PubMed:28619714, PubMed:29227475). 12-S-HETE-binding leads to activation of ERK1/2 (MAPK3/MAPK1), MEK, and NF-kappa-B pathways leading to cell growth (PubMed:21712392, PubMed:29227475). Plays a crucial role for proliferation, survival and macropinocytosis of KRAS-dependent cancer cells by mediating the translocation of KRAS from the endoplasmic reticulum to the plasma membrane (PM) and its association with the PM (PubMed:28619714). Contributes to enhanced immune responses by inducing dendrite protrusion of small intestinal CX3CR1(+) phagocytes for the uptake of luminal antigens (By similarity). Acts also as a key receptor for 12-(S)-HETE-mediated liver ischemia reperfusion injury (PubMed:29227475) Proton-sensing G protein-coupled receptor",,,,Cell membrane,21712392|26965684|28619714|29227475|31119277,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
GPX6,ENSG00000198704,Neither,Low,False,False,3.2,3.2,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.319616327768,0.2,,Neither,oncoref.target-sets.2026-10-23.2,0.3196 TPM; blood/TH1; dice_th1; vital,0.2 nTPM; skin/basal keratinocytes; hpa_single_cell_tissue; manageable,Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P59796,https://www.uniprot.org/uniprotkb/P59796/entry,,Expressed in olfactory epithelium and embryos,,,Secreted,,12775843,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
GSC2,ENSG00000063515,Neither,Antibody,False,False,2.2,2.2,82,2,Positive somewhere,False,False,False,False,Excluded,Normal,False,,Not assessed,,,retina: 1 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: High, HPA043011; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA043011; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA043011; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA043011; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA043011; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA043011; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA043011; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA043011; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA043011; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA043011; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA043011; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA043011; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA043011; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA043011; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA043011; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA043011; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA043011; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA043011; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA043011; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA043011; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA043011; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA043011; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA043011; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA043011; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA043011; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA043011; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA043011; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA043011; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA043011; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA043011; conflicting or uncurated primary profile; Spleen/Cells in red pulp: High, HPA043011; conflicting or uncurated primary profile; Spleen/Cells in white pulp: High, HPA043011; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA043011; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA043011; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA043011; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA043011; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.615886924119,3.4,,Neither,oncoref.target-sets.2026-10-23.2,0.6159 TPM; blood/TH1; dice_th1; vital,3.4 nTPM; unsited/Cone photoreceptor cells; hpa_single_cell; unresolved,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 2/283 (0.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),cervical cancer: 12/12 (100.0%); melanoma: 12/12 (100.0%),31,20,O15499,https://www.uniprot.org/uniprotkb/O15499/entry,May have a role in development. May regulate its own transcription. May bind the bicoid consensus sequence TAATCC,"Detected in adult testis and pituitary, and in 9-10 week fetal tissue (thorax). Probably expressed in other tissues at low levels",,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GSTT4,ENSG00000276950,Neither,Low,False,False,2.3,2.3,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.57264974547,3.4,,Neither,oncoref.target-sets.2026-10-23.2,2.573 TPM; blood/NK; dice_nk; vital,3.4 nTPM; small intestine/enteroendocrine cells; hpa_single_cell_tissue; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 0/283 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,A0A1W2PR19,https://www.uniprot.org/uniprotkb/A0A1W2PR19/entry,Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles,,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GTSF1L,ENSG00000124196,Neither,Cellular,False,False,217.5,217.5,88,4,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 3/91 values ≥5 TPM, max 6.86703; DICE TREG_MEM (unstimulated): 66/89 values ≥5 TPM, max 17.5276; DICE TREG_NAIVE (unstimulated): 44/89 values ≥5 TPM, max 16.3105; DICE CD8_NAIVE (unstimulated): 7/89 values ≥5 TPM, max 7.16588",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,17.527562772,12.4,,CTA,oncoref.target-sets.2026-10-23.2,17.53 TPM; blood/TREG_MEM; dice_treg_mem; vital,12.4 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%); Kidney Renal Papillary Cell Carcinoma (TCGA): 2/282 (0.7%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9H1H1,https://www.uniprot.org/uniprotkb/Q9H1H1/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
H1-6,ENSG00000187475,Neither,Screening,False,False,1.0,1.0,87,5,Positive somewhere,False,False,False,True,Excluded,Reproductive,True,,Not assessed,,,family exclusion; family exclusion,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.6617,5.2,,Neither,oncoref.target-sets.2026-10-23.2,2.662 TPM; blood/neutrophil; hpa_immune_cell_samples; vital,5.2 nTPM; esophagus/plasma cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 19/58 (32.8%); Pancreatic Adenocarcinoma (validation): 2/80 (2.5%); Rectum Adenocarcinoma (validation): 2/207 (1.0%),testis cancer: 7/11 (63.6%); stomach cancer: 1/12 (8.3%),29,20,P22492,https://www.uniprot.org/uniprotkb/P22492/entry,"Testis-specific histone H1 that forms less compacted chromatin compared to other H1 histone subtypes (PubMed:26757249). Formation of more relaxed chromatin may be required to promote chromatin architecture required for proper chromosome regulation during meiosis, such as homologous recombination (PubMed:26757249). Histones H1 act as linkers that bind to nucleosomes and compact polynucleosomes into a higher-order chromatin configuration (Probable)",Testis-specific,,,Nucleus Chromosome,26757249,1889752|8175896,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
H2AB3,ENSG00000277745,Neither,Screening,False,False,30.5,30.5,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.06086477679,1.4,,Neither,oncoref.target-sets.2026-10-23.2,1.061 TPM; blood/NK; dice_nk; vital,1.4 nTPM; spleen/bulk; hpa_rna_consensus; manageable,Head and Neck Squamous Cell Carcinoma (TCGA): 9/492 (1.8%); Lung Squamous Cell Carcinoma (TCGA): 8/489 (1.6%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 4/283 (1.4%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,P0C5Z0,https://www.uniprot.org/uniprotkb/P0C5Z0/entry,"Atypical histone H2A which can replace conventional H2A in some nucleosomes and is associated with active transcription and mRNA processing. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. Nucleosomes containing this histone are less rigid and organize less DNA than canonical nucleosomes in vivo. They are enriched in actively transcribed genes and associate with the elongating form of RNA polymerase. They associate with spliceosome components and are required for mRNA splicing. May participate in spermatogenesis",Present in mature sperm,,,Nucleus Chromosome,15257289|16287874|16957777|17591702|17726088|18329190|22795134,20008104,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
H2BC1,ENSG00000146047,Neither,Screening,False,False,6.2,6.2,86,5,Positive somewhere,False,False,False,True,Excluded,Reproductive,False,,Not assessed,,,family exclusion; family exclusion,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,1.2,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1.2 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 1/58 (1.7%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),testis cancer: 6/12 (50.0%); liver cancer: 4/11 (36.4%),29,20,Q96A08,https://www.uniprot.org/uniprotkb/Q96A08/entry,"Variant histone specifically required to direct the transformation of dissociating nucleosomes to protamine in male germ cells (By similarity). Entirely replaces classical histone H2B prior nucleosome to protamine transition and probably acts as a nucleosome dissociating factor that creates a more dynamic chromatin, facilitating the large-scale exchange of histones (By similarity). Core component of nucleosome (By similarity). Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template (By similarity). Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability (By similarity). DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling (By similarity). Also found in fat cells, its function and the presence of post-translational modifications specific to such cells are still unclear (PubMed:21249133)","Mainly expressed in testis, and the corresponding protein is also present in mature sperm (at protein level). Also found in some fat cells",,,Nucleus Chromosome,21249133,12213818|21249133,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
H2BW1,ENSG00000123569,Neither,Antibody,False,False,0.5,0.5,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA056289; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA056289; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA056289; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA056289; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA056289; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA056289; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA056289; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA056289; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA056289; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA056289; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA056289; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA056289; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA056289; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA056289; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA056289; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA056289; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA056289; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA056289; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA056289; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA056289; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA056289; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA056289; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA056289; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA056289; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA056289; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA056289; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA056289; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA056289; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA056289; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA056289; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA056289; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.0661377366299998,0.1,,Neither,oncoref.target-sets.2026-10-23.2,1.066 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,0.1 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Bladder Urothelial Carcinoma (TCGA): 3/169 (1.8%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Lung Squamous Cell Carcinoma (TCGA): 3/489 (0.6%),breast cancer: 9/12 (75.0%); prostate cancer: 7/12 (58.3%),29,20,Q7Z2G1,https://www.uniprot.org/uniprotkb/Q7Z2G1/entry,"Atypical histone H2B that can form nucleosomes structurally and dynamically indistinguishable from those containing conventional H2B. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling (PubMed:15475252, PubMed:16449661). However, unlike conventional H2B, does not recruit chromosome condensation factors and does not participate in the assembly of mitotic chromosomes (PubMed:16449661). May be important for telomere function and play a role in spermatogenesis (PubMed:16449661, PubMed:19583817)",Testis-specific (at protein level),,,"Nucleus membrane Chromosome Chromosome, telomere",15475252|16449661|19583817,15475252|19583817,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
H2BW2,ENSG00000101812,Neither,Low,False,False,2.3,2.3,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,existing nomination or manual review; nomination unresolved; retina: 0.7 nTPM; continuous selectivity; smooth muscle: 1 nTPM; continuous selectivity; thymus: 1.9 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,3.9141706895,1.9,,Neither,oncoref.target-sets.2026-10-23.2,3.914 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,1.9 nTPM; thymus/bulk; hpa_rna_consensus; manageable,Glioblastoma Multiforme (TCGA): 5/141 (3.5%); Bladder Urothelial Carcinoma (TCGA): 4/169 (2.4%); Uterine Corpus Endometrial Carcinoma (TCGA): 3/176 (1.7%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P0C1H6,https://www.uniprot.org/uniprotkb/P0C1H6/entry,"Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling",,,,Nucleus Chromosome,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
HES3,ENSG00000173673,Neither,Antibody,False,False,0.1,0.7,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,thymus: 0.7 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA047927; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA047927; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA047927; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA047927; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA047927; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA047927; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA047927; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA047927; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA047927; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA047927; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA047927; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA047927; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA047927; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA047927; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA047927; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA047927; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA047927; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA047927; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA047927; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.896213210205,0.7,,Neither,oncoref.target-sets.2026-10-23.2,0.8962 TPM; blood/NK; dice_nk; vital,0.7 nTPM; thymus/bulk; hpa_rna_consensus; manageable,Testicular Germ Cell Tumor (TCGA): 16/133 (12.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Lung Adenocarcinoma (TCGA): 1/497 (0.2%),stomach cancer: 6/11 (54.5%); breast cancer: 6/12 (50.0%),31,20,Q5TGS1,https://www.uniprot.org/uniprotkb/Q5TGS1/entry,Transcriptional repressor of genes that require a bHLH protein for their transcription,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
HIGD1C,ENSG00000214511,Neither,Cellular,False,False,0.3,0.8,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,existing nomination or manual review; nomination unresolved; adipose tissue: 0.3 nTPM; continuous selectivity;reproductive not higher; liver: 0.6 nTPM; continuous selectivity;reproductive not higher; lung: 0.2 nTPM; continuous selectivity; lymph node: 0.3 nTPM; continuous selectivity;reproductive not higher; pancreas: 0.8 nTPM; continuous selectivity;reproductive not higher; parathyroid gland: 0.3 nTPM; continuous selectivity;reproductive not higher; retina: 0.2 nTPM; continuous selectivity; skeletal muscle: 0.4 nTPM; continuous selectivity;reproductive not higher; skin: 0.4 nTPM; continuous selectivity;reproductive not higher; smooth muscle: 0.2 nTPM; continuous selectivity; stomach: 0.4 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 0.4 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 4/91 values ≥5 TPM, max 8.57834",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,8.57833886157,6.6,,Neither,oncoref.target-sets.2026-10-23.2,8.578 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,6.6 nTPM; unsited/Oligodendrocyte precursor cells; hpa_single_cell; unresolved,Glioblastoma Multiforme (validation): 1/58 (1.7%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A8MV81,https://www.uniprot.org/uniprotkb/A8MV81/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
HIGD2B,ENSG00000175202,Neither,Antibody,False,False,3.5,3.5,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA019016; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA019016; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA019016; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA019016; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA019016; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA019016; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA019016; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA019016; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA019016; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA019016; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA019016; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA019016; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA019016; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA019016; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA019016; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA019016; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA019016; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA019016; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA019016; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA019016; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA019016; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA019016; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA019016; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA019016; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA042715; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA042715; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA042715; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA042715; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA042715; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA042715; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA042715; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA042715; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA042715; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA042715; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA042715; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA042715; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA042715; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA042715; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA042715; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA042715; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA042715; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA042715; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA042715; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA042715; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA042715; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA042715; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA042715; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA042715; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA042715; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA042715; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA042715; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA042715; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA042715; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA042715; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA042715; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA042715; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA042715; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA042715; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.884744013101,1.5,,Neither,oncoref.target-sets.2026-10-23.2,0.8847 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1.5 nTPM; lymph node/b-cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%),liver cancer: 3/11 (27.3%); renal cancer: 2/12 (16.7%),31,20,Q4VC39,https://www.uniprot.org/uniprotkb/Q4VC39/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT | Gong2021_reproductive_PC,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
HNRNPCL1,ENSG00000179172,Neither,Low,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.37734525164,4.2,,Neither,oncoref.target-sets.2026-10-23.2,1.377 TPM; blood/CD4_STIM; dice_cd4_stim; vital,4.2 nTPM; bronchus/smooth muscle cells; hpa_single_cell_tissue; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Breast Invasive Carcinoma (validation): 0/50 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O60812,https://www.uniprot.org/uniprotkb/O60812/entry,May play a role in nucleosome assembly by neutralizing basic proteins such as A and B core hnRNPs,,,,Nucleus,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
HNRNPCL2,ENSG00000275774,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.5164419999059999,0.1,,Neither,oncoref.target-sets.2026-10-23.2,0.5164 TPM; blood/TH1; dice_th1; vital,0.1 nTPM; skeletal muscle/fibroblasts; hpa_single_cell_tissue; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 0/283 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,B2RXH8,https://www.uniprot.org/uniprotkb/B2RXH8/entry,May play a role in nucleosome assembly by neutralizing basic proteins such as A and B core hnRNPs,,,,Nucleus,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
HNRNPCL4,ENSG00000179412,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.135,0.1403,,Neither,oncoref.target-sets.2026-10-23.2,0.135 TPM; blood/NK-cell; hpa_immune_cell_samples; vital,0.1403 nTPM; blood/total PBMC; hpa_immune_cell_samples; vital,Liver Hepatocellular Carcinoma (TCGA): 1/362 (0.3%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,B7ZW38 | P0DMR1,https://www.uniprot.org/uniprotkb/B7ZW38/entry | https://www.uniprot.org/uniprotkb/P0DMR1/entry,,,,,Nucleus,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
HORMAD1,ENSG00000143452,Neither,Cellular,False,False,114.3,114.3,86,3,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 33/91 values ≥5 TPM, max 11.3605; DICE MONOCYTES (unstimulated): 90/91 values ≥5 TPM, max 19.7327; DICE M2 (unstimulated): 48/90 values ≥5 TPM, max 14.6589; hpa_immune_monaco neutrophil: 5.7 TPM",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,19.7327157711,14.8,,CTA,oncoref.target-sets.2026-10-23.2,19.73 TPM; blood/MONOCYTES; dice_monocytes; vital,14.8 nTPM; tongue/basal keratinocytes; hpa_single_cell_tissue; protected,Testicular Germ Cell Tumor (TCGA): 76/133 (57.1%); Lung Squamous Cell Carcinoma (validation): 34/68 (50.0%); Lung Adenocarcinoma (validation): 41/105 (39.0%),colorectal cancer: 2/10 (20.0%); testis cancer: 2/11 (18.2%),31,20,Q86X24,https://www.uniprot.org/uniprotkb/Q86X24/entry,"Plays a key role in meiotic progression. Regulates 3 different functions during meiosis: ensures that sufficient numbers of processed DNA double-strand breaks (DSBs) are available for successful homology search by increasing the steady-state numbers of single-stranded DSB ends. Promotes synaptonemal-complex formation independently of its role in homology search. Plays a key role in the male mid-pachytene checkpoint and the female meiotic prophase checkpoint: required for efficient build-up of ATR activity on unsynapsed chromosome regions, a process believed to form the basis of meiotic silencing of unsynapsed chromatin (MSUC) and meiotic prophase quality control in both sexes",Testis-specific. Over-expressed in carcinomas,,,Nucleus Chromosome,,15999985,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,Why is RNA repeatedly detected in monocytes and naive B cells despite reproductive-positive curated IHC?,Review gene-specific read mapping and obtain reliable protein evidence in the implicated immune populations.,DICE observations are not paired RNA/IHC donors; negative bulk-organ IHC does not assess every sorted immune population.,,,,,
HSF5,ENSG00000176160,Neither,Cellular,False,False,47.3,47.3,85,5,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 91/91 values ≥5 TPM, max 16.8101; DICE TREG_MEM (unstimulated): 27/89 values ≥5 TPM, max 7.17248; DICE CD4_NAIVE (unstimulated): 77/88 values ≥5 TPM, max 9.02848; DICE CD4_STIM (activated): 62/88 values ≥5 TPM, max 12.9683; DICE TREG_NAIVE (unstimulated): 82/89 values ≥5 TPM, max 10.9035; DICE TFH (unstimulated): 9/89 values ≥5 TPM, max 6.31628; DICE TH2 (unstimulated): 12/89 values ≥5 TPM, max 8.15023; DICE CD8_NAIVE (unstimulated): 37/89 values ≥5 TPM, max 8.84617; DICE CD8_STIM (activated): 65/88 values ≥5 TPM, max 9.69145; hpa_immune_monaco naive B-cell: 5.3 TPM; hpa_immune_monaco naive CD4 T-cell: 5.6 TPM; hpa_immune_monaco T-reg: 5.5 TPM",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,16.8101161325,8.1,,CTA,oncoref.target-sets.2026-10-23.2,16.81 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,8.1 nTPM; lymph node/b-cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 1/283 (0.4%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),urothelial cancer: 1/11 (9.1%); ovarian cancer: 1/12 (8.3%),31,20,Q4G112,https://www.uniprot.org/uniprotkb/Q4G112/entry,"DNA-binding transcription factor that is essential for male fertility, spermatogenesis and meiotic prophase progression in spermatocytes under non-stress conditions. Positvely and negatively regulates gene expression to ensure progression of meiotic prophase beyond pachytene stage in spermatocytes",,,,Nucleus Chromosome,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Carter2023_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
HSFX3,ENSG00000283697,Neither,Screening,False,False,14.0,14.0,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.32699658219,1.2,,Neither,oncoref.target-sets.2026-10-23.2,2.327 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,1.2 nTPM; adrenal gland/bulk; hpa_rna_consensus; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 1/283 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,A0A1B0GWH4,https://www.uniprot.org/uniprotkb/A0A1B0GWH4/entry,,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
HSFY1,ENSG00000172468,Neither,Screening,False,False,10.3,10.3,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.3,0.7,,Neither,oncoref.target-sets.2026-10-23.2,0.3 TPM; blood/Progenitor cell; hpa_immune_monaco; vital,0.7 nTPM; hypothalamus/bulk; hpa_rna_consensus; vital,Bladder Urothelial Carcinoma (TCGA): 10/169 (5.9%); Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%); Lung Adenocarcinoma (validation): 1/105 (1.0%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,Q96LI6,https://www.uniprot.org/uniprotkb/Q96LI6/entry,,Testis-specific. Present in Sertoli cells and spermatogenic cells (at protein level),,,Nucleus Cytoplasm,,12815422|15044259,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
HTRA4,ENSG00000169495,Neither,Cellular,False,False,64.5,64.5,76,1,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 39/91 values ≥5 TPM, max 9.49539",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,9.49538980889,27.6,,CTA,oncoref.target-sets.2026-10-23.2,9.495 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,27.6 nTPM; lung/macrophages; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 132/207 (63.8%); Colon Adenocarcinoma (validation): 303/486 (62.3%); Lung Adenocarcinoma (validation): 38/105 (36.2%),prostate cancer: 2/11 (18.2%); renal cancer: 1/11 (9.1%),31,20,P83105,https://www.uniprot.org/uniprotkb/P83105/entry,Serine protease,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
IGBP1C,ENSG00000266826,Neither,Antibody,False,False,8.5,8.5,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,True,"Adrenal gland/Glandular cells: Medium, HPA000634; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA000634; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA000634; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA000634; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA000634; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA000634; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA000634; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA000634; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA000634; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA000634; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA000634; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA000634; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA000634; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA000634; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA000634; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA000634; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA000634; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA000634; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA000634; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA000634; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA000634; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA000634; conflicting or uncurated primary profile; Lymph node/Germinal center cells: High, HPA000634; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA000634; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA000634; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA000634; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA000634; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA000634; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA000634; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA000634; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA000634; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA000634; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA000634; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA000634; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA000634; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA000634; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA000634; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA000634; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA000634; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA000634; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA000634; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA000634; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA001004; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA001004; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA001004; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA001004; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA001004; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA001004; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA001004; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA001004; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA001004; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA001004; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA001004; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA001004; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA001004; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA001004; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA001004; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA001004; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA001004; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA001004; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA001004; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA001004; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA001004; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA001004; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA001004; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA001004; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA001004; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA001004; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA001004; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.984059638701,6.4,,Neither,oncoref.target-sets.2026-10-23.2,0.9841 TPM; blood/TH2; dice_th2; vital,6.4 nTPM; esophagus/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),breast cancer: 12/12 (100.0%); colorectal cancer: 9/9 (100.0%),29,20,A0A1W2PR95,https://www.uniprot.org/uniprotkb/A0A1W2PR95/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
IL31,ENSG00000204671,Neither,Antibody,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE CD4_STIM (activated): 18/88 values ≥5 TPM, max 16.2381",True,True,False,,True,True,"Bone marrow/Hematopoietic cells: High, CAB025657; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, CAB025657; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, CAB025657; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, CAB025657; conflicting or uncurated primary profile; Lung/Macrophages: Medium, CAB025657; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, CAB025657; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, CAB025657; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, CAB025657; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, CAB025657; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, CAB025657; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, CAB025657; conflicting or uncurated primary profile; Spleen/Cells in red pulp: High, CAB025657; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, CAB025657; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,16.238079715599998,0.6,,Neither,oncoref.target-sets.2026-10-23.2,16.24 TPM; blood/CD4_STIM; dice_cd4_stim; vital,0.6 nTPM; unsited/Horizontal cells; hpa_single_cell; unresolved,Liver Hepatocellular Carcinoma (validation): 2/231 (0.9%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Head and Neck Squamous Cell Carcinoma (TCGA): 1/492 (0.2%),urothelial cancer: 3/12 (25.0%); breast cancer: 2/11 (18.2%),31,20,Q6EBC2,https://www.uniprot.org/uniprotkb/Q6EBC2/entry,"Functions as a cytokine that binds to IL31RA, a membrane-bound signal-transducing subunit of the IL31 receptor complex (heterodimer composed of OSMR and IL31RA) (PubMed:15184896, PubMed:15627637). Functionally, IL31 signaling via OSMR/IL31RA is particularly important in skin immunity (PubMed:15184896). Mechanistically, ligand binding to IL31RA, induces heterodimerization with OSMR, activating JAK1 and JAK2 (and to a lesser extent TYK2) associated with the intracellular domains of IL31RA and OSMR (PubMed:15627637). These kinases phosphorylate tyrosine residues on IL31RA and OSMR, creating docking sites for STAT1, STAT3, and STAT5B, which are then phosphorylated and activated (PubMed:15184896, PubMed:15627637). In addition, the IL31 receptor complex activates the MAPK pathway (MAPK3/ERK1-MAPK1/ERK2) via recruitment of the adapter protein SHC1 (PubMed:15627637). Enhances myeloid progenitor cell survival in vitro (By similarity). Induces RETNLA and serum amyloid A protein expression in macrophages (By similarity)","Detected at low levels in testis, bone marrow, skeletal muscle, kidney, colon, thymus, small intestine and trachea",,,Secreted,15184896|15627637,15184896,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
IQCA1L,ENSG00000278685,Neither,Low,False,False,4.3,4.3,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.76297124981,0.7,,Neither,oncoref.target-sets.2026-10-23.2,2.763 TPM; blood/THSTAR; dice_thstar; vital,0.7 nTPM; lymph node/b-cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,A6NCM1,https://www.uniprot.org/uniprotkb/A6NCM1/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
IQCJ,ENSG00000214216,Neither,Antibody,False,False,0.8,0.8,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,pituitary gland: 0.5 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA052835; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA052835; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA052835; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA052835; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA052835; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA052835; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA052835; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA052835; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA052835; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA052835; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA052835; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA052835; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA052835; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA052835; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA052835; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA052835; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA052835; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA052835; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA052835; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA052835; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA052835; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA052835; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.342656703518,0.6,,Neither,oncoref.target-sets.2026-10-23.2,0.3427 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.6 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 1/50 (2.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Breast Invasive Carcinoma (TCGA): 3/1022 (0.3%),pancreatic cancer: 6/12 (50.0%); colorectal cancer: 5/12 (41.7%),31,20,Q1A5X6,https://www.uniprot.org/uniprotkb/Q1A5X6/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
IQCM,ENSG00000234828,Neither,Cellular,False,False,4.4,4.4,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE NK (unstimulated): 6/90 values ≥5 TPM, max 6.69334; DICE CD4_NAIVE (unstimulated): 8/88 values ≥5 TPM, max 6.75189; DICE TREG_NAIVE (unstimulated): 10/89 values ≥5 TPM, max 6.00018; DICE TH2 (unstimulated): 5/89 values ≥5 TPM, max 6.48947",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,6.75188791028,5.7,,Neither,oncoref.target-sets.2026-10-23.2,6.752 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,5.7 nTPM; colon/undifferentiated cells; hpa_single_cell_tissue; protected,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Colon Adenocarcinoma (validation): 1/486 (0.2%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A0A1B0GVH7,https://www.uniprot.org/uniprotkb/A0A1B0GVH7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
IZUMO2,ENSG00000161652,Neither,Antibody,False,False,62.8,62.8,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA042143; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA042143; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA042143; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA042143; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA042143; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA042143; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA042143; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA042143; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA042143; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA042143; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA042143; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA042143; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA042143; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA042143; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA042143; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA042143; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA042143; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA042143; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA042143; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA042143; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA042143; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA042143; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA042143; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA042143; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA042143; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA042143; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA042143; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA042143; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA042143; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA042143; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA042143; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA042143; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,5.42317113087,6.7,,CTA,oncoref.target-sets.2026-10-23.2,5.423 TPM; blood/TFH; dice_tfh; vital,6.7 nTPM; rectum/enteroendocrine cells; hpa_single_cell_tissue; protected,Pancreatic Adenocarcinoma (validation): 6/80 (7.5%); Rectum Adenocarcinoma (TCGA): 6/88 (6.8%); Rectum Adenocarcinoma (validation): 9/207 (4.3%),pancreatic cancer: 7/9 (77.8%); prostate cancer: 9/12 (75.0%),30,20,Q6UXV1,https://www.uniprot.org/uniprotkb/Q6UXV1/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
KCNA10,ENSG00000143105,Neither,Low,False,False,0.4,0.4,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.305382849813,0.2,,Neither,oncoref.target-sets.2026-10-23.2,0.3054 TPM; blood/TH2; dice_th2; vital,0.2 nTPM; thymus/bulk; hpa_rna_consensus; manageable,Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q16322,https://www.uniprot.org/uniprotkb/Q16322/entry,"Voltage-gated potassium ion channel that mediates K(+) permeability of excitable membranes. When opened in response to the voltage difference across the membrane, KCNA10 channel selectively allows the flow of potassium ions across the membrane down their electrochemical gradient","Detected in kidney, in proximal tubules, glomerular endothelium, in vascular endothelium and in smooth muscle cells",,,Membrane,10836990,12444201,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
KIF4B,ENSG00000226650,Neither,Antibody,False,False,3.4,3.4,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA034745; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA034745; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA034745; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA034745; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA034745; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA034745; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA034745; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA034745; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA034745; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA034745; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA034745; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA034745; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA034745; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA034745; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA034745; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA034745; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA034745; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA034745; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA034745; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA034745; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA034745; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA034745; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA034745; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA034745; conflicting or uncurated primary profile; Lymph node/Germinal center cells: High, HPA034745; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA034745; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA034745; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA034745; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA034745; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA034745; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA034745; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA034745; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA034745; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA034745; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA034745; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA034745; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA034745; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA034745; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA034745; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA034745; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA034745; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA034745; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: Low, HPA034746; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA034746; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA034746; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA034746; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA034746; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA034746; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA034746; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA034746; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA034746; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA034746; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA034746; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA034746; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA034746; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA034746; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA034746; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA034746; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA034746; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA034746; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA034746; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA034746; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA034746; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA034746; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA034746; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA034746; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA034746; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA034746; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA034746; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA034746; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA034746; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA034746; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA034746; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA034746; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA034746; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA034746; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA034746; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA034746; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA034746; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA034746; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA034746; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA034746; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA034746; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.505682780558,2.5,,Neither,oncoref.target-sets.2026-10-23.2,0.5057 TPM; blood/NK; dice_nk; vital,2.5 nTPM; bronchus/smooth muscle cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),prostate cancer: 12/12 (100.0%); breast cancer: 11/11 (100.0%),31,20,Q2VIQ3,https://www.uniprot.org/uniprotkb/Q2VIQ3/entry,"Iron-sulfur (Fe-S) cluster binding motor protein that has a role in chromosome segregation during mitosis (By similarity). Translocates PRC1 to the plus ends of interdigitating spindle microtubules during the metaphase to anaphase transition, an essential step for the formation of an organized central spindle midzone and midbody and for successful cytokinesis (By similarity). May play a role in mitotic chromosomal positioning and bipolar spindle stabilization (By similarity)",Specifically expressed in testis,,,"Nucleus matrix Cytoplasm, cytoskeleton",,16201836,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
KRT26,ENSG00000186393,Neither,Cellular,False,False,0.5,5.7,100,1,Positive somewhere,False,False,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 0.9 nTPM; continuous selectivity;reproductive not higher; skin: 5.7 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_monaco neutrophil: 9.3 TPM,True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,9.3,5.7,,Neither,oncoref.target-sets.2026-10-23.2,9.3 TPM; blood/neutrophil; hpa_immune_monaco; vital,5.7 nTPM; skin/bulk; hpa_rna_consensus; manageable,Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 3/283 (1.1%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),31,20,Q7Z3Y9,https://www.uniprot.org/uniprotkb/Q7Z3Y9/entry,,"Strongly expressed in skin and scalp, and weak expression observed in thymus and tongue. In the hair follicle, expression is restricted to the mid- to upper inner root sheath cuticle, being present slightly above the apex of the dermal papilla (at protein level)",,,,,15617563|16874310,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
KRTAP10-12,ENSG00000189169,Neither,Screening,False,False,0.0,9.5,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.25506280219,9.5,,Neither,oncoref.target-sets.2026-10-23.2,0.2551 TPM; blood/TH1; dice_th1; vital,9.5 nTPM; skin/bulk; hpa_rna_consensus; manageable,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 1/283 (0.4%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P60413,https://www.uniprot.org/uniprotkb/P60413/entry,"In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins","Restricted to a narrow region of the hair fiber cuticle, lying approximately 20 cell layers above the apex of the dermal papilla of the hair root; not detected in any other tissues",,,,,14962103|15028290,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
KRTAP10-6,ENSG00000188155,Neither,Low,False,False,0.2,2.5,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; skin: 2.5 nTPM; continuous selectivity;reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.252323513846,2.5,,Neither,oncoref.target-sets.2026-10-23.2,0.2523 TPM; blood/CD8_NAIVE; dice_cd8_naive; vital,2.5 nTPM; skin/bulk; hpa_rna_consensus; manageable,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P60371,https://www.uniprot.org/uniprotkb/P60371/entry,"In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins","Restricted to a narrow region of the hair fiber cuticle, lying approximately 20 cell layers above the apex of the dermal papilla of the hair root; not detected in any other tissues",,,,,14962103|15028290,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
KRTAP12-4,ENSG00000212933,Neither,Low,False,False,0.0,0.5,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.37929255295,0.5,,Neither,oncoref.target-sets.2026-10-23.2,1.379 TPM; blood/TH2; dice_th2; vital,0.5 nTPM; skin/bulk; hpa_rna_consensus; manageable,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P60329,https://www.uniprot.org/uniprotkb/P60329/entry,"In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins","Restricted to a narrow region of the hair fiber cuticle, lying approximately 20 cell layers above the apex of the dermal papilla of the hair root; not detected in any other tissues",,,,,14962103|15028290,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
KRTAP13-1,ENSG00000198390,Neither,Selectivity,False,False,0.2,8.7,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,skin: 8.7 nTPM; continuous selectivity;reproductive not higher,Fails reproductive selectivity without above-ceiling normal RNA or a normal-protein veto,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Selectivity,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,8.7,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,8.7 nTPM; skin/bulk; hpa_rna_consensus; manageable,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q8IUC0,https://www.uniprot.org/uniprotkb/Q8IUC0/entry,"In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins",Weak expression seen in the late matrix and entire cortex area of the hair follicle,,The sequence of 1-41 of PubMed:12359730 has not been submitted,,,12359730,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
KRTAP19-8,ENSG00000206102,Neither,Low,False,False,0.4,0.4,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,4.14491552624,0.2,,Neither,oncoref.target-sets.2026-10-23.2,4.145 TPM; blood/TH2; dice_th2; vital,0.2 nTPM; bone marrow/bulk; hpa_rna_consensus; vital,Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q3LI54,https://www.uniprot.org/uniprotkb/Q3LI54/entry,"In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins",,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
KRTAP20-1,ENSG00000244624,Neither,Low,False,False,0.1,0.4,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; skin: 0.4 nTPM; continuous selectivity;reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.4,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.4 nTPM; skin/bulk; hpa_rna_consensus; manageable,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q3LI63,https://www.uniprot.org/uniprotkb/Q3LI63/entry,"In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins",,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
KRTAP20-2,ENSG00000184032,Neither,Low,False,False,0.1,1.4,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; skin: 1.4 nTPM; continuous selectivity;reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.721957521758,1.4,,Neither,oncoref.target-sets.2026-10-23.2,0.722 TPM; blood/CD8_NAIVE; dice_cd8_naive; vital,1.4 nTPM; skin/bulk; hpa_rna_consensus; manageable,Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 1/283 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q3LI61,https://www.uniprot.org/uniprotkb/Q3LI61/entry,"In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins",,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
KRTAP21-1,ENSG00000187005,Neither,Low,False,False,0.0,0.2,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.0006933474,0.2,,Neither,oncoref.target-sets.2026-10-23.2,1.001 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,0.2 nTPM; skin/bulk; hpa_rna_consensus; manageable,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q3LI58,https://www.uniprot.org/uniprotkb/Q3LI58/entry,"In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins",,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
KRTAP21-2,ENSG00000187026,Neither,Low,False,False,1.6,1.6,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; skin: 1.3 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.36999218034,1.3,,Neither,oncoref.target-sets.2026-10-23.2,1.37 TPM; blood/THSTAR; dice_thstar; vital,1.3 nTPM; skin/bulk; hpa_rna_consensus; manageable,Glioblastoma Multiforme (validation): 1/58 (1.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Breast Invasive Carcinoma (TCGA): 3/1022 (0.3%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q3LI59,https://www.uniprot.org/uniprotkb/Q3LI59/entry,"In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins",,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
KRTAP6-1,ENSG00000184724,Neither,Low,False,False,0.0,2.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.39412185783,2.0,,Neither,oncoref.target-sets.2026-10-23.2,0.3941 TPM; blood/CD8_STIM; dice_cd8_stim; vital,2 nTPM; skin/bulk; hpa_rna_consensus; manageable,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q3LI64,https://www.uniprot.org/uniprotkb/Q3LI64/entry,"In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins",,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
LCE3C,ENSG00000244057,Neither,Selectivity,False,False,0.2,23.4,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,esophagus: 0.2 nTPM; continuous selectivity;reproductive not higher; skin: 1.7 nTPM; continuous selectivity;reproductive not higher,Fails reproductive selectivity without above-ceiling normal RNA or a normal-protein veto,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Selectivity,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,1.7,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1.7 nTPM; skin/bulk; hpa_rna_consensus; manageable,Head and Neck Squamous Cell Carcinoma (TCGA): 71/492 (14.4%); Skin Cuteneous Melanoma (TCGA): 8/99 (8.1%); Bladder Urothelial Carcinoma (TCGA): 2/169 (1.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5T5A8,https://www.uniprot.org/uniprotkb/Q5T5A8/entry,"A structural component of the cornified envelope of the stratum corneum involved in innate cutaneous host defense (Probable). Possesses defensin-like antimicrobial activity against a broad spectrum of Gram-positive and Gram-negative bacteria, both aerobic and anaerobic species. Upon inflammation, may regulate skin barrier repair by shaping cutaneous microbiota composition and immune response to bacterial antigens (PubMed:28634035)","Skin-specific. Expression was readily detected in adult trunk skin, adult arm skin, fetal skin, penal skin, vulva, esophagus and tongue. Not expressed in the cervix, rectum, lung, colon, or placenta",,,,28634035,15854049,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
LHX8,ENSG00000162624,Neither,Low,False,False,1.0,2.6,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,basal ganglia: 1.3 nTPM; continuous selectivity;reproductive not higher; esophagus: 0.7 nTPM; continuous selectivity; salivary gland: 2.6 nTPM; continuous selectivity;reproductive not higher; tongue: 1 nTPM; continuous selectivity;reproductive not higher; urinary bladder: 0.5 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0720102727851999,12.3,,Neither,oncoref.target-sets.2026-10-23.2,0.07201 TPM; blood/TH2; dice_th2; vital,12.3 nTPM; tongue/smooth muscle cells; hpa_single_cell_tissue; protected,Testicular Germ Cell Tumor (TCGA): 7/133 (5.3%); Head and Neck Squamous Cell Carcinoma (TCGA): 13/492 (2.6%); Lung Squamous Cell Carcinoma (TCGA): 11/489 (2.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q68G74,https://www.uniprot.org/uniprotkb/Q68G74/entry,Transcription factor involved in differentiation of certain neurons and mesenchymal cells,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
LIPJ,ENSG00000204022,Neither,Antibody,False,False,6.8,6.8,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA048594; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA048594; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA048594; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA048594; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA048594; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA048594; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA048594; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA048594; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA048594; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA048594; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA048594; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA048594; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA048594; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA048594; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA048594; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA048594; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA048594; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA048594; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA048594; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA048594; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA048594; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA048594; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA048594; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.4762251458400004,2.7,,CTA,oncoref.target-sets.2026-10-23.2,2.476 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,2.7 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 1/58 (1.7%); Prostate Adenocarcinoma (TCGA): 4/480 (0.8%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 2/283 (0.7%),breast cancer: 6/12 (50.0%); pancreatic cancer: 3/10 (30.0%),31,20,Q5W064,https://www.uniprot.org/uniprotkb/Q5W064/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
LITAFD,ENSG00000283516,Neither,Screening,False,False,6.9,6.9,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,3.3035885379799996,1.8,,Neither,oncoref.target-sets.2026-10-23.2,3.304 TPM; blood/TFH; dice_tfh; vital,1.8 nTPM; liver/kupffer cells; hpa_single_cell_tissue; vital,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 24/283 (8.5%); Testicular Germ Cell Tumor (TCGA): 7/133 (5.3%); Kidney Renal Papillary Cell Carcinoma (TCGA): 12/282 (4.3%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,A0A1B0GVX0,https://www.uniprot.org/uniprotkb/A0A1B0GVX0/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
LRRC72,ENSG00000205858,Neither,Antibody,False,False,2.5,2.5,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA020554; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA020554; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA020554; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA020554; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA020554; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA020554; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA020554; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA020554; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA020554; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA020554; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA020554; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA020554; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA020554; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA020554; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA020554; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA020554; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA020554; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA020554; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA020554; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA020554; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA020554; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA020554; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA020554; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA020554; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA020554; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA020554; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA020554; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA020554; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA020554; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA020554; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA020554; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA020554; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA020554; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA020554; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA020554; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA020554; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA020554; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA020554; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA020554; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA020554; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA020554; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA020554; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA020554; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.771166156479,0.7,,Neither,oncoref.target-sets.2026-10-23.2,0.7712 TPM; blood/TFH; dice_tfh; vital,0.7 nTPM; bone marrow/erythroid cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),ovarian cancer: 12/12 (100.0%); cervical cancer: 11/11 (100.0%),29,20,A6NJI9,https://www.uniprot.org/uniprotkb/A6NJI9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
LRRC74A,ENSG00000100565,Neither,Antibody,False,False,6.4,6.4,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA035094; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA035094; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA035094; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA035094; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA035094; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: High, HPA035094; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA035094; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA035094; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA035094; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA035094; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA035094; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA035094; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA035094; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA035094; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA035094; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA035094; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA035094; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA035094; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA035094; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA035094; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA035094; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA035094; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA035094; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA035094; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA035094; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA035094; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA035094; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA035094; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA035094; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA035094; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA035094; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA035094; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA035094; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA035094; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA035094; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA035094; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA035094; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA035094; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA035094; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA035094; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA035094; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.70196169716,0.9,,CTA,oncoref.target-sets.2026-10-23.2,1.702 TPM; blood/M2; dice_m2; vital,0.9 nTPM; unsited/Microglial cells; hpa_single_cell; unresolved,Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Pancreatic Adenocarcinoma (TCGA): 1/176 (0.6%),colorectal cancer: 11/11 (100.0%); prostate cancer: 6/8 (75.0%),29,20,Q0VAA2,https://www.uniprot.org/uniprotkb/Q0VAA2/entry,,,,It is uncertain whether Met-1 or Met-27 is the initiator,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
LRRIQ4,ENSG00000188306,Neither,Antibody,False,False,2.8,2.8,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bronchus/Respiratory epithelial cells: Medium, HPA036706; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA036706; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA036706; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA036706; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA036706; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA036706; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA036706; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA036706; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.25899791267,2.4,,Neither,oncoref.target-sets.2026-10-23.2,1.259 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,2.4 nTPM; esophagus/t-cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 8/207 (3.9%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 9/283 (3.2%); Colon Adenocarcinoma (validation): 10/486 (2.1%),pancreatic cancer: 8/9 (88.9%); stomach cancer: 9/12 (75.0%),31,20,A6NIV6,https://www.uniprot.org/uniprotkb/A6NIV6/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
MAGEA2,ENSG00000268606,Neither,Low,False,False,4.1,4.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Skin Cuteneous Melanoma (TCGA): 33/99 (33.3%); Lung Squamous Cell Carcinoma (TCGA): 149/489 (30.5%); Lung Squamous Cell Carcinoma (validation): 20/68 (29.4%),No exact-ID IHC coverage in the HPA cancer snapshot,28,0,P43356,https://www.uniprot.org/uniprotkb/P43356/entry,Reduces p53/TP53 transactivation function through recruitment of HDAC3 to p53/TP53 transcription sites. Also represses p73/TP73 activity. Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination by TRIM28 potentially in presence of Ubl-conjugating enzyme UBE2H. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in embryonal development and tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. Negatively regulates acetylation and sumoylation of PML and represses PML-induced p53/TP53 acetylation and activation,"Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes",,,"Nucleus Nucleus, PML body",16847267|17942928|20864041|22117195,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Loriot2025_S1,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
MAGEA2B,ENSG00000183305,Neither,Low,False,False,1.9,1.9,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Skin Cuteneous Melanoma (TCGA): 32/99 (32.3%); Lung Squamous Cell Carcinoma (TCGA): 108/489 (22.1%); Stomach Adenocarcinoma (TCGA): 71/346 (20.5%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,P43356,https://www.uniprot.org/uniprotkb/P43356/entry,Reduces p53/TP53 transactivation function through recruitment of HDAC3 to p53/TP53 transcription sites. Also represses p73/TP73 activity. Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination by TRIM28 potentially in presence of Ubl-conjugating enzyme UBE2H. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in embryonal development and tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. Negatively regulates acetylation and sumoylation of PML and represses PML-induced p53/TP53 acetylation and activation,"Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes",,,"Nucleus Nucleus, PML body",16847267|17942928|20864041|22117195,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Jamin2021_CT | Jamin2021_core,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
MAGEA9,ENSG00000123584,Neither,Low,False,False,3.6,3.6,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.420792571852,1.3,,Neither,oncoref.target-sets.2026-10-23.2,0.4208 TPM; blood/CD4_STIM; dice_cd4_stim; vital,1.3 nTPM; liver/t-cells; hpa_single_cell_tissue; vital,Lung Squamous Cell Carcinoma (validation): 14/68 (20.6%); Lung Squamous Cell Carcinoma (TCGA): 94/489 (19.2%); Bladder Urothelial Carcinoma (TCGA): 15/169 (8.9%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,P43362,https://www.uniprot.org/uniprotkb/P43362/entry,"Not known, though may play a role in embryonal development and tumor transformation or aspects of tumor progression","Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes and placenta",,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Jamin2021_CT | Loriot2025_S1 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
MAGEB10,ENSG00000177689,Neither,Antibody,False,False,2.4,2.4,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA000611; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA000611; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: High, HPA000611; conflicting or uncurated primary profile; Colon/Endothelial cells: High, HPA000611; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA000611; conflicting or uncurated primary profile; Lung/Alveolar cells: High, HPA000611; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA000611; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA000611; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA000611; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA000611; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA000611; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA000611; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.02483648315,1.2,,Neither,oncoref.target-sets.2026-10-23.2,2.025 TPM; blood/TH1; dice_th1; vital,1.2 nTPM; skin/langerhans cells; hpa_single_cell_tissue; manageable,Uterine Corpus Endometrial Carcinoma (TCGA): 12/176 (6.8%); Testicular Germ Cell Tumor (TCGA): 8/133 (6.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 8/283 (2.8%),melanoma: 3/10 (30.0%); renal cancer: 1/11 (9.1%),31,20,Q96LZ2,https://www.uniprot.org/uniprotkb/Q96LZ2/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
MAGEB16,ENSG00000189023,Neither,Antibody,False,False,3.1,3.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bone marrow/Hematopoietic cells: Medium, HPA055743; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA055743; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA055743; conflicting or uncurated primary profile; Colon/Endothelial cells: High, HPA055743; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA055743; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA055743; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA055743; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA055743; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA055743; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA055743; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA055743; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA055743; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA055743; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA055743; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA055743; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA055743; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA055743; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA055743; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA055743; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA055743; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA055743; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0141,0.2,,Neither,oncoref.target-sets.2026-10-23.2,0.0141 TPM; blood/naive CD4 T-cell; hpa_immune_cell_samples; vital,0.2 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 18/133 (13.5%); Skin Cuteneous Melanoma (TCGA): 3/99 (3.0%); Bladder Urothelial Carcinoma (TCGA): 3/169 (1.8%),colorectal cancer: 11/12 (91.7%); skin cancer: 6/11 (54.5%),31,20,A2A368,https://www.uniprot.org/uniprotkb/A2A368/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S1 | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
MAGEB17,ENSG00000182798,Neither,Antibody,False,False,1.6,1.9,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,existing nomination or manual review; nomination unresolved; pancreas: 1.9 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA003756; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA003756; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA003756; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA003756; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA003756; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA003756; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA003756; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA003756; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA003756; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA003756; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA003756; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA003756; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA003756; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA003756; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA003756; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA003756; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA003756; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA003756; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA003756; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: High, HPA003756; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA003756; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA003756; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA003756; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA003756; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA003756; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA003756; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA003756; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA003756; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA003756; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA003756; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA003756; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.19964511702,2.8,,Neither,oncoref.target-sets.2026-10-23.2,1.2 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,2.8 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 70/207 (33.8%); Colon Adenocarcinoma (validation): 112/486 (23.0%); Colon Adenocarcinoma (TCGA): 56/254 (22.0%),glioma: 11/12 (91.7%); liver cancer: 11/12 (91.7%),29,20,A8MXT2,https://www.uniprot.org/uniprotkb/A8MXT2/entry,,,,"Formerly thought to be the product of a pseudogene, although could be a bona fide protein. However, scarce EST evidence confirms only the C-terminal sequence",,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
MAGEB5,ENSG00000188408,Neither,Antibody,False,False,0.9,0.9,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA052627; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA052627; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA052627; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: High, HPA052627; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA052627; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA052627; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA052627; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA052627; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA052627; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA052627; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA052627; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA052627; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: High, HPA052627; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA052627; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA052627; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA052627; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA052627; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA052627; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA052627; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.231567045449,0.3,,Neither,oncoref.target-sets.2026-10-23.2,0.2316 TPM; blood/TH17; dice_th17; vital,0.3 nTPM; pancreas/exocrine glandular cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),melanoma: 11/11 (100.0%); renal cancer: 7/11 (63.6%),29,20,Q9BZ81,https://www.uniprot.org/uniprotkb/Q9BZ81/entry,,"Expressed in testis. Not expressed in other normal tissues, but is expressed in tumors of different histological origins",,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
MAGEB6,ENSG00000176746,Neither,Unassessed,False,False,3.1,3.1,90,4,Positive somewhere,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,reviewed unreliable ihc; reviewed unreliable ihc,Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,kidney / proximal tubules (microvilli): Medium (Enhanced),reviewed_unreliable_ihc,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,1.2,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1.2 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 9/133 (6.8%); Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),stomach cancer: 1/12 (8.3%); breast cancer: 0/10 (0.0%),31,20,Q8N7X4,https://www.uniprot.org/uniprotkb/Q8N7X4/entry,,"Expressed in testis. Not expressed in other normal tissues, but is expressed in tumors of different histological origins",,,,,10861452,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Carter2023_CT | Loriot2025_S1 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
MAGEB6B,ENSG00000232030,Neither,Low,False,False,0.5,0.5,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0061,0.0055,,Neither,oncoref.target-sets.2026-10-23.2,0.0061 TPM; blood/MAIT T-cell; hpa_immune_cell_samples; vital,0.0055 nTPM; blood/MAIT T-cell; hpa_immune_cell_samples; vital,Glioblastoma Multiforme (validation): 1/58 (1.7%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A0A0J9YX57,https://www.uniprot.org/uniprotkb/A0A0J9YX57/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
MAJIN,ENSG00000168070,Neither,Cellular,False,False,21.8,21.8,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_monaco naive CD8 T-cell: 5.8 TPM; hpa_immune_monaco Non-switched memory B-cell: 11.4 TPM,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,11.4,23.6,,CTA,oncoref.target-sets.2026-10-23.2,11.4 TPM; blood/Non-switched memory B-cell; hpa_immune_monaco; vital,23.6 nTPM; kidney/proximal tubular cells; hpa_single_cell_tissue; vital,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 56/283 (19.8%); Kidney Renal Papillary Cell Carcinoma (TCGA): 37/282 (13.1%); Ovary Serous Cystadenocarcinoma (TCGA): 36/349 (10.3%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q3KP22,https://www.uniprot.org/uniprotkb/Q3KP22/entry,"Meiosis-specific telomere-associated protein involved in meiotic telomere attachment to the nucleus inner membrane, a crucial step for homologous pairing and synapsis. Component of the MAJIN-TERB1-TERB2 complex, which promotes telomere cap exchange by mediating attachment of telomeric DNA to the inner nuclear membrane and replacement of the protective cap of telomeric chromosomes: in early meiosis, the MAJIN-TERB1-TERB2 complex associates with telomeric DNA and the shelterin/telosome complex. During prophase, the complex matures and promotes release of the shelterin/telosome complex from telomeric DNA. In the complex, MAJIN acts as the anchoring subunit to the nucleus inner membrane. MAJIN shows DNA-binding activity, possibly for the stabilization of telomere attachment on the nucleus inner membrane",,,,"Nucleus inner membrane Chromosome, telomere",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Loriot2025_S1 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
MBD3L2,ENSG00000230522,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Testicular Germ Cell Tumor (TCGA): 12/133 (9.0%); Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%); Ovary Serous Cystadenocarcinoma (TCGA): 2/349 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NHZ7,https://www.uniprot.org/uniprotkb/Q8NHZ7/entry,May displace the NuRD complex from chromatin,"Detected at low levels in several somatic tissues (PubMed:12504854, PubMed:15701600). Highly expressed in the ovarian teratocarcinoma cell line PA-1 (PubMed:12504854)",,,Nucleus,15701600,12504854|15701600,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
MBD3L3,ENSG00000182315,Neither,Low,False,False,0.8,0.8,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.8,0.8329,,Neither,oncoref.target-sets.2026-10-23.2,0.8 TPM; blood/Memory CD4 T-cell Th1; hpa_immune_monaco; vital,0.8329 nTPM; blood/myeloid DC; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 5/133 (3.8%); Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,A6NE82,https://www.uniprot.org/uniprotkb/A6NE82/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
MBD3L4,ENSG00000205718,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A6NDZ8,https://www.uniprot.org/uniprotkb/A6NDZ8/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
MBD3L5,ENSG00000237247,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.1,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.1 nTPM; tongue/basal keratinocytes; hpa_single_cell_tissue; protected,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A6NJ08,https://www.uniprot.org/uniprotkb/A6NJ08/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
MEIOSIN,ENSG00000237452,Neither,Antibody,False,False,7.1,7.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA049521; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA049521; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA049521; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA049521; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA049521; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA049521; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA049521; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA049521; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA049521; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA049521; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA049521; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA049521; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.55820658676,1.2,,CTA,oncoref.target-sets.2026-10-23.2,0.5582 TPM; blood/NK; dice_nk; vital,1.2 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 3/283 (1.1%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),endometrial cancer: 1/11 (9.1%); renal cancer: 1/12 (8.3%),29,20,C9JSJ3,https://www.uniprot.org/uniprotkb/C9JSJ3/entry,"Gatekeeper of meiotic initiation in both male and female germ cells. In complex with STRA8, directly activates the transcription of a subset of critical meiotic genes playing a central role in cell-cycle switching from mitosis to meiosis. Temporal expression of MEIOSIN is required for meiotic entry decision",,,Contains a degenerate basic motif not likely to bind DNA,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
MEX3B,ENSG00000183496,Neither,Cellular,False,False,45.5,45.5,86,4,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE MONOCYTES (unstimulated): 3/91 values ≥5 TPM, max 5.37881; hpa_immune_monaco Progenitor cell: 7.6 TPM",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,7.6,28.4,,CTA,oncoref.target-sets.2026-10-23.2,7.6 TPM; blood/Progenitor cell; hpa_immune_monaco; vital,28.4 nTPM; skin/fibroblasts; hpa_single_cell_tissue; manageable,Breast Invasive Carcinoma (validation): 43/50 (86.0%); Testicular Germ Cell Tumor (TCGA): 73/133 (54.9%); Glioblastoma Multiforme (validation): 29/58 (50.0%),testis cancer: 3/12 (25.0%); breast cancer: 0/11 (0.0%),31,20,Q6ZN04,https://www.uniprot.org/uniprotkb/Q6ZN04/entry,RNA-binding protein. May be involved in post-transcriptional regulatory mechanisms,"Highest levels found in fetal brain and testis. Detected in the adult intestinal epithelium, specifically in goblet cell at protein level",,,"Nucleus Cytoplasm Cytoplasm, P-body Cytoplasmic granule",,17267406,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
MMP20,ENSG00000137674,Neither,Low,False,False,0.6,0.6,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.241183130695,1.7,,Neither,oncoref.target-sets.2026-10-23.2,0.2412 TPM; blood/TH2; dice_th2; vital,1.7 nTPM; kidney/proximal tubular cells; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (TCGA): 20/1022 (2.0%); Ovary Serous Cystadenocarcinoma (validation): 1/81 (1.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O60882,https://www.uniprot.org/uniprotkb/O60882/entry,"Degrades amelogenin, the major protein component of the enamel matrix and two of the macromolecules characterizing the cartilage extracellular matrix: aggrecan and the cartilage oligomeric matrix protein (COMP). May play a central role in tooth enamel formation. Cleaves aggrecan at the '360-Asn-|-Phe-361' site",Expressed specifically in the enamel organ,"Amelogenesis imperfecta, hypomaturation type, 2A2: A defect of enamel formation. The disorder involves both primary and secondary dentitions. The teeth have a shiny agar jelly appearance and the enamel is softer than normal. Brown pigment is present in middle layers of enamel.",,"Secreted, extracellular space, extracellular matrix",10922468|9398237,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
MOS,ENSG00000172680,Neither,Low,False,False,0.7,0.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.611153883395,0.2,,Neither,oncoref.target-sets.2026-10-23.2,0.6112 TPM; blood/TH1; dice_th1; vital,0.2 nTPM; fallopian tube/granulocytes; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Liver Hepatocellular Carcinoma (TCGA): 1/362 (0.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P00540,https://www.uniprot.org/uniprotkb/P00540/entry,Serine/threonine kinase involved in the regulation of MAPK signaling. Is an activator of the ERK1/2 signaling cascade playing an essential role in the stimulation of oocyte maturation,Highly expressed in oocytes. Lower expression is detected in early embryo,"Oocyte/zygote/embryo maturation arrest 20: An autosomal recessive, female infertility disorder characterized by early embryonic arrest and fragmentation. Early embryo fragmentation is defined by the presence of anucleate cell fragments derived from the blastomeres. Excessive embryo fragmentation is associated with deleterious outcomes, including decreased implantation rate.",,Cytoplasm,34779126|34997960|35670744,34779126,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
MPC1L,ENSG00000238205,Neither,Screening,False,False,17.9,17.9,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.49705368646,2.2,,Neither,oncoref.target-sets.2026-10-23.2,1.497 TPM; blood/CD4_STIM; dice_cd4_stim; vital,2.2 nTPM; pancreas/exocrine glandular cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 16/133 (12.0%); Lung Adenocarcinoma (TCGA): 3/497 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P0DKB6,https://www.uniprot.org/uniprotkb/P0DKB6/entry,Mediates the uptake of pyruvate into mitochondria,,,,Mitochondrion inner membrane,27317664|35278701,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
MRGPRG,ENSG00000182170,Neither,Antibody,False,False,0.7,0.7,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bronchus/Respiratory epithelial cells: High, HPA058909; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA058909; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.284751843125,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0.2848 TPM; blood/CD4_STIM; dice_cd4_stim; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q86SM5,https://www.uniprot.org/uniprotkb/Q86SM5/entry,"Orphan receptor. May regulate nociceptor function and/or development, including the sensation or modulation of pain (By similarity)",,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
MRGPRX4,ENSG00000179817,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,1.1,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1.1 nTPM; bronchus/basal respiratory cells; hpa_single_cell_tissue; vital,Skin Cuteneous Melanoma (TCGA): 2/99 (2.0%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96LA9,https://www.uniprot.org/uniprotkb/Q96LA9/entry,"G protein-coupled receptor for bile acids, which is specifically expressed in sensory neurons of dorsal root ganglion and is involved in itch perception (PubMed:31068464, PubMed:31500698, PubMed:34789874, PubMed:38718132, PubMed:39476841). Activated by bile acids, such as deoxycholate, chenodeoxycholate, taurocholate, taurodeoxycholate and taurodeoxycholate (PubMed:31068464, PubMed:31500698, PubMed:39476841). Has a preference for 3-sulfated bile acids, such as deoxycholate 3-sulfate, glycoursodeoxycholate 3-sulfate and tauroursodeoxycholate 3-sulfate, which are present at high level in cholestatic patients with itch symptoms (PubMed:39476841). Bile acid-binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors (PubMed:30768591, PubMed:31068464, PubMed:31500698, PubMed:34789874, PubMed:38718132, PubMed:39476841). MRGPRX4 is coupled to G(q)/G(11) G alpha proteins and activates phospholipase C-beta, releasing diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) second messengers that modulate the activity of phosphatidylinositol 3-kinase and promote the release of Ca2+ ions from intracellular stores, respectively (PubMed:30768591, PubMed:31068464, PubMed:31500698, PubMed:34789874, PubMed:38718132, PubMed:39476841)",Uniquely localized in a subset of small dorsal root and trigeminal sensory neurons,,"Bilirubin IXalpha was initially reported to act as a ligand (PubMed:30657454). However, it was later shown to act as a positive allosteric modulator that facilites MRGPRX4 activation by nile acids (PubMed:31500698)",Cell membrane,30768591|31068464|31500698|34789874|38718132|39476841,11850634|31500698,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
MS4A13,ENSG00000204979,Neither,Antibody,False,False,3.4,3.4,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Kidney/Cells in tubules: Medium, HPA045017; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA045017; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA045017; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA063626; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA063626; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA063626; conflicting or uncurated primary profile; Colon/Endothelial cells: High, HPA063626; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA063626; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA063626; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA063626; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA063626; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA063626; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA063626; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA063626; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA063626; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA063626; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA063626; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA063626; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA063626; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA063626; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA063626; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA063626; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.226785506148,4.1,,Neither,oncoref.target-sets.2026-10-23.2,0.2268 TPM; blood/TFH; dice_tfh; vital,4.1 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%),breast cancer: 2/10 (20.0%); urothelial cancer: 2/11 (18.2%),31,20,Q5J8X5,https://www.uniprot.org/uniprotkb/Q5J8X5/entry,May be involved in signal transduction as a component of a multimeric receptor complex,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
MS4A5,ENSG00000166930,Neither,Antibody,False,False,43.3,43.3,82,2,Positive somewhere,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA043732; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA043732; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA043732; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA043732; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA043732; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA043732; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA043732; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA043732; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA043732; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA043732; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA043732; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA043732; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA043732; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA043732; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA043732; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA043732; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.6,3.7,,CTA,oncoref.target-sets.2026-10-23.2,1.6 TPM; blood/Switched memory B-cell; hpa_immune_monaco; vital,3.7 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Breast Invasive Carcinoma (TCGA): 3/1022 (0.3%),prostate cancer: 3/8 (37.5%); liver cancer: 4/12 (33.3%),31,20,Q9H3V2,https://www.uniprot.org/uniprotkb/Q9H3V2/entry,May be involved in signal transduction as a component of a multimeric receptor complex,"Expressed at high level in the testis. Detected also in the pancreas, heart and in the brain",,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
MSL3B,ENSG00000293137,Neither,Unassessed,False,False,,,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"incomplete routine rna; insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete routine rna; missing normal RNA: adipose tissue, adrenal gland, amygdala, basal ganglia, bone marrow, cerebellum, cerebral cortex, choroid plexus, colon, duodenum, esophagus, heart muscle, hippocampal formation, hypothalamus, kidney, liver, lung, lymph node, midbrain, pancreas, parathyroid gland, pituitary gland, rectum, retina, salivary gland, skeletal muscle, skin, small intestine, smooth muscle, spinal cord, spleen, stomach, thymus, thyroid gland, tongue, urinary bladder; incomplete tissue evidence",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,False,False,,False,False,False,,False,False,,False,False,False,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,False,False,,,,Neither,oncoref.target-sets.2026-10-23.2,,,No exact-ID RNA coverage in the HPA cancer snapshot,No exact-ID IHC coverage in the HPA cancer snapshot,0,0,P0C860,https://www.uniprot.org/uniprotkb/P0C860/entry,"Probable non-catalytic component of the MSL histone acetyltransferase complex, a multiprotein complex that mediates the majority of histone H4 acetylation at 'Lys-16' (H4K16ac), an epigenetic mark that prevents chromatin compaction",,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MYO1H,ENSG00000174527,Neither,Antibody,False,False,0.9,0.9,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA039516; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA039516; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA039516; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA039516; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA039516; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA039516; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA039516; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA039516; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA039516; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA039516; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA039516; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA039516; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA039516; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA039516; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA039516; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA039516; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA039516; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA039516; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA039516; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA039516; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA039516; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA039516; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA039516; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA039516; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA039516; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA039516; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA039516; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA039516; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA039516; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA039516; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA039516; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA039516; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA039516; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA039516; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA039516; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA039516; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA039516; conflicting or uncurated primary profile; Skin 1/Langerhans: High, HPA039516; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA039516; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA039516; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA039516; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA039516; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA039516; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA039516; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA039516; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA039516; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA039516; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,5.118363405899999,2.6,,Neither,oncoref.target-sets.2026-10-23.2,5.118 TPM; blood/NK; dice_nk; vital,2.6 nTPM; skeletal muscle/mixed cell types; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 4/50 (8.0%); Kidney Chromophobe (TCGA): 4/64 (6.2%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%),liver cancer: 12/12 (100.0%); pancreatic cancer: 11/11 (100.0%),31,20,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
NBPF4,ENSG00000196427,Neither,Antibody,False,False,4.3,4.3,79,1,Positive somewhere,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA045044; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA045044; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA045044; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA045044; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA045044; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA045044; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA045044; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA045044; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA045044; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA045044; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA045044; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA045044; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA045044; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA045044; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA045044; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA045044; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA045044; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA045044; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA045044; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA045044; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA045044; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA045044; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA045044; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA045044; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA045044; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA045044; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA045044; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA045044; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA045044; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA045044; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA045044; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA045044; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA045044; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA045044; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA045044; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA045044; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA045044; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA045044; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA045044; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA045044; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA045044; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA045044; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA045044; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA045044; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA046411; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA046411; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA046411; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA046411; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA046411; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA046411; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA046411; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA046411; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA046411; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA046411; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA046411; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA046411; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA047447; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA047447; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA047447; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA047447; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA047447; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA047447; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA047447; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA047447; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA047447; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA047447; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA047447; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA047447; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA047447; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA047447; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA047447; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA047447; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA047447; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA047447; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA047447; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA047447; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA047447; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA058050; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA058050; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA058050; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA058050; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA058050; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA058050; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA058050; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA058050; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA058050; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA058050; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA058050; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA058050; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA058050; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA058050; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA058050; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA058050; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.3981255788,1.1,,CTA,oncoref.target-sets.2026-10-23.2,1.398 TPM; blood/TREG_MEM; dice_treg_mem; vital,1.1 nTPM; small intestine/bulk; hpa_rna_consensus; vital,Breast Invasive Carcinoma (validation): 30/50 (60.0%); Breast Invasive Carcinoma (TCGA): 299/1022 (29.3%); Rectum Adenocarcinoma (validation): 10/207 (4.8%),melanoma: 6/12 (50.0%); urothelial cancer: 4/12 (33.3%),31,20,Q96M43,https://www.uniprot.org/uniprotkb/Q96M43/entry,,Expressed in testis,,,Cytoplasm,,16079250,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
NEUROG1,ENSG00000181965,Neither,Low,False,False,0.0,0.7,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,10.8,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,10.8 nTPM; eye/bipolar cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 12/133 (9.0%); Bladder Urothelial Carcinoma (TCGA): 2/169 (1.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q92886,https://www.uniprot.org/uniprotkb/Q92886/entry,Acts as a transcriptional regulator. Involved in the initiation of neuronal differentiation. Activates transcription by binding to the E box (5'-CANNTG-3'). Associates with chromatin to enhancer regulatory elements in genes encoding key transcriptional regulators of neurogenesis (By similarity),Expression restricted to the embryonic nervous system,"Cranial dysinnervation disorder, congenital, with absent corneal reflex and developmental delay: An autosomal recessive form of congenital cranial dysinnervation disorder. This term defines a heterogeneous group of neurodevelopmental disorders caused by a primary disturbance of innervation due to deficient, absent, or misguided cranial nerves. CCDDRD is characterized by developmental delay, corneal opacity, absent corneal reflex, expressionless face with asymmetry, sensorineural hearing loss, trigeminal nerve hypoplasia, and bilateral agenesis or severe hypoplasia of the VIII nerve with marked atresia of the internal auditory canals and cochlear labyrinth malformation. Additional features include hypotonia, impaired intellectual development, and behavioral abnormalities.",,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
NFILZ,ENSG00000268480,Neither,Cellular,False,False,1.6,1.6,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,"existing nomination or manual review; incomplete routine rna; nomination unresolved; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord; bone marrow: 0.8 nTPM; continuous selectivity; retina: 0.5 nTPM; continuous selectivity",Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_cell NK-cell: 14.5 nTPM; hpa_immune_monaco Memory CD4 T-cell Th2: 9 TPM; hpa_immune_monaco NK-cell: 13.6 TPM; hpa_immune_monaco Terminal effector memory CD8 T-cell: 5.9 TPM,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,24.258,23.7218,,Neither,oncoref.target-sets.2026-10-23.2,24.26 TPM; blood/NK-cell; hpa_immune_cell_samples; vital,23.72 nTPM; blood/NK-cell; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Colon Adenocarcinoma (validation): 1/486 (0.2%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A0A5F9ZHS7,https://www.uniprot.org/uniprotkb/A0A5F9ZHS7/entry,,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_ncRNA,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
NKX1-1,ENSG00000235608,Neither,Antibody,False,False,0.5,0.5,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bone marrow/Hematopoietic cells: Medium, HPA029367; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA029367; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA029367; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA029367; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA029367; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA029367; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA029367; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA029367; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA029367; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA029367; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA029367; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA029367; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA029367; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.484016992544,0.2,,Neither,oncoref.target-sets.2026-10-23.2,0.484 TPM; blood/TH2; dice_th2; vital,0.2 nTPM; adipose tissue/macrophages; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),glioma: 3/10 (30.0%); liver cancer: 3/12 (25.0%),29,20,Q15270,https://www.uniprot.org/uniprotkb/Q15270/entry,"May be required for the coordinated crosstalk of factors involved in the maintenance of energy homeostasis, possibly by regulating the transcription of specific factors involved in energy balance",Expressed in hemopoietic progenitor cells,,,Nucleus,,7518789,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
NKX2-4,ENSG00000125816,Neither,Low,False,False,1.1,1.1,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,hypothalamus: 0.5 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.538760009959,0.5,,Neither,oncoref.target-sets.2026-10-23.2,0.5388 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.5 nTPM; hypothalamus/bulk; hpa_rna_consensus; vital,Kidney Renal Papillary Cell Carcinoma (TCGA): 9/282 (3.2%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 9/283 (3.2%); Skin Cuteneous Melanoma (TCGA): 2/99 (2.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q9H2Z4,https://www.uniprot.org/uniprotkb/Q9H2Z4/entry,Probable transcription factor,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
NLRP11,ENSG00000179873,Neither,Antibody,False,False,1.1,1.1,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,liver: 1 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bronchus/Respiratory epithelial cells: High, HPA046402; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA046402; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA046402; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: High, HPA046402; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: High, HPA046402; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA046402; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA046402; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA046402; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA046402; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA046402; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA046402; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA046402; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA046402; conflicting or uncurated primary profile; Skin 1/Keratinocytes: High, HPA046402; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA046402; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA046402; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA046402; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA046402; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.994924075323,5.9,,Neither,oncoref.target-sets.2026-10-23.2,0.9949 TPM; blood/NK; dice_nk; vital,5.9 nTPM; esophagus/b-cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 3/58 (5.2%); Lung Adenocarcinoma (validation): 4/105 (3.8%); Liver Hepatocellular Carcinoma (validation): 8/231 (3.5%),skin cancer: 9/12 (75.0%); glioma: 5/12 (41.7%),31,20,P59045,https://www.uniprot.org/uniprotkb/P59045/entry,Involved in inflammation,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Carter2023_CT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene,,,,,,,,
NLRP8,ENSG00000179709,Neither,Antibody,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Retained,Normal,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bronchus/Respiratory epithelial cells: Low, HPA056989; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA056989; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA056989; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA056989; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA056989; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA056989; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA056989; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA056989; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA056989; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA056989; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA056989; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA056989; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA056989; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA056989; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA056989; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA056989; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA056989; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA056989; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA056989; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.43620870491,1.4,,Neither,oncoref.target-sets.2026-10-23.2,0.4362 TPM; blood/NK; dice_nk; vital,1.4 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 4/176 (2.3%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Breast Invasive Carcinoma (TCGA): 1/1022 (0.1%),colorectal cancer: 4/12 (33.3%); stomach cancer: 3/10 (30.0%),31,20,Q86W28,https://www.uniprot.org/uniprotkb/Q86W28/entry,Involved in inflammation,,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
NLRP9,ENSG00000185792,Neither,Unassessed,False,False,2.0,2.0,78,31,Positive somewhere,False,False,False,False,Excluded,Unassessed,True,,Not assessed,,,reviewed unreliable ihc; reviewed unreliable ihc,Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Low (Approved); bronchus / respiratory epithelial cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in tubules: Medium (Approved); lung / macrophages: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: High (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / Langerhans: Low (Approved); small intestine / glandular cells: High (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),reviewed_unreliable_ihc,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.37767271317,2.2,,Neither,oncoref.target-sets.2026-10-23.2,2.378 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,2.2 nTPM; lymph node/b-cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 71/133 (53.4%); Liver Hepatocellular Carcinoma (validation): 6/231 (2.6%); Prostate Adenocarcinoma (TCGA): 10/480 (2.1%),colorectal cancer: 7/12 (58.3%); stomach cancer: 5/11 (45.5%),31,20,Q7RTR0,https://www.uniprot.org/uniprotkb/Q7RTR0/entry,"As the sensor component of the NLRP9 inflammasome, plays a crucial role in innate immunity and inflammation. In response to pathogens, including rotavirus, initiates the formation of the inflammasome polymeric complex, made of NLRP9, PYCARD and CASP1. Recruitment of proCASP1 to the inflammasome promotes its activation and CASP1-catalyzed IL1B and IL18 maturation and release in the extracellular milieu. The active cytokines stimulate inflammatory responses. Inflammasomes can also induce pyroptosis, an inflammatory form of programmed cell death. NLRP9 inflammasome activation may be initiated by DHX9 interaction with viral double-stranded RNA (dsRNA), preferentially to short dsRNA segments","Expressed in ileum intestinal epithelial cells. Not detected in peripheral blood mononuclear cells (PubMed:28636595). Expressed in cerebral endothelial cells and, at much lower levels, in brain pericytes (PubMed:28432035)",,,Cytoplasm Inflammasome,28636595,28432035|28636595,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination; inclusion depends on TGCT under this study's thresholds,,,,,,,,
NMBR,ENSG00000135577,Neither,Cellular,False,False,0.7,0.7,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,basal ganglia: 0.4 nTPM; continuous selectivity; hypothalamus: 0.3 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,True,"brain/inhibitory neurons cluster c-17: 27.9 nTPM, 901 reads; reproductive-cell max 11.8",True,False,,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.443815632556,27.9,,Neither,oncoref.target-sets.2026-10-23.2,0.4438 TPM; blood/NK; dice_nk; vital,27.9 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P28336,https://www.uniprot.org/uniprotkb/P28336/entry,"Receptor for neuromedin-B (PubMed:1655761). Contributes to the maintenance of basal sigh rate through signaling in the pre-Botzinger complex, a cluster of several thousand neurons in the ventrolateral medulla responsible for inspiration during respiratory activity (By similarity). Contributes to the induction of sneezing following exposure to chemical irritants or allergens which causes release of NMB by nasal sensory neurons and activation of NMBR-expressing neurons in the sneeze-evoking region of the brainstem (By similarity). These in turn activate neurons of the caudal ventral respiratory group, giving rise to the sneezing response (By similarity). Contributes to induction of acute itch, possibly through its activation on dorsal root ganglion neurons by the NMB peptide (By similarity). Plays a role in the innate immune response to influenza A virus infection by enhancing interferon alpha expression and reducing expression of IL6 (PubMed:31601264). Plays a role in CSF1-induced proliferation of osteoclast precursors by contributing to the positive regulation of the expression of the CSF1 receptor CSF1R (By similarity)",Expressed in epididymis (at protein level),,,Cell membrane,1655761|31601264,20736409,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
NMS,ENSG00000204640,Neither,Low,False,False,0.3,0.8,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; hypothalamus: 0.8 nTPM; continuous selectivity;reproductive not higher; spinal cord: 0.4 nTPM; continuous selectivity;reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.09366450778,2.3,,Neither,oncoref.target-sets.2026-10-23.2,1.094 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,2.3 nTPM; skeletal muscle/smooth muscle cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Stomach Adenocarcinoma (TCGA): 1/346 (0.3%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5H8A3,https://www.uniprot.org/uniprotkb/Q5H8A3/entry,Implicated in the regulation of circadian rhythms through autocrine and/or paracrine actions,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
NOBOX,ENSG00000106410,Neither,Low,False,False,0.5,0.5,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.411405559888,0.4,,Neither,oncoref.target-sets.2026-10-23.2,0.4114 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.4 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Head and Neck Squamous Cell Carcinoma (TCGA): 30/492 (6.1%); Lung Squamous Cell Carcinoma (TCGA): 14/489 (2.9%); Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O60393,https://www.uniprot.org/uniprotkb/O60393/entry,"Transcription factor which may play a role in oogenesis. Binds preferentially to the DNA sequences 5'-TAATTG-3', 5'-TAGTTG-3' and 5'-TAATTA-3'","Expressed in ovaries, testes and pancreas. Expressed within all stages of the adult female germline, from primordial follicles through to MII oocytes","Premature ovarian failure 5: An ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol.",,Nucleus,25514101|27798098,16597639,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
NOX5,ENSG00000255346,Neither,Selectivity,False,False,1.0,8.4,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,smooth muscle: 0.8 nTPM; continuous selectivity; spleen: 8.4 nTPM; continuous selectivity;reproductive not higher,Fails reproductive selectivity without above-ceiling normal RNA or a normal-protein veto,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Selectivity,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.6350181309440001,11.8,,Neither,oncoref.target-sets.2026-10-23.2,0.635 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,11.8 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 13/50 (26.0%); Kidney Renal Clear Cell Carcinoma (validation): 20/100 (20.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 9/176 (5.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96PH1,https://www.uniprot.org/uniprotkb/Q96PH1/entry,"Calcium-dependent NADPH oxidase that catalyzes the generation of superoxide from molecular oxygen utilizing NADPH as an electron donor (PubMed:12686516). Also synthesizes NAADP from its reduced NAADPH form which promotes Ca(2+) signaling during T cell activation (PubMed:34784249). May play a role in cell growth and apoptosis (PubMed:12686516) Calcium-dependent NADPH oxidase that catalyzes the generation of superoxide from molecular oxygen utilizing NADPH as an electron donor (PubMed:11483596, PubMed:14982937, PubMed:17275676, PubMed:17587483, PubMed:21642394, PubMed:22387196, PubMed:22427510, PubMed:24505490, PubMed:36653838). Involved in endothelial generation of reactive oxygen species (ROS), proliferation and angiogenesis and contributes to endothelial response to thrombin (PubMed:17275676). Regulates redox-dependent processes in lymphocytes and spermatozoa (PubMed:11483596) Calcium-dependent NADPH oxidase that catalyzes the generation of superoxide from molecular oxygen utilizing NADPH as an electron donor This isoform lacks calcium-binding domains and was showed to present a NADPH oxidase activity in a calcium-independent manner (PubMed:17275676, PubMed:36653838). May be involved in endothelial generation of reactive oxygen species (ROS), proliferation and angiogenesis and contribute to endothelial response to thrombin (PubMed:17275676). However another study showed an absence of oxidase activity (PubMed:22427510). Subject to rapid degradation (PubMed:36653838) Lacks calcium-dependent NADPH oxidase activity","Mainly expressed in pachytene spermatocytes of testis and in lymphocyte-rich areas of spleen and lymph nodes. Also detected in ovary, placenta, pancreas, cardiac fibroblasts. Expressed in B-cells and prostate malignant cells Expressed in spleen (PubMed:11483596). Expressed in endothelial cells, pulmonary artery smooth muscle cells and epithelial colorectal adenocarcinoma cells (PubMed:17275676, PubMed:22427510) Expressed in microvascular endothelial cells (at protein level) (PubMed:17275676). Expressed in testis (PubMed:11483596). Expressed in endothelial cells and pulmonary artery smooth muscle cells (PubMed:17275676, PubMed:22427510) Expressed in pulmonary artery smooth muscle cells and epithelial colorectal adenocarcinoma cells Expressed in endothelial cells and pulmonary artery smooth muscle cells Expressed in microvascular endothelial cells (at protein level)",,This isoform was proposed to act as a calcium-dependent proton channel to compensate charge and pH alterations due to electron export; however the channel activity seems to lack strong experimental evidence,Endoplasmic reticulum Cell membrane,11483596|12686516|14982937|17275676|17587483|21319793|21642394|22387196|22427510|24505490|34784249|36653838,11376945|11483596|12686516|16179589|16339585|17275676|22427510,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
NPAP1,ENSG00000185823,Neither,Antibody,False,False,2.8,2.8,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,kidney: 0.8 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bronchus/Respiratory epithelial cells: Medium, HPA018828; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA018828; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA018828; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA018828; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA018828; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA018828; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA018828; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA018828; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA018828; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA018828; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA018828; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA018828; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA018828; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA018828; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA018828; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA018828; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA018828; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA018828; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA018828; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA018828; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA018828; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA018828; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA018828; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA019562; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA019562; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA019562; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA019562; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA019562; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA019562; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA019562; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA019562; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA019562; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.8,7.5,,Neither,oncoref.target-sets.2026-10-23.2,2.8 TPM; blood/naive CD8 T-cell; hpa_immune_monaco; vital,7.5 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 6/176 (3.4%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%),colorectal cancer: 5/12 (41.7%); stomach cancer: 2/12 (16.7%),29,20,Q9NZP6,https://www.uniprot.org/uniprotkb/Q9NZP6/entry,May be involved in spermatogenesis,Testis-specific in adults. In fetal brain expressed only from the paternal allele,,,"Nucleus, nucleoplasm Nucleus inner membrane",,10783265|17337158|20020165,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
NT5C1B,ENSG00000185013,Neither,Antibody,False,False,34.5,34.5,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_monaco Central memory CD8 T-cell: 9.1 TPM; hpa_immune_monaco MAIT T-cell: 5.2 TPM; hpa_immune_monaco Memory CD4 T-cell Th1: 5.2 TPM; hpa_immune_monaco Memory CD4 T-cell Th1/Th17: 5.6 TPM; hpa_immune_monaco Memory CD4 T-cell Th17: 5.5 TPM; hpa_immune_monaco Memory CD4 T-cell Th2: 5.7 TPM; hpa_immune_monaco naive CD4 T-cell: 6.2 TPM; hpa_immune_monaco naive CD8 T-cell: 8.9 TPM; hpa_immune_monaco T-reg: 6.3 TPM; hpa_immune_monaco Vd2 gdTCR: 5.4 TPM,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA056683; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA056683; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA056683; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA056683; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA056683; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA056683; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA056683; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA056683; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA056683; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA056683; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA056683; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA056683; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA056683; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA056683; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA056683; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA056683; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA056683; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA056683; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA056683; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA056683; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA056683; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA056683; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA056683; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA056683; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA056683; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA056683; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA056683; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA056683; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,9.1,2.4809,,CTA,oncoref.target-sets.2026-10-23.2,9.1 TPM; blood/Central memory CD8 T-cell; hpa_immune_monaco; vital,2.481 nTPM; blood/plasmacytoid DC; hpa_immune_cell_samples; vital,Kidney Chromophobe (TCGA): 4/64 (6.2%); Bladder Urothelial Carcinoma (TCGA): 4/169 (2.4%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%),colorectal cancer: 9/12 (75.0%); liver cancer: 8/12 (66.7%),31,20,Q96P26,https://www.uniprot.org/uniprotkb/Q96P26/entry,"Catalyzes the hydrolysis of nucleotide monophosphates, releasing inorganic phosphate and the corresponding nucleoside, AMP is the major substrate","Highly expressed in testis, placenta and pancreas. Detected at lower levels in heart, kidney, liver and lung",,,Cytoplasm,,11690631,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
NT5C1B-RDH14,ENSG00000250741,Neither,Antibody,False,False,16.1,16.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA056683; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA056683; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA056683; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA056683; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA056683; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA056683; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA056683; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA056683; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA056683; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA056683; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA056683; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA056683; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA056683; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA056683; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA056683; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA056683; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA056683; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA056683; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA056683; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA056683; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA056683; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA056683; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA056683; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA056683; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA056683; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA056683; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA056683; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA056683; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.1113,0.1017,,CTA,oncoref.target-sets.2026-10-23.2,0.1113 TPM; blood/gdT-cell; hpa_immune_cell_samples; vital,0.1017 nTPM; blood/gdT-cell; hpa_immune_cell_samples; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 0/283 (0.0%),colorectal cancer: 9/12 (75.0%); liver cancer: 8/12 (66.7%),29,20,Q96P26,https://www.uniprot.org/uniprotkb/Q96P26/entry,"Catalyzes the hydrolysis of nucleotide monophosphates, releasing inorganic phosphate and the corresponding nucleoside, AMP is the major substrate","Highly expressed in testis, placenta and pancreas. Detected at lower levels in heart, kidney, liver and lung",,,Cytoplasm,,11690631,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
OCM2,ENSG00000135175,Neither,Antibody,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Kidney/Cells in tubules: Medium, HPA046422; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA046422; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA046422; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA046422; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA046422; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA046422; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA046422; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA046422; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.7655004081,0.2439,,Neither,oncoref.target-sets.2026-10-23.2,1.766 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,0.2439 nTPM; blood/T-reg; hpa_immune_cell_samples; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Breast Invasive Carcinoma (validation): 0/50 (0.0%),liver cancer: 1/12 (8.3%); breast cancer: 0/11 (0.0%),31,20,P0CE71,https://www.uniprot.org/uniprotkb/P0CE71/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR10A4,ENSG00000170782,Neither,Low,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.863748808559,0.6687,,Neither,oncoref.target-sets.2026-10-23.2,0.8637 TPM; blood/TREG_MEM; dice_treg_mem; vital,0.6687 nTPM; blood/plasmacytoid DC; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 1/283 (0.4%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9H209,https://www.uniprot.org/uniprotkb/Q9H209/entry,Odorant receptor (Potential). May be involved in taste perception,Expressed in the tongue,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR10A7,ENSG00000179919,Neither,Antibody,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA055111; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA055111; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA055111; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA055111; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA055111; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA055111; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA055111; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA055111; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA055111; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.264947429971,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0.2649 TPM; blood/CD8_STIM; dice_cd8_stim; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Glioblastoma Multiforme (validation): 1/58 (1.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),breast cancer: 1/10 (10.0%); ovarian cancer: 1/11 (9.1%),31,20,Q8NGE5,https://www.uniprot.org/uniprotkb/Q8NGE5/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR10D3,ENSG00000197309,Neither,Low,False,False,0.8,0.8,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.322108803621,0.0042,,Neither,oncoref.target-sets.2026-10-23.2,0.3221 TPM; blood/TH1; dice_th1; vital,0.0042 nTPM; blood/NK-cell; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q8NH80,https://www.uniprot.org/uniprotkb/Q8NH80/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
OR10H5,ENSG00000172519,Neither,Low,False,False,0.2,0.6,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 0.6 nTPM; continuous selectivity;reproductive not higher; retina: 0.3 nTPM; continuous selectivity;reproductive not higher; skeletal muscle: 0.6 nTPM; continuous selectivity;reproductive not higher; skin: 0.3 nTPM; continuous selectivity;reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.8173,1.7,,Neither,oncoref.target-sets.2026-10-23.2,1.817 TPM; blood/NK-cell; hpa_immune_cell_samples; vital,1.7 nTPM; skin/b-cells; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 16/176 (9.1%); Bladder Urothelial Carcinoma (TCGA): 4/169 (2.4%); Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGA6,https://www.uniprot.org/uniprotkb/Q8NGA6/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR10J1,ENSG00000196184,Neither,Screening,False,False,6.8,6.8,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.23757775901,1.7,,Neither,oncoref.target-sets.2026-10-23.2,1.238 TPM; blood/THSTAR; dice_thstar; vital,1.7 nTPM; unsited/Cone photoreceptor cells; hpa_single_cell; unresolved,Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 1/283 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P30954,https://www.uniprot.org/uniprotkb/P30954/entry,Odorant receptor,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
OR11A1,ENSG00000204694,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.398230778263,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0.3982 TPM; blood/TH1; dice_th1; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9GZK7,https://www.uniprot.org/uniprotkb/Q9GZK7/entry,Odorant receptor,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR11G2,ENSG00000196832,Neither,Cellular,False,False,0.0,0.2,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"existing nomination or manual review; incomplete routine rna; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord; incomplete tissue evidence",Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,True,"tongue/t-cells cluster c-6: 5.5 nTPM, 33 reads; reproductive-cell max 5.5",True,False,,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.7014,5.5,,Neither,oncoref.target-sets.2026-10-23.2,1.701 TPM; blood/neutrophil; hpa_immune_cell_samples; vital,5.5 nTPM; tongue/t-cells; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR11H4,ENSG00000176198,Neither,Antibody,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"incomplete routine rna; insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord; incomplete tissue evidence",Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA052790; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA052790; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA052790; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA052790; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA052790; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA052790; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA052790; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA052790; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA052790; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA052790; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA052790; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA052790; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA052790; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA052790; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA052790; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA052790; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA052790; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA052790; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA052790; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA052790; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA052790; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA052790; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA052790; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.03179005352,1.3,,Neither,oncoref.target-sets.2026-10-23.2,2.032 TPM; blood/NK; dice_nk; vital,1.3 nTPM; lung/b-cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),colorectal cancer: 9/10 (90.0%); pancreatic cancer: 7/12 (58.3%),31,20,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR11H6,ENSG00000176219,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.964988908481,0.2,,Neither,oncoref.target-sets.2026-10-23.2,0.965 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.2 nTPM; lymph node/b-cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGC7,https://www.uniprot.org/uniprotkb/Q8NGC7/entry,Odorant receptor,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR13C3,ENSG00000204246,Neither,Unassessed,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"incomplete routine rna; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.3710858658929999,0.7,,Neither,oncoref.target-sets.2026-10-23.2,0.3711 TPM; blood/CD8_STIM; dice_cd8_stim; vital,0.7 nTPM; bone marrow/erythroid cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR13D1,ENSG00000179055,Neither,Unassessed,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"incomplete routine rna; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.52133959546,0.5,,Neither,oncoref.target-sets.2026-10-23.2,1.521 TPM; blood/TFH; dice_tfh; vital,0.5 nTPM; bone marrow/t-cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR13G1,ENSG00000197437,Neither,Low,False,False,0.3,0.3,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.5,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0.5 TPM; blood/basophil; hpa_immune_monaco; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGZ3,https://www.uniprot.org/uniprotkb/Q8NGZ3/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR14A16,ENSG00000196772,Neither,Low,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,retina: 0.1 nTPM; reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.131386736643,0.5,,Neither,oncoref.target-sets.2026-10-23.2,0.1314 TPM; blood/M2; dice_m2; vital,0.5 nTPM; colon/undifferentiated cells; hpa_single_cell_tissue; protected,Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Lung Adenocarcinoma (TCGA): 2/497 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NHC5,https://www.uniprot.org/uniprotkb/Q8NHC5/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR14A2,ENSG00000241128,Neither,Antibody,False,False,2.8,2.8,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Duodenum/Glandular cells: Medium, HPA052685; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA052685; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA052685; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA052685; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA052685; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA052685; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA052685; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.5,0.6,,Neither,oncoref.target-sets.2026-10-23.2,0.5 TPM; blood/Progenitor cell; hpa_immune_monaco; vital,0.6 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),prostate cancer: 1/12 (8.3%); breast cancer: 0/11 (0.0%),29,20,Q96R54,https://www.uniprot.org/uniprotkb/Q96R54/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
OR14J1,ENSG00000204695,Neither,Cellular,False,False,0.6,1.8,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,existing nomination or manual review; nomination unresolved; bone marrow: 0.9 nTPM; continuous selectivity;reproductive not higher; liver: 0.5 nTPM; continuous selectivity; retina: 1.8 nTPM; continuous selectivity;reproductive not higher; skeletal muscle: 0.4 nTPM; continuous selectivity; skin: 0.7 nTPM; continuous selectivity;reproductive not higher; small intestine: 0.4 nTPM; continuous selectivity; spleen: 0.4 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 38/91 values ≥5 TPM, max 7.99642; DICE NK (unstimulated): 6/90 values ≥5 TPM, max 6.3949; DICE CD4_NAIVE (unstimulated): 11/88 values ≥5 TPM, max 6.39651; DICE TREG_NAIVE (unstimulated): 24/89 values ≥5 TPM, max 7.22709; DICE TFH (unstimulated): 4/89 values ≥5 TPM, max 6.27538; DICE THSTAR (unstimulated): 8/88 values ≥5 TPM, max 8.445; DICE TH2 (unstimulated): 9/89 values ≥5 TPM, max 6.50423; hpa_immune_monaco basophil: 8 TPM; hpa_immune_monaco Central memory CD8 T-cell: 5.6 TPM; hpa_immune_monaco Effector memory CD8 T-cell: 5 TPM; hpa_immune_monaco Memory CD4 T-cell TFH: 5.5 TPM; hpa_immune_monaco Memory CD4 T-cell Th1: 5.1 TPM; hpa_immune_monaco Memory CD4 T-cell Th1/Th17: 5.1 TPM; hpa_immune_monaco naive B-cell: 6 TPM; hpa_immune_monaco naive CD4 T-cell: 5.4 TPM; hpa_immune_monaco naive CD8 T-cell: 7.3 TPM; hpa_immune_monaco NK-cell: 5.2 TPM; hpa_immune_monaco Non-switched memory B-cell: 5.3 TPM; hpa_immune_monaco Progenitor cell: 6.2 TPM; hpa_immune_monaco Switched memory B-cell: 5.5 TPM; hpa_immune_monaco Terminal effector memory CD4 T-cell: 5.7 TPM",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,8.44500422033,2.0195,,Neither,oncoref.target-sets.2026-10-23.2,8.445 TPM; blood/THSTAR; dice_thstar; vital,2.019 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 173/207 (83.6%); Colon Adenocarcinoma (validation): 404/486 (83.1%); Uterine Corpus Endometrial Carcinoma (TCGA): 18/176 (10.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9UGF5,https://www.uniprot.org/uniprotkb/Q9UGF5/entry,Odorant receptor,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR1C1,ENSG00000221888,Neither,Low,False,False,2.5,2.5,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.5,0.3893,,Neither,oncoref.target-sets.2026-10-23.2,0.5 TPM; blood/Terminal effector memory CD4 T-cell; hpa_immune_monaco; vital,0.3893 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q15619,https://www.uniprot.org/uniprotkb/Q15619/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
OR1E1,ENSG00000180016,Neither,Low,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Retained,Normal,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.51630817114,0.7662,,Neither,oncoref.target-sets.2026-10-23.2,1.516 TPM; blood/NK; dice_nk; vital,0.7662 nTPM; blood/plasmacytoid DC; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Glioblastoma Multiforme (TCGA): 1/141 (0.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P30953,https://www.uniprot.org/uniprotkb/P30953/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR1G1,ENSG00000183024,Neither,Low,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.2855719101,0.7,,Neither,oncoref.target-sets.2026-10-23.2,1.286 TPM; blood/NK; dice_nk; vital,0.7 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P47890,https://www.uniprot.org/uniprotkb/P47890/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR1J4,ENSG00000239590,Neither,Low,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,4.38913549701,0.3,,Neither,oncoref.target-sets.2026-10-23.2,4.389 TPM; blood/TREG_MEM; dice_treg_mem; vital,0.3 nTPM; adipose tissue/t-cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGS1,https://www.uniprot.org/uniprotkb/Q8NGS1/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR1K1,ENSG00000165204,Neither,Low,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.35558380777,0.5434,,Neither,oncoref.target-sets.2026-10-23.2,2.356 TPM; blood/TREG_MEM; dice_treg_mem; vital,0.5434 nTPM; blood/memory CD8 T-cell; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 1/283 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGR3,https://www.uniprot.org/uniprotkb/Q8NGR3/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR1L3,ENSG00000171481,Neither,Antibody,False,False,0.0,0.1,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Colon/Endothelial cells: Medium, HPA058878; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA058878; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.25472425413,0.2,,Neither,oncoref.target-sets.2026-10-23.2,1.255 TPM; blood/NK; dice_nk; vital,0.2 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),glioma: 2/12 (16.7%); breast cancer: 0/10 (0.0%),31,20,Q8NH93,https://www.uniprot.org/uniprotkb/Q8NH93/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR1N1,ENSG00000171505,Neither,Low,False,False,0.1,0.2,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,retina: 0.2 nTPM; continuous selectivity;reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.5491846753999998,0.2,,Neither,oncoref.target-sets.2026-10-23.2,1.549 TPM; blood/TREG_MEM; dice_treg_mem; vital,0.2 nTPM; retina/bulk; hpa_rna_consensus; vital,Ovary Serous Cystadenocarcinoma (TCGA): 17/349 (4.9%); Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGS0,https://www.uniprot.org/uniprotkb/Q8NGS0/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR2AK2,ENSG00000187080,Neither,Cellular,False,False,0.1,0.2,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,bone marrow: 0.2 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 11/91 values ≥5 TPM, max 10.391",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,10.3910482234,0.7,,Neither,oncoref.target-sets.2026-10-23.2,10.39 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.7 nTPM; eye/bipolar cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR2C3,ENSG00000196242,Neither,Low,False,False,0.7,0.7,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,retina: 0.4 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,3.5056,6.3136,,Neither,oncoref.target-sets.2026-10-23.2,3.506 TPM; blood/basophil; hpa_immune_cell_samples; vital,6.314 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8N628,https://www.uniprot.org/uniprotkb/Q8N628/entry,Odorant receptor,,,It is uncertain whether Met-1 or Met-2 is the initiator,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
OR2D2,ENSG00000166368,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.7955174857170001,1.4,,Neither,oncoref.target-sets.2026-10-23.2,0.7955 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,1.4 nTPM; stomach/fibroblasts; hpa_single_cell_tissue; protected,Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9H210,https://www.uniprot.org/uniprotkb/Q9H210/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR2F1,ENSG00000213215,Neither,Unassessed,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"existing nomination or manual review; incomplete routine rna; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord; incomplete tissue evidence",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.287526675146,2.0,,Neither,oncoref.target-sets.2026-10-23.2,0.2875 TPM; blood/TH1; dice_th1; vital,2 nTPM; colon/distal enterocytes; hpa_single_cell_tissue; protected,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q13607,https://www.uniprot.org/uniprotkb/Q13607/entry,Odorant receptor,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR2F2,ENSG00000221910,Neither,Low,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.648302986324,0.1,,Neither,oncoref.target-sets.2026-10-23.2,0.6483 TPM; blood/TREG_MEM; dice_treg_mem; vital,0.1 nTPM; vascular/smooth muscle cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O95006,https://www.uniprot.org/uniprotkb/O95006/entry,Odorant receptor,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR2G6,ENSG00000188558,Neither,Low,False,False,0.2,0.5,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 0.3 nTPM; continuous selectivity;reproductive not higher; duodenum: 0.2 nTPM; continuous selectivity;reproductive not higher; pancreas: 0.3 nTPM; continuous selectivity;reproductive not higher; retina: 0.5 nTPM; continuous selectivity;reproductive not higher; salivary gland: 0.2 nTPM; continuous selectivity;reproductive not higher; skin: 0.2 nTPM; continuous selectivity;reproductive not higher; stomach: 0.2 nTPM; continuous selectivity;reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,3.5915881584500005,3.2,,Neither,oncoref.target-sets.2026-10-23.2,3.592 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,3.2 nTPM; vascular/t-cells; hpa_single_cell_tissue; vital,Kidney Renal Papillary Cell Carcinoma (TCGA): 3/282 (1.1%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5TZ20,https://www.uniprot.org/uniprotkb/Q5TZ20/entry,Odorant receptor,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR2J2,ENSG00000204700,Neither,Low,False,False,0.4,0.4,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.73853328014,4.8,,Neither,oncoref.target-sets.2026-10-23.2,0.7385 TPM; blood/NK; dice_nk; vital,4.8 nTPM; skin/granulocytes; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O76002,https://www.uniprot.org/uniprotkb/O76002/entry,Odorant receptor,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR2J3,ENSG00000204701,Neither,Low,False,False,0.3,0.3,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.247555918303,0.2,,Neither,oncoref.target-sets.2026-10-23.2,0.2476 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,0.2 nTPM; skeletal muscle/fibroblasts; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O76001,https://www.uniprot.org/uniprotkb/O76001/entry,"Odorant receptor involved in the detection of the flavor compound cis-3-hexen-1-ol (C3HEX), a compound typically described as 'green grassy' or the smell of 'cut grass'",,,,Cell membrane,22714804,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR2K2,ENSG00000171133,Neither,Antibody,False,False,0.2,0.8,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,hippocampal formation: 0.2 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 0.2 nTPM; continuous selectivity;reproductive not higher; midbrain: 0.5 nTPM; continuous selectivity;reproductive not higher; retina: 0.2 nTPM; continuous selectivity;reproductive not higher; skeletal muscle: 0.5 nTPM; continuous selectivity;reproductive not higher; spinal cord: 0.8 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA024261; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA024261; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA024261; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA024261; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA024261; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA024261; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA024261; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA024261; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA024261; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA024261; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA024261; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA024261; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA024261; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA024261; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA024261; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA024261; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA024261; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA024261; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA024261; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA024261; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA024261; conflicting or uncurated primary profile; Lymph node/Germinal center cells: High, HPA024261; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA024261; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA024261; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA024261; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA024261; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA024261; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA024261; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA024261; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA024261; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA024261; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA024261; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA024261; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA024261; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA024261; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA024261; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA024261; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA024261; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA024261; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.3220135209,1.3,,Neither,oncoref.target-sets.2026-10-23.2,1.322 TPM; blood/TFH; dice_tfh; vital,1.3 nTPM; esophagus/macrophages; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),testis cancer: 8/9 (88.9%); melanoma: 7/10 (70.0%),31,20,Q8NGT1,https://www.uniprot.org/uniprotkb/Q8NGT1/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR2V2,ENSG00000182613,Neither,Antibody,False,False,0.2,0.4,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 0.4 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA049953; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA049953; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA049953; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA049953; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA049953; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA049953; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA049953; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA049953; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA049953; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA049953; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.1869,1.8609,,Neither,oncoref.target-sets.2026-10-23.2,1.187 TPM; blood/basophil; hpa_immune_cell_samples; vital,1.861 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 4/176 (2.3%); Kidney Chromophobe (TCGA): 1/64 (1.6%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%),ovarian cancer: 1/11 (9.1%); melanoma: 1/12 (8.3%),31,20,Q96R30,https://www.uniprot.org/uniprotkb/Q96R30/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR2W1,ENSG00000204704,Neither,Low,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.430944807678,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0.4309 TPM; blood/TREG_MEM; dice_treg_mem; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Breast Invasive Carcinoma (validation): 0/50 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9Y3N9,https://www.uniprot.org/uniprotkb/Q9Y3N9/entry,Odorant receptor,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR3A2,ENSG00000221882,Neither,Unassessed,False,False,2.8,2.8,0,0,Missing,False,False,False,False,Excluded,Unassessed,True,,Not assessed,,,"incomplete routine rna; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord; retina: 0.9 nTPM; continuous selectivity",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,4.824812054430001,3.4869,,Neither,oncoref.target-sets.2026-10-23.2,4.825 TPM; blood/TFH; dice_tfh; vital,3.487 nTPM; blood/MAIT T-cell; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 15/133 (11.3%); Uterine Corpus Endometrial Carcinoma (TCGA): 10/176 (5.7%); Ovary Serous Cystadenocarcinoma (TCGA): 10/349 (2.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Carter2023_CT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene,,,,,,,,
OR4A16,ENSG00000181961,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Lung Adenocarcinoma (TCGA): 1/497 (0.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NH70,https://www.uniprot.org/uniprotkb/Q8NH70/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR4D1,ENSG00000141194,Neither,Cellular,False,False,0.2,0.5,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 0.5 nTPM; continuous selectivity;reproductive not higher; lymph node: 0.4 nTPM; continuous selectivity;reproductive not higher; spleen: 0.3 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,True,"pbmc/t-cells cluster c-1: 10.8 nTPM, 30 reads; reproductive-cell max 2.6",True,False,,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,5.996994920440001,13.1,,Neither,oncoref.target-sets.2026-10-23.2,5.997 TPM; blood/CD8_NAIVE; dice_cd8_naive; vital,13.1 nTPM; pbmc/nk-cells; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 8/176 (4.5%); Bladder Urothelial Carcinoma (TCGA): 3/169 (1.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q15615,https://www.uniprot.org/uniprotkb/Q15615/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR4D6,ENSG00000166884,Neither,Low,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.285370621455,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0.2854 TPM; blood/TREG_MEM; dice_treg_mem; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGJ1,https://www.uniprot.org/uniprotkb/Q8NGJ1/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR4E1,ENSG00000276240,Neither,Unassessed,False,False,0.0,0.1,0,0,Missing,False,False,False,False,Excluded,Unassessed,True,,Not assessed,,,"existing nomination or manual review; incomplete routine rna; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord; incomplete tissue evidence",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,3.64552777625,0.807,,Neither,oncoref.target-sets.2026-10-23.2,3.646 TPM; blood/CD8_NAIVE; dice_cd8_naive; vital,0.807 nTPM; blood/naive CD8 T-cell; hpa_immune_cell_samples; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,P0C645,https://www.uniprot.org/uniprotkb/P0C645/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR4E2,ENSG00000221977,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.00153464436,0.1434,,Neither,oncoref.target-sets.2026-10-23.2,1.002 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,0.1434 nTPM; blood/neutrophil; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR4F3,ENSG00000230178,Neither,Antibody,False,False,0.3,0.3,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bone marrow/Hematopoietic cells: Medium, HPA047705; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA047705; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA047705; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.4,0.4002,,Neither,oncoref.target-sets.2026-10-23.2,0.4 TPM; blood/Memory CD4 T-cell Th2; hpa_immune_monaco; vital,0.4002 nTPM; blood/NK-cell; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),cervical cancer: 1/10 (10.0%); breast cancer: 0/10 (0.0%),29,20,Q6IEY1,https://www.uniprot.org/uniprotkb/Q6IEY1/entry,Odorant receptor,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR4K1,ENSG00000155249,Neither,Antibody,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA028877; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA028877; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA028877; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA028877; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA028877; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA028877; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA028877; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA028877; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA028877; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA028877; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA028877; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA028877; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: High, HPA028877; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA028877; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA028877; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA028877; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA028877; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA028877; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA028877; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA028877; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA028877; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA028877; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA028877; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA028877; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA028877; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA028877; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: High, HPA028877; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA028877; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA028877; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA028877; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA028877; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA028877; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA028877; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA028877; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA028877; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA028877; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA028877; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA028877; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA028877; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.550215197444,0.1,,Neither,oncoref.target-sets.2026-10-23.2,0.5502 TPM; blood/CD4_STIM; dice_cd4_stim; vital,0.1 nTPM; unsited/Oligodendrocytes; hpa_single_cell; unresolved,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),prostate cancer: 11/12 (91.7%); liver cancer: 4/12 (33.3%),31,20,Q8NGD4,https://www.uniprot.org/uniprotkb/Q8NGD4/entry,Odorant receptor,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR4M1,ENSG00000176299,Neither,Antibody,False,False,0.7,0.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bone marrow/Hematopoietic cells: Low, HPA058889; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA058889; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA058889; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA058889; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA058889; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA058889; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA058889; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA058889; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA058889; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA058889; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA058889; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA058889; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA058889; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA058889; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA058889; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA058889; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA058889; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA058889; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA058889; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA058889; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.29201131834,1.0,,Neither,oncoref.target-sets.2026-10-23.2,0.292 TPM; blood/NK; dice_nk; vital,1 nTPM; unsited/Skeletal myocytes; hpa_single_cell; unresolved,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),lymphoma: 2/11 (18.2%); lung cancer: 2/12 (16.7%),30,20,Q8NGD0,https://www.uniprot.org/uniprotkb/Q8NGD0/entry,"Olfactory receptor that acts as a receptor of Asprosin hormone, potentially at the surface of hepatocytes and may help to promote hepatocyte glucose release",Highly expressed in the testis and olfactory bulb,,,Cell membrane,31230984,31230984,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
OR4M2,ENSG00000274102,Neither,Antibody,False,False,0.4,0.4,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bone marrow/Hematopoietic cells: Low, HPA058889; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA058889; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA058889; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA058889; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA058889; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA058889; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA058889; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA058889; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA058889; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA058889; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA058889; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA058889; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA058889; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA058889; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA058889; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA058889; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA058889; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA058889; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA058889; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA058889; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.3,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.3 nTPM; skeletal muscle/mixed cell types; hpa_single_cell_tissue; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Breast Invasive Carcinoma (validation): 0/50 (0.0%),lymphoma: 2/11 (18.2%); lung cancer: 2/12 (16.7%),28,20,Q8NGB6,https://www.uniprot.org/uniprotkb/Q8NGB6/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR4M2B,ENSG00000182974,Neither,Antibody,False,False,0.5,0.5,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,True,"Bone marrow/Hematopoietic cells: Low, HPA058889; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA058889; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA058889; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA058889; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA058889; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA058889; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA058889; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA058889; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA058889; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA058889; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA058889; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA058889; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA058889; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA058889; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA058889; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA058889; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA058889; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA058889; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA058889; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA058889; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 0/283 (0.0%),lymphoma: 2/11 (18.2%); lung cancer: 2/12 (16.7%),29,20,A0A0X1KG70,https://www.uniprot.org/uniprotkb/A0A0X1KG70/entry,Odorant receptor,,,,Membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
OR4N2,ENSG00000176294,Neither,Low,False,False,3.7,3.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.225583860357,2.3,,Neither,oncoref.target-sets.2026-10-23.2,0.2256 TPM; blood/TREG_MEM; dice_treg_mem; vital,2.3 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 19/58 (32.8%); Glioblastoma Multiforme (TCGA): 11/141 (7.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,Q8NGD1,https://www.uniprot.org/uniprotkb/Q8NGD1/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR4N4,ENSG00000183706,Neither,Antibody,False,False,7.8,7.8,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Caudate/Neuronal cells: Medium, HPA057442; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA057442; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA057442; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA057442; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA057442; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA057442; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA057442; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.4,,CTA,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.4 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Liver Hepatocellular Carcinoma (validation): 2/231 (0.9%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),31,20,Q8N0Y3,https://www.uniprot.org/uniprotkb/Q8N0Y3/entry,Odorant receptor,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
OR4N4C,ENSG00000279408,Neither,Antibody,False,False,1.1,1.1,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,True,"Caudate/Neuronal cells: Medium, HPA057442; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA057442; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA057442; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA057442; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA057442; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA057442; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA057442; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.2126,1.5,,Neither,oncoref.target-sets.2026-10-23.2,0.2126 TPM; blood/plasmacytoid DC; hpa_immune_cell_samples; vital,1.5 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),26,20,A0A096LPK9,https://www.uniprot.org/uniprotkb/A0A096LPK9/entry,Odorant receptor,,,,Membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
OR4Q3,ENSG00000182652,Neither,Antibody,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"existing nomination or manual review; incomplete routine rna; nomination unresolved; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord",Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Heart muscle/Cardiomyocytes: Medium, HPA049924; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA049924; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA049924; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA049924; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA049924; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.6373236901739999,0.2,,Neither,oncoref.target-sets.2026-10-23.2,0.6373 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,0.2 nTPM; adipose tissue/nk-cells; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 3/176 (1.7%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),lymphoma: 3/9 (33.3%); breast cancer: 0/11 (0.0%),31,20,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR51A7,ENSG00000176895,Neither,Antibody,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bone marrow/Hematopoietic cells: High, HPA061356; conflicting or uncurated primary profile; Spleen/Cells in red pulp: High, HPA061356; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.147122661824,0.4,,Neither,oncoref.target-sets.2026-10-23.2,0.1471 TPM; blood/TH1; dice_th1; vital,0.4 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q8NH64,https://www.uniprot.org/uniprotkb/Q8NH64/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR51I2,ENSG00000187918,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.568238488582,1.1,,Neither,oncoref.target-sets.2026-10-23.2,0.5682 TPM; blood/NK; dice_nk; vital,1.1 nTPM; eye/muller glia cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9H344,https://www.uniprot.org/uniprotkb/Q9H344/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR51Q1,ENSG00000167360,Neither,Antibody,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA044998; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA044998; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA044998; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA044998; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA044998; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA044998; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA044998; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA044998; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA044998; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA044998; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA044998; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA044998; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA044998; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA044998; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA044998; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA044998; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA044998; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA044998; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA044998; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA044998; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA044998; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA044998; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA044998; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA044998; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA044998; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA044998; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.322017967167,0.3,,Neither,oncoref.target-sets.2026-10-23.2,0.322 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.3 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),prostate cancer: 9/11 (81.8%); pancreatic cancer: 6/8 (75.0%),31,20,Q8NH59,https://www.uniprot.org/uniprotkb/Q8NH59/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR51S1,ENSG00000176922,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0239,0.3,,Neither,oncoref.target-sets.2026-10-23.2,0.0239 TPM; blood/myeloid DC; hpa_immune_cell_samples; vital,0.3 nTPM; unsited/Astrocytes; hpa_single_cell; unresolved,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,Q8NGJ8,https://www.uniprot.org/uniprotkb/Q8NGJ8/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR52D1,ENSG00000181609,Neither,Antibody,False,False,1.1,1.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bronchus/Respiratory epithelial cells: Low, HPA046965; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA046965; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA046965; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA046965; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA046965; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA046965; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA046965; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA046965; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA046965; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA046965; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA046965; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA046965; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA046965; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA046965; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA046965; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA046965; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA046965; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA046965; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA046965; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.4543207267299998,0.1,,Neither,oncoref.target-sets.2026-10-23.2,1.454 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,0.1 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Colon Adenocarcinoma (validation): 2/486 (0.4%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q9H346,https://www.uniprot.org/uniprotkb/Q9H346/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR52E2,ENSG00000176787,Neither,Antibody,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA045748; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA045748; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA045748; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA045748; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA045748; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA045748; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA045748; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA045748; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA045748; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA045748; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA045748; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA045748; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA045748; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA045748; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA045748; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA045748; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA045748; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA045748; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA045748; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA045748; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.23623991835,1.5,,Neither,oncoref.target-sets.2026-10-23.2,0.2362 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,1.5 nTPM; eye/bipolar cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Ovary Serous Cystadenocarcinoma (TCGA): 1/349 (0.3%); Colon Adenocarcinoma (validation): 1/486 (0.2%),stomach cancer: 8/11 (72.7%); colorectal cancer: 7/12 (58.3%),31,20,Q8NGJ4,https://www.uniprot.org/uniprotkb/Q8NGJ4/entry,Odorant receptor,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR52E4,ENSG00000180974,Neither,Low,False,False,0.5,0.6,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,existing nomination or manual review; nomination unresolved; retina: 0.6 nTPM; continuous selectivity;reproductive not higher; skin: 0.4 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.1,0.6,,Neither,oncoref.target-sets.2026-10-23.2,1.1 TPM; blood/basophil; hpa_immune_monaco; vital,0.6 nTPM; retina/bulk; hpa_rna_consensus; vital,Colon Adenocarcinoma (validation): 19/486 (3.9%); Rectum Adenocarcinoma (validation): 8/207 (3.9%); Uterine Corpus Endometrial Carcinoma (TCGA): 4/176 (2.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGH9,https://www.uniprot.org/uniprotkb/Q8NGH9/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR52E6,ENSG00000205409,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.484702078755,0.1,,Neither,oncoref.target-sets.2026-10-23.2,0.4847 TPM; blood/THSTAR; dice_thstar; vital,0.1 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96RD3,https://www.uniprot.org/uniprotkb/Q96RD3/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | daSilva2017_testis_biased | Gong2021_reproductive_PC,No tumor-antigen validation in this source | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
OR52E8,ENSG00000183269,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0175,0.6,,Neither,oncoref.target-sets.2026-10-23.2,0.0175 TPM; blood/non-classical monocyte; hpa_immune_cell_samples; vital,0.6 nTPM; unsited/Horizontal cells; hpa_single_cell; unresolved,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6IFG1,https://www.uniprot.org/uniprotkb/Q6IFG1/entry,Odorant receptor,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
OR52H1,ENSG00000181616,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,3.5396078349,1.5,,Neither,oncoref.target-sets.2026-10-23.2,3.54 TPM; blood/TFH; dice_tfh; vital,1.5 nTPM; pbmc/b-cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 1/58 (1.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGJ2,https://www.uniprot.org/uniprotkb/Q8NGJ2/entry,Odorant receptor,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR52L1,ENSG00000183313,Neither,Low,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.03903658943,0.0128,,Neither,oncoref.target-sets.2026-10-23.2,1.039 TPM; blood/TFH; dice_tfh; vital,0.0128 nTPM; blood/memory CD8 T-cell; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGH7,https://www.uniprot.org/uniprotkb/Q8NGH7/entry,Odorant receptor,,,It is uncertain whether Met-1 or Met-16 is the initiator,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR56A1,ENSG00000180934,Neither,Unassessed,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,"existing nomination or manual review; incomplete routine rna; nomination unresolved; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord; bone marrow: 0.2 nTPM; continuous selectivity;reproductive not higher; retina: 0.2 nTPM; continuous selectivity;reproductive not higher",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.6,0.2012,,Neither,oncoref.target-sets.2026-10-23.2,0.6 TPM; blood/basophil; hpa_immune_monaco; vital,0.2012 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR56A3,ENSG00000184478,Neither,Low,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.242801144505,0.4,,Neither,oncoref.target-sets.2026-10-23.2,0.2428 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,0.4 nTPM; eye/rod photoreceptor cells; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 3/50 (6.0%); Bladder Urothelial Carcinoma (TCGA): 4/169 (2.4%); Liver Hepatocellular Carcinoma (validation): 4/231 (1.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NH54,https://www.uniprot.org/uniprotkb/Q8NH54/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR56A5,ENSG00000188691,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.00460089935,0.1,,Neither,oncoref.target-sets.2026-10-23.2,1.005 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,0.1 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Breast Invasive Carcinoma (validation): 0/50 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P0C7T3,https://www.uniprot.org/uniprotkb/P0C7T3/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR5A1,ENSG00000172320,Neither,Low,False,False,0.2,0.4,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 0.4 nTPM; continuous selectivity;reproductive not higher; retina: 0.4 nTPM; continuous selectivity;reproductive not higher; skin: 0.3 nTPM; continuous selectivity;reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.50012966212,2.8,,Neither,oncoref.target-sets.2026-10-23.2,2.5 TPM; blood/CD8_NAIVE; dice_cd8_naive; vital,2.8 nTPM; unsited/Lymphatic endothelial cells; hpa_single_cell; unresolved,Colon Adenocarcinoma (validation): 17/486 (3.5%); Rectum Adenocarcinoma (validation): 6/207 (2.9%); Stomach Adenocarcinoma (TCGA): 3/346 (0.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGJ0,https://www.uniprot.org/uniprotkb/Q8NGJ0/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR5AC2,ENSG00000196578,Neither,Low,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0978,0.1843,,Neither,oncoref.target-sets.2026-10-23.2,0.0978 TPM; blood/neutrophil; hpa_immune_cell_samples; vital,0.1843 nTPM; blood/neutrophil; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9NZP5,https://www.uniprot.org/uniprotkb/Q9NZP5/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR5B12,ENSG00000172362,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.57863122531,0.6,,Neither,oncoref.target-sets.2026-10-23.2,1.579 TPM; blood/TFH; dice_tfh; vital,0.6 nTPM; breast/t-cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Ovary Serous Cystadenocarcinoma (TCGA): 1/349 (0.3%); Prostate Adenocarcinoma (TCGA): 1/480 (0.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96R08,https://www.uniprot.org/uniprotkb/Q96R08/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR5B2,ENSG00000172365,Neither,Low,False,False,0.1,0.2,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; bone marrow: 0.2 nTPM; continuous selectivity;reproductive not higher; lymph node: 0.1 nTPM; reproductive not higher; retina: 0.2 nTPM; continuous selectivity;reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.69256004165,0.6,,Neither,oncoref.target-sets.2026-10-23.2,1.693 TPM; blood/CD8_NAIVE; dice_cd8_naive; vital,0.6 nTPM; stomach/t-cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96R09,https://www.uniprot.org/uniprotkb/Q96R09/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR5B21,ENSG00000198283,Neither,Low,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,4.06499523971,1.6,,Neither,oncoref.target-sets.2026-10-23.2,4.065 TPM; blood/TFH; dice_tfh; vital,1.6 nTPM; adipose tissue/dendritic cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A6NL26,https://www.uniprot.org/uniprotkb/A6NL26/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR5C1,ENSG00000148215,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.930006652843,0.8,,Neither,oncoref.target-sets.2026-10-23.2,0.93 TPM; blood/TREG_MEM; dice_treg_mem; vital,0.8 nTPM; bone marrow/b-cells; hpa_single_cell_tissue; vital,Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGR4,https://www.uniprot.org/uniprotkb/Q8NGR4/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR5H14,ENSG00000236032,Neither,Low,False,False,0.3,0.3,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; bone marrow: 0.2 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.5724,5.2,,Neither,oncoref.target-sets.2026-10-23.2,0.5724 TPM; blood/basophil; hpa_immune_cell_samples; vital,5.2 nTPM; kidney/b-cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A6NHG9,https://www.uniprot.org/uniprotkb/A6NHG9/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR5H15,ENSG00000233412,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A6NDH6,https://www.uniprot.org/uniprotkb/A6NDH6/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR5H6,ENSG00000230301,Neither,Low,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.231551599648,0.6,,Neither,oncoref.target-sets.2026-10-23.2,0.2316 TPM; blood/TH17; dice_th17; vital,0.6 nTPM; salivary gland/mixed immune cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGV6,https://www.uniprot.org/uniprotkb/Q8NGV6/entry,Odorant receptor,,,It is uncertain whether Met-1 or Met-17 is the initiator,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR5M11,ENSG00000255223,Neither,Low,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,urinary bladder: 0.1 nTPM; reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.680289811642,0.1,,Neither,oncoref.target-sets.2026-10-23.2,0.6803 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,0.1 nTPM; urinary bladder/bulk; hpa_rna_consensus; protected,Breast Invasive Carcinoma (validation): 1/50 (2.0%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96RB7,https://www.uniprot.org/uniprotkb/Q96RB7/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR5M8,ENSG00000181371,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGP6,https://www.uniprot.org/uniprotkb/Q8NGP6/entry,Odorant receptor,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR5V1,ENSG00000243729,Neither,Antibody,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA046707; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA046707; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA046707; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA046707; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA046707; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA046707; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA046707; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA046707; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA046707; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA046707; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA046707; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA046707; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA046707; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA046707; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA046707; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA046707; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA046707; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA046707; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA046707; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA046707; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA046707; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA046707; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA046707; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA046707; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA046707; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA046707; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA046707; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA046707; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA046707; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA046707; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA046707; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA046707; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA046707; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA046707; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA046707; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA046707; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA046707; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA046707; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA046707; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA046707; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA046707; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA046707; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA046707; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA046707; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.1738789649729999,1.2,,Neither,oncoref.target-sets.2026-10-23.2,0.1739 TPM; blood/CD8_STIM; dice_cd8_stim; vital,1.2 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),breast cancer: 9/12 (75.0%); stomach cancer: 9/12 (75.0%),31,20,Q9UGF6,https://www.uniprot.org/uniprotkb/Q9UGF6/entry,"G protein-coupled receptor that acts both as an odorant receptor, and as a classical G protein-coupled receptor outside the olfactory epithelium (By similarity). Ligand-binding causes a conformation change that triggers signaling via G(s)-class of G alpha proteins (GNAL/G(olf) or GNAS/G(s)) (By similarity). In olfactory epithelium, activation by methyl (9R,10E,12E)-9-methoxyoctadeca-10,12-dienoate, a plant odorant isolated from E.fortunei Turcz, promotes coupling to GNAL/G(olf), mediating activation of adenylate cyclase activity and increased production of cAMP, initiating a neuronal response that triggers the perception of a smell (By similarity). Beyond its role in olfaction, also acts as a regulator of glucose metabolism (By similarity). In liver, activation by oxylipin 12(S)-hydroxyeicosapentaenoate (12(S)-HEPE), initiates a signaling that enhances hepatic fatty acid oxidation via PKA-dependent activation of the transcription factor ATF2, which promotes expression of carnitine palmitoyltransferase CPT1A (By similarity). Outside of the olfactory system, in tissues lacking GNAL/G(olf), couples to GNAS/G(s), promoting activation of adenylate cyclase activity and production of cAMP (By similarity)",,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR6A2,ENSG00000184933,Neither,Low,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.351543298521,3.4,,Neither,oncoref.target-sets.2026-10-23.2,0.3515 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,3.4 nTPM; unsited/Cone photoreceptor cells; hpa_single_cell; unresolved,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O95222,https://www.uniprot.org/uniprotkb/O95222/entry,"Odorant receptor for medium-chain aliphatic aldehydes, such as octanal, nonanal and trans-2-decenal (PubMed:41570822). Activated by aliphatic aldehydes with chains ranging from 5 to 11 carbon atoms, with preference for octanal (C8) (PubMed:41570822). Ligand-binding involves the formation of a reversible covalent Schiff base linkage with the aldehyde, causing a conformation change that triggers signaling via G(s)-class of G alpha proteins (GNAL/G(olf) or GNAS/G(s)) (PubMed:41570822). In olfactory epithelium, couples to GNAL/G(olf), mediating activation of adenylate cyclase activity and increased production of cAMP, initiating a neuronal response that triggers the perception of a smell (PubMed:41570822). Beyond its role in olfaction, also acts as a regulator of inflammation (PubMed:35025664). In macrophages, activation by octanal, a product of lipid peroxidation during oxidative stress, triggers a signaling that promotes activation of the NLRP3 inflammasome, leading to the production of pro-inflammatory cytokines, such as IL1B, exacerbating inflammatory processes in vascular macrophages and contributing to atherosclerosis (PubMed:35025664). Outside of the olfactory system, in tissues lacking GNAL/G(olf), couples to GNAS/G(s), promoting activation of adenylate cyclase activity and production of cAMP (PubMed:41570822)","Olfactory epithelium (PubMed:14983052). Also expressed in vascular macrophages, bone marrow-derived macrophages and aortic macrophages (PubMed:35025664)",,,Cell membrane,35025664|41570822,14983052|35025664,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR6B1,ENSG00000221813,Neither,Antibody,False,False,0.2,0.5,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; pancreas: 0.5 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA053164; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA053164; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA053164; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA053164; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA053164; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA053164; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA053164; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA053164; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA053164; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA053164; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA053164; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA053164; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA053164; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA053164; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA053164; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA053164; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA053164; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA053164; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA053164; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA053164; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA053164; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA053164; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA053164; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA053164; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA053164; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA053164; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA053164; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA053164; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA053164; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA053164; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA053164; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA053164; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA053164; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA053164; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA053164; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA053164; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA053164; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA053164; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA053164; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA053164; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA053164; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA053164; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA053164; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.3,0.5,,Neither,oncoref.target-sets.2026-10-23.2,0.3 TPM; blood/Progenitor cell; hpa_immune_monaco; vital,0.5 nTPM; pancreas/bulk; hpa_rna_consensus; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),pancreatic cancer: 7/9 (77.8%); liver cancer: 7/11 (63.6%),31,20,O95007,https://www.uniprot.org/uniprotkb/O95007/entry,Odorant receptor,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR6B2,ENSG00000182083,Neither,Antibody,False,False,0.4,0.4,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,retina: 0.3 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bone marrow/Hematopoietic cells: Low, HPA047529; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA047529; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA047529; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA047529; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA047529; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA047529; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA047529; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA047529; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA047529; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA047529; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA047529; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA047529; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA047529; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA047529; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA047529; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA047529; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA047529; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.5012991542759999,0.3,,Neither,oncoref.target-sets.2026-10-23.2,0.5013 TPM; blood/CD8_NAIVE; dice_cd8_naive; vital,0.3 nTPM; retina/bulk; hpa_rna_consensus; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Colon Adenocarcinoma (validation): 1/486 (0.2%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),melanoma: 1/10 (10.0%); breast cancer: 0/12 (0.0%),31,20,Q6IFH4,https://www.uniprot.org/uniprotkb/Q6IFH4/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR6F1,ENSG00000169214,Neither,Low,False,False,1.3,1.3,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.1616214330599999,0.4,,Neither,oncoref.target-sets.2026-10-23.2,0.1616 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,0.4 nTPM; eye/muller glia cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGZ6,https://www.uniprot.org/uniprotkb/Q8NGZ6/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
OR6V1,ENSG00000225781,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.641010610599,0.0091,,Neither,oncoref.target-sets.2026-10-23.2,0.641 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,0.0091 nTPM; blood/naive CD8 T-cell; hpa_immune_cell_samples; vital,Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8N148,https://www.uniprot.org/uniprotkb/Q8N148/entry,Odorant receptor,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR7D4,ENSG00000174667,Neither,Low,False,False,0.1,0.3,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,bone marrow: 0.3 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 0.1 nTPM; reproductive not higher; retina: 0.3 nTPM; continuous selectivity;reproductive not higher; skeletal muscle: 0.1 nTPM; reproductive not higher; skin: 0.1 nTPM; reproductive not higher; small intestine: 0.1 nTPM; reproductive not higher; spleen: 0.1 nTPM; reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,3.2,2.3075,,Neither,oncoref.target-sets.2026-10-23.2,3.2 TPM; blood/basophil; hpa_immune_monaco; vital,2.308 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 18/133 (13.5%); Uterine Corpus Endometrial Carcinoma (TCGA): 13/176 (7.4%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 7/283 (2.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NG98,https://www.uniprot.org/uniprotkb/Q8NG98/entry,Odorant receptor. Selectively activated by androstenone and the related odorous steroid androstadienone,Nasal olfactory epithelium,,,Cell membrane,,17509148,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR7E24,ENSG00000237521,Neither,Low,False,False,1.8,1.8,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.172456082737,0.0463,,Neither,oncoref.target-sets.2026-10-23.2,0.1725 TPM; blood/TH1; dice_th1; vital,0.0463 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 32/133 (24.1%); Uterine Corpus Endometrial Carcinoma (TCGA): 4/176 (2.3%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6IFN5,https://www.uniprot.org/uniprotkb/Q6IFN5/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
OR8A1,ENSG00000196119,Neither,Cellular,False,False,0.3,0.9,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 0.9 nTPM; continuous selectivity;reproductive not higher; liver: 0.8 nTPM; continuous selectivity;reproductive not higher; pancreas: 0.2 nTPM; continuous selectivity; retina: 0.5 nTPM; continuous selectivity;reproductive not higher; skin: 0.6 nTPM; continuous selectivity;reproductive not higher; small intestine: 0.2 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,True,"brain/excitatory neurons cluster c-40: 9.3 nTPM, 94 reads; reproductive-cell max 6",True,False,,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.8,9.3,,Neither,oncoref.target-sets.2026-10-23.2,1.8 TPM; blood/basophil; hpa_immune_monaco; vital,9.3 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 4/176 (2.3%); Rectum Adenocarcinoma (validation): 3/207 (1.4%); Kidney Renal Papillary Cell Carcinoma (TCGA): 3/282 (1.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGG7,https://www.uniprot.org/uniprotkb/Q8NGG7/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR8B12,ENSG00000170953,Neither,Low,False,False,0.4,0.4,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.294148375621,0.126,,Neither,oncoref.target-sets.2026-10-23.2,0.2941 TPM; blood/THSTAR; dice_thstar; vital,0.126 nTPM; blood/gdT-cell; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGG6,https://www.uniprot.org/uniprotkb/Q8NGG6/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR8B2,ENSG00000284680,Neither,Unassessed,False,False,1.1,1.1,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"incomplete routine rna; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.253358003435,0.6,,Neither,oncoref.target-sets.2026-10-23.2,0.2534 TPM; blood/TH17; dice_th17; vital,0.6 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,28,0,Q96RD0,https://www.uniprot.org/uniprotkb/Q96RD0/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
OR8B3,ENSG00000284609,Neither,Unassessed,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"existing nomination or manual review; incomplete routine rna; nomination unresolved; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.146409698394,0.4,,Neither,oncoref.target-sets.2026-10-23.2,0.1464 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,0.4 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,28,0,Q8NGG8,https://www.uniprot.org/uniprotkb/Q8NGG8/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR8D1,ENSG00000196341,Neither,Antibody,False,False,0.6,0.6,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA059510; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA059510; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA059510; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA059510; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA059510; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA059510; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: High, HPA059510; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA059510; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA059510; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA059510; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA059510; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA059510; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA059510; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA059510; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA059510; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA059510; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA059510; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA059510; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA059510; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.2142,0.4,,Neither,oncoref.target-sets.2026-10-23.2,0.2142 TPM; blood/eosinophil; hpa_immune_cell_samples; vital,0.4 nTPM; heart muscle/smooth muscle cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Lung Squamous Cell Carcinoma (TCGA): 1/489 (0.2%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),colorectal cancer: 2/11 (18.2%); breast cancer: 1/11 (9.1%),31,20,Q8WZ84,https://www.uniprot.org/uniprotkb/Q8WZ84/entry,Odorant receptor (Potential). May be involved in taste perception,Expressed in the tongue,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
OR8G1,ENSG00000197849,Neither,Low,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.6,1.5,,Neither,oncoref.target-sets.2026-10-23.2,0.6 TPM; blood/basophil; hpa_immune_monaco; vital,1.5 nTPM; eye/bipolar cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,Q15617,https://www.uniprot.org/uniprotkb/Q15617/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR8G5,ENSG00000255298,Neither,Unassessed,False,False,2.4,2.4,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"existing nomination or manual review; incomplete routine rna; nomination unresolved; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.19663744848,23.3,,Neither,oncoref.target-sets.2026-10-23.2,1.197 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,23.3 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Lung Adenocarcinoma (validation): 1/105 (1.0%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR8S1,ENSG00000284723,Neither,Unassessed,False,False,0.0,0.1,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"existing nomination or manual review; incomplete routine rna; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord; incomplete tissue evidence",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.752874296552,1.1,,Neither,oncoref.target-sets.2026-10-23.2,0.7529 TPM; blood/CD4_STIM; dice_cd4_stim; vital,1.1 nTPM; eye/muller glia cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,28,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR9Q2,ENSG00000186513,Neither,Low,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.1,3.6,,Neither,oncoref.target-sets.2026-10-23.2,0.1 TPM; blood/Central memory CD8 T-cell; hpa_immune_monaco; vital,3.6 nTPM; colon/paneth cells; hpa_single_cell_tissue; protected,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGE9,https://www.uniprot.org/uniprotkb/Q8NGE9/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OTOG,ENSG00000188162,Neither,Low,False,False,0.8,1.3,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; pituitary gland: 1.3 nTPM; continuous selectivity;reproductive not higher; retina: 0.5 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.212675429969,4.5,,Neither,oncoref.target-sets.2026-10-23.2,0.2127 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,4.5 nTPM; eye/muller glia cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 1/58 (1.7%); Kidney Renal Clear Cell Carcinoma (validation): 1/100 (1.0%); Liver Hepatocellular Carcinoma (TCGA): 3/362 (0.8%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q6ZRI0,https://www.uniprot.org/uniprotkb/Q6ZRI0/entry,Glycoprotein specific to acellular membranes of the inner ear. May be required for the anchoring of the otoconial membranes and cupulae to the underlying neuroepithelia in the vestibule. May be involved in the organization and/or stabilization of the fibrillar network that compose the tectorial membrane in the cochlea. May play a role in mechanotransduction processes (By similarity),,"Deafness, autosomal recessive, 18B: A form of non-syndromic deafness characterized by a moderate hearing impairment, which can be associated with vestibular dysfunction, and a flat to shallow 'U' or slightly downsloping shaped audiograms.",,"Apical cell membrane Secreted, extracellular space",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OVOL3,ENSG00000105261,Neither,Cellular,False,False,3.7,3.7,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,True,"salivary gland/plasma cells cluster c-18: 10.7 nTPM, 24 reads; reproductive-cell max 2",True,False,,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,3.1164811321599997,10.7,,Neither,oncoref.target-sets.2026-10-23.2,3.116 TPM; blood/CD8_STIM; dice_cd8_stim; vital,10.7 nTPM; salivary gland/plasma cells; hpa_single_cell_tissue; vital,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 7/283 (2.5%); Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%); Lung Squamous Cell Carcinoma (TCGA): 8/489 (1.6%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,O00110,https://www.uniprot.org/uniprotkb/O00110/entry,May act as a transcription regulator,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
P3R3URF,ENSG00000250719,Neither,Screening,False,False,137.1,137.1,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.5054728777400004,10.5,,Neither,oncoref.target-sets.2026-10-23.2,2.505 TPM; blood/NK; dice_nk; vital,10.5 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Kidney Chromophobe (TCGA): 2/64 (3.1%); Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A0A087WWA1,https://www.uniprot.org/uniprotkb/A0A087WWA1/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PADI6,ENSG00000276747,Neither,Cellular,False,False,5.6,5.6,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE NK (unstimulated): 21/90 values ≥5 TPM, max 17.7796",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,17.779603884,3.7,,Neither,oncoref.target-sets.2026-10-23.2,17.78 TPM; blood/NK; dice_nk; vital,3.7 nTPM; pbmc/t-cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 2/207 (1.0%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,28,0,Q6TGC4,https://www.uniprot.org/uniprotkb/Q6TGC4/entry,"Structural constituent of cytoplasmic lattices, which plays a key role in early embryonic development (PubMed:37922900, PubMed:41772195). Cytoplasmic lattices consist in fibrous structures found in the cytoplasm of oocytes and preimplantation embryos: they are required to store maternal proteins critical for embryonic development, such as ribosomal proteins, cytoskeletal tubulins and proteins controlling epigenetic reprogramming of the preimplantation embryo, in a poised but restrained state, regulating their availability for early embryonic development (PubMed:37922900, PubMed:41772195). Cytoplasmic lattices also tightly control ubiquitination during the oocyte-to-embryo transition by trapping E3 ubiquitin-protein ligase UHRF1 in a compact autoinhibited conformation and maintaining SCF ubiquitin ligase complexes inactive (PubMed:41772195). PADI6 oligomers acts as an essential structural scaffolding element of cytoplasmic lattices (By similarity). In contrast to other members of the family, does not show protein-arginine deiminase activity due to its inability to bind Ca(2+) (PubMed:38656308, PubMed:39286527)",Highly expressed in oocytes and weakly expressed in other somatic tissues,"Oocyte/zygote/embryo maturation arrest 16: A rare cause of female primary infertility. In affected women, ovulation and fertilization proceed normally but embryos are arrested at early stages of development. Inheritance is autosomal recessive.","In contrast to other members of the family, does not bind Ca(2+) and is inactive in in vitro assays against standard PADIs substrate (PubMed:39286527). At the structural level, the putative active site is in an unsuitable conformation for substrate binding (PubMed:38656308, PubMed:39286527)","Cytoplasm Cytoplasmic vesicle, secretory vesicle, Cortical granule Nucleus",37922900|38656308|39286527|41772195,15625577|27545678,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PAGE3,ENSG00000204279,Neither,Antibody,False,False,7.4,7.4,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA062248; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA062248; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA062248; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA062248; conflicting or uncurated primary profile; Caudate/Glial cells: High, HPA062248; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA062248; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: High, HPA062248; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: High, HPA062248; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA062248; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: High, HPA062248; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: High, HPA062248; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA062248; conflicting or uncurated primary profile; Colon/Endothelial cells: High, HPA062248; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA062248; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA062248; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA062248; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA062248; conflicting or uncurated primary profile; Hippocampus/Glial cells: High, HPA062248; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA062248; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: High, HPA062248; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA062248; conflicting or uncurated primary profile; Liver/Cholangiocytes: High, HPA062248; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA062248; conflicting or uncurated primary profile; Lung/Alveolar cells: High, HPA062248; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA062248; conflicting or uncurated primary profile; Lymph node/Germinal center cells: High, HPA062248; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA062248; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA062248; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA062248; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA062248; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: High, HPA062248; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA062248; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA062248; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA062248; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA062248; conflicting or uncurated primary profile; Skin 1/Fibroblasts: High, HPA062248; conflicting or uncurated primary profile; Skin 1/Keratinocytes: High, HPA062248; conflicting or uncurated primary profile; Skin 1/Langerhans: High, HPA062248; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA062248; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA062248; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA062248; conflicting or uncurated primary profile; Spleen/Cells in red pulp: High, HPA062248; conflicting or uncurated primary profile; Spleen/Cells in white pulp: High, HPA062248; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA062248; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA062248; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA062248; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA062248; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,1.9,,CTA,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1.9 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%),cervical cancer: 12/12 (100.0%); endometrial cancer: 12/12 (100.0%),31,20,Q5JUK9,https://www.uniprot.org/uniprotkb/Q5JUK9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PAGE5,ENSG00000158639,Neither,Cellular,False,False,25.8,25.8,86,1,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE THSTAR (unstimulated): 7/88 values ≥5 TPM, max 7.99924",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,17.3672358703,19.5,,CTA,oncoref.target-sets.2026-10-23.2,17.37 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,19.5 nTPM; esophagus/t-cells; hpa_single_cell_tissue; vital,Liver Hepatocellular Carcinoma (validation): 54/231 (23.4%); Testicular Germ Cell Tumor (TCGA): 31/133 (23.3%); Skin Cuteneous Melanoma (TCGA): 20/99 (20.2%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q96GU1,https://www.uniprot.org/uniprotkb/Q96GU1/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Carter2023_CT | Loriot2025_S1 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PANX3,ENSG00000154143,Neither,Low,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,basal ganglia: 0.2 nTPM; continuous selectivity;reproductive not higher; salivary gland: 0.2 nTPM; continuous selectivity;reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.17709877125,3.0,,Neither,oncoref.target-sets.2026-10-23.2,1.177 TPM; blood/CD4_STIM; dice_cd4_stim; vital,3 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96QZ0,https://www.uniprot.org/uniprotkb/Q96QZ0/entry,Regulator of osteoblast differentiation by functioning as a Ca(2+) channel in the endoplasmic reticulum which regulates calmodulin (CaM) pathways. Allows ATP release into the extracellular space and activation or purinergic receptors,,,,"Cell membrane Cell junction, gap junction Endoplasmic reticulum membrane",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PCDHA13,ENSG00000239389,Neither,Low,False,False,0.5,3.4,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 1 nTPM; continuous selectivity;reproductive not higher; basal ganglia: 1.1 nTPM; continuous selectivity;reproductive not higher; cerebellum: 1.8 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 1.4 nTPM; continuous selectivity;reproductive not higher; hippocampal formation: 1.1 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 0.8 nTPM; continuous selectivity;reproductive not higher; midbrain: 0.5 nTPM; continuous selectivity;reproductive not higher; pancreas: 0.6 nTPM; continuous selectivity;reproductive not higher; parathyroid gland: 3.4 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 0.4 nTPM; continuous selectivity; retina: 1.1 nTPM; continuous selectivity;reproductive not higher; spinal cord: 0.4 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0563403559681999,7.2,,Neither,oncoref.target-sets.2026-10-23.2,0.05634 TPM; blood/TH1; dice_th1; vital,7.2 nTPM; eye/bipolar cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 11/58 (19.0%); Liver Hepatocellular Carcinoma (validation): 28/231 (12.1%); Breast Invasive Carcinoma (validation): 4/50 (8.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9Y5I0,https://www.uniprot.org/uniprotkb/Q9Y5I0/entry,Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
PCDHA3,ENSG00000255408,Neither,Low,False,False,1.3,2.0,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 0.7 nTPM; continuous selectivity; amygdala: 1 nTPM; continuous selectivity; basal ganglia: 1.1 nTPM; continuous selectivity; cerebellum: 2 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 1.3 nTPM; continuous selectivity;reproductive not higher; hippocampal formation: 1.1 nTPM; continuous selectivity; hypothalamus: 1.1 nTPM; continuous selectivity; kidney: 0.6 nTPM; continuous selectivity; lung: 0.8 nTPM; continuous selectivity; midbrain: 0.8 nTPM; continuous selectivity; pancreas: 1.1 nTPM; continuous selectivity; pituitary gland: 1.4 nTPM; continuous selectivity;reproductive not higher; retina: 0.9 nTPM; continuous selectivity; spinal cord: 1.3 nTPM; continuous selectivity;reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0693820458121,6.5,,Neither,oncoref.target-sets.2026-10-23.2,0.06938 TPM; blood/NK; dice_nk; vital,6.5 nTPM; esophagus/endothelial cells; hpa_single_cell_tissue; protected,Glioblastoma Multiforme (validation): 15/58 (25.9%); Breast Invasive Carcinoma (validation): 10/50 (20.0%); Liver Hepatocellular Carcinoma (validation): 30/231 (13.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9Y5H8,https://www.uniprot.org/uniprotkb/Q9Y5H8/entry,Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PCDHA7,ENSG00000204963,Neither,Low,False,False,0.8,1.7,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,basal ganglia: 0.4 nTPM; continuous selectivity; cerebellum: 1.7 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 0.8 nTPM; continuous selectivity;reproductive not higher; hippocampal formation: 0.5 nTPM; continuous selectivity; hypothalamus: 0.4 nTPM; continuous selectivity; midbrain: 0.5 nTPM; continuous selectivity; pituitary gland: 0.4 nTPM; continuous selectivity; retina: 0.4 nTPM; continuous selectivity; spinal cord: 1.2 nTPM; continuous selectivity;reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.183754429761,7.4,,Neither,oncoref.target-sets.2026-10-23.2,0.1838 TPM; blood/TH1; dice_th1; vital,7.4 nTPM; lung/ciliated cells; hpa_single_cell_tissue; vital,Liver Hepatocellular Carcinoma (validation): 31/231 (13.4%); Breast Invasive Carcinoma (validation): 3/50 (6.0%); Glioblastoma Multiforme (validation): 3/58 (5.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9UN72,https://www.uniprot.org/uniprotkb/Q9UN72/entry,"Calcium-dependent cell-adhesion protein involved in cells self-recognition and non-self discrimination. Thereby, it is involved in the establishment and maintenance of specific neuronal connections in the brain",,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PCDHA8,ENSG00000204962,Neither,Antibody,False,False,0.3,1.8,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,amygdala: 0.3 nTPM; continuous selectivity;reproductive not higher; basal ganglia: 0.2 nTPM; continuous selectivity; cerebellum: 1.8 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 0.5 nTPM; continuous selectivity;reproductive not higher; hippocampal formation: 0.3 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 0.3 nTPM; continuous selectivity;reproductive not higher; midbrain: 0.2 nTPM; continuous selectivity; pituitary gland: 0.3 nTPM; continuous selectivity;reproductive not higher; retina: 0.5 nTPM; continuous selectivity;reproductive not higher; spinal cord: 0.3 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bone marrow/Hematopoietic cells: Low, HPA044585; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA044585; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA044585; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA044585; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA044585; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA044585; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA044585; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA044585; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA044585; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA044585; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA044585; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA044585; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA044585; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.046191691958,1.8,,Neither,oncoref.target-sets.2026-10-23.2,0.04619 TPM; blood/TH17; dice_th17; vital,1.8 nTPM; cerebellum/bulk; hpa_rna_consensus; vital,Liver Hepatocellular Carcinoma (validation): 29/231 (12.6%); Glioblastoma Multiforme (validation): 6/58 (10.3%); Glioblastoma Multiforme (TCGA): 3/141 (2.1%),prostate cancer: 1/11 (9.1%); breast cancer: 0/9 (0.0%),31,20,Q9Y5H6,https://www.uniprot.org/uniprotkb/Q9Y5H6/entry,Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
PCDHA9,ENSG00000204961,Neither,Low,False,False,1.1,1.1,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,cerebellum: 0.8 nTPM; continuous selectivity; cerebral cortex: 0.4 nTPM; continuous selectivity; pancreas: 0.7 nTPM; continuous selectivity; spinal cord: 0.4 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.4736378776899999,3.4,,Neither,oncoref.target-sets.2026-10-23.2,0.4736 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,3.4 nTPM; unsited/Cone photoreceptor cells; hpa_single_cell; unresolved,Glioblastoma Multiforme (validation): 12/58 (20.7%); Liver Hepatocellular Carcinoma (validation): 29/231 (12.6%); Pancreatic Adenocarcinoma (validation): 3/80 (3.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9Y5H5,https://www.uniprot.org/uniprotkb/Q9Y5H5/entry,Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
PCDHB13,ENSG00000187372,Neither,Cellular,False,False,1.5,1.9,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.1 nTPM; continuous selectivity; adrenal gland: 1.2 nTPM; continuous selectivity; amygdala: 0.5 nTPM; continuous selectivity; basal ganglia: 0.6 nTPM; continuous selectivity; cerebellum: 0.9 nTPM; continuous selectivity; cerebral cortex: 1.1 nTPM; continuous selectivity; colon: 1 nTPM; continuous selectivity; esophagus: 0.7 nTPM; continuous selectivity; heart muscle: 1.4 nTPM; continuous selectivity; hippocampal formation: 0.5 nTPM; continuous selectivity; hypothalamus: 0.5 nTPM; continuous selectivity; kidney: 0.8 nTPM; continuous selectivity; liver: 0.5 nTPM; continuous selectivity; lung: 0.8 nTPM; continuous selectivity; pancreas: 1.9 nTPM; continuous selectivity;reproductive not higher; parathyroid gland: 0.7 nTPM; continuous selectivity; pituitary gland: 1.4 nTPM; continuous selectivity; retina: 1.2 nTPM; continuous selectivity; salivary gland: 1.4 nTPM; continuous selectivity; skin: 1.8 nTPM; continuous selectivity;reproductive not higher; smooth muscle: 1.3 nTPM; continuous selectivity; spinal cord: 0.6 nTPM; continuous selectivity; spleen: 0.8 nTPM; continuous selectivity; stomach: 0.7 nTPM; continuous selectivity; thyroid gland: 0.8 nTPM; continuous selectivity; tongue: 0.7 nTPM; continuous selectivity; urinary bladder: 0.8 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,True,"bronchus/club cells cluster c-4: 5.6 nTPM, 20 reads; reproductive-cell max 4.4; salivary gland/mucus glandular cells cluster c-4: 5.4 nTPM, 250 reads; reproductive-cell max 4.4",True,False,,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,3.1886,9.9,,Neither,oncoref.target-sets.2026-10-23.2,3.189 TPM; blood/neutrophil; hpa_immune_cell_samples; vital,9.9 nTPM; skeletal muscle/fibroblasts; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 28/50 (56.0%); Pancreatic Adenocarcinoma (validation): 40/80 (50.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9Y5F0,https://www.uniprot.org/uniprotkb/Q9Y5F0/entry,Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PCDHB3,ENSG00000113205,Neither,Antibody,False,False,3.5,3.5,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.7 nTPM; continuous selectivity; adrenal gland: 1.2 nTPM; continuous selectivity; basal ganglia: 1 nTPM; continuous selectivity; heart muscle: 1.1 nTPM; continuous selectivity; kidney: 1.1 nTPM; continuous selectivity; lung: 1 nTPM; continuous selectivity; pancreas: 1.1 nTPM; continuous selectivity; parathyroid gland: 1.6 nTPM; continuous selectivity; pituitary gland: 1.7 nTPM; continuous selectivity; smooth muscle: 1 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Colon/Glandular cells: Low, HPA050296; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA050296; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA050296; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA050296; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA050296; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA050296; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA050296; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA050296; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA050296; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA050296; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA050296; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA050296; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA050296; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA050296; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.313275558033,6.5,,Neither,oncoref.target-sets.2026-10-23.2,0.3133 TPM; blood/TH2; dice_th2; vital,6.5 nTPM; esophagus/endothelial cells; hpa_single_cell_tissue; protected,Glioblastoma Multiforme (validation): 54/58 (93.1%); Breast Invasive Carcinoma (validation): 18/50 (36.0%); Glioblastoma Multiforme (TCGA): 47/141 (33.3%),liver cancer: 2/12 (16.7%); stomach cancer: 1/11 (9.1%),31,20,Q9Y5E6,https://www.uniprot.org/uniprotkb/Q9Y5E6/entry,Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PCDHB6,ENSG00000113211,Neither,Antibody,False,False,1.9,1.9,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 0.6 nTPM; continuous selectivity; amygdala: 1.3 nTPM; continuous selectivity; basal ganglia: 1.5 nTPM; continuous selectivity; cerebellum: 1.4 nTPM; continuous selectivity; cerebral cortex: 1.8 nTPM; continuous selectivity; heart muscle: 0.7 nTPM; continuous selectivity; hippocampal formation: 1.3 nTPM; continuous selectivity; hypothalamus: 0.7 nTPM; continuous selectivity; kidney: 0.6 nTPM; continuous selectivity; lung: 0.6 nTPM; continuous selectivity; midbrain: 0.8 nTPM; continuous selectivity; parathyroid gland: 1.8 nTPM; continuous selectivity; pituitary gland: 1 nTPM; continuous selectivity; retina: 0.9 nTPM; continuous selectivity; smooth muscle: 0.9 nTPM; continuous selectivity; spinal cord: 1.1 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA029566; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA029566; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA029566; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA029566; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA029566; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA029566; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA029566; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA029566; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA029566; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA029566; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA029566; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA029566; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA029566; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA029566; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA029566; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA029566; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA029566; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA029566; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA029566; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA029566; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.3592207992189999,3.5,,Neither,oncoref.target-sets.2026-10-23.2,0.3592 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,3.5 nTPM; unsited/Lymphatic endothelial cells; hpa_single_cell; unresolved,Glioblastoma Multiforme (validation): 32/58 (55.2%); Glioblastoma Multiforme (TCGA): 35/141 (24.8%); Breast Invasive Carcinoma (validation): 12/50 (24.0%),breast cancer: 7/12 (58.3%); colorectal cancer: 7/12 (58.3%),31,20,Q9Y5E3,https://www.uniprot.org/uniprotkb/Q9Y5E3/entry,"Calcium-dependent cell-adhesion protein involved in cells self-recognition and non-self discrimination. Thereby, it is involved in the establishment and maintenance of specific neuronal connections in the brain",,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT | Jamin2021_core,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
PCDHGA1,ENSG00000204956,Neither,Antibody,False,False,1.0,1.8,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 0.7 nTPM; continuous selectivity; basal ganglia: 1.5 nTPM; continuous selectivity;reproductive not higher; cerebellum: 1.3 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 1.8 nTPM; continuous selectivity;reproductive not higher; choroid plexus: 0.5 nTPM; continuous selectivity; colon: 0.5 nTPM; continuous selectivity; heart muscle: 1.2 nTPM; continuous selectivity;reproductive not higher; hippocampal formation: 0.8 nTPM; continuous selectivity; hypothalamus: 0.6 nTPM; continuous selectivity; midbrain: 0.5 nTPM; continuous selectivity; pancreas: 0.5 nTPM; continuous selectivity; parathyroid gland: 0.5 nTPM; continuous selectivity; pituitary gland: 0.8 nTPM; continuous selectivity; retina: 1.1 nTPM; continuous selectivity;reproductive not higher; skeletal muscle: 0.6 nTPM; continuous selectivity; smooth muscle: 0.4 nTPM; continuous selectivity; spinal cord: 0.4 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA008755; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA008755; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA008755; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA008755; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA008755; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA008755; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA008755; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA008755; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA008755; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA008755; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA008755; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA008755; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA008755; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA008755; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA008755; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA008755; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA008755; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA008755; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA008755; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA008755; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA008755; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA008755; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA008755; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA008755; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA008755; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA008755; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA008755; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA008755; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA008755; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA008755; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA008755; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA008755; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA008755; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA008755; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA008755; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA008755; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA008755; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA008755; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA008755; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA008755; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA008755; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA008755; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA008755; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA008755; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA008755; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA008755; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA008755; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA008755; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: Low, HPA036547; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA036547; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA036547; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA036547; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA036547; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA036547; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA036547; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA036547; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA036547; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: High, HPA036547; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA036547; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA036547; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA036547; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA036547; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA036547; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA036547; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA036547; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA036547; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA036547; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA036547; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA036547; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA036547; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA036547; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA036547; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA036547; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA036547; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA036547; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA036547; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA036547; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA036547; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA036547; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA036547; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA036547; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA036547; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA036547; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA036547; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA036547; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA036547; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA036547; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.6528,6.8,,Neither,oncoref.target-sets.2026-10-23.2,0.6528 TPM; blood/NK-cell; hpa_immune_cell_samples; vital,6.8 nTPM; unsited/Skeletal myocytes; hpa_single_cell; unresolved,Liver Hepatocellular Carcinoma (validation): 180/231 (77.9%); Glioblastoma Multiforme (validation): 43/58 (74.1%); Glioblastoma Multiforme (TCGA): 12/141 (8.5%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,Q9Y5H4,https://www.uniprot.org/uniprotkb/Q9Y5H4/entry,Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PIWIL3,ENSG00000184571,Neither,Antibody,False,False,0.8,0.8,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bronchus/Respiratory epithelial cells: Medium, HPA061955; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA061955; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA061955; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA061955; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA061955; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA061955; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA061955; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA061955; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA061955; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA061955; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA061955; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA061955; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA061955; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA061955; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA061955; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA061955; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA061955; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA061955; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA061955; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA061955; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA061955; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA061955; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA061955; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA061955; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.04199513185,1.5,,Neither,oncoref.target-sets.2026-10-23.2,1.042 TPM; blood/NK; dice_nk; vital,1.5 nTPM; bone marrow/erythroid cells; hpa_single_cell_tissue; vital,Lung Adenocarcinoma (TCGA): 15/497 (3.0%); Bladder Urothelial Carcinoma (TCGA): 4/169 (2.4%); Lung Adenocarcinoma (validation): 1/105 (1.0%),prostate cancer: 11/12 (91.7%); colorectal cancer: 9/12 (75.0%),31,20,Q7Z3Z3,https://www.uniprot.org/uniprotkb/Q7Z3Z3/entry,"May play a role during spermatogenesis by repressing transposable elements and preventing their mobilization, which is essential for the germline integrity. Acts via the piRNA metabolic process, which mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and govern the methylation and subsequent repression of transposons. Directly binds piRNAs, a class of 24 to 30 nucleotide RNAs that are generated by a Dicer-independent mechanism and are primarily derived from transposons and other repeated sequence elements. Besides their function in transposable elements repression, piRNAs are probably involved in other processes during meiosis such as translation regulation (By similarity)",Expressed in testis,,,Cytoplasm,,12906857,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PLA2G2E,ENSG00000188784,Neither,Antibody,False,False,0.0,2.4,0,0,Missing,False,False,False,False,Excluded,Other,True,Disposable,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA064085; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Low, HPA064085; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA064085; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA064085; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA064085; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA064085; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA064085; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA064085; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA064085; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA064085; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.729785784239,0.4,,Neither,oncoref.target-sets.2026-10-23.2,0.7298 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,0.4 nTPM; skin/bulk; hpa_rna_consensus; manageable,Thyroid Carcinoma (TCGA): 5/495 (1.0%); Stomach Adenocarcinoma (TCGA): 2/346 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9NZK7,https://www.uniprot.org/uniprotkb/Q9NZK7/entry,"Secretory calcium-dependent phospholipase A2 that primarily targets extracellular phospholipids (PubMed:10681567, PubMed:11922621, PubMed:28883454). Hydrolyzes the ester bond of the fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity), releasing various unsaturated fatty acids including oleoate, linoleoate, arachidonate, docosahexaenoate and lysophosphatidylethanolamines in preference to lysophosphatidylcholines (PubMed:10681567, PubMed:28883454). In response to high-fat diet, hydrolyzes minor lipoprotein phospholipids including phosphatidylserines, phosphatidylinositols and phosphatidylglycerols, altering lipoprotein composition and fat storage in adipose tissue and liver (By similarity). May act in an autocrine and paracrine manner (PubMed:11922621). Contributes to lipid remodeling of cellular membranes and generation of lipid mediators involved in pathogen clearance. Cleaves sn-2 fatty acyl chains of phosphatidylglycerols and phosphatidylethanolamines, which are major components of membrane phospholipids in bacteria (PubMed:11922621). Acts as a hair follicle phospholipase A2. Selectively releases lysophosphatidylethanolamines (LPE) and various unsaturated fatty acids in skin to regulate hair follicle homeostasis (By similarity). May regulate the inflammatory response by releasing arachidonate, a precursor of prostaglandins and leukotrienes (PubMed:11922621). Upon allergen exposure, may participate in allergic inflammatory response by enhancing leukotriene C4 synthesis and degranulation in mast cells (By similarity)","Restricted to the brain, heart, lung, and placenta",,,Secreted Cytoplasm,10681567|11922621|28883454,10681567,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
PLSCR2,ENSG00000163746,Neither,Cellular,False,False,13.2,13.2,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_monaco classical monocyte: 6.8 TPM; hpa_immune_monaco myeloid DC: 5.4 TPM; hpa_immune_monaco neutrophil: 10.1 TPM,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,10.1,3.7,,CTA,oncoref.target-sets.2026-10-23.2,10.1 TPM; blood/neutrophil; hpa_immune_monaco; vital,3.7 nTPM; placenta/mixed immune cells; hpa_single_cell_tissue; vital,Colon Adenocarcinoma (validation): 12/486 (2.5%); Glioblastoma Multiforme (validation): 1/58 (1.7%); Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9NRY7,https://www.uniprot.org/uniprotkb/Q9NRY7/entry,"May catalyze calcium-induced ATP-independent rapid bidirectional and non-specific movement of phospholipids (lipid scrambling or lipid flip-flop) between the inner and outer leaflet of the plasma membrane Has no phospholipid scramblase activity, due to the lack of a N-terminal proline-rich domain",Expression of isoform 1 seems restricted to testis,,,Membrane Nucleus,24648509,10930526,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PMIS2,ENSG00000283758,Neither,Low,False,False,0.7,0.7,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.03733892279,0.0,,Neither,oncoref.target-sets.2026-10-23.2,1.037 TPM; blood/CD4_STIM; dice_cd4_stim; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,A0A1W2PS18,https://www.uniprot.org/uniprotkb/A0A1W2PS18/entry,May play a role in spermatozoa mobility,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PNMA6E,ENSG00000214897,Neither,Screening,False,False,11.6,11.6,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.212929065631,0.6,,Neither,oncoref.target-sets.2026-10-23.2,0.2129 TPM; blood/THSTAR; dice_thstar; vital,0.6 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 8/176 (4.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 6/283 (2.1%); Head and Neck Squamous Cell Carcinoma (TCGA): 10/492 (2.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A0A0J9YXQ4,https://www.uniprot.org/uniprotkb/A0A0J9YXQ4/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
POM121L2,ENSG00000158553,Neither,Antibody,False,False,7.3,7.3,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA046150; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA046150; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA046150; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA046150; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA046150; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA046150; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA046150; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA046150; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA046150; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA046150; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA046150; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA046150; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA046150; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA046150; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA046150; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA046150; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA046150; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA046150; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA046150; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA046150; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA046150; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA046150; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA046150; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA046150; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA046150; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA046150; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA046150; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA046150; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA046150; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA046150; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA046150; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA046150; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA046150; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA046150; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.326340673646,0.4,,CTA,oncoref.target-sets.2026-10-23.2,0.3263 TPM; blood/TH1; dice_th1; vital,0.4 nTPM; eye/muller glia cells; hpa_single_cell_tissue; vital,Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),prostate cancer: 12/12 (100.0%); lung cancer: 11/11 (100.0%),31,20,Q96KW2,https://www.uniprot.org/uniprotkb/Q96KW2/entry,,,,This sequence lacks full-length transcript support,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
POTEA,ENSG00000188877,Neither,Unassessed,False,False,1.1,1.1,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"existing nomination or manual review; incomplete routine rna; nomination unresolved; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.335825676764,1.2,,Neither,oncoref.target-sets.2026-10-23.2,0.3358 TPM; blood/TH17; dice_th17; vital,1.2 nTPM; unsited/Astrocytes; hpa_single_cell; unresolved,No exact-ID RNA coverage in the HPA cancer snapshot,No exact-ID IHC coverage in the HPA cancer snapshot,0,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
POTEB,ENSG00000233917,Neither,Low,False,False,1.3,1.3,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Breast Invasive Carcinoma (validation): 0/50 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,A0A0A6YYL3 | H3BUK9,https://www.uniprot.org/uniprotkb/A0A0A6YYL3/entry | https://www.uniprot.org/uniprotkb/H3BUK9/entry,,,,Maps to a duplicated region on chromosome 15; the gene is present in at least 3 almost identical copies,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
POTEB2,ENSG00000230031,Neither,Low,False,False,1.3,1.3,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.1,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.1 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 0/283 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A0A0A6YYL3 | H3BUK9,https://www.uniprot.org/uniprotkb/A0A0A6YYL3/entry | https://www.uniprot.org/uniprotkb/H3BUK9/entry,,,,Maps to a duplicated region on chromosome 15; the gene is present in at least 3 almost identical copies,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
POTEB3,ENSG00000278522,Neither,Low,False,False,4.9,4.9,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.6,0.8,,Neither,oncoref.target-sets.2026-10-23.2,0.6 TPM; blood/Central memory CD8 T-cell; hpa_immune_monaco; vital,0.8 nTPM; placenta/t-cells; hpa_single_cell_tissue; vital,Prostate Adenocarcinoma (TCGA): 9/480 (1.9%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,A0JP26,https://www.uniprot.org/uniprotkb/A0JP26/entry,,,,Maps to a duplicated region on chromosome 15; the gene is present in at least 3 almost identical copies,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
POTEC,ENSG00000183206,Neither,Low,False,False,2.4,2.4,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.460519445095,1.6,,Neither,oncoref.target-sets.2026-10-23.2,0.4605 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1.6 nTPM; skeletal muscle/fibroblasts; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 4/50 (8.0%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,B2RU33,https://www.uniprot.org/uniprotkb/B2RU33/entry,,Expressed in prostate and testis,,,,,12475935,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S1 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
POTED,ENSG00000166351,Neither,Low,False,False,4.2,4.2,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.7816,1.2254,,Neither,oncoref.target-sets.2026-10-23.2,0.7816 TPM; blood/basophil; hpa_immune_cell_samples; vital,1.225 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Breast Invasive Carcinoma (validation): 1/50 (2.0%); Breast Invasive Carcinoma (TCGA): 1/1022 (0.1%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q86YR6,https://www.uniprot.org/uniprotkb/Q86YR6/entry,,"Expressed in prostate, ovary, testis, placenta and prostate cancer cell lines. Localizes to basal and terminal prostate epithelial cells",,,Cell membrane,,12475935,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
POTEF,ENSG00000196604,Neither,Antibody,False,False,1.7,1.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA041264; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA041264; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA041264; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA041264; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA041264; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA041264; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA041264; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA041264; conflicting or uncurated primary profile; Colon/Endothelial cells: High, HPA041264; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA041264; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: High, HPA041264; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA041264; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA041264; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA041264; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA041264; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA041264; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA041264; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA041264; conflicting or uncurated primary profile; Lung/Alveolar cells: High, HPA041264; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA041264; conflicting or uncurated primary profile; Lymph node/Germinal center cells: High, HPA041264; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA041264; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA041264; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA041264; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA041264; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA041264; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA041264; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA041264; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA041264; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA041264; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA041264; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA041264; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA041264; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA041264; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA041264; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA041264; conflicting or uncurated primary profile; Spleen/Cells in red pulp: High, HPA041264; conflicting or uncurated primary profile; Spleen/Cells in white pulp: High, HPA041264; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA041264; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA041264; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA041264; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA041264; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: Low, HPA041271; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA041271; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA041271; conflicting or uncurated primary profile; Colon/Enterocytes - Microvilli: High, HPA041271; conflicting or uncurated primary profile; Duodenum/Enterocytes - Microvilli: High, HPA041271; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA041271; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA041271; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA041271; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA041271; conflicting or uncurated primary profile; Lymph node/Germinal center cells: High, HPA041271; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA041271; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA041271; conflicting or uncurated primary profile; Rectum/Enterocytes - Microvilli: High, HPA041271; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA041271; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA041271; conflicting or uncurated primary profile; Skin 1/Fibrohistiocytic cells: Low, HPA041271; conflicting or uncurated primary profile; Skin 2/Endothelial cells: Medium, HPA041271; conflicting or uncurated primary profile; Skin 2/Fibrohistiocytic cells: High, HPA041271; conflicting or uncurated primary profile; Skin 2/Langerhans cells: Medium, HPA041271; conflicting or uncurated primary profile; Skin 2/Lymphocytes: Medium, HPA041271; conflicting or uncurated primary profile; Small intestine/Enterocytes - Microvilli: High, HPA041271; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA041271; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA041271; conflicting or uncurated primary profile; Spleen/Cells in white pulp: High, HPA041271; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA041271; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA041271; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA043260; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA043260; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA043260; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA043260; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA043260; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA043260; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA043260; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA043260; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA043260; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA043260; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA043260; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA043260; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA043260; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA043260; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA043260; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA043260; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA043260; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA043260; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA043260; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA043260; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA043260; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA043260; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA043260; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA043260; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA043260; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA043260; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA043260; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA043260; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA043260; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA043260; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA043260; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA043260; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA043260; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA043260; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.2668,4.4007,,Neither,oncoref.target-sets.2026-10-23.2,1.267 TPM; blood/total PBMC; hpa_immune_cell_samples; vital,4.401 nTPM; blood/total PBMC; hpa_immune_cell_samples; vital,Breast Invasive Carcinoma (validation): 5/50 (10.0%); Colon Adenocarcinoma (validation): 46/486 (9.5%); Rectum Adenocarcinoma (validation): 18/207 (8.7%),testis cancer: 12/12 (100.0%); endometrial cancer: 11/11 (100.0%),31,20,A5A3E0,https://www.uniprot.org/uniprotkb/A5A3E0/entry,,Expressed in breast cancer cell lines (at protein level),,,"Cytoplasm, cell cortex",,17101985,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Loriot2025_S1 | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
POTEH,ENSG00000198062,Neither,Low,False,False,1.6,1.6,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.12835950349,0.4,,Neither,oncoref.target-sets.2026-10-23.2,0.1284 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.4 nTPM; adipose tissue/b-cells; hpa_single_cell_tissue; vital,Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Prostate Adenocarcinoma (TCGA): 2/480 (0.4%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6S545,https://www.uniprot.org/uniprotkb/Q6S545/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
POTEI,ENSG00000196834,Neither,Antibody,False,False,3.2,3.2,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA041264; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA041264; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA041264; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA041264; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA041264; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA041264; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA041264; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA041264; conflicting or uncurated primary profile; Colon/Endothelial cells: High, HPA041264; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA041264; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: High, HPA041264; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA041264; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA041264; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA041264; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA041264; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA041264; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA041264; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA041264; conflicting or uncurated primary profile; Lung/Alveolar cells: High, HPA041264; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA041264; conflicting or uncurated primary profile; Lymph node/Germinal center cells: High, HPA041264; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA041264; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA041264; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA041264; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA041264; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA041264; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA041264; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA041264; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA041264; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA041264; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA041264; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA041264; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA041264; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA041264; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA041264; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA041264; conflicting or uncurated primary profile; Spleen/Cells in red pulp: High, HPA041264; conflicting or uncurated primary profile; Spleen/Cells in white pulp: High, HPA041264; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA041264; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA041264; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA041264; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA041264; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: Low, HPA041271; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA041271; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA041271; conflicting or uncurated primary profile; Colon/Enterocytes - Microvilli: High, HPA041271; conflicting or uncurated primary profile; Duodenum/Enterocytes - Microvilli: High, HPA041271; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA041271; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA041271; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA041271; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA041271; conflicting or uncurated primary profile; Lymph node/Germinal center cells: High, HPA041271; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA041271; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA041271; conflicting or uncurated primary profile; Rectum/Enterocytes - Microvilli: High, HPA041271; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA041271; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA041271; conflicting or uncurated primary profile; Skin 1/Fibrohistiocytic cells: Low, HPA041271; conflicting or uncurated primary profile; Skin 2/Endothelial cells: Medium, HPA041271; conflicting or uncurated primary profile; Skin 2/Fibrohistiocytic cells: High, HPA041271; conflicting or uncurated primary profile; Skin 2/Langerhans cells: Medium, HPA041271; conflicting or uncurated primary profile; Skin 2/Lymphocytes: Medium, HPA041271; conflicting or uncurated primary profile; Small intestine/Enterocytes - Microvilli: High, HPA041271; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA041271; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA041271; conflicting or uncurated primary profile; Spleen/Cells in white pulp: High, HPA041271; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA041271; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA041271; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA043260; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA043260; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA043260; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA043260; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA043260; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA043260; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA043260; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA043260; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA043260; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA043260; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA043260; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA043260; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA043260; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA043260; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA043260; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA043260; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA043260; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA043260; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA043260; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA043260; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA043260; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA043260; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA043260; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA043260; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA043260; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA043260; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA043260; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA043260; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA043260; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA043260; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA043260; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA043260; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA043260; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA043260; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.568094227283,1.4,,Neither,oncoref.target-sets.2026-10-23.2,0.5681 TPM; blood/NK; dice_nk; vital,1.4 nTPM; colon/distal enterocytes; hpa_single_cell_tissue; protected,Prostate Adenocarcinoma (TCGA): 109/480 (22.7%); Breast Invasive Carcinoma (TCGA): 82/1022 (8.0%); Pancreatic Adenocarcinoma (validation): 5/80 (6.2%),testis cancer: 12/12 (100.0%); endometrial cancer: 11/11 (100.0%),29,20,P0CG38,https://www.uniprot.org/uniprotkb/P0CG38/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
POU4F2,ENSG00000151615,Neither,Low,False,False,1.0,1.0,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,retina: 1 nTPM; continuous selectivity;reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.22167792283,4.6,,Neither,oncoref.target-sets.2026-10-23.2,0.2217 TPM; blood/MONOCYTES; dice_monocytes; vital,4.6 nTPM; eye/bipolar cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 1/58 (1.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q12837,https://www.uniprot.org/uniprotkb/Q12837/entry,"Tissue-specific DNA-binding transcription factor involved in the development and differentiation of target cells (PubMed:19266028, PubMed:23805044). Functions either as activator or repressor modulating the rate of target gene transcription through RNA polymerase II enzyme in a promoter-dependent manner (PubMed:19266028, PubMed:23805044). Binds to the consensus octamer motif 5'-AT[A/T]A[T/A]T[A/T]A-3' of promoter of target genes. Plays a fundamental role in the gene regulatory network essential for retinal ganglion cell (RGC) differentiation. Binds to an octamer site to form a ternary complex with ISL1; cooperates positively with ISL1 and ISL2 to potentiate transcriptional activation of RGC target genes being involved in RGC fate commitment in the developing retina and RGC axon formation and pathfinding. Inhibits DLX1 and DLX2 transcriptional activities preventing DLX1- and DLX2-mediated ability to promote amacrine cell fate specification. In cooperation with TP53 potentiates transcriptional activation of BAX promoter activity increasing neuronal cell apoptosis. Negatively regulates BAX promoter activity in the absence of TP53. Acts as a transcriptional coactivator via its interaction with the transcription factor ESR1 by enhancing its effect on estrogen response element (ERE)-containing promoter. Antagonizes the transcriptional stimulatory activity of POU4F1 by preventing its binding to an octamer motif. Involved in TNFSF11-mediated terminal osteoclast differentiation (By similarity)",Expressed in the brain (PubMed:7691107). Expressed in the ganglion cell layer of the retina (PubMed:7691107),,,Nucleus Nucleus speckle Cytoplasm,19266028|23805044,7691107,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PP2D1,ENSG00000183977,Neither,Cellular,False,False,7.2,7.2,85,2,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 91/91 values ≥5 TPM, max 24.2124; DICE MONOCYTES (unstimulated): 17/91 values ≥5 TPM, max 7.0667; DICE M2 (unstimulated): 79/90 values ≥5 TPM, max 13.5273; DICE NK (unstimulated): 60/90 values ≥5 TPM, max 12.2266; DICE TREG_MEM (unstimulated): 80/89 values ≥5 TPM, max 16.4634; DICE CD4_NAIVE (unstimulated): 88/88 values ≥5 TPM, max 16.7731; DICE TREG_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 18.2759; DICE TFH (unstimulated): 64/89 values ≥5 TPM, max 15.1817; DICE TH1 (unstimulated): 74/81 values ≥5 TPM, max 14.5555; DICE THSTAR (unstimulated): 88/88 values ≥5 TPM, max 18.8836; DICE TH17 (unstimulated): 89/89 values ≥5 TPM, max 15.7425; DICE TH2 (unstimulated): 89/89 values ≥5 TPM, max 15.6177; DICE CD8_NAIVE (unstimulated): 88/89 values ≥5 TPM, max 17.1371",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,24.21243045,2.5,,CTA,oncoref.target-sets.2026-10-23.2,24.21 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,2.5 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Liver Hepatocellular Carcinoma (validation): 152/231 (65.8%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%),testis cancer: 1/11 (9.1%); colorectal cancer: 1/12 (8.3%),30,20,A8MPX8,https://www.uniprot.org/uniprotkb/A8MPX8/entry,,,,"Although it belongs to the protein phosphatase 2C family, it lacks some of the conserved residues that bind manganese, suggesting it has no phosphatase activity",,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PPP3R2,ENSG00000188386,Neither,Antibody,False,False,78.6,78.6,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA047157; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA047157; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA047157; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA047157; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA047157; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA047157; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA047157; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA047157; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA047157; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA047157; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA047157; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA047157; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA047157; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA047157; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA047157; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA047157; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA047157; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA047157; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA047157; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA047157; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA047157; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA047157; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA047157; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA047157; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA047157; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA047157; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA047157; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA047157; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA047157; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA047157; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA047157; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA047157; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.27944475719,10.5,,CTA,oncoref.target-sets.2026-10-23.2,1.279 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,10.5 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),renal cancer: 8/12 (66.7%); endometrial cancer: 7/12 (58.3%),31,20,Q96LZ3,https://www.uniprot.org/uniprotkb/Q96LZ3/entry,"Regulatory subunit of calcineurin, a calcium-dependent, calmodulin stimulated protein phosphatase. Confers calcium sensitivity",Testis-specific,,,Mitochondrion,,15865209,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PPP4R3C,ENSG00000224960,Neither,Low,False,False,1.8,1.8,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.166820668138,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0.1668 TPM; blood/CD4_STIM; dice_cd4_stim; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Testicular Germ Cell Tumor (TCGA): 14/133 (10.5%); Liver Hepatocellular Carcinoma (TCGA): 16/362 (4.4%); Lung Squamous Cell Carcinoma (validation): 2/68 (2.9%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q6ZMV5,https://www.uniprot.org/uniprotkb/Q6ZMV5/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Carter2023_CT | Loriot2025_S1 | Gong2021_reproductive_PC,Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PRAMEF1,ENSG00000116721,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O95521,https://www.uniprot.org/uniprotkb/O95521/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PRAMEF11,ENSG00000239810,Neither,Low,False,False,0.5,0.5,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0027,0.0027,,Neither,oncoref.target-sets.2026-10-23.2,0.0027 TPM; blood/plasmacytoid DC; hpa_immune_cell_samples; vital,0.0027 nTPM; blood/plasmacytoid DC; hpa_immune_cell_samples; vital,Ovary Serous Cystadenocarcinoma (validation): 1/81 (1.2%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O60813,https://www.uniprot.org/uniprotkb/O60813/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PRAMEF12,ENSG00000116726,Neither,Unassessed,False,False,0.0,0.1,79,34,Positive somewhere,False,False,False,False,Excluded,Unassessed,True,,Not assessed,,,reviewed unreliable ihc; unresolved reproductive selectivity; reviewed unreliable ihc; unresolved reproductive selectivity; incomplete tissue evidence,Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,cerebral cortex / endothelial cells: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: High (Uncertain); kidney / cells in tubules: High (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: High (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),reviewed_unreliable_ihc;unresolved_reproductive_selectivity,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0148,0.2,,Neither,oncoref.target-sets.2026-10-23.2,0.0148 TPM; blood/neutrophil; hpa_immune_cell_samples; vital,0.2 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),colorectal cancer: 12/12 (100.0%); skin cancer: 12/12 (100.0%),31,20,O95522,https://www.uniprot.org/uniprotkb/O95522/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PRAMEF13,ENSG00000279169,Neither,Low,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.006,0.0075,,Neither,oncoref.target-sets.2026-10-23.2,0.006 TPM; blood/naive B-cell; hpa_immune_cell_samples; vital,0.0075 nTPM; blood/naive B-cell; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,28,0,Q5VWM6,https://www.uniprot.org/uniprotkb/Q5VWM6/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
PRAMEF14,ENSG00000204481,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.6,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.6 nTPM; endometrium/macrophages; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Liver Hepatocellular Carcinoma (TCGA): 1/362 (0.3%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5SWL7,https://www.uniprot.org/uniprotkb/Q5SWL7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
PRAMEF15,ENSG00000204501,Neither,Low,False,False,0.0,0.1,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0069,0.1,,Neither,oncoref.target-sets.2026-10-23.2,0.0069 TPM; blood/naive B-cell; hpa_immune_cell_samples; vital,0.1 nTPM; liver/bulk; hpa_rna_consensus; vital,Liver Hepatocellular Carcinoma (TCGA): 27/362 (7.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,P0DUQ2 | P0DUQ1,https://www.uniprot.org/uniprotkb/P0DUQ2/entry | https://www.uniprot.org/uniprotkb/P0DUQ1/entry,"Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex, which mediates ubiquitination of target proteins, leading to their degradation (PubMed:26138980). The CRL2(PRAMEF9) complex mediates ubiquitination and degradation of truncated MSRB1/SEPX1 selenoproteins produced by failed UGA/Sec decoding (PubMed:26138980)",,,,,26138980,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
PRAMEF19,ENSG00000204480,Neither,Antibody,False,False,0.0,0.4,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Duodenum/Glandular cells: Medium, HPA057423; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA057423; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA057423; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA057423; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA057423; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA057423; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.2,0.4,,Neither,oncoref.target-sets.2026-10-23.2,0.2 TPM; blood/Memory CD4 T-cell Th2; hpa_immune_monaco; vital,0.4 nTPM; bone marrow/bulk; hpa_rna_consensus; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Breast Invasive Carcinoma (TCGA): 1/1022 (0.1%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),colorectal cancer: 3/12 (25.0%); melanoma: 1/11 (9.1%),30,20,Q5SWL8,https://www.uniprot.org/uniprotkb/Q5SWL8/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
PRAMEF2,ENSG00000120952,Neither,Low,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.365912681656,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0.3659 TPM; blood/TREG_MEM; dice_treg_mem; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Liver Hepatocellular Carcinoma (TCGA): 2/362 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Liver Hepatocellular Carcinoma (validation): 1/231 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O60811,https://www.uniprot.org/uniprotkb/O60811/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
PRAMEF20,ENSG00000204478,Neither,Low,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.44159065359,0.6,,Neither,oncoref.target-sets.2026-10-23.2,0.4416 TPM; blood/TH1; dice_th1; vital,0.6 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5VT98,https://www.uniprot.org/uniprotkb/Q5VT98/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PRAMEF27,ENSG00000274764,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.326663866477,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0.3267 TPM; blood/TH2; dice_th2; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,A3QJZ7,https://www.uniprot.org/uniprotkb/A3QJZ7/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
PRAMEF4,ENSG00000243073,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0041,0.0109,,Neither,oncoref.target-sets.2026-10-23.2,0.0041 TPM; blood/total PBMC; hpa_immune_cell_samples; vital,0.0109 nTPM; blood/total PBMC; hpa_immune_cell_samples; vital,Liver Hepatocellular Carcinoma (validation): 16/231 (6.9%); Liver Hepatocellular Carcinoma (TCGA): 20/362 (5.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O60810,https://www.uniprot.org/uniprotkb/O60810/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PRAMEF5,ENSG00000270601,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Breast Invasive Carcinoma (validation): 0/50 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q5TYX0,https://www.uniprot.org/uniprotkb/Q5TYX0/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
PRAMEF6,ENSG00000232423,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Head and Neck Squamous Cell Carcinoma (TCGA): 1/492 (0.2%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5VXH4,https://www.uniprot.org/uniprotkb/Q5VXH4/entry,"Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex, which mediates ubiquitination of target proteins, leading to their degradation (PubMed:26138980). The CRL2(PRAMEF6) complex mediates ubiquitination and degradation of truncated MSRB1/SEPX1 selenoproteins produced by failed UGA/Sec decoding (PubMed:26138980)",,,,,26138980,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PRDM13,ENSG00000112238,Neither,Antibody,False,False,0.0,0.5,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,True,"eye/horizontal cells cluster c-5: 16.4 nTPM, 26 reads; reproductive-cell max 4.6",True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA070592; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA070592; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA070592; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA070592; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA070592; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA070592; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA070592; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA070592; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA070592; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA070592; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA070592; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA070592; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA070592; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA070592; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.83315692822,16.4,,Neither,oncoref.target-sets.2026-10-23.2,1.833 TPM; blood/NK; dice_nk; vital,16.4 nTPM; unsited/Horizontal cells; hpa_single_cell; unresolved,Glioblastoma Multiforme (validation): 2/58 (3.4%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 7/283 (2.5%); Skin Cuteneous Melanoma (TCGA): 2/99 (2.0%),breast cancer: 0/8 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q9H4Q3,https://www.uniprot.org/uniprotkb/Q9H4Q3/entry,"May be involved in transcriptional regulation. Is required for the differentiation of KISS1-expressing neurons in the arcuate (Arc) nucleus of the hypothalamus. Is a critical regulator of GABAergic cell fate in the cerebellum, required for normal postnatal cerebellar development (By similarity)","In the embryo, expressed in neural stem cells of the hindbrain","Cerebellar dysfunction, impaired intellectual development, and hypogonadotropic hypogonadism: An autosomal recessive disorder characterized by delayed motor development, ataxia with cerebellar hypoplasia, severe progressive scoliosis, moderate to severe intellectual disability, and delayed puberty with congenital hypogonadotropic hypogonadism. Pontocerebellar hypoplasia 17: A form of pontocerebellar hypoplasia, a disorder characterized by structural defects of the pons and cerebellum, evident upon brain imaging. PCH17 is an autosomal recessive, severe form clinically characterized by neonatal hypotonia, feeding and respiratory difficulties, central apnea, and bradycardia. Most affected individuals die in infancy. Brain imaging shows cerebellar and brainstem hypoplasia.",,Nucleus,,35390279,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PRDM14,ENSG00000147596,Neither,Antibody,False,False,0.7,0.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA019094; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA019094; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA019094; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA019094; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA019094; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA019094; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA019094; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA019094; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA019094; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA019094; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA019094; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA019094; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA019094; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA019094; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA019094; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA019094; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA019094; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA019094; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA019094; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA019094; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA019094; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA019094; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA019094; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA019094; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA019094; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA019094; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA019094; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA019094; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA019094; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA019094; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA019094; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA019094; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA019094; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA019094; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA019094; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA019094; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA019094; conflicting or uncurated primary profile; Skin 1/Keratinocytes: High, HPA019094; conflicting or uncurated primary profile; Skin 1/Langerhans: High, HPA019094; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA019094; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA019094; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA019094; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA019094; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA019094; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA019094; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA019094; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA019094; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA019094; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.6970479145139999,1.3,,Neither,oncoref.target-sets.2026-10-23.2,0.697 TPM; blood/TH1; dice_th1; vital,1.3 nTPM; kidney/proximal tubular cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 106/133 (79.7%); Uterine Corpus Endometrial Carcinoma (TCGA): 7/176 (4.0%); Glioblastoma Multiforme (validation): 1/58 (1.7%),colorectal cancer: 10/11 (90.9%); pancreatic cancer: 8/10 (80.0%),31,20,Q9GZV8,https://www.uniprot.org/uniprotkb/Q9GZV8/entry,"Transcription factor that has both positive and negative roles on transcription. Required for the maintenance of embryonic stem cell identity and the reacquisition of pluripotency in somatic cells. May play an essential role in germ cell development at 2 levels: the reacquisition of potential pluripotency, including SOX2 up-regulation, and successful epigenetic reprogramming, characterized by EHMT1 repression. Its association with CBFA2T2 is required for the functions in pluripotency and germ cell formation (By similarity). Directly up-regulates the expression of pluripotency gene POU5F1 through its proximal enhancer. Binds to the DNA consensus sequence 5'-GGTC[TC]CTAA-3'",Expressed in embryonic stem cells. Tends to be overexpressed in breast cancer (at protein level),,,Nucleus,17942894|20953172,17942894|20953172,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PRDM9,ENSG00000164256,Neither,Antibody,False,False,3.9,3.9,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Kidney/Cells in tubules: Medium, HPA059555; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA059555; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA059555; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,3.9546,3.2541,,Neither,oncoref.target-sets.2026-10-23.2,3.955 TPM; blood/NK-cell; hpa_immune_cell_samples; vital,3.254 nTPM; blood/NK-cell; hpa_immune_cell_samples; vital,Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%); Bladder Urothelial Carcinoma (TCGA): 2/169 (1.2%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q9NQV7,https://www.uniprot.org/uniprotkb/Q9NQV7/entry,"Histone methyltransferase that sequentially mono-, di-, and tri-methylates both 'Lys-4' (H3K4) and 'Lys-36' (H3K36) of histone H3 to produce respectively trimethylated 'Lys-4' (H3K4me3) and trimethylated 'Lys-36' (H3K36me3) histone H3 and plays a key role in meiotic prophase by determining hotspot localization thereby promoting meiotic recombination (PubMed:18941885, PubMed:24095733, PubMed:24634223, PubMed:26833727, PubMed:27129774). Can also methylate all four core histones with H3 being the best substrate and the most highly modified (PubMed:24095733, PubMed:24634223, PubMed:26833727). Is also able, on one hand, to mono and di-methylate H4K20 and on other hand to trimethylate H3K9 with the di-methylated H3K9 as the best substrate (By similarity). During meiotic prophase, binds specific DNA sequences through its zinc finger domains thereby determining hotspot localization where it promotes local H3K4me3 and H3K36me3 enrichment on the same nucleosomes through its histone methyltransferase activity (PubMed:26833727). Thereby promotes double-stranded breaks (DSB) formation, at this subset of PRDM9-binding sites, that initiates meiotic recombination for the proper meiotic progression (By similarity). During meiotic progression hotspot-bound PRDM9 interacts with several complexes; in early leptonema binds CDYL and EHMT2 followed by EWSR1 and CXXC1 by the end of leptonema. EWSR1 joins PRDM9 with the chromosomal axis through REC8 (By similarity). In this way, controls the DSB repair pathway, pairing of homologous chromosomes and sex body formation (By similarity). Moreover plays a central role in the transcriptional activation of genes during early meiotic prophase thanks to H3K4me3 and H3K36me3 enrichment that represents a specific tag for epigenetic transcriptional activation (By similarity). In addition performs automethylation (By similarity). Acetylation and phosphorylation of histone H3 attenuate or prevent histone H3 methylation (By similarity)",,,,Nucleus Chromosome,18941885|24095733|24634223|26833727,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S1 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PRR20A,ENSG00000204919,Neither,Antibody,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Stomach 1/Glandular cells: Medium, HPA059485; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA059485; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.003,0.0027,,Neither,oncoref.target-sets.2026-10-23.2,0.003 TPM; blood/gdT-cell; hpa_immune_cell_samples; vital,0.0027 nTPM; blood/gdT-cell; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),30,20,P86479 | P86480 | P86478 | P86481 | P86496,https://www.uniprot.org/uniprotkb/P86479/entry | https://www.uniprot.org/uniprotkb/P86480/entry | https://www.uniprot.org/uniprotkb/P86478/entry | https://www.uniprot.org/uniprotkb/P86481/entry | https://www.uniprot.org/uniprotkb/P86496/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
PRR20B,ENSG00000204918,Neither,Antibody,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Stomach 1/Glandular cells: Medium, HPA059485; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA059485; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.003,0.0027,,Neither,oncoref.target-sets.2026-10-23.2,0.003 TPM; blood/gdT-cell; hpa_immune_cell_samples; vital,0.0027 nTPM; blood/gdT-cell; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),30,20,P86479 | P86480 | P86478 | P86481 | P86496,https://www.uniprot.org/uniprotkb/P86479/entry | https://www.uniprot.org/uniprotkb/P86480/entry | https://www.uniprot.org/uniprotkb/P86478/entry | https://www.uniprot.org/uniprotkb/P86481/entry | https://www.uniprot.org/uniprotkb/P86496/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
PRR20C,ENSG00000229665,Neither,Antibody,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Stomach 1/Glandular cells: Medium, HPA059485; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA059485; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.006,0.0054,,Neither,oncoref.target-sets.2026-10-23.2,0.006 TPM; blood/gdT-cell; hpa_immune_cell_samples; vital,0.0054 nTPM; blood/gdT-cell; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),30,20,P86479 | P86480 | P86478 | P86481 | P86496,https://www.uniprot.org/uniprotkb/P86479/entry | https://www.uniprot.org/uniprotkb/P86480/entry | https://www.uniprot.org/uniprotkb/P86478/entry | https://www.uniprot.org/uniprotkb/P86481/entry | https://www.uniprot.org/uniprotkb/P86496/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
PRR20D,ENSG00000227151,Neither,Antibody,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Stomach 1/Glandular cells: Medium, HPA059485; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA059485; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.003,0.0027,,Neither,oncoref.target-sets.2026-10-23.2,0.003 TPM; blood/gdT-cell; hpa_immune_cell_samples; vital,0.0027 nTPM; blood/gdT-cell; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),30,20,P86479 | P86480 | P86478 | P86481 | P86496,https://www.uniprot.org/uniprotkb/P86479/entry | https://www.uniprot.org/uniprotkb/P86480/entry | https://www.uniprot.org/uniprotkb/P86478/entry | https://www.uniprot.org/uniprotkb/P86481/entry | https://www.uniprot.org/uniprotkb/P86496/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
PRR20E,ENSG00000234278,Neither,Antibody,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Stomach 1/Glandular cells: Medium, HPA059485; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA059485; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.003,0.0027,,Neither,oncoref.target-sets.2026-10-23.2,0.003 TPM; blood/gdT-cell; hpa_immune_cell_samples; vital,0.0027 nTPM; blood/gdT-cell; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),29,20,P86479 | P86480 | P86478 | P86481 | P86496,https://www.uniprot.org/uniprotkb/P86479/entry | https://www.uniprot.org/uniprotkb/P86480/entry | https://www.uniprot.org/uniprotkb/P86478/entry | https://www.uniprot.org/uniprotkb/P86481/entry | https://www.uniprot.org/uniprotkb/P86496/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
PRR20G,ENSG00000239620,Neither,Unassessed,False,False,3.9,3.9,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"incomplete routine rna; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.00093389356,1.1,,Neither,oncoref.target-sets.2026-10-23.2,1.001 TPM; blood/TREG_MEM; dice_treg_mem; vital,1.1 nTPM; pancreas/mixed cell types; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 23/133 (17.3%); Stomach Adenocarcinoma (TCGA): 17/346 (4.9%); Uterine Corpus Endometrial Carcinoma (TCGA): 8/176 (4.5%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P0DPQ3,https://www.uniprot.org/uniprotkb/P0DPQ3/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Carter2023_CT,Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene,,,,,,,,
PRR23A,ENSG00000206260,Neither,Antibody,False,False,1.5,1.5,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA047473; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA047473; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA047473; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA047473; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA047473; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA047473; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA047473; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA047473; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA047473; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA047473; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA047473; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA047473; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA047473; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA047473; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.3,1.0,,Neither,oncoref.target-sets.2026-10-23.2,1.3 TPM; blood/basophil; hpa_immune_monaco; vital,1 nTPM; skin/endothelial cells; hpa_single_cell_tissue; manageable,Testicular Germ Cell Tumor (TCGA): 13/133 (9.8%); Bladder Urothelial Carcinoma (TCGA): 5/169 (3.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 5/176 (2.8%),melanoma: 1/11 (9.1%); liver cancer: 1/12 (8.3%),31,20,A6NEV1,https://www.uniprot.org/uniprotkb/A6NEV1/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PRR23B,ENSG00000184814,Neither,Antibody,False,False,1.2,1.2,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA047473; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA047473; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA047473; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA047473; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA047473; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA047473; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA047473; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA047473; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA047473; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA047473; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA047473; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA047473; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA047473; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA047473; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),melanoma: 1/11 (9.1%); liver cancer: 1/12 (8.3%),31,20,Q6ZRT6,https://www.uniprot.org/uniprotkb/Q6ZRT6/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PRR23C,ENSG00000233701,Neither,Antibody,False,False,0.9,0.9,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA047473; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA047473; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA047473; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA047473; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA047473; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA047473; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA047473; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA047473; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA047473; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA047473; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA047473; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA047473; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA047473; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA047473; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.29080833871,2.2123,,Neither,oncoref.target-sets.2026-10-23.2,1.291 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,2.212 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 7/176 (4.0%); Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%),melanoma: 1/11 (9.1%); liver cancer: 1/12 (8.3%),31,20,Q6ZRP0,https://www.uniprot.org/uniprotkb/Q6ZRP0/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PRR23D1,ENSG00000255251,Neither,Screening,False,False,181.8,181.8,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.7185,0.8328,,Neither,oncoref.target-sets.2026-10-23.2,0.7185 TPM; blood/T-reg; hpa_immune_cell_samples; vital,0.8328 nTPM; blood/T-reg; hpa_immune_cell_samples; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Lung Squamous Cell Carcinoma (TCGA): 2/489 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,E9PI22 | P0DMB1,https://www.uniprot.org/uniprotkb/E9PI22/entry | https://www.uniprot.org/uniprotkb/P0DMB1/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
PRR23D2,ENSG00000255378,Neither,Low,False,False,1.3,1.3,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.2,0.1,,Neither,oncoref.target-sets.2026-10-23.2,0.2 TPM; blood/NK-cell; hpa_immune_monaco; vital,0.1 nTPM; basal ganglia/bulk; hpa_rna_consensus; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Lung Squamous Cell Carcinoma (TCGA): 2/489 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,E9PI22 | P0DMB1,https://www.uniprot.org/uniprotkb/E9PI22/entry | https://www.uniprot.org/uniprotkb/P0DMB1/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
PRR23E,ENSG00000214324,Neither,Unassessed,False,False,0.5,0.5,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"existing nomination or manual review; incomplete routine rna; nomination unresolved; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.3987749797959999,2.5,,Neither,oncoref.target-sets.2026-10-23.2,0.3988 TPM; blood/TREG_MEM; dice_treg_mem; vital,2.5 nTPM; skeletal muscle/fibroblasts; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 6/133 (4.5%); Stomach Adenocarcinoma (TCGA): 2/346 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q8N813,https://www.uniprot.org/uniprotkb/Q8N813/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_ncRNA,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PRSS38,ENSG00000185888,Neither,Low,False,False,4.1,4.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.3346,2.8,,Neither,oncoref.target-sets.2026-10-23.2,2.335 TPM; blood/NK-cell; hpa_immune_cell_samples; vital,2.8 nTPM; adipose tissue/t-cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Kidney Renal Papillary Cell Carcinoma (TCGA): 2/282 (0.7%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A1L453,https://www.uniprot.org/uniprotkb/A1L453/entry,,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PRSS41,ENSG00000215148,Neither,Cellular,False,False,1.2,1.2,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_cell eosinophil: 10.5 nTPM,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,12.645,16.5426,,Neither,oncoref.target-sets.2026-10-23.2,12.64 TPM; blood/eosinophil; hpa_immune_cell_samples; vital,16.54 nTPM; blood/eosinophil; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 17/133 (12.8%); Pancreatic Adenocarcinoma (TCGA): 8/176 (4.5%); Stomach Adenocarcinoma (TCGA): 14/346 (4.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PSMA8,ENSG00000154611,Neither,Cellular,False,False,16.4,16.4,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE CD8_NAIVE (unstimulated): 4/89 values ≥5 TPM, max 7.14671",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,7.842199802260001,8.5,,CTA,oncoref.target-sets.2026-10-23.2,7.842 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,8.5 nTPM; liver/plasma cells; hpa_single_cell_tissue; vital,Liver Hepatocellular Carcinoma (validation): 3/231 (1.3%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8TAA3,https://www.uniprot.org/uniprotkb/Q8TAA3/entry,"Component of the spermatoproteasome, a proteasome specifically found in testis that promotes acetylation-dependent degradation of histones, thereby participating actively to the exchange of histones during spermatogenesis. The proteasome is a protein complex that degrades unneeded or damaged proteins by proteolysis, a chemical reaction that breaks peptide bonds. Required for 20S core proteasome assembly, essential for the degradation of meiotic proteins RAD51 and RPA1 at late prophase I and the progression of meiosis I during spermatogenesis. Localizes to the synaptonemal complex, a 'zipper'-like structure that holds homologous chromosome pairs in synapsis during meiotic prophase I",,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PTH2,ENSG00000142538,Neither,Low,False,False,0.2,1.0,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; cerebellum: 1 nTPM; continuous selectivity;reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.8247,10.2,,Neither,oncoref.target-sets.2026-10-23.2,1.825 TPM; blood/naive B-cell; hpa_immune_cell_samples; vital,10.2 nTPM; colon/undifferentiated cells; hpa_single_cell_tissue; protected,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 1/283 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96A98,https://www.uniprot.org/uniprotkb/Q96A98/entry,"Plays a role as a potent and selective agonist of PTH2R resulting in adenyl cyclase activation and intracellular calcium levels elevation. Induces protein kinase C beta activation, recruitment of beta-arrestin and PTH2R internalization. May inhibit cell proliferation via its action on PTH2R activation. Neuropeptide which may also have a role in spermatogenesis. May activate nociceptors and nociceptive circuits","Highly expressed in fetal and adult brain, cerebellum and trachea. Weakly expressed in spinal cord, fetal liver, kidney and heart",,,Secreted,11861531|12559132|12754053|14988434,12098667,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
PXT1,ENSG00000179165,Neither,Low,False,False,2.2,2.2,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.85961235007,5.7,,Neither,oncoref.target-sets.2026-10-23.2,1.86 TPM; blood/MONOCYTES; dice_monocytes; vital,5.7 nTPM; fallopian tube/neutrophils; hpa_single_cell_tissue; vital,Kidney Chromophobe (TCGA): 1/64 (1.6%); Bladder Urothelial Carcinoma (TCGA): 2/169 (1.2%); Kidney Renal Papillary Cell Carcinoma (TCGA): 3/282 (1.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NFP0,https://www.uniprot.org/uniprotkb/Q8NFP0/entry,,,,It is uncertain whether Met-1 or Met-40 is the initiator,Peroxisome,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
RBAK-RBAKDN,ENSG00000272968,Neither,Screening,False,False,56.5,56.5,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.5,1.6,,Neither,oncoref.target-sets.2026-10-23.2,1.5 TPM; blood/Non-Vd2 gdTCR; hpa_immune_monaco; vital,1.6 nTPM; skeletal muscle/fibroblasts; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 27/133 (20.3%); Skin Cuteneous Melanoma (TCGA): 16/99 (16.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 22/176 (12.5%),No exact-ID IHC coverage in the HPA cancer snapshot,27,0,Q9NYW8,https://www.uniprot.org/uniprotkb/Q9NYW8/entry,May repress E2F-dependent transcription. May promote AR-dependent transcription,"Expressed in bone, brain, heart, kidney, liver, lung, pancreas and placenta",,,Nucleus,10702291|14664718,10702291,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
RBAKDN,ENSG00000273313,Neither,Unassessed,False,False,,,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"existing nomination or manual review; incomplete routine rna; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete routine rna; missing normal RNA: adipose tissue, adrenal gland, amygdala, basal ganglia, bone marrow, cerebellum, cerebral cortex, choroid plexus, colon, duodenum, esophagus, heart muscle, hippocampal formation, hypothalamus, kidney, liver, lung, lymph node, midbrain, pancreas, parathyroid gland, pituitary gland, rectum, retina, salivary gland, skeletal muscle, skin, small intestine, smooth muscle, spinal cord, spleen, stomach, thymus, thyroid gland, tongue, urinary bladder; incomplete tissue evidence",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,False,False,,True,False,False,,True,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,6.12078323485,,,Neither,oncoref.target-sets.2026-10-23.2,6.121 TPM; blood/NK; dice_nk; vital,,No exact-ID RNA coverage in the HPA cancer snapshot,No exact-ID IHC coverage in the HPA cancer snapshot,0,0,A6NC62,https://www.uniprot.org/uniprotkb/A6NC62/entry,,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_ncRNA,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
RBM44,ENSG00000177483,Neither,Cellular,False,False,15.3,15.3,83,4,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 44/91 values ≥5 TPM, max 10.9298; DICE MONOCYTES (unstimulated): 50/91 values ≥5 TPM, max 11.7777; DICE M2 (unstimulated): 17/90 values ≥5 TPM, max 8.5767; DICE NK (unstimulated): 43/90 values ≥5 TPM, max 13.899; DICE TREG_MEM (unstimulated): 4/89 values ≥5 TPM, max 7.28378; DICE CD4_NAIVE (unstimulated): 7/88 values ≥5 TPM, max 7.66026; DICE TREG_NAIVE (unstimulated): 5/89 values ≥5 TPM, max 7.51367; DICE TFH (unstimulated): 16/89 values ≥5 TPM, max 8.83017; DICE TH1 (unstimulated): 26/81 values ≥5 TPM, max 8.41698; DICE THSTAR (unstimulated): 67/88 values ≥5 TPM, max 14.9333; DICE TH17 (unstimulated): 50/89 values ≥5 TPM, max 10.625; DICE TH2 (unstimulated): 52/89 values ≥5 TPM, max 11.5387; DICE CD8_NAIVE (unstimulated): 11/89 values ≥5 TPM, max 6.9037",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,14.9332762331,6.4,,CTA,oncoref.target-sets.2026-10-23.2,14.93 TPM; blood/THSTAR; dice_thstar; vital,6.4 nTPM; skeletal muscle/fibroblasts; hpa_single_cell_tissue; vital,Pancreatic Adenocarcinoma (validation): 3/80 (3.8%); Glioblastoma Multiforme (validation): 2/58 (3.4%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q6ZP01,https://www.uniprot.org/uniprotkb/Q6ZP01/entry,Component of intercellular bridges during meiosis. Intercellular bridges are evolutionarily conserved structures that connect differentiating germ cells. Not required for fertility (By similarity),,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
RFPL4AL1,ENSG00000229292,Neither,Antibody,False,False,0.2,0.6,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; liver: 0.6 nTPM; continuous selectivity;reproductive not higher; spleen: 0.3 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,True,"adipose tissue/schwann cells cluster c-19: 16 nTPM, 41 reads; reproductive-cell max 7.2",True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA046368; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA046368; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA046368; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA046368; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA046368; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA046368; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA046368; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA046368; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA046368; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA046368; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA046368; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA046368; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA046368; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA046368; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA046368; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA046368; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA046368; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA046368; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA046368; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA046368; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA046368; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA046368; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA046368; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA046368; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA046368; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA046368; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA046368; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA046368; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA046368; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA046368; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA046368; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA046368; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA046368; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA046368; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA046368; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA046368; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA046368; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA046368; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA046368; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA046368; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA046368; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA046368; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA046368; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA046368; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA046368; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,4.0594,16.0,,Neither,oncoref.target-sets.2026-10-23.2,4.059 TPM; blood/classical monocyte; hpa_immune_cell_samples; vital,16 nTPM; adipose tissue/schwann cells; hpa_single_cell_tissue; manageable,Testicular Germ Cell Tumor (TCGA): 11/133 (8.3%); Liver Hepatocellular Carcinoma (TCGA): 5/362 (1.4%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%),colorectal cancer: 12/12 (100.0%); endometrial cancer: 12/12 (100.0%),29,20,F8VTS6,https://www.uniprot.org/uniprotkb/F8VTS6/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
RFPL4B,ENSG00000251258,Neither,Antibody,False,False,1.6,1.6,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA059324; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA059324; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA059324; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA059324; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA059324; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA059324; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA059324; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA059324; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA059324; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA059324; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA059324; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA059324; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA059324; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: Medium, HPA066464; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA066464; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA066464; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA066464; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA066464; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA066464; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA066464; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA066464; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA066464; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA066464; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA066464; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA066464; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA066464; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA066464; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA066464; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA066464; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA066464; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA066464; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA066464; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA066464; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA066464; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA066464; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA066464; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA066464; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA066464; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA066464; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA066464; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,4.8,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,4.8 nTPM; skin/granulocytes; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 21/133 (15.8%); Liver Hepatocellular Carcinoma (validation): 27/231 (11.7%); Liver Hepatocellular Carcinoma (TCGA): 26/362 (7.2%),colorectal cancer: 9/12 (75.0%); pancreatic cancer: 5/11 (45.5%),31,20,Q6ZWI9,https://www.uniprot.org/uniprotkb/Q6ZWI9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S1 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
RGPD3,ENSG00000153165,Neither,Antibody,False,False,6.7,6.7,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bone marrow/Hematopoietic cells: Low, HPA049497; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA049497; conflicting or uncurated primary profile; Caudate/Glial cells: High, HPA049497; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA049497; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA049497; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA049497; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA049497; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: High, HPA049497; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: High, HPA049497; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA049497; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA049497; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA049497; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA049497; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA049497; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA049497; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA049497; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA049497; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA049497; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA049497; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA049497; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA049497; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA049497; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA049497; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA051675; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA051675; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA051675; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA051675; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA051675; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA051675; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA051675; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA051675; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA051675; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA051675; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA051675; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA051675; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA051675; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA051675; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA051675; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA051675; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA051675; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA051675; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA051675; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA051675; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA051675; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA051675; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA051675; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA051675; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA051675; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA051675; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA051675; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA051675; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA051675; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA051675; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA051675; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.20400027353,4.8,,CTA,oncoref.target-sets.2026-10-23.2,1.204 TPM; blood/CD4_STIM; dice_cd4_stim; vital,4.8 nTPM; skin/granulocytes; hpa_single_cell_tissue; vital,Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%); Pancreatic Adenocarcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),liver cancer: 5/11 (45.5%); melanoma: 3/10 (30.0%),31,20,A6NKT7,https://www.uniprot.org/uniprotkb/A6NKT7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RGPD4,ENSG00000196862,Neither,Antibody,False,False,3.6,3.6,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,retina: 1 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bone marrow/Hematopoietic cells: Low, HPA049497; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA049497; conflicting or uncurated primary profile; Caudate/Glial cells: High, HPA049497; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA049497; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA049497; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA049497; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA049497; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: High, HPA049497; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: High, HPA049497; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA049497; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA049497; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA049497; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA049497; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA049497; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA049497; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA049497; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA049497; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA049497; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA049497; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA049497; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA049497; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA049497; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA049497; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA051675; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA051675; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA051675; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA051675; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA051675; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA051675; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA051675; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA051675; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA051675; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA051675; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA051675; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA051675; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA051675; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA051675; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA051675; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA051675; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA051675; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA051675; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA051675; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA051675; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA051675; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA051675; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA051675; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA051675; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA051675; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA051675; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA051675; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA051675; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA051675; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA051675; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA051675; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.6810347708069999,3.7,,Neither,oncoref.target-sets.2026-10-23.2,0.681 TPM; blood/CD8_STIM; dice_cd8_stim; vital,3.7 nTPM; lymph node/b-cells; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 12/50 (24.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),liver cancer: 5/11 (45.5%); melanoma: 3/10 (30.0%),31,20,Q7Z3J3,https://www.uniprot.org/uniprotkb/Q7Z3J3/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Carter2023_CT | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
RGSL1,ENSG00000121446,Neither,Low,False,False,4.8,4.8,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.442026870674,2.2,,Neither,oncoref.target-sets.2026-10-23.2,0.442 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,2.2 nTPM; pancreas/exocrine glandular cells; hpa_single_cell_tissue; vital,Liver Hepatocellular Carcinoma (validation): 21/231 (9.1%); Pancreatic Adenocarcinoma (validation): 5/80 (6.2%); Liver Hepatocellular Carcinoma (TCGA): 4/362 (1.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A5PLK6,https://www.uniprot.org/uniprotkb/A5PLK6/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
RIMBP3B,ENSG00000274600,Neither,Screening,False,False,13.2,13.2,80,6,Positive somewhere,False,False,False,True,Excluded,Reproductive,True,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.5,1.5,,Neither,oncoref.target-sets.2026-10-23.2,1.5 TPM; blood/Progenitor cell; hpa_immune_monaco; vital,1.5 nTPM; bone marrow/t-cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%); Colon Adenocarcinoma (TCGA): 6/254 (2.4%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),27,20,A6NNM3,https://www.uniprot.org/uniprotkb/A6NNM3/entry,"Probable component of the manchette, a microtubule-based structure which plays a key role in sperm head morphogenesis during late stages of sperm development",,,It is uncertain whether Met-1 or Met-95 is the initiator,"Cytoplasm, cytoskeleton",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
RNASE11,ENSG00000173464,Neither,Antibody,False,False,643.4,643.4,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA003724; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA003724; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA003724; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA003724; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA003724; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA003724; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: High, HPA003724; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA003724; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA003724; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA003724; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA003724; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA003724; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA003724; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA003724; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA003724; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA003724; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA003724; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA003724; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA003724; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA003724; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA003724; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA003724; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA003724; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA003724; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA003724; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA003724; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: High, HPA003724; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA003724; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA003724; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA003724; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA003724; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA003724; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA003724; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA003724; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA003724; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA003724; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA003724; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA003724; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA003724; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA003724; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA003724; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.132804078222,0.5,,CTA,oncoref.target-sets.2026-10-23.2,0.1328 TPM; blood/NK; dice_nk; vital,0.5 nTPM; colon/distal enterocytes; hpa_single_cell_tissue; protected,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Kidney Renal Papillary Cell Carcinoma (TCGA): 2/282 (0.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),colorectal cancer: 11/11 (100.0%); prostate cancer: 10/11 (90.9%),31,20,Q8TAA1,https://www.uniprot.org/uniprotkb/Q8TAA1/entry,,,,Predicted to be catalytically inactive based on its sequences lacking the RNase A family-specific catalytic residues,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
RTL9,ENSG00000243978,Neither,Cellular,False,False,7.6,7.6,84,2,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,True,"brain/excitatory neurons cluster c-9: 5 nTPM, 346 reads; reproductive-cell max 2.7; brain/inhibitory neurons cluster c-17: 6.1 nTPM, 196 reads; reproductive-cell max 2.7; brain/excitatory neurons cluster c-18: 5.5 nTPM, 271 reads; reproductive-cell max 2.7; brain/inhibitory neurons cluster c-21: 9.2 nTPM, 279 reads; reproductive-cell max 2.7; brain/inhibitory neurons cluster c-26: 7.8 nTPM, 174 reads; reproductive-cell max 2.7; brain/inhibitory neurons cluster c-28: 5.3 nTPM, 107 reads; reproductive-cell max 2.7; brain/inhibitory neurons cluster c-30: 5.5 nTPM, 132 reads; reproductive-cell max 2.7",True,False,,True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.1353742708159999,9.2,,CTA,oncoref.target-sets.2026-10-23.2,0.1354 TPM; blood/CD8_STIM; dice_cd8_stim; vital,9.2 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Kidney Chromophobe (TCGA): 4/64 (6.2%); Glioblastoma Multiforme (validation): 3/58 (5.2%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%),pancreatic cancer: 1/11 (9.1%); prostate cancer: 1/11 (9.1%),29,20,Q8NET4,https://www.uniprot.org/uniprotkb/Q8NET4/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
RTP2,ENSG00000198471,Neither,Low,False,False,1.2,1.9,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,skeletal muscle: 1.9 nTPM; continuous selectivity;reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.517266520896,1.9,,Neither,oncoref.target-sets.2026-10-23.2,0.5173 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1.9 nTPM; skeletal muscle/bulk; hpa_rna_consensus; vital,Kidney Chromophobe (TCGA): 12/64 (18.8%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5QGT7,https://www.uniprot.org/uniprotkb/Q5QGT7/entry,"Specifically promotes functional cell surface expression of olfactory receptors, but not of other GPCRs",Expressed in circumvallate papillae and testis,,,Cell membrane,,16720576,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
SAXO5,ENSG00000198723,Neither,Cellular,False,False,20.0,20.0,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 23/91 values ≥5 TPM, max 15.7834",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,15.7833975979,28.3,,CTA,oncoref.target-sets.2026-10-23.2,15.78 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,28.3 nTPM; eye/rod photoreceptor cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 16/207 (7.7%); Colon Adenocarcinoma (validation): 25/486 (5.1%); Uterine Corpus Endometrial Carcinoma (TCGA): 5/176 (2.8%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q8NA69,https://www.uniprot.org/uniprotkb/Q8NA69/entry,,Highly expressed in testis,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
SCAND3,ENSG00000232040,Neither,Antibody,False,False,8.5,8.5,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA007246; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA007246; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA007246; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA007246; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA007246; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA007246; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA007246; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA007246; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA007246; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA007246; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA007246; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA007246; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: High, HPA007246; conflicting or uncurated primary profile; Colon/Endothelial cells: High, HPA007246; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA007246; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA007246; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA007246; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA007246; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA007246; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA007246; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA007246; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA007246; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA007246; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA007246; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA007246; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA007246; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA007246; conflicting or uncurated primary profile; Lymph node/Germinal center cells: High, HPA007246; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA007246; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA007246; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA007246; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA007246; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA007246; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA007246; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA007246; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA007246; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA007246; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA007246; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA007246; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA007246; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA007246; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA007246; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA007246; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA007246; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA007246; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA007246; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA007246; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA007246; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.0487743119,19.2,,CTA,oncoref.target-sets.2026-10-23.2,2.049 TPM; blood/CD4_STIM; dice_cd4_stim; vital,19.2 nTPM; prostate/t-cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 30/58 (51.7%); Prostate Adenocarcinoma (TCGA): 57/480 (11.9%); Uterine Corpus Endometrial Carcinoma (TCGA): 6/176 (3.4%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),29,20,Q6R2W3,https://www.uniprot.org/uniprotkb/Q6R2W3/entry,,Weakly expressed in the lung (at protein level),,,Nucleus,,28418919,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SCGB1D1,ENSG00000168515,Neither,Low,False,False,1.2,1.2,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.594802066872,1.2,,Neither,oncoref.target-sets.2026-10-23.2,0.5948 TPM; blood/TH1; dice_th1; vital,1.2 nTPM; unsited/Secretory cells; hpa_single_cell; unresolved,Ovary Serous Cystadenocarcinoma (TCGA): 117/349 (33.5%); Ovary Serous Cystadenocarcinoma (validation): 26/81 (32.1%); Uterine Corpus Endometrial Carcinoma (TCGA): 30/176 (17.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O95968,https://www.uniprot.org/uniprotkb/O95968/entry,"May bind androgens and other steroids, may also bind estramustine, a chemotherapeutic agent used for prostate cancer. May be under transcriptional regulation of steroid hormones","Expressed in lachrymal gland, thymus, kidney, testis, ovary and salivary gland",,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
SCN10A,ENSG00000185313,Neither,Low,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,heart muscle: 0.1 nTPM; reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0679161194529,1.0,,Neither,oncoref.target-sets.2026-10-23.2,0.06792 TPM; blood/CD4_STIM; dice_cd4_stim; vital,1 nTPM; heart muscle/cardiomyocytes; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9Y5Y9,https://www.uniprot.org/uniprotkb/Q9Y5Y9/entry,"Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms",Expressed in the dorsal root ganglia and sciatic nerve,"Episodic pain syndrome, familial, 2: An autosomal dominant neurologic disorder characterized by adult-onset of paroxysmal pain mainly affecting the distal lower extremities.",,Cell membrane,23115331|9839820,9839820,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
SERPINA2,ENSG00000258597,Neither,Unassessed,False,False,104.5,104.5,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"existing nomination or manual review; incomplete routine rna; nomination unresolved; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.9097357997000004,3.3216,,Neither,oncoref.target-sets.2026-10-23.2,2.91 TPM; blood/M2; dice_m2; vital,3.322 nTPM; blood/intermediate monocyte; hpa_immune_cell_samples; vital,No exact-ID RNA coverage in the HPA cancer snapshot,No exact-ID IHC coverage in the HPA cancer snapshot,0,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
SKIDA1,ENSG00000180592,Neither,Antibody,False,False,1.6,1.6,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 0.5 nTPM; continuous selectivity; amygdala: 0.6 nTPM; continuous selectivity; basal ganglia: 0.9 nTPM; continuous selectivity; bone marrow: 0.6 nTPM; continuous selectivity; cerebellum: 0.9 nTPM; continuous selectivity; cerebral cortex: 1 nTPM; continuous selectivity; heart muscle: 1.2 nTPM; continuous selectivity; hippocampal formation: 0.6 nTPM; continuous selectivity; hypothalamus: 0.5 nTPM; continuous selectivity; kidney: 1.2 nTPM; continuous selectivity; liver: 1.4 nTPM; continuous selectivity; pancreas: 0.5 nTPM; continuous selectivity; parathyroid gland: 1 nTPM; continuous selectivity; pituitary gland: 0.5 nTPM; continuous selectivity; retina: 1.5 nTPM; continuous selectivity; skin: 1 nTPM; continuous selectivity; thyroid gland: 1.2 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA039208; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA039208; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA039208; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA039208; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA039208; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA039208; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA039208; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA039208; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA039208; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA039208; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA039208; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA039208; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA039208; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA039208; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA039208; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA039208; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA039208; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA039208; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA039208; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA039208; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA039208; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA039208; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA039208; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA039208; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA039208; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA039208; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA039208; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA039208; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA039208; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA039208; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA039208; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA039208; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA039208; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA039208; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA039208; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA039208; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA039208; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA039208; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA039208; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA040439; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: High, HPA040439; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA040439; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.7,24.3,,Neither,oncoref.target-sets.2026-10-23.2,0.7 TPM; blood/plasmacytoid DC; hpa_immune_monaco; vital,24.3 nTPM; eye/bipolar cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 15/58 (25.9%); Testicular Germ Cell Tumor (TCGA): 13/133 (9.8%); Ovary Serous Cystadenocarcinoma (TCGA): 11/349 (3.2%),pancreatic cancer: 1/11 (9.1%); breast cancer: 0/12 (0.0%),29,20,Q1XH10,https://www.uniprot.org/uniprotkb/Q1XH10/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SKOR2,ENSG00000215474,Neither,Antibody,False,False,0.7,0.7,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; cerebellum: 0.3 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA046206; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA046206; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA046206; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA046206; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA046206; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA046206; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA046206; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA046206; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA046206; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA046206; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA046206; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA046206; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA046206; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA046206; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA046206; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA046206; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA046206; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA046206; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA046206; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA046206; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA046206; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA046206; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA046206; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA046206; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA046206; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA046206; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA046206; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA046206; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA046206; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA046206; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.109849456366,3.1,,Neither,oncoref.target-sets.2026-10-23.2,0.1098 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,3.1 nTPM; eye/bipolar cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (TCGA): 3/141 (2.1%); Thyroid Carcinoma (TCGA): 6/495 (1.2%); Ovary Serous Cystadenocarcinoma (TCGA): 3/349 (0.9%),colorectal cancer: 3/12 (25.0%); stomach cancer: 1/8 (12.5%),29,20,Q2VWA4,https://www.uniprot.org/uniprotkb/Q2VWA4/entry,"Has transcriptional corepressor activity. In the developing cerebellum, it down-regulates BMP signaling resulting in up-regulation of SHH expression in Purkinje cells and promoting their early differentiation. It is also involved in regulating the proliferation of cerebellar granule cell precursors","Expressed in cerebellum, spinal cord and testis. Isoform 2 is present in cerebellum (at protein level)","Valence-Farazi cerebellar ataxia syndrome: An autosomal recessive disorder characterized by hypotonia, delayed motor development, ataxic gait, clumsiness, and cerebellar hypoplasia or dysplasia on brain imaging. Additional features may include scoliosis, strabismus, nystagmus, dysarthria, and dysmorphic facial features. Some affected individuals may have mildly impaired intellectual development, speech delay, or learning disabilities.",,Nucleus Cytoplasm,,16200078,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
SLC24A5,ENSG00000188467,Neither,Cellular,False,False,1.6,8.0,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,midbrain: 0.6 nTPM; continuous selectivity; skin: 8 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,True,"melanocytes: max 2.03583 mean CP10K, 3 supported sample groups",True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.44785449889,8.7,,Neither,oncoref.target-sets.2026-10-23.2,0.4479 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,8.7 nTPM; eye/rod photoreceptor cells; hpa_single_cell_tissue; vital,Skin Cuteneous Melanoma (TCGA): 94/99 (94.9%); Breast Invasive Carcinoma (validation): 41/50 (82.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 72/176 (40.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q71RS6,https://www.uniprot.org/uniprotkb/Q71RS6/entry,"Calcium, potassium:sodium antiporter that transports 1 Ca(2+) and 1 K(+) to the melanosome in exchange for 4 cytoplasmic Na(+) (PubMed:18166528). Involved in pigmentation, possibly by participating in ion transport in melanosomes (PubMed:16357253, PubMed:18166528). Predominant sodium-calcium exchanger in melanocytes (PubMed:16357253, PubMed:18166528)",,"Albinism, oculocutaneous, 6: A disorder characterized by a reduction or complete loss of melanin in the skin, hair and eyes. Patients show reduced or lacking pigmentation often accompanied by eye symptoms such as photophobia, strabismus, moderate to severe visual impairment, and nystagmus.",,"Golgi apparatus, trans-Golgi network membrane Melanosome",16357253|18166528,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SLC25A2,ENSG00000120329,Neither,Antibody,False,False,6.4,6.4,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA042146; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Low, HPA042146; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA042146; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA042146; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA042146; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA042146; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA042146; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA042146; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA042146; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA042146; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA042146; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA042146; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA042146; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA042146; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA042146; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA042146; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA042146; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,3.3612529479799997,1.0,,CTA,oncoref.target-sets.2026-10-23.2,3.361 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1 nTPM; eye/bipolar cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 1/58 (1.7%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%),liver cancer: 8/11 (72.7%); prostate cancer: 4/10 (40.0%),31,20,Q9BXI2,https://www.uniprot.org/uniprotkb/Q9BXI2/entry,"Mitochondrial transporter of the positively charged amino acids ornithine, lysine and arginine, and the neutral amino acid citrulline (PubMed:12807890). In addition, transports the basic amino acids histidine, homoarginine, and asymmetric dimethylarginine (aDMA), but not symmetric DMA, and the D-forms of lysine, arginine, ornithine and histidine (PubMed:12807890, PubMed:26403849). Functions by both counter-exchange and uniport mechanisms (PubMed:26403849)","Expressed in liver, testis, spleen, lung, pancreas, and small intestine and expressed poorly in other tissues",,,Mitochondrion membrane Mitochondrion inner membrane,12807890|26403849,12807890,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Carter2023_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene,,,,,,,,
SLC25A52,ENSG00000141437,Neither,Antibody,False,False,10.1,10.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bone marrow/Hematopoietic cells: Medium, HPA058261; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA058261; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA058261; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA058261; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA058261; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA058261; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA058261; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,4.79131432908,2.2,,CTA,oncoref.target-sets.2026-10-23.2,4.791 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,2.2 nTPM; eye/rod photoreceptor cells; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%); Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),endometrial cancer: 3/12 (25.0%); breast cancer: 2/12 (16.7%),29,20,Q3SY17,https://www.uniprot.org/uniprotkb/Q3SY17/entry,"Mitochondrial membrane carrier protein that mediates the import of NAD(+) into mitochondria (PubMed:32906142). Compared to SLC25A51, SLC25A52-mediated transport is not essential for the import of NAD(+) in mitochondria (PubMed:32906142). The transport mechanism, uniport or antiport, its electrogenicity and substrate selectivity, remain to be elucidated",,,,Mitochondrion inner membrane,32906142,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
SLC26A8,ENSG00000112053,Neither,Cellular,False,False,42.8,42.8,86,1,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_monaco basophil: 8.5 TPM; hpa_immune_monaco neutrophil: 11.8 TPM,True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,11.8,25.3,,CTA,oncoref.target-sets.2026-10-23.2,11.8 TPM; blood/neutrophil; hpa_immune_monaco; vital,25.3 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Pancreatic Adenocarcinoma (validation): 5/80 (6.2%); Breast Invasive Carcinoma (validation): 1/50 (2.0%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%),breast cancer: 1/10 (10.0%); cervical cancer: 0/12 (0.0%),31,20,Q96RN1,https://www.uniprot.org/uniprotkb/Q96RN1/entry,"Antiporter that mediates the exchange of sulfate and oxalate against chloride ions across a membrane (PubMed:11278976, PubMed:11834742). Stimulates anion transport activity of CFTR (PubMed:22121115, PubMed:23582645). May cooperate with CFTR in the regulation of chloride and bicarbonate ions fluxes required for activation of the ADCY10/PKA pathway during sperm motility and sperm capacitation (By similarity). May play a role in sperm tail differentiation and motility and hence male fertility (By similarity)","Expression observed exclusively in testis, restricted to the meiotic phase of the germ cell (PubMed:11834742). Abundant expression located in the seminiferous tubules, concentrated on the luminal side of the tubuli harboring the spermatocytes and spermatids (PubMed:11278976, PubMed:11834742)","Spermatogenic failure 3: A disorder characterized by primary infertility, sperm morphologic abnormalities, and moderate to severe asthenozoospermia, condition in which the percentage of progressively motile sperm is abnormally low.",,Membrane,11278976|11834742|22121115|23582645,11278976|11834742,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SLC35G3,ENSG00000164729,Neither,Low,False,False,2.3,2.3,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,4.40643543194,4.3,,Neither,oncoref.target-sets.2026-10-23.2,4.406 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,4.3 nTPM; heart muscle/cardiomyocytes; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q8N808,https://www.uniprot.org/uniprotkb/Q8N808/entry,Testis-specific UDP-N-acetylglucosamine transporter that mediates transport of nucleotide sugars to facilitate the proper glycosylation of proteins critical for sperm function,Expressed in testis,,,Golgi apparatus membrane,,17101974,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SLC35G4,ENSG00000236396,Neither,Low,False,False,0.3,0.3,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.310458095117,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0.3105 TPM; blood/TREG_MEM; dice_treg_mem; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 0/283 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P0C7Q5,https://www.uniprot.org/uniprotkb/P0C7Q5/entry,"Mediates choline transport, although the underlying transport mechanism remains to be elucidated",,,"A previous study suggested that the intronless gene encoding this protein arose by SVA-mediated retrotransposition of the SLC35G6 gene in the primate lineage, with no evidence for transcription. However, it is also possible that the gene arose by the duplication of a prior retroinsertion event as opposed to a retrotransposition event itself and could be protein-coding",Membrane,40972734,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
SLC45A2,ENSG00000164175,Neither,Low,False,False,1.0,1.2,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,kidney: 0.4 nTPM; continuous selectivity; liver: 1.2 nTPM; continuous selectivity;reproductive not higher; retina: 0.4 nTPM; continuous selectivity; skin: 1 nTPM; continuous selectivity;reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.31316578292,10.3,,Neither,oncoref.target-sets.2026-10-23.2,1.313 TPM; blood/NK; dice_nk; vital,10.3 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Skin Cuteneous Melanoma (TCGA): 93/99 (93.9%); Prostate Adenocarcinoma (TCGA): 70/480 (14.6%); Liver Hepatocellular Carcinoma (validation): 17/231 (7.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9UMX9,https://www.uniprot.org/uniprotkb/Q9UMX9/entry,"Proton-associated glucose and sucrose transporter (By similarity). May be able to transport also fructose (By similarity). Expressed at a late melanosome maturation stage where functions as proton/glucose exporter which increase lumenal pH by decreasing glycolysis (PubMed:32966160, PubMed:35469906). Regulates melanogenesis by maintaining melanosome neutralization that is initially initiated by transient OCA2 and required for a proper function of the tyrosinase TYR (PubMed:32966160, PubMed:35469906)",Expressed in mature melanocytes,"Albinism, oculocutaneous, 4: A disorder of pigmentation characterized by reduced biosynthesis of melanin in the skin, hair and eyes. Patients show reduced or lacking pigmentation associated with classic albinism ocular abnormalities, including decreased visual acuity, macular hypoplasia, optic dysplasia, atypical choroidal vessels, and nystagmus.",,Melanosome membrane,18563784|18683857|32966160|35469906,32966160,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SLC6A5,ENSG00000165970,Neither,Low,False,False,0.3,0.9,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,cerebellum: 0.7 nTPM; continuous selectivity;reproductive not higher; lung: 0.9 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 0.6 nTPM; continuous selectivity;reproductive not higher; spinal cord: 0.8 nTPM; continuous selectivity;reproductive not higher,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0823975043756,0.9,,Neither,oncoref.target-sets.2026-10-23.2,0.0824 TPM; blood/THSTAR; dice_thstar; vital,0.9 nTPM; lung/bulk; hpa_rna_consensus; vital,Lung Adenocarcinoma (validation): 1/105 (1.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Ovary Serous Cystadenocarcinoma (TCGA): 1/349 (0.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9Y345,https://www.uniprot.org/uniprotkb/Q9Y345/entry,"Sodium- and chloride-dependent glycine transporter (PubMed:10381548, PubMed:10606742, PubMed:16751771, PubMed:31370103, PubMed:9845349). Terminates the action of glycine by its high affinity sodium-dependent reuptake into presynaptic terminals (PubMed:9845349). May be responsible for the termination of neurotransmission at strychnine-sensitive glycinergic synapses (PubMed:9845349) Lacks sodium- and chloride-dependent glycine transporter activity","Expressed in medulla, and to a lesser extent in spinal cord and cerebellum","Hyperekplexia 3: A neurologic disorder characterized by neonatal hypertonia, an exaggerated startle response to tactile or acoustic stimuli, and life-threatening neonatal apnea episodes. Notably, in some cases, symptoms resolved in the first year of life.",,Cell membrane,10381548|10606742|16751771|31370103|40725001|9845349,9845349,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
SLFNL1,ENSG00000171790,Neither,Cellular,False,False,73.9,73.9,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE CD4_STIM (activated): 54/88 values ≥5 TPM, max 9.18486; DICE CD8_STIM (activated): 19/88 values ≥5 TPM, max 7.51181",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,9.18485605405,6.5,,CTA,oncoref.target-sets.2026-10-23.2,9.185 TPM; blood/CD4_STIM; dice_cd4_stim; vital,6.5 nTPM; lung/alveolar cells type 2; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 4/50 (8.0%); Lung Adenocarcinoma (TCGA): 29/497 (5.8%); Kidney Renal Papillary Cell Carcinoma (TCGA): 16/282 (5.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q499Z3,https://www.uniprot.org/uniprotkb/Q499Z3/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SMIM10L2B-AS1,ENSG00000228372,Neither,Unassessed,False,False,,,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"existing nomination or manual review; incomplete routine rna; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete routine rna; missing normal RNA: adipose tissue, adrenal gland, amygdala, basal ganglia, bone marrow, cerebellum, cerebral cortex, choroid plexus, colon, duodenum, esophagus, heart muscle, hippocampal formation, hypothalamus, kidney, liver, lung, lymph node, midbrain, pancreas, parathyroid gland, pituitary gland, rectum, retina, salivary gland, skeletal muscle, skin, small intestine, smooth muscle, spinal cord, spleen, stomach, thymus, thyroid gland, tongue, urinary bladder; incomplete tissue evidence",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,False,False,,True,False,False,,True,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.14268474282,,,Neither,oncoref.target-sets.2026-10-23.2,1.143 TPM; blood/NK; dice_nk; vital,,No exact-ID RNA coverage in the HPA cancer snapshot,No exact-ID IHC coverage in the HPA cancer snapshot,0,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_ncRNA,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SMIM47,ENSG00000261341,Neither,Cellular,False,False,210.2,210.2,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE CD4_STIM (activated): 3/88 values ≥5 TPM, max 6.76639",True,True,False,,False,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,6.76639222837,17.4,,Neither,oncoref.target-sets.2026-10-23.2,6.766 TPM; blood/CD4_STIM; dice_cd4_stim; vital,17.4 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Ovary Serous Cystadenocarcinoma (TCGA): 15/349 (4.3%); Skin Cuteneous Melanoma (TCGA): 2/99 (2.0%); Rectum Adenocarcinoma (validation): 4/207 (1.9%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,D0EPY3,https://www.uniprot.org/uniprotkb/D0EPY3/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SPACA5B,ENSG00000171478,Neither,Screening,False,False,23.2,23.2,86,2,Positive somewhere,False,False,False,True,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.31291707757,2.0039,,Neither,oncoref.target-sets.2026-10-23.2,2.313 TPM; blood/TFH; dice_tfh; vital,2.004 nTPM; blood/T-reg; hpa_immune_cell_samples; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 0/283 (0.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),30,20,Q96QH8,https://www.uniprot.org/uniprotkb/Q96QH8/entry,,,,,Secreted,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
SPANXN1,ENSG00000203923,Neither,Low,False,False,1.4,1.4,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.7509670737630001,2.2,,Neither,oncoref.target-sets.2026-10-23.2,0.751 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,2.2 nTPM; pancreas/exocrine glandular cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5VSR9,https://www.uniprot.org/uniprotkb/Q5VSR9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SPANXN2,ENSG00000268988,Neither,Low,False,False,3.4,3.4,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Breast Invasive Carcinoma (TCGA): 1/1022 (0.1%),No exact-ID IHC coverage in the HPA cancer snapshot,28,0,Q5MJ10,https://www.uniprot.org/uniprotkb/Q5MJ10/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SPANXN4,ENSG00000189326,Neither,Antibody,False,False,25.2,25.2,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA045730; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA045730; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA045730; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA045730; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA045730; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA045730; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA045730; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA045730; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA045730; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA045730; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA045730; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA045730; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA045730; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA045730; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA045730; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA045730; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA045730; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA045730; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA045730; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA045730; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA045730; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA045730; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA045730; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA045730; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA045730; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA045730; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA045730; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA045730; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA045730; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA045730; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA045730; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA045730; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA045730; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA045730; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA045730; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA045730; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA045730; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA045730; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA045730; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA045730; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA045730; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA045730; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA045730; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA045730; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.7397173504700003,1.0974,,CTA,oncoref.target-sets.2026-10-23.2,1.74 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,1.097 nTPM; blood/neutrophil; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),breast cancer: 12/12 (100.0%); melanoma: 12/12 (100.0%),31,20,Q5MJ08,https://www.uniprot.org/uniprotkb/Q5MJ08/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SPATA31A3,ENSG00000275969,Neither,Low,False,False,4.6,4.6,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0012,0.0012,,Neither,oncoref.target-sets.2026-10-23.2,0.0012 TPM; blood/NK-cell; hpa_immune_cell_samples; vital,0.0012 nTPM; blood/NK-cell; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Lung Squamous Cell Carcinoma (TCGA): 1/489 (0.2%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,Q5VYP0,https://www.uniprot.org/uniprotkb/Q5VYP0/entry,May play a role in spermatogenesis,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SPATA31A5,ENSG00000276581,Neither,Low,False,False,1.0,1.0,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.1,0.0005,,Neither,oncoref.target-sets.2026-10-23.2,0.1 TPM; blood/neutrophil; hpa_immune_monaco; vital,0.0005 nTPM; blood/NK-cell; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,Q5VU36,https://www.uniprot.org/uniprotkb/Q5VU36/entry,May play a role in spermatogenesis,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
SPATA31A6,ENSG00000185775,Neither,Low,False,False,1.9,1.9,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0028,0.1,,Neither,oncoref.target-sets.2026-10-23.2,0.0028 TPM; blood/myeloid DC; hpa_immune_cell_samples; vital,0.1 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q5VVP1,https://www.uniprot.org/uniprotkb/Q5VVP1/entry,May play a role in spermatogenesis,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SPATA31A7,ENSG00000276040,Neither,Low,False,False,2.8,2.8,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.177226877465,0.2,,Neither,oncoref.target-sets.2026-10-23.2,0.1772 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,0.2 nTPM; skeletal muscle/endothelial cells; hpa_single_cell_tissue; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 0/283 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,Q8IWB4,https://www.uniprot.org/uniprotkb/Q8IWB4/entry,May play a role in spermatogenesis,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
SPATA31C1,ENSG00000230246,Neither,Unassessed,False,False,7.1,7.1,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"incomplete routine rna; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.752743975758,2.2,,Neither,oncoref.target-sets.2026-10-23.2,0.7527 TPM; blood/TREG_MEM; dice_treg_mem; vital,2.2 nTPM; bone marrow/erythroid cells; hpa_single_cell_tissue; vital,No exact-ID RNA coverage in the HPA cancer snapshot,No exact-ID IHC coverage in the HPA cancer snapshot,0,0,P0DKV0,https://www.uniprot.org/uniprotkb/P0DKV0/entry,May play a role in spermatogenesis,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
SPATA31C2,ENSG00000177910,Neither,Unassessed,False,False,22.5,22.5,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"incomplete routine rna; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.871,1.8663,,Neither,oncoref.target-sets.2026-10-23.2,1.871 TPM; blood/T-reg; hpa_immune_cell_samples; vital,1.866 nTPM; blood/T-reg; hpa_immune_cell_samples; vital,No exact-ID RNA coverage in the HPA cancer snapshot,No exact-ID IHC coverage in the HPA cancer snapshot,0,0,B4DYI2,https://www.uniprot.org/uniprotkb/B4DYI2/entry,May play a role in spermatogenesis,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Carter2023_CT | Loriot2025_S1,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
SPATA31D1,ENSG00000214929,Neither,Antibody,False,False,10.8,10.8,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA047897; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA047897; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA047897; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA047897; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA047897; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA047897; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA047897; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA047897; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA047897; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA047897; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA047897; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA047897; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA047897; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA047897; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA047897; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA047897; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA047897; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA047897; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA047897; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA047897; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA047897; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA047897; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA047897; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA047897; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA047897; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA047897; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA047897; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA047897; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA047897; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA047897; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA047897; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA047897; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA047897; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA047897; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA047897; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA047897; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0419470392631999,0.2,,CTA,oncoref.target-sets.2026-10-23.2,0.04195 TPM; blood/NK; dice_nk; vital,0.2 nTPM; prostate/t-cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),colorectal cancer: 11/12 (91.7%); pancreatic cancer: 9/11 (81.8%),29,20,Q6ZQQ2,https://www.uniprot.org/uniprotkb/Q6ZQQ2/entry,May play a role in spermatogenesis,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SPATA31F3,ENSG00000187791,Neither,Screening,False,False,28.1,28.1,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.40894926044,8.5,,Neither,oncoref.target-sets.2026-10-23.2,0.4089 TPM; blood/TFH; dice_tfh; vital,8.5 nTPM; unsited/Cone photoreceptor cells; hpa_single_cell; unresolved,Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Lung Squamous Cell Carcinoma (TCGA): 3/489 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A6NFA0,https://www.uniprot.org/uniprotkb/A6NFA0/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SPATA31H1,ENSG00000221843,Neither,Antibody,False,False,5.5,5.5,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,retina: 1.5 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA052136; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA052136; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA052136; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: High, HPA052136; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA052136; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA052136; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA052136; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA052136; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA052136; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA052136; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA052136; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA052136; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA052136; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA052136; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA052136; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA052136; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA052136; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA052136; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA052136; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA052136; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA052136; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA052136; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA052136; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA052136; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA052136; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA052136; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA052136; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA052136; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA052136; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA052136; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA056962; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA056962; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA056962; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA056962; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA056962; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA056962; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA056962; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA056962; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.33478162932,8.4,,Neither,oncoref.target-sets.2026-10-23.2,1.335 TPM; blood/M2; dice_m2; vital,8.4 nTPM; eye/rod photoreceptor cells; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 2/50 (4.0%); Liver Hepatocellular Carcinoma (validation): 9/231 (3.9%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%),lymphoma: 1/11 (9.1%); testis cancer: 1/11 (9.1%),31,20,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Carter2023_CT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene,,,,,,,,
SPATA31J1,ENSG00000204661,Neither,Unassessed,False,False,,,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"incomplete routine rna; insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete routine rna; missing normal RNA: adipose tissue, adrenal gland, amygdala, basal ganglia, bone marrow, cerebellum, cerebral cortex, choroid plexus, colon, duodenum, esophagus, heart muscle, hippocampal formation, hypothalamus, kidney, liver, lung, lymph node, midbrain, pancreas, parathyroid gland, pituitary gland, rectum, retina, salivary gland, skeletal muscle, skin, small intestine, smooth muscle, spinal cord, spleen, stomach, thymus, thyroid gland, tongue, urinary bladder; incomplete tissue evidence",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,False,False,,True,False,False,,True,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.863003396649,,,Neither,oncoref.target-sets.2026-10-23.2,0.863 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,,No exact-ID RNA coverage in the HPA cancer snapshot,No exact-ID IHC coverage in the HPA cancer snapshot,0,0,A6NFR6,https://www.uniprot.org/uniprotkb/A6NFR6/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SPATA32,ENSG00000184361,Neither,Cellular,False,False,42.4,42.4,87,1,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE CD4_NAIVE (unstimulated): 60/88 values ≥5 TPM, max 10.9286; DICE CD4_STIM (activated): 5/88 values ≥5 TPM, max 6.07798; DICE TREG_NAIVE (unstimulated): 43/89 values ≥5 TPM, max 9.13001; DICE TFH (unstimulated): 32/89 values ≥5 TPM, max 7.84891; DICE TH2 (unstimulated): 10/89 values ≥5 TPM, max 6.68748; DICE CD8_NAIVE (unstimulated): 64/89 values ≥5 TPM, max 11.0959; DICE CD8_STIM (activated): 9/88 values ≥5 TPM, max 6.95492",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,11.0958646649,2.9,,CTA,oncoref.target-sets.2026-10-23.2,11.1 TPM; blood/CD8_NAIVE; dice_cd8_naive; vital,2.9 nTPM; unsited/Skeletal myocytes; hpa_single_cell; unresolved,Bladder Urothelial Carcinoma (TCGA): 3/169 (1.8%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 5/283 (1.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%),pancreatic cancer: 6/12 (50.0%); breast cancer: 3/10 (30.0%),29,20,Q96LK8,https://www.uniprot.org/uniprotkb/Q96LK8/entry,,"Detected in testis, and on the acrosomal cap of spermatids",,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SPDYE1,ENSG00000136206,Neither,Cellular,False,False,6.7,6.7,85,2,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE TFH (unstimulated): 3/89 values ≥5 TPM, max 6.71155; hpa_immune_monaco basophil: 8.7 TPM; hpa_immune_monaco Central memory CD8 T-cell: 6.8 TPM; hpa_immune_monaco Effector memory CD8 T-cell: 5.4 TPM; hpa_immune_monaco MAIT T-cell: 6 TPM; hpa_immune_monaco Memory CD4 T-cell TFH: 9.3 TPM; hpa_immune_monaco Memory CD4 T-cell Th1: 8.6 TPM; hpa_immune_monaco Memory CD4 T-cell Th1/Th17: 6.6 TPM; hpa_immune_monaco Memory CD4 T-cell Th17: 5 TPM; hpa_immune_monaco Memory CD4 T-cell Th2: 7.2 TPM; hpa_immune_monaco naive B-cell: 6.2 TPM; hpa_immune_monaco naive CD4 T-cell: 9.7 TPM; hpa_immune_monaco naive CD8 T-cell: 8 TPM; hpa_immune_monaco NK-cell: 6.9 TPM; hpa_immune_monaco Non-switched memory B-cell: 5.8 TPM; hpa_immune_monaco Non-Vd2 gdTCR: 5.3 TPM; hpa_immune_monaco plasmacytoid DC: 5.9 TPM; hpa_immune_monaco Progenitor cell: 6.8 TPM; hpa_immune_monaco T-reg: 6.6 TPM; hpa_immune_monaco Terminal effector memory CD8 T-cell: 5.9 TPM",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,9.7,13.0,,CTA,oncoref.target-sets.2026-10-23.2,9.7 TPM; blood/naive CD4 T-cell; hpa_immune_monaco; vital,13 nTPM; heart muscle/endothelial cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 166/207 (80.2%); Colon Adenocarcinoma (validation): 352/486 (72.4%); Stomach Adenocarcinoma (TCGA): 26/346 (7.5%),breast cancer: 0/10 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q8NFV5,https://www.uniprot.org/uniprotkb/Q8NFV5/entry,,Predominantly expressed in testis and heart,,,,,22763696,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SPDYE3,ENSG00000214300,Neither,Cellular,False,False,2.4,2.4,85,2,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 89/91 values ≥5 TPM, max 10.7248; DICE NK (unstimulated): 76/90 values ≥5 TPM, max 11.2924; DICE TREG_MEM (unstimulated): 76/89 values ≥5 TPM, max 8.75416; DICE CD4_NAIVE (unstimulated): 88/88 values ≥5 TPM, max 10.3603; DICE CD4_STIM (activated): 88/88 values ≥5 TPM, max 18.173; DICE TREG_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 11.3536; DICE TFH (unstimulated): 88/89 values ≥5 TPM, max 10.3948; DICE TH1 (unstimulated): 77/81 values ≥5 TPM, max 9.57276; DICE THSTAR (unstimulated): 86/88 values ≥5 TPM, max 9.20514; DICE TH17 (unstimulated): 86/89 values ≥5 TPM, max 7.96783; DICE TH2 (unstimulated): 87/89 values ≥5 TPM, max 8.94959; DICE CD8_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 10.1189; DICE CD8_STIM (activated): 88/88 values ≥5 TPM, max 20.0306",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,20.0305596053,16.2,,CTA,oncoref.target-sets.2026-10-23.2,20.03 TPM; blood/CD8_STIM; dice_cd8_stim; vital,16.2 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 46/50 (92.0%); Ovary Serous Cystadenocarcinoma (validation): 24/81 (29.6%); Liver Hepatocellular Carcinoma (validation): 8/231 (3.5%),breast cancer: 0/10 (0.0%); cervical cancer: 0/11 (0.0%),31,20,A6NKU9,https://www.uniprot.org/uniprotkb/A6NKU9/entry,,Predominantly expressed in testis and spleen,,,,,22763696,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SPEM2,ENSG00000184560,Neither,Antibody,False,False,124.5,124.5,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bronchus/Respiratory epithelial cells: Low, HPA023649; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA023649; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA023649; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA023649; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA023649; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA023649; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA023649; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA023649; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA023649; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.6683190664399999,9.9,,CTA,oncoref.target-sets.2026-10-23.2,0.6683 TPM; blood/CD8_NAIVE; dice_cd8_naive; vital,9.9 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Colon Adenocarcinoma (validation): 1/486 (0.2%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),ovarian cancer: 8/12 (66.7%); colorectal cancer: 6/12 (50.0%),29,20,Q0P670,https://www.uniprot.org/uniprotkb/Q0P670/entry,,,,,Membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SPEM3,ENSG00000283439,Neither,Screening,False,False,54.7,54.7,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.477815339686,1.2,,Neither,oncoref.target-sets.2026-10-23.2,0.4778 TPM; blood/NK; dice_nk; vital,1.2 nTPM; liver/hepatocytes; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Lung Squamous Cell Carcinoma (TCGA): 1/489 (0.2%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,A0A1B0GUW6,https://www.uniprot.org/uniprotkb/A0A1B0GUW6/entry,,,,,Membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SPMAP1,ENSG00000275489,Neither,Antibody,False,False,18.9,18.9,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA051696; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA051696; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA051696; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA051696; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA051696; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA051696; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA051696; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA051696; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA051696; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA051696; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA051696; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: High, HPA051696; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA051696; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA051696; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA051696; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA051696; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA051696; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA051696; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA051696; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA051696; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA051696; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA051696; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA051696; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA051696; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA051696; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: High, HPA051696; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA051696; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA051696; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA051696; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA051696; conflicting or uncurated primary profile; Skin 1/Fibroblasts: High, HPA051696; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA051696; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA051696; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA051696; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA051696; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA051696; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA051696; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA051696; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA051696; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA051696; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA051696; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.96312063756,6.1,,CTA,oncoref.target-sets.2026-10-23.2,2.963 TPM; blood/TH2; dice_th2; vital,6.1 nTPM; unsited/Distal tubular cells; hpa_single_cell; unresolved,Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%); Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 2/283 (0.7%),pancreatic cancer: 12/12 (100.0%); testis cancer: 12/12 (100.0%),28,20,A8MV24,https://www.uniprot.org/uniprotkb/A8MV24/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SPMAP2L,ENSG00000249693,Neither,Antibody,False,False,3.4,3.4,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA068093; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA068093; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA068093; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA068093; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA068093; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA068093; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA068093; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA068093; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA068093; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA068093; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA068093; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA068093; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA068093; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA068093; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA068093; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA068093; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA068093; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA068093; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA068093; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA068093; conflicting or uncurated primary profile; Lung/Alveolar cells: High, HPA068093; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA068093; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA068093; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA068093; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA068093; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA068093; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA068093; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA068093; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA068093; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA068093; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA068093; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA068093; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA068093; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA068093; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA068093; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA068093; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA068093; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.859343929152,12.0,,Neither,oncoref.target-sets.2026-10-23.2,0.8593 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,12 nTPM; esophagus/schwann cells; hpa_single_cell_tissue; protected,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),prostate cancer: 8/11 (72.7%); renal cancer: 8/12 (66.7%),29,20,P0DJG4,https://www.uniprot.org/uniprotkb/P0DJG4/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT | Carter2023_CT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene,,,,,,,,
SPMIP3,ENSG00000173728,Neither,Cellular,False,False,34.0,34.0,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 18/91 values ≥5 TPM, max 7.82929; DICE NK (unstimulated): 6/90 values ≥5 TPM, max 6.38208; DICE CD4_NAIVE (unstimulated): 6/88 values ≥5 TPM, max 5.98895; DICE TREG_NAIVE (unstimulated): 4/89 values ≥5 TPM, max 7.32078; DICE TFH (unstimulated): 3/89 values ≥5 TPM, max 5.77194; DICE TH1 (unstimulated): 5/81 values ≥5 TPM, max 5.90216; DICE THSTAR (unstimulated): 4/88 values ≥5 TPM, max 5.79202; DICE TH2 (unstimulated): 4/89 values ≥5 TPM, max 6.77606; DICE CD8_NAIVE (unstimulated): 7/89 values ≥5 TPM, max 6.33637",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,7.82929465147,6.2,,CTA,oncoref.target-sets.2026-10-23.2,7.829 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,6.2 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Kidney Chromophobe (TCGA): 1/64 (1.6%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5SVJ3,https://www.uniprot.org/uniprotkb/Q5SVJ3/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Carter2023_CT | Loriot2025_S2 | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SPMIP7,ENSG00000164500,Neither,Antibody,False,False,4.2,4.2,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA026094; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA026094; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA026094; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA026094; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA026094; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA026094; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA026094; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA026094; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA026094; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA026094; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA026094; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA026094; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA026094; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA026094; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA026094; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA026094; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA026094; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA026094; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA026094; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA026094; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA026094; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA026094; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA026094; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA026094; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA026094; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA026094; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA026094; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA026094; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA026094; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA026094; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.839744407692,8.9,,Neither,oncoref.target-sets.2026-10-23.2,0.8397 TPM; blood/CD4_STIM; dice_cd4_stim; vital,8.9 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Ovary Serous Cystadenocarcinoma (validation): 1/81 (1.2%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Stomach Adenocarcinoma (TCGA): 1/346 (0.3%),colorectal cancer: 2/11 (18.2%); liver cancer: 2/12 (16.7%),29,20,A4D263,https://www.uniprot.org/uniprotkb/A4D263/entry,Essential for normal spermatogenesis,Testis-specific,,,,,29700843|36896575,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SSU72L6,ENSG00000230268,Neither,Low,False,False,1.3,1.3,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Head and Neck Squamous Cell Carcinoma (TCGA): 2/492 (0.4%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 1/283 (0.4%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A0A1W2PR75,https://www.uniprot.org/uniprotkb/A0A1W2PR75/entry,Protein phosphatase that catalyzes the dephosphorylation of the C-terminal domain of RNA polymerase II. Plays a role in RNA processing and termination,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SSX7,ENSG00000187754,Neither,Selectivity,False,False,0.1,0.6,85,4,Positive somewhere,False,False,False,True,Excluded,Normal,True,,Not assessed,,,bone marrow: 0.2 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 0.2 nTPM; continuous selectivity;reproductive not higher; duodenum: 0.1 nTPM; reproductive not higher; esophagus: 0.3 nTPM; continuous selectivity;reproductive not higher; lung: 0.1 nTPM; reproductive not higher; lymph node: 0.1 nTPM; reproductive not higher; retina: 0.6 nTPM; continuous selectivity;reproductive not higher; salivary gland: 0.3 nTPM; continuous selectivity;reproductive not higher; skin: 0.3 nTPM; continuous selectivity;reproductive not higher; spleen: 0.1 nTPM; reproductive not higher; stomach: 0.1 nTPM; reproductive not higher,Fails reproductive selectivity without above-ceiling normal RNA or a normal-protein veto,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Selectivity,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.0,0.6,,Neither,oncoref.target-sets.2026-10-23.2,1 TPM; blood/NK-cell; hpa_immune_monaco; vital,0.6 nTPM; retina/bulk; hpa_rna_consensus; vital,Bladder Urothelial Carcinoma (TCGA): 5/169 (3.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 4/283 (1.4%); Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%),melanoma: 3/10 (30.0%); liver cancer: 2/11 (18.2%),31,20,Q7RTT5,https://www.uniprot.org/uniprotkb/Q7RTT5/entry,Could act as a modulator of transcription,Testis-specific. Expressed in a melanoma cell line,,,,,12216073,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
STKLD1,ENSG00000198870,Neither,Antibody,False,False,9.7,9.7,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA029902; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA029902; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA029902; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA029902; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA029902; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA029902; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA029902; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA029902; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA029902; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA029902; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA029902; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA029902; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA029902; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA029902; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA029902; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA029902; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA029902; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA029902; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA029902; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA029902; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA029902; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA029902; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA029902; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA029902; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA029902; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA029902; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA029902; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,4.79008505976,6.1,,CTA,oncoref.target-sets.2026-10-23.2,4.79 TPM; blood/CD8_NAIVE; dice_cd8_naive; vital,6.1 nTPM; lymph node/t-cells; hpa_single_cell_tissue; vital,Pancreatic Adenocarcinoma (validation): 3/80 (3.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),pancreatic cancer: 9/12 (75.0%); stomach cancer: 8/12 (66.7%),29,20,Q8NE28,https://www.uniprot.org/uniprotkb/Q8NE28/entry,,,,Asn-157 is present instead of the conserved Asp which is expected to be an active site residue,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
SULT6B1,ENSG00000138068,Neither,Low,False,False,1.8,1.8,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,3.7376,6.7314,,Neither,oncoref.target-sets.2026-10-23.2,3.738 TPM; blood/basophil; hpa_immune_cell_samples; vital,6.731 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 2/207 (1.0%); Stomach Adenocarcinoma (TCGA): 3/346 (0.9%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6IMI4,https://www.uniprot.org/uniprotkb/Q6IMI4/entry,Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of thyroxine. Involved in the metabolism of thyroxine (By similarity),Specifically expressed in kidney and testis,,,"Cytoplasm, cytosol",,19505954,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SYCE2,ENSG00000161860,Neither,Cellular,False,False,25.9,25.9,88,2,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 17/91 values ≥5 TPM, max 6.27979; DICE NK (unstimulated): 3/90 values ≥5 TPM, max 5.16026; DICE TREG_MEM (unstimulated): 6/89 values ≥5 TPM, max 5.73604; DICE CD4_NAIVE (unstimulated): 64/88 values ≥5 TPM, max 9.71807; DICE CD4_STIM (activated): 86/88 values ≥5 TPM, max 12.919; DICE TREG_NAIVE (unstimulated): 43/89 values ≥5 TPM, max 9.4664; DICE TFH (unstimulated): 31/89 values ≥5 TPM, max 9.21247; DICE TH1 (unstimulated): 17/81 values ≥5 TPM, max 9.6738; DICE THSTAR (unstimulated): 9/88 values ≥5 TPM, max 6.82177; DICE TH17 (unstimulated): 4/89 values ≥5 TPM, max 6.2129; DICE TH2 (unstimulated): 11/89 values ≥5 TPM, max 6.67768; DICE CD8_NAIVE (unstimulated): 63/89 values ≥5 TPM, max 9.02913; DICE CD8_STIM (activated): 85/88 values ≥5 TPM, max 11.8605",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,13.4775,11.0902,,CTA,oncoref.target-sets.2026-10-23.2,13.48 TPM; blood/NK-cell; hpa_immune_cell_samples; vital,11.09 nTPM; blood/NK-cell; hpa_immune_cell_samples; vital,Breast Invasive Carcinoma (validation): 31/50 (62.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 126/283 (44.5%); Ovary Serous Cystadenocarcinoma (TCGA): 109/349 (31.2%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q6PIF2,https://www.uniprot.org/uniprotkb/Q6PIF2/entry,"Major component of the transverse central element of synaptonemal complexes (SCS), formed between homologous chromosomes during meiotic prophase. Requires SYCP1 in order to be incorporated into the central element. May have a role in the synaptonemal complex assembly, stabilization and recombination (By similarity)",,,,Nucleus Chromosome,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SYCP3,ENSG00000139351,Neither,Cellular,False,False,80.5,80.5,87,2,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 8/91 values ≥5 TPM, max 7.13556; DICE NK (unstimulated): 43/90 values ≥5 TPM, max 8.69999",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,8.69998736988,16.9,,CTA,oncoref.target-sets.2026-10-23.2,8.7 TPM; blood/NK; dice_nk; vital,16.9 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Liver Hepatocellular Carcinoma (validation): 229/231 (99.1%); Testicular Germ Cell Tumor (TCGA): 103/133 (77.4%); Pancreatic Adenocarcinoma (validation): 2/80 (2.5%),renal cancer: 2/12 (16.7%); breast cancer: 0/12 (0.0%),31,20,Q8IZU3,https://www.uniprot.org/uniprotkb/Q8IZU3/entry,"Component of the synaptonemal complexes (SCS), formed between homologous chromosomes during meiotic prophase. Required for centromere pairing during meiosis in male germ cells (By similarity). Required for normal meiosis during spermatogenesis and male fertility (PubMed:14643120). Plays a lesser role in female fertility. Required for efficient phosphorylation of HORMAD1 and HORMAD2 (By similarity)",Testis-specific,"Spermatogenic failure 4: An infertility disorder characterized by azoospermia, a condition of having no sperm present in the ejaculate. Testicular histology shows arrest of spermatogenesis at the pachytene stage of primary spermatocytes. Pregnancy loss, recurrent, 4: A common complication of pregnancy, resulting in spontaneous abortion before the fetus has reached viability. The term includes all miscarriages from the time of conception until 24 weeks of gestation. Recurrent pregnancy loss is defined as 3 or more consecutive spontaneous abortions.",,"Nucleus Chromosome Chromosome, centromere",14643120,12213195|14643120,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TAAR2,ENSG00000146378,Neither,Low,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.1043,0.9,,Neither,oncoref.target-sets.2026-10-23.2,0.1043 TPM; blood/gdT-cell; hpa_immune_cell_samples; vital,0.9 nTPM; unsited/Astrocytes; hpa_single_cell; unresolved,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9P1P5,https://www.uniprot.org/uniprotkb/Q9P1P5/entry,Orphan olfactory receptor specific for trace amines. Trace amine compounds are enriched in animal body fluids and act on trace amine-associated receptors (TAARs) to elicit both intraspecific and interspecific innate behaviors. Ligand-binding causes a conformation change that triggers signaling via the G(s)-class of G proteins which activate adenylate cyclase,"Not expressed in the pons, thalamus, hypothalamus, hippocampus, caudate, putamen, frontal cortex, basal forebrain, midbrain or liver",,,Cell membrane,,10684976,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
TAF1L,ENSG00000122728,Neither,Antibody,False,False,1.6,1.6,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,retina: 1.6 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,True,"eye/bipolar cells cluster c-1: 20.1 nTPM, 58 reads; reproductive-cell max 12.5",True,False,,True,True,False,,True,True,"Bone marrow/Hematopoietic cells: Low, HPA056605; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA056605; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA056605; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA056605; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA056605; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA056605; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.6642160312659999,21.5,,Neither,oncoref.target-sets.2026-10-23.2,0.6642 TPM; blood/TH2; dice_th2; vital,21.5 nTPM; eye/bipolar cells; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 1/50 (2.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Breast Invasive Carcinoma (TCGA): 1/1022 (0.1%),breast cancer: 1/12 (8.3%); lung cancer: 1/12 (8.3%),31,20,Q8IZX4,https://www.uniprot.org/uniprotkb/Q8IZX4/entry,"May act as a functional substitute for TAF1/TAFII250 during male meiosis, when sex chromosomes are transcriptionally silenced","Testis specific, expressed apparently in germ cells",,,Nucleus,12217962,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
TAS2R1,ENSG00000169777,Neither,Antibody,False,False,7.3,7.3,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Cerebellum/Cells in granular layer: Low, HPA051879; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA051879; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: High, HPA051879; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA051879; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA051879; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA051879; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.3,0.5,,CTA,oncoref.target-sets.2026-10-23.2,0.3 TPM; blood/Central memory CD8 T-cell; hpa_immune_monaco; vital,0.5 nTPM; heart muscle/cardiomyocytes; hpa_single_cell_tissue; vital,Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),glioma: 2/11 (18.2%); breast cancer: 0/12 (0.0%),31,20,Q9NYW7,https://www.uniprot.org/uniprotkb/Q9NYW7/entry,"Receptor that may play a role in the perception of bitterness and is gustducin-linked. May play a role in sensing the chemical composition of the gastrointestinal content. The activity of this receptor may stimulate alpha gustducin, mediate PLC-beta-2 activation and lead to the gating of TRPM5",Expressed in subsets of taste receptor cells of the tongue and palate epithelium and exclusively in gustducin-positive cells,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
TAS2R41,ENSG00000221855,Neither,Antibody,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bone marrow/Hematopoietic cells: Medium, HPA057063; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA057063; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA057063; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,5.67623110115,1.4,,Neither,oncoref.target-sets.2026-10-23.2,5.676 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,1.4 nTPM; colon/distal enterocytes; hpa_single_cell_tissue; protected,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Breast Invasive Carcinoma (validation): 0/50 (0.0%),liver cancer: 1/12 (8.3%); breast cancer: 0/12 (0.0%),31,20,P59536,https://www.uniprot.org/uniprotkb/P59536/entry,"Receptor that may play a role in the perception of bitterness and is gustducin-linked. May play a role in sensing the chemical composition of the gastrointestinal content. The activity of this receptor may stimulate alpha gustducin, mediate PLC-beta-2 activation and lead to the gating of TRPM5 (By similarity)",Expressed in subsets of taste receptor cells of the tongue and exclusively in gustducin-positive cells,,,Membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TBC1D3F,ENSG00000275954,Neither,Screening,False,False,6.6,6.6,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.622115125505,0.6,,Neither,oncoref.target-sets.2026-10-23.2,0.6221 TPM; blood/TFH; dice_tfh; vital,0.6 nTPM; cerebellum/bulk; hpa_rna_consensus; vital,Liver Hepatocellular Carcinoma (validation): 19/231 (8.2%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Breast Invasive Carcinoma (TCGA): 1/1022 (0.1%),No exact-ID IHC coverage in the HPA cancer snapshot,27,0,A6NER0,https://www.uniprot.org/uniprotkb/A6NER0/entry,Acts as a GTPase activating protein for RAB5. Does not act on RAB4 or RAB11 (By similarity),"Expressed in most tissues including pancreas, thymus and testis",,,Cell membrane,,16863688,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
TBC1D3I,ENSG00000274933,Neither,Screening,False,False,6.8,6.8,84,3,Positive somewhere,False,False,False,True,Excluded,Reproductive,True,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.8,1.5,,Neither,oncoref.target-sets.2026-10-23.2,1.8 TPM; blood/Progenitor cell; hpa_immune_monaco; vital,1.5 nTPM; pbmc/b-cells; hpa_single_cell_tissue; vital,Kidney Renal Papillary Cell Carcinoma (TCGA): 2/282 (0.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Breast Invasive Carcinoma (TCGA): 1/1022 (0.1%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),26,20,A0A087WXS9,https://www.uniprot.org/uniprotkb/A0A087WXS9/entry,Acts as a GTPase activating protein for RAB5. Does not act on RAB4 or RAB11 (By similarity),,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TBX22,ENSG00000122145,Neither,Screening,False,False,10.8,10.8,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.197723123404,4.6,,Neither,oncoref.target-sets.2026-10-23.2,0.1977 TPM; blood/TFH; dice_tfh; vital,4.6 nTPM; thyroid gland/bulk; hpa_rna_consensus; manageable,Breast Invasive Carcinoma (validation): 1/50 (2.0%); Thyroid Carcinoma (TCGA): 2/495 (0.4%); Breast Invasive Carcinoma (TCGA): 1/1022 (0.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9Y458,https://www.uniprot.org/uniprotkb/Q9Y458/entry,Probable transcriptional regulator involved in developmental processes. This is major determinant crucial to palatogenesis,Seems to be expressed at a low level,"Cleft palate with or without ankyloglossia, X-linked: A congenital mouth abnormality characterized by fissure of the soft and/or hard palate, due to faulty fusion. Some patients also manifest ankyloglossia, a condition in which movements of the tongue are restricted. Complete ankyloglossia is due to fusion between the tongue and the floor of the mouth. Partial ankyloglossia is due to a short lingual frenum or one which is attached too near the tip of the tongue. Abruzzo-Erickson syndrome: A disease characterized by cleft palate, coloboma, hypospadias, deafness, short stature, and radial synostosis.",,Nucleus,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TCHHL1,ENSG00000182898,Neither,Selectivity,False,False,0.1,0.7,84,1,Positive somewhere,False,False,False,False,Excluded,Normal,True,,Not assessed,,,skin: 0.7 nTPM; continuous selectivity;reproductive not higher,Fails reproductive selectivity without above-ceiling normal RNA or a normal-protein veto,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Selectivity,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.234921832045,0.7,,Neither,oncoref.target-sets.2026-10-23.2,0.2349 TPM; blood/TH1; dice_th1; vital,0.7 nTPM; skin/bulk; hpa_rna_consensus; manageable,Uterine Corpus Endometrial Carcinoma (TCGA): 3/176 (1.7%); Head and Neck Squamous Cell Carcinoma (TCGA): 5/492 (1.0%); Rectum Adenocarcinoma (validation): 2/207 (1.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q5QJ38,https://www.uniprot.org/uniprotkb/Q5QJ38/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
TDRD1,ENSG00000095627,Neither,Cellular,False,False,15.2,15.2,87,4,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE CD4_STIM (activated): 3/88 values ≥5 TPM, max 6.43364; hpa_immune_monaco plasmacytoid DC: 6.4 TPM",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,6.4336436593499995,10.8,,CTA,oncoref.target-sets.2026-10-23.2,6.434 TPM; blood/CD4_STIM; dice_cd4_stim; vital,10.8 nTPM; heart muscle/cardiomyocytes; hpa_single_cell_tissue; vital,Prostate Adenocarcinoma (TCGA): 200/480 (41.7%); Lung Adenocarcinoma (validation): 12/105 (11.4%); Pancreatic Adenocarcinoma (validation): 8/80 (10.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9BXT4,https://www.uniprot.org/uniprotkb/Q9BXT4/entry,"Plays a central role during spermatogenesis by participating in the repression transposable elements and preventing their mobilization, which is essential for the germline integrity. Acts via the piRNA metabolic process, which mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and governs the methylation and subsequent repression of transposons. Required for the localization of Piwi proteins to the meiotic nuage. Involved in the piRNA metabolic process by ensuring the entry of correct transcripts into the normal piRNA pool and limiting the entry of cellular transcripts into the piRNA pathway. May act by allowing the recruitment of piRNA biogenesis or loading factors that ensure the correct entry of transcripts and piRNAs into Piwi proteins (By similarity)",Testis and ovary specific. Also expressed in several cancers,,,Cytoplasm,,12704671,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT | Carter2023_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Normal reproductive-tissue enrichment; no tumor validation,Are the few activated-CD4 values and Monaco plasmacytoid-DC summary reproducible?,Resolve the borderline immune RNA with source-specific read review and reliable local protein evidence.,Three of 88 activated-CD4 DICE values reach 5 TPM; this is a review threshold rather than demonstrated toxicity.,,,,,
TDRD12,ENSG00000173809,Neither,Cellular,False,False,13.9,13.9,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE TREG_MEM (unstimulated): 3/89 values ≥5 TPM, max 11.9599; DICE CD4_NAIVE (unstimulated): 5/88 values ≥5 TPM, max 14.8615; DICE TREG_NAIVE (unstimulated): 6/89 values ≥5 TPM, max 18.5064; DICE TFH (unstimulated): 4/89 values ≥5 TPM, max 16.0156; DICE THSTAR (unstimulated): 3/88 values ≥5 TPM, max 14.6862; DICE CD8_NAIVE (unstimulated): 5/89 values ≥5 TPM, max 16.0651; DICE CD8_STIM (activated): 3/88 values ≥5 TPM, max 15.8982",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,18.5064341372,4.1,,CTA,oncoref.target-sets.2026-10-23.2,18.51 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,4.1 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 96/133 (72.2%); Lung Squamous Cell Carcinoma (validation): 9/68 (13.2%); Skin Cuteneous Melanoma (TCGA): 8/99 (8.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q587J7,https://www.uniprot.org/uniprotkb/Q587J7/entry,"Probable ATP-binding RNA helicase required during spermatogenesis to repress transposable elements and preventing their mobilization, which is essential for the germline integrity. Acts via the piRNA metabolic process, which mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and governs the methylation and subsequent repression of transposons. Involved in the secondary piRNAs metabolic process. Acts via the PET complex, a multiprotein complex required during the secondary piRNAs metabolic process for the PIWIL2 slicing-triggered loading of PIWIL4 piRNAs",,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
TDRD15,ENSG00000218819,Neither,Antibody,False,False,5.3,5.3,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Colon/Endothelial cells: Medium, HPA051770; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA051770; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA051770; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA051770; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA051770; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA051770; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA051770; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Low, HPA054675; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA054675; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA054675; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA054675; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA054675; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA054675; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA054675; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA054675; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA054675; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA054675; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA054675; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA054675; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA054675; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA054675; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.31571578162,12.1,,CTA,oncoref.target-sets.2026-10-23.2,2.316 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,12.1 nTPM; small intestine/mixed immune cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Lung Squamous Cell Carcinoma (TCGA): 1/489 (0.2%),pancreatic cancer: 1/11 (9.1%); renal cancer: 1/11 (9.1%),29,20,B5MCY1,https://www.uniprot.org/uniprotkb/B5MCY1/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TENT5D,ENSG00000174016,Neither,Antibody,False,False,3.3,3.3,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bronchus/Respiratory epithelial cells: Medium, HPA059362; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA059362; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA059362; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA059362; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA059362; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA059362; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA059362; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA059362; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA059362; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA059362; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA059362; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA059362; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA059362; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA059362; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA059362; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.434019104339,1.4,,Neither,oncoref.target-sets.2026-10-23.2,0.434 TPM; blood/TREG_MEM; dice_treg_mem; vital,1.4 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),breast cancer: 8/12 (66.7%); pancreatic cancer: 4/10 (40.0%),29,20,Q8NEK8,https://www.uniprot.org/uniprotkb/Q8NEK8/entry,Catalyzes the transfer of one adenosine molecule from an ATP to an mRNA poly(A) tail bearing a 3'-OH terminal group,restricted to testis,,,,28931820|32433990,19540335,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TERB1,ENSG00000249961,Neither,Cellular,False,False,12.2,12.2,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_monaco Memory CD4 T-cell Th2: 5.1 TPM; hpa_immune_monaco naive CD8 T-cell: 8.4 TPM; hpa_immune_monaco neutrophil: 6 TPM; hpa_immune_monaco NK-cell: 6.4 TPM; hpa_immune_monaco Non-switched memory B-cell: 6.3 TPM; hpa_immune_monaco Progenitor cell: 7.4 TPM; hpa_immune_monaco Switched memory B-cell: 6.3 TPM,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,8.4,6.3822,,CTA,oncoref.target-sets.2026-10-23.2,8.4 TPM; blood/naive CD8 T-cell; hpa_immune_monaco; vital,6.382 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Pancreatic Adenocarcinoma (validation): 17/80 (21.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 25/176 (14.2%); Kidney Chromophobe (TCGA): 8/64 (12.5%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q8NA31,https://www.uniprot.org/uniprotkb/Q8NA31/entry,"Meiosis-specific telomere-associated protein involved in meiotic telomere attachment to the nucleus inner membrane, a crucial step for homologous pairing and synapsis. Component of the MAJIN-TERB1-TERB2 complex, which promotes telomere cap exchange by mediating attachment of telomeric DNA to the inner nuclear membrane and replacement of the protective cap of telomeric chromosomes: in early meiosis, the MAJIN-TERB1-TERB2 complex associates with telomeric DNA and the shelterin/telosome complex. During prophase, the complex matures and promotes release of the shelterin/telosome complex from telomeric DNA. In the MAJIN-TERB1-TERB2 complex, TERB1 probably mediates association with the shelterin/telosome complex via interaction with TERF1, promoting priming telomeric DNA attachment'. Promotes telomere association with the nuclear envelope and deposition of the SUN-KASH/LINC complex. Also recruits cohesin to telomeres to develop structural rigidity",,"Spermatogenic failure 60: An autosomal recessive male infertility disorder characterized by non-obstructive azoospermia, due to sperm maturation arrest before the pachytene stage.",,"Chromosome, telomere Nucleus inner membrane",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TEX13B,ENSG00000170925,Neither,Low,False,False,0.4,0.4,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.5480563586330001,0.3,,Neither,oncoref.target-sets.2026-10-23.2,0.5481 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,0.3 nTPM; eye/bipolar cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%); Breast Invasive Carcinoma (validation): 1/50 (2.0%); Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9BXU2,https://www.uniprot.org/uniprotkb/Q9BXU2/entry,,Testis specific,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TEX13C,ENSG00000282815,Neither,Low,False,False,1.6,1.6,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.119947336548,0.1,,Neither,oncoref.target-sets.2026-10-23.2,0.1199 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.1 nTPM; adipose tissue/fibroblasts; hpa_single_cell_tissue; manageable,Skin Cuteneous Melanoma (TCGA): 8/99 (8.1%); Liver Hepatocellular Carcinoma (TCGA): 6/362 (1.7%); Lung Adenocarcinoma (TCGA): 8/497 (1.6%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,A0A0J9YWL9,https://www.uniprot.org/uniprotkb/A0A0J9YWL9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Carter2023_CT | Loriot2025_S1 | Gong2021_reproductive_PC,Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TEX13D,ENSG00000282419,Neither,Low,False,False,1.7,1.7,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.3462580751699999,0.6,,Neither,oncoref.target-sets.2026-10-23.2,0.3463 TPM; blood/TFH; dice_tfh; vital,0.6 nTPM; pbmc/t-cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,A0A0J9YY54,https://www.uniprot.org/uniprotkb/A0A0J9YY54/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TEX28,ENSG00000278057,Neither,Screening,False,False,8.7,8.7,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.6604,3.7,,Neither,oncoref.target-sets.2026-10-23.2,0.6604 TPM; blood/naive CD8 T-cell; hpa_immune_cell_samples; vital,3.7 nTPM; skin/smooth muscle cells; hpa_single_cell_tissue; manageable,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,28,0,O15482,https://www.uniprot.org/uniprotkb/O15482/entry,,Testis specific,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TEX35,ENSG00000240021,Neither,Cellular,False,False,114.7,114.7,85,3,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_monaco basophil: 8.5 TPM,True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,8.5,6.2,,CTA,oncoref.target-sets.2026-10-23.2,8.5 TPM; blood/basophil; hpa_immune_monaco; vital,6.2 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 189/207 (91.3%); Colon Adenocarcinoma (validation): 428/486 (88.1%); Testicular Germ Cell Tumor (TCGA): 7/133 (5.3%),liver cancer: 4/12 (33.3%); pancreatic cancer: 2/11 (18.2%),29,20,Q5T0J7,https://www.uniprot.org/uniprotkb/Q5T0J7/entry,,Testis-specific,,,,,17077512,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TEX48,ENSG00000230601,Neither,Cellular,False,False,25.7,25.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 5/91 values ≥5 TPM, max 6.60179",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,6.60178795732,4.3,,CTA,oncoref.target-sets.2026-10-23.2,6.602 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,4.3 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Bladder Urothelial Carcinoma (TCGA): 2/169 (1.2%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A0A1B0GUV7,https://www.uniprot.org/uniprotkb/A0A1B0GUV7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Loriot2025_S1 | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TEX50,ENSG00000232113,Neither,Screening,False,False,20.2,20.2,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.453775174275,5.0,,Neither,oncoref.target-sets.2026-10-23.2,0.4538 TPM; blood/TH2; dice_th2; vital,5 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A0A1B0GTY4,https://www.uniprot.org/uniprotkb/A0A1B0GTY4/entry,Sperm membrane protein required for stability of the sperm acrosome after its formation in the testis. Essential for male fertility,Testis-specific,,,Membrane,,40906813,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TEX53,ENSG00000230054,Neither,Cellular,False,False,66.3,66.3,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 35/91 values ≥5 TPM, max 10.7248",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,10.7248347852,6.2,,Neither,oncoref.target-sets.2026-10-23.2,10.72 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,6.2 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 1/283 (0.4%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A0A1B0GU33,https://www.uniprot.org/uniprotkb/A0A1B0GU33/entry,,Expressed in Testis,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TFDP3,ENSG00000183434,Neither,Low,False,False,4.1,4.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.195950300354,0.4,,Neither,oncoref.target-sets.2026-10-23.2,0.196 TPM; blood/CD8_NAIVE; dice_cd8_naive; vital,0.4 nTPM; lung/macrophages; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 8/50 (16.0%); Testicular Germ Cell Tumor (TCGA): 15/133 (11.3%); Liver Hepatocellular Carcinoma (validation): 17/231 (7.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5H9I0,https://www.uniprot.org/uniprotkb/Q5H9I0/entry,Competitive inhibitor of E2F-mediated transactivation activity. Impairs E2F-mediated cell-cycle progression from G(1) to S phase,Predominantly expressed in testis. Low level of expression in pancreas. Highly expressed in ovarian and colon cancer cell lines,,,Nucleus Cytoplasm,16418725|17062573|20559320,12097419|16418725,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Carter2023_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TGIF2LY,ENSG00000176679,Neither,Low,False,False,3.9,3.9,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,0.0,,Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0 nTPM; blood/MAIT T-cell; hpa_immune_cell; vital,Testicular Germ Cell Tumor (TCGA): 6/133 (4.5%); Lung Squamous Cell Carcinoma (TCGA): 3/489 (0.6%); Lung Adenocarcinoma (TCGA): 2/497 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IUE0,https://www.uniprot.org/uniprotkb/Q8IUE0/entry,May have a transcription role in testis. May act as a competitor/regulator of TGIF2LX,Specifically expressed in adult testis,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TGM7,ENSG00000159495,Neither,Low,False,False,0.8,1.6,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,esophagus: 0.4 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.356445438032,21.0,,Neither,oncoref.target-sets.2026-10-23.2,0.3564 TPM; blood/TH2; dice_th2; vital,21 nTPM; tongue/suprabasal keratinocytes; hpa_single_cell_tissue; protected,Uterine Corpus Endometrial Carcinoma (TCGA): 12/176 (6.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 1/283 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96PF1,https://www.uniprot.org/uniprotkb/Q96PF1/entry,Catalyzes the cross-linking of proteins and the conjugation of polyamines to proteins,Widely expressed,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TKTL2,ENSG00000151005,Neither,Cellular,False,False,56.1,56.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 7/91 values ≥5 TPM, max 9.70645",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,9.7064458454,3.1,,CTA,oncoref.target-sets.2026-10-23.2,9.706 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,3.1 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 1/58 (1.7%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9H0I9,https://www.uniprot.org/uniprotkb/Q9H0I9/entry,"Plays an essential role in total transketolase activity and cell proliferation in cancer cells; after transfection with anti-TKTL1 siRNA, total transketolase activity dramatically decreases and proliferation was significantly inhibited in cancer cells. Plays a pivotal role in carcinogenesis",Overexpressed in hepatoma cancer cells,,,,17321041,17321041,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TLE7,ENSG00000260734,Neither,Low,False,False,0.7,0.7,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.462647843398,0.1,,Neither,oncoref.target-sets.2026-10-23.2,0.4626 TPM; blood/TFH; dice_tfh; vital,0.1 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 10/133 (7.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Lung Squamous Cell Carcinoma (TCGA): 1/489 (0.2%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A0A1W2PR48,https://www.uniprot.org/uniprotkb/A0A1W2PR48/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TMEM239,ENSG00000198326,Neither,Screening,False,False,103.4,103.4,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.24536363511,0.8,,Neither,oncoref.target-sets.2026-10-23.2,1.245 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,0.8 nTPM; retina/bulk; hpa_rna_consensus; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 7/176 (4.0%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 3/283 (1.1%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q8WW34,https://www.uniprot.org/uniprotkb/Q8WW34/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TMEM247,ENSG00000284701,Neither,Unassessed,False,False,21.2,21.2,83,1,Positive somewhere,False,False,False,True,Excluded,Unassessed,False,,Not assessed,,,"existing nomination or manual review; incomplete routine rna; nomination unresolved; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.491129487546,3.1,,Neither,oncoref.target-sets.2026-10-23.2,0.4911 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,3.1 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 4/492 (0.8%); Lung Squamous Cell Carcinoma (TCGA): 3/489 (0.6%),stomach cancer: 1/9 (11.1%); breast cancer: 0/11 (0.0%),26,20,A6NEH6,https://www.uniprot.org/uniprotkb/A6NEH6/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
TMEM262,ENSG00000187066,Neither,Cellular,False,False,20.5,20.5,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 60/91 values ≥5 TPM, max 7.4826; DICE NK (unstimulated): 34/90 values ≥5 TPM, max 6.95176; DICE CD4_NAIVE (unstimulated): 5/88 values ≥5 TPM, max 5.55803; DICE TFH (unstimulated): 5/89 values ≥5 TPM, max 5.60458; DICE TH1 (unstimulated): 4/81 values ≥5 TPM, max 6.02376; DICE THSTAR (unstimulated): 3/88 values ≥5 TPM, max 5.28132; DICE TH17 (unstimulated): 3/89 values ≥5 TPM, max 5.93142; DICE TH2 (unstimulated): 5/89 values ≥5 TPM, max 5.82464",True,True,False,,False,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,7.48259970009,3.1,,Neither,oncoref.target-sets.2026-10-23.2,7.483 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,3.1 nTPM; spleen/t-cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,E9PQX1,https://www.uniprot.org/uniprotkb/E9PQX1/entry,"Auxiliary component of the CatSper complex, a complex involved in sperm cell hyperactivation",,,"In mouse, Slco6c1 is an additional auxiliary subunit of the CatSper complex. It is unclear if the related SLCO6A1 protein performs the same role in non-rodent species","Cell projection, cilium, flagellum membrane",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TMEM89,ENSG00000183396,Neither,Antibody,False,False,24.1,24.1,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bronchus/Respiratory epithelial cells: Medium, HPA053577; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA053577; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA053577; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA053577; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA053577; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA053577; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.84191155521,3.5,,CTA,oncoref.target-sets.2026-10-23.2,2.842 TPM; blood/NK; dice_nk; vital,3.5 nTPM; small intestine/paneth cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 3/207 (1.4%); Colon Adenocarcinoma (validation): 6/486 (1.2%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 3/283 (1.1%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,A2RUT3,https://www.uniprot.org/uniprotkb/A2RUT3/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TMPRSS7,ENSG00000176040,Neither,Antibody,False,False,1.3,1.3,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA040630; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Low, HPA040630; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA040630; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA040630; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA040630; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA040630; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA040630; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA040630; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA040630; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA040630; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA040630; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA040630; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA040630; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA040630; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA040630; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA040630; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA040630; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA040630; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA040630; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA040630; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA040630; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA040630; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA040630; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA040630; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA040630; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA040630; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA040630; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA040630; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA040630; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA040630; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA040630; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA040630; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA040630; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA040630; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA040630; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA040630; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA040630; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA040630; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.7266780039730001,10.4,,Neither,oncoref.target-sets.2026-10-23.2,0.7267 TPM; blood/TREG_MEM; dice_treg_mem; vital,10.4 nTPM; lung/ciliated cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 6/58 (10.3%); Kidney Chromophobe (TCGA): 1/64 (1.6%); Glioblastoma Multiforme (TCGA): 2/141 (1.4%),melanoma: 11/11 (100.0%); skin cancer: 8/10 (80.0%),31,20,Q7RTY8,https://www.uniprot.org/uniprotkb/Q7RTY8/entry,Serine protease which preferentially hydrolyzes peptides with Arg at the P1 position,"Expressed in brain, ovary, testis, salivary gland, trachea and lung",,,Cell membrane,,15853774,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
TOPAZ1,ENSG00000173769,Neither,Antibody,False,False,3.4,3.4,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA047431; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA047431; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA047431; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA047431; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA047431; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: High, HPA047431; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA047431; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA047431; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA047431; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA047431; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA047431; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: High, HPA047431; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA047431; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA047431; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA047431; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA047431; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA047431; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA047431; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA047431; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: High, HPA047431; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA047431; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA047431; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA047431; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA047431; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA047431; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA047431; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA047431; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: High, HPA047431; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA047431; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA047431; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA047431; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA047431; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA047431; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA047431; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA047431; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA047431; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA047431; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA047431; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA047431; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA047431; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA047431; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA047431; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA051034; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA051034; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA051034; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA051034; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA051034; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA051034; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA051034; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA051034; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA051034; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA051034; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA051034; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA051034; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA051034; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA051034; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA051034; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA051034; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA051034; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA051034; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA051034; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA051034; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA051034; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA051034; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA051034; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA051034; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA051034; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA051034; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA051034; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA051034; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA051034; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA051034; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA051034; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA051034; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.359292833191,2.3,,Neither,oncoref.target-sets.2026-10-23.2,0.3593 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,2.3 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),stomach cancer: 11/11 (100.0%); pancreatic cancer: 10/10 (100.0%),29,20,Q8N9V7,https://www.uniprot.org/uniprotkb/Q8N9V7/entry,"Important for normal spermatogenesis and male fertility. Specifically required for progression to the post-meiotic stages of spermatocyte development. Seems to be necessary for normal expression levels of a number of testis-expressed gene transcripts, although its role in this process is unclear",,,,"Cytoplasm, cytosol",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TP53TG3,ENSG00000183632,Neither,Screening,False,False,6.7,6.7,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.223668116916,0.3,,Neither,oncoref.target-sets.2026-10-23.2,0.2237 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,0.3 nTPM; adrenal gland/bulk; hpa_rna_consensus; vital,Ovary Serous Cystadenocarcinoma (validation): 2/81 (2.5%); Skin Cuteneous Melanoma (TCGA): 2/99 (2.0%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,Q9ULZ0,https://www.uniprot.org/uniprotkb/Q9ULZ0/entry,May play a significant role in p53/TP53-mediating signaling pathway,"Strongly expressed in testis. Weakly expressed in heart, placenta and skeletal muscle",,,Cytoplasm Nucleus,10534768,10534768,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
TP53TG3B,ENSG00000261509,Neither,Low,False,False,4.3,4.3,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0036,0.1,,Neither,oncoref.target-sets.2026-10-23.2,0.0036 TPM; blood/neutrophil; hpa_immune_cell_samples; vital,0.1 nTPM; cerebellum/bulk; hpa_rna_consensus; vital,Skin Cuteneous Melanoma (TCGA): 7/99 (7.1%); Breast Invasive Carcinoma (validation): 2/50 (4.0%); Ovary Serous Cystadenocarcinoma (TCGA): 12/349 (3.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9ULZ0,https://www.uniprot.org/uniprotkb/Q9ULZ0/entry,May play a significant role in p53/TP53-mediating signaling pathway,"Strongly expressed in testis. Weakly expressed in heart, placenta and skeletal muscle",,,Cytoplasm Nucleus,10534768,10534768,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
TP53TG3C,ENSG00000205457,Neither,Low,False,False,0.3,0.3,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; pancreas: 0.2 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.2856,0.4017,,Neither,oncoref.target-sets.2026-10-23.2,0.2856 TPM; blood/neutrophil; hpa_immune_cell_samples; vital,0.4017 nTPM; blood/neutrophil; hpa_immune_cell_samples; vital,Ovary Serous Cystadenocarcinoma (validation): 6/81 (7.4%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q9ULZ0,https://www.uniprot.org/uniprotkb/Q9ULZ0/entry,May play a significant role in p53/TP53-mediating signaling pathway,"Strongly expressed in testis. Weakly expressed in heart, placenta and skeletal muscle",,,Cytoplasm Nucleus,10534768,10534768,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
TP53TG3D,ENSG00000205456,Neither,Low,False,False,4.4,4.4,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,cerebellum: 2 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.9,7.4,,Neither,oncoref.target-sets.2026-10-23.2,0.9 TPM; blood/naive B-cell; hpa_immune_monaco; vital,7.4 nTPM; lung/ciliated cells; hpa_single_cell_tissue; vital,Ovary Serous Cystadenocarcinoma (validation): 8/81 (9.9%); Skin Cuteneous Melanoma (TCGA): 5/99 (5.1%); Ovary Serous Cystadenocarcinoma (TCGA): 10/349 (2.9%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q9ULZ0,https://www.uniprot.org/uniprotkb/Q9ULZ0/entry,May play a significant role in p53/TP53-mediating signaling pathway,"Strongly expressed in testis. Weakly expressed in heart, placenta and skeletal muscle",,,Cytoplasm Nucleus,10534768,10534768,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TPRX1,ENSG00000178928,Neither,Antibody,False,False,1.1,1.1,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,retina: 1.1 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA044922; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA044922; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA044922; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA044922; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA044922; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA044922; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA044922; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA044922; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA044922; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA044922; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA044922; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA044922; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA044922; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA044922; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA044922; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA044922; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA044922; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA044922; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA044922; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA044922; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA044922; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA044922; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA044922; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA044922; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA044922; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA044922; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA044922; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA044922; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA044922; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA044922; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA044922; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA044922; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA044922; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA044922; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA044922; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA044922; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.808905296559999,2.7,,Neither,oncoref.target-sets.2026-10-23.2,2.809 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,2.7 nTPM; eye/rod photoreceptor cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 15/133 (11.3%); Uterine Corpus Endometrial Carcinoma (TCGA): 4/176 (2.3%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),colorectal cancer: 11/12 (91.7%); lymphoma: 9/12 (75.0%),31,20,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TRIM43,ENSG00000144015,Neither,Antibody,False,False,0.3,0.3,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,thymus: 0.3 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA042223; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA042223; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA042223; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA042223; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA042223; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA042223; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA042223; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA042223; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA042223; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA042223; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA042223; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA042223; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA042223; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA042223; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA042223; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA042223; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA042223; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA042223; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA042223; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA042223; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA042223; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA042223; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA042223; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA042223; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA042223; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA042223; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA042223; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA042223; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA042223; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA042223; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA042223; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA042223; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA042223; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA042223; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: Low, HPA042772; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA042772; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA042772; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA042772; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA042772; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA042772; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA042772; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA042772; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA042772; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA042772; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA042772; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA042772; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA042772; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA042772; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA042772; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA042772; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA042772; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA042772; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA042772; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA042772; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA042772; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA042772; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA042772; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA042772; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA042772; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA042772; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA042772; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA042772; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA042772; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA042772; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA042772; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA042772; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA042772; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA042772; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA042772; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.422596058764,0.3,,Neither,oncoref.target-sets.2026-10-23.2,0.4226 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,0.3 nTPM; thymus/bulk; hpa_rna_consensus; manageable,Testicular Germ Cell Tumor (TCGA): 10/133 (7.5%); Uterine Corpus Endometrial Carcinoma (TCGA): 10/176 (5.7%); Ovary Serous Cystadenocarcinoma (TCGA): 8/349 (2.3%),pancreatic cancer: 8/11 (72.7%); prostate cancer: 7/12 (58.3%),31,20,Q96BQ3,https://www.uniprot.org/uniprotkb/Q96BQ3/entry,E3 ligase that regulates nuclear lamina integrity and the association of viral chromatin with transcriptionally-active host chromatin. Acts thereby as a herpesvirus-specific antiviral factor and mediates the ubiquitination-dependent proteasomal degradation of PCNT,,,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",30420784,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
TRIM43B,ENSG00000144010,Neither,Antibody,False,False,0.3,0.3,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; thymus: 0.3 nTPM; continuous selectivity;reproductive not higher,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA042223; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA042223; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA042223; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA042223; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA042223; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA042223; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA042223; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA042223; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA042223; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA042223; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA042223; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA042223; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA042223; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA042223; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA042223; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA042223; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA042223; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA042223; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA042223; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA042223; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA042223; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA042223; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA042223; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA042223; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA042223; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA042223; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA042223; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA042223; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA042223; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA042223; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA042223; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA042223; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA042223; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA042223; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: Low, HPA042772; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA042772; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA042772; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA042772; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA042772; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA042772; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA042772; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA042772; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA042772; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA042772; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA042772; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA042772; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA042772; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA042772; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA042772; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA042772; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA042772; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA042772; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA042772; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA042772; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA042772; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA042772; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA042772; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA042772; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA042772; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA042772; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA042772; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA042772; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA042772; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA042772; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA042772; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA042772; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA042772; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA042772; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA042772; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.353667686296,0.3,,Neither,oncoref.target-sets.2026-10-23.2,0.3537 TPM; blood/TREG_MEM; dice_treg_mem; vital,0.3 nTPM; thymus/bulk; hpa_rna_consensus; manageable,Testicular Germ Cell Tumor (TCGA): 17/133 (12.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 4/176 (2.3%); Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%),pancreatic cancer: 8/11 (72.7%); prostate cancer: 7/12 (58.3%),30,20,A6NCK2,https://www.uniprot.org/uniprotkb/A6NCK2/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
TRIM48,ENSG00000150244,Neither,Low,False,False,0.0,0.2,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.1751,0.2,,Neither,oncoref.target-sets.2026-10-23.2,0.1751 TPM; blood/basophil; hpa_immune_cell_samples; vital,0.2 nTPM; skin/bulk; hpa_rna_consensus; manageable,Skin Cuteneous Melanoma (TCGA): 8/99 (8.1%); Glioblastoma Multiforme (validation): 2/58 (3.4%); Glioblastoma Multiforme (TCGA): 3/141 (2.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IWZ4,https://www.uniprot.org/uniprotkb/Q8IWZ4/entry,"E3 ubiquitin-protein ligase which promotes K48-linked polyubiquitination of protein methyltransferase PRMT1, leading to PRMT1 degradation (PubMed:29186683). This suppresses methylation of the PRMT1 substrate MAP3K5/ASK1, promoting its activation and increasing MAP3K5-dependent cell death induced by oxidative stress (PubMed:29186683). TRIM48-mediated ubiquitination of PRMT1 also suppresses methylation of FOXO1 by PRMT1, leading to inhibition of FOXO1 transcriptional activity (PubMed:29186683). Additionally, it inhibits RIG-I-mediated antiviral signaling, functioning as an inducible negative feedback regulator of this pathway (PubMed:40609779)",,,,"Cytoplasm, cytosol",29186683|40609779,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
TRIM49,ENSG00000168930,Neither,Low,False,False,0.3,0.3,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.2,0.3407,,Neither,oncoref.target-sets.2026-10-23.2,1.2 TPM; blood/basophil; hpa_immune_monaco; vital,0.3407 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 5/133 (3.8%); Lung Squamous Cell Carcinoma (TCGA): 5/489 (1.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 5/492 (1.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P0CI25,https://www.uniprot.org/uniprotkb/P0CI25/entry,,Preferentially expressed in testis,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
TRIM49B,ENSG00000182053,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.140699695851,0.3,,Neither,oncoref.target-sets.2026-10-23.2,0.1407 TPM; blood/TH1; dice_th1; vital,0.3 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Head and Neck Squamous Cell Carcinoma (TCGA): 3/492 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Lung Squamous Cell Carcinoma (TCGA): 2/489 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A6NDI0,https://www.uniprot.org/uniprotkb/A6NDI0/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
TRIM49C,ENSG00000204449,Neither,Low,False,False,0.1,0.1,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.2,0.3407,,Neither,oncoref.target-sets.2026-10-23.2,1.2 TPM; blood/basophil; hpa_immune_monaco; vital,0.3407 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Head and Neck Squamous Cell Carcinoma (TCGA): 3/492 (0.6%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P0CI26,https://www.uniprot.org/uniprotkb/P0CI26/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
TRIM51,ENSG00000124900,Neither,Antibody,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_cell basophil: 11.2 nTPM; hpa_immune_monaco basophil: 14.1 TPM,True,True,False,,True,True,"Bronchus/Respiratory epithelial cells: Low, HPA044988; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA044988; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA044988; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA044988; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA044988; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA044988; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA044988; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA044988; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA044988; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA044988; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA044988; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA044988; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,14.1,15.8479,,Neither,oncoref.target-sets.2026-10-23.2,14.1 TPM; blood/basophil; hpa_immune_monaco; vital,15.85 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Skin Cuteneous Melanoma (TCGA): 46/99 (46.5%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),cervical cancer: 4/11 (36.4%); liver cancer: 3/12 (25.0%),29,20,Q9BSJ1,https://www.uniprot.org/uniprotkb/Q9BSJ1/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
TRIM60,ENSG00000176979,Neither,Antibody,False,False,1.5,1.5,79,2,Positive somewhere,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA035809; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA035809; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA035809; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA035809; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA035809; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA035809; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA035809; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA035809; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA035809; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA035809; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA035809; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA035809; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA035809; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA035809; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA035809; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA035809; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA035809; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA035809; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA035810; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA035810; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA035810; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA035810; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA035810; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA035810; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA035810; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA035810; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA035810; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA035810; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA035810; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA035810; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA035810; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA035810; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA035810; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA035810; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA035810; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA035810; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA035810; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA035810; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA035810; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA035810; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA035810; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA035810; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA035810; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA035810; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA035810; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA035810; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA035810; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA035810; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA035810; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA035810; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA035810; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA035810; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA035810; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA035810; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA035810; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA061496; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA061496; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA061496; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA061496; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA061496; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA061496; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA061496; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA061496; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA061496; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA061496; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA061496; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA061496; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA061496; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.5,2.4,,CTA,oncoref.target-sets.2026-10-23.2,0.5 TPM; blood/Central memory CD8 T-cell; hpa_immune_monaco; vital,2.4 nTPM; vascular/endothelial cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 62/133 (46.6%); Stomach Adenocarcinoma (TCGA): 2/346 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),liver cancer: 6/12 (50.0%); renal cancer: 6/12 (50.0%),31,20,Q495X7,https://www.uniprot.org/uniprotkb/Q495X7/entry,E3 SUMO-protein ligase that mediates SUMOylation of TAB2 leading to inhibition of NF-kappa-B and MAPK pathways by suppressing the TRAF6/TAB2/TAK1 complex,,,,,33184450,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TRIM71,ENSG00000206557,Neither,Antibody,False,False,4.7,4.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA038141; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA038141; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA038141; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA038141; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA038141; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA038141; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA038141; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA038141; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA038141; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA038141; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA038141; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA038141; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA038141; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA038141; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA038141; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA038141; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA038141; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA038141; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA038141; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA038141; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA038141; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA038141; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA038141; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA038141; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA038141; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA038141; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA038141; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA038141; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA038141; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA038141; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA038141; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA038141; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA038141; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA038141; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA038141; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA038141; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA038141; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA038141; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA038141; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA038141; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA038141; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA038141; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA038142; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA038142; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA038142; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA038142; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA038142; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA038142; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA038142; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA038142; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA038142; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA038142; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA038142; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA038142; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA038142; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA038142; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA038142; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA038142; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA038142; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: High, HPA038142; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA038142; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA038142; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA038142; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA038142; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA038142; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA038142; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA038142; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA038142; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA038142; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA038142; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA038142; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA038142; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA038142; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA038142; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA038142; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA038142; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA038142; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA038142; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA038142; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA038142; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA038142; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,3.5896804151599997,12.0,,Neither,oncoref.target-sets.2026-10-23.2,3.59 TPM; blood/MONOCYTES; dice_monocytes; vital,12 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 125/133 (94.0%); Glioblastoma Multiforme (validation): 11/58 (19.0%); Liver Hepatocellular Carcinoma (TCGA): 26/362 (7.2%),endometrial cancer: 12/12 (100.0%); liver cancer: 12/12 (100.0%),31,20,Q2Q1W2,https://www.uniprot.org/uniprotkb/Q2Q1W2/entry,"E3 ubiquitin-protein ligase that cooperates with the microRNAs (miRNAs) machinery and promotes embryonic stem cells proliferation and maintenance (Probable). Binds to miRNAs and associates with AGO2, participating in post-transcriptional repression of transcripts such as CDKN1A (By similarity). In addition, participates in post-transcriptional mRNA repression in a miRNA independent mechanism (PubMed:23125361). Facilitates the G1-S transition to promote rapid embryonic stem cell self-renewal by repressing CDKN1A expression. Required to maintain proliferation and prevent premature differentiation of neural progenitor cells during early neural development: positively regulates FGF signaling by controlling the stability of SHCBP1 (By similarity). Specific regulator of miRNA biogenesis. Binds to miRNA MIR29A hairpin and postranscriptionally modulates MIR29A levels, which indirectly regulates TET proteins expression (PubMed:28431233)",Specifically expressed in testis,"Hydrocephalus, congenital, 4: An autosomal dominant form of congenital hydrocephalus, a disease characterized by in utero onset of enlarged ventricles due to accumulation of ventricular cerebrospinal fluid. HYC4 occurs in the absence of obstruction to cerebrospinal fluid flow between the ventricles (communicating hydrocephalus). Affected individuals have neurodevelopmental delay and epilepsy.",,"Cytoplasm, P-body",23125361|24239284|28431233,15722555,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TRIML2,ENSG00000179046,Neither,Antibody,False,False,3.9,3.9,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA043838; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA043838; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA043838; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA043838; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA043838; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA043838; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA043838; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA043838; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA043838; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA043838; conflicting or uncurated primary profile; Lymph node/Germinal center cells: High, HPA043838; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA043838; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA043838; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA043838; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA043838; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA043838; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA043838; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA043838; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA043838; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA043838; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA043838; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA043838; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA043838; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA043838; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.7906523949429999,5.7,,Neither,oncoref.target-sets.2026-10-23.2,0.7907 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,5.7 nTPM; colon/undifferentiated cells; hpa_single_cell_tissue; protected,Testicular Germ Cell Tumor (TCGA): 115/133 (86.5%); Head and Neck Squamous Cell Carcinoma (TCGA): 39/492 (7.9%); Pancreatic Adenocarcinoma (validation): 3/80 (3.8%),colorectal cancer: 12/12 (100.0%); cervical cancer: 10/11 (90.9%),31,20,Q8N7C3,https://www.uniprot.org/uniprotkb/Q8N7C3/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S1,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
TSGA13,ENSG00000213265,Neither,Antibody,False,False,13.6,13.6,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Bone marrow/Hematopoietic cells: Low, HPA022968; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA022968; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA022968; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA022968; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.48263187031,1.9,,CTA,oncoref.target-sets.2026-10-23.2,1.483 TPM; blood/CD8_NAIVE; dice_cd8_naive; vital,1.9 nTPM; eye/rod photoreceptor cells; hpa_single_cell_tissue; vital,Kidney Chromophobe (TCGA): 9/64 (14.1%); Pancreatic Adenocarcinoma (validation): 5/80 (6.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 6/176 (3.4%),melanoma: 7/12 (58.3%); glioma: 1/12 (8.3%),31,20,Q96PP4,https://www.uniprot.org/uniprotkb/Q96PP4/entry,,Testis-specific,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT | Gong2021_reproductive_PC,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TSKS,ENSG00000126467,Neither,Cellular,False,False,116.7,116.7,84,2,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE M2 (unstimulated): 43/90 values ≥5 TPM, max 13.0023; DICE TREG_MEM (unstimulated): 18/89 values ≥5 TPM, max 13.4443; DICE CD4_NAIVE (unstimulated): 23/88 values ≥5 TPM, max 11.8415; DICE TREG_NAIVE (unstimulated): 37/89 values ≥5 TPM, max 17.2002; DICE TFH (unstimulated): 21/89 values ≥5 TPM, max 10.4231; DICE TH1 (unstimulated): 12/81 values ≥5 TPM, max 10.7301; DICE THSTAR (unstimulated): 5/88 values ≥5 TPM, max 6.12486; DICE TH17 (unstimulated): 8/89 values ≥5 TPM, max 7.79966; DICE TH2 (unstimulated): 6/89 values ≥5 TPM, max 7.40269; DICE CD8_NAIVE (unstimulated): 25/89 values ≥5 TPM, max 11.7636",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,17.200163089100002,8.1,,CTA,oncoref.target-sets.2026-10-23.2,17.2 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,8.1 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 38/133 (28.6%); Head and Neck Squamous Cell Carcinoma (TCGA): 62/492 (12.6%); Bladder Urothelial Carcinoma (TCGA): 7/169 (4.1%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q9UJT2,https://www.uniprot.org/uniprotkb/Q9UJT2/entry,"May play a role in testicular physiology, most probably in the process of spermatogenesis or spermatid development","Highly expressed in testis. Expressed at low levels in prostate, female breast, placenta, ovary and thymus",,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole",,11444856|15044604,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TSSK2,ENSG00000206203,Neither,Screening,False,False,132.1,132.1,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.6387,11.2,,Neither,oncoref.target-sets.2026-10-23.2,0.6387 TPM; blood/eosinophil; hpa_immune_cell_samples; vital,11.2 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 6/133 (4.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 5/283 (1.8%); Bladder Urothelial Carcinoma (TCGA): 2/169 (1.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96PF2,https://www.uniprot.org/uniprotkb/Q96PF2/entry,"Testis-specific serine/threonine-protein kinase required during spermatid development. Phosphorylates TSKS at 'Ser-288' and SPAG16. Involved in the late stages of spermatogenesis, during the reconstruction of the cytoplasm. During spermatogenesis, required for the transformation of a ring-shaped structure around the base of the flagellum originating from the chromatoid body",Testis-specific. Present in mature spermatozoa (at protein level),,,"Cytoplasm Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole",15044604|18533145|20729278,15044604|18533145|20729278,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
TSSK6,ENSG00000178093,Neither,Cellular,False,False,162.9,162.9,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE TREG_MEM (unstimulated): 20/89 values ≥5 TPM, max 7.53617; DICE TREG_NAIVE (unstimulated): 17/89 values ≥5 TPM, max 8.61343; DICE TFH (unstimulated): 32/89 values ≥5 TPM, max 8.14938; DICE TH1 (unstimulated): 3/81 values ≥5 TPM, max 6.17102; DICE TH2 (unstimulated): 8/89 values ≥5 TPM, max 7.29447; DICE CD8_NAIVE (unstimulated): 7/89 values ≥5 TPM, max 6.50772",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,8.613433498169998,22.9,,CTA,oncoref.target-sets.2026-10-23.2,8.613 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,22.9 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 37/50 (74.0%); Glioblastoma Multiforme (validation): 8/58 (13.8%); Kidney Chromophobe (TCGA): 7/64 (10.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9BXA6,https://www.uniprot.org/uniprotkb/Q9BXA6/entry,Serine/threonine-protein kinase component of the sperm flagellar doublet microtubules (PubMed:15870294). May act as a regulator of sperm motility by mediating phosphorylation of sperm doublet microtubule proteins (By similarity). Plays a role in DNA condensation during postmeiotic chromatin remodeling and histone-to-protamine transition during spermatogenesis (By similarity),"Highly expressed in testis. Expressed at lower levels in colon, small intestine, ovary, prostate, thymus, spleen and peripheral blood leukocytes",,,"Cytoplasm, cytoskeleton, flagellum axoneme Nucleus",15870294,15870294,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TTLL2,ENSG00000120440,Neither,Cellular,False,False,17.9,17.9,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE THSTAR (unstimulated): 12/88 values ≥5 TPM, max 7.19184",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,7.19183903763,1.6,,CTA,oncoref.target-sets.2026-10-23.2,7.192 TPM; blood/THSTAR; dice_thstar; vital,1.6 nTPM; liver/bulk; hpa_rna_consensus; vital,Liver Hepatocellular Carcinoma (validation): 8/231 (3.5%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Kidney Renal Clear Cell Carcinoma (validation): 1/100 (1.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9BWV7,https://www.uniprot.org/uniprotkb/Q9BWV7/entry,"Probable tubulin polyglutamylase that generates side chains of glutamate on the gamma-carboxyl group of specific glutamate residues within the C-terminal tail of target proteins (By similarity). Similar to TTLL1, may acquire enzymatic activity only in complex with other proteins as it is most likely lacking domains important for autonomous activity (By similarity). Probably involved in the side-chain initiation step of the polyglutamylation reaction rather than the elongation step (By similarity)",Testis,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TTLL8,ENSG00000138892,Neither,Antibody,False,False,4.0,4.0,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA016882; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA016882; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA016882; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA016882; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA016882; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA016882; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA016882; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA016882; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA016882; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA016882; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA016882; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA016882; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA016882; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA016882; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA016882; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA016882; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA016882; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA016882; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA016882; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA016882; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA016882; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA016882; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA016882; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA016882; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA016882; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA016882; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA016882; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA016882; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA016882; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA016882; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA016882; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA016882; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA016882; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA016882; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA016882; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA016882; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA016882; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA016882; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.492481345111,0.8,,Neither,oncoref.target-sets.2026-10-23.2,0.4925 TPM; blood/CD4_STIM; dice_cd4_stim; vital,0.8 nTPM; bone marrow/b-cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),colorectal cancer: 11/11 (100.0%); liver cancer: 11/12 (91.7%),30,20,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TUBA3C,ENSG00000198033,Neither,Antibody,False,False,393.6,393.6,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,family exclusion; family exclusion,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA039247; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA039247; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA039247; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA039247; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA039247; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA039247; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA039247; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA039247; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA039247; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA039247; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA039247; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA039247; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: High, HPA039247; conflicting or uncurated primary profile; Colon/Endothelial cells: High, HPA039247; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA039247; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: High, HPA039247; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA039247; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA039247; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA039247; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA039247; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA039247; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA039247; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA039247; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA039247; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA039247; conflicting or uncurated primary profile; Lung/Alveolar cells: High, HPA039247; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA039247; conflicting or uncurated primary profile; Lymph node/Germinal center cells: High, HPA039247; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA039247; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA039247; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA039247; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA039247; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: High, HPA039247; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA039247; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA039247; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA039247; conflicting or uncurated primary profile; Skin 1/Cells in basal layer: High, HPA039247; conflicting or uncurated primary profile; Skin 1/Cells in granular layer: Medium, HPA039247; conflicting or uncurated primary profile; Skin 1/Cells in spinous layer: Medium, HPA039247; conflicting or uncurated primary profile; Skin 1/Eccrine glands: High, HPA039247; conflicting or uncurated primary profile; Skin 1/Endothelial cells: High, HPA039247; conflicting or uncurated primary profile; Skin 1/Fibrohistiocytic cells: High, HPA039247; conflicting or uncurated primary profile; Skin 1/Langerhans cells: Medium, HPA039247; conflicting or uncurated primary profile; Skin 1/Lymphocytes: High, HPA039247; conflicting or uncurated primary profile; Skin 1/Sebaceous glands: High, HPA039247; conflicting or uncurated primary profile; Skin 1/Vascular mural cells: High, HPA039247; conflicting or uncurated primary profile; Skin 2/Cells in basal layer: High, HPA039247; conflicting or uncurated primary profile; Skin 2/Cells in corneal layer: Medium, HPA039247; conflicting or uncurated primary profile; Skin 2/Cells in granular layer: Medium, HPA039247; conflicting or uncurated primary profile; Skin 2/Cells in spinous layer: Medium, HPA039247; conflicting or uncurated primary profile; Skin 2/Eccrine glands: High, HPA039247; conflicting or uncurated primary profile; Skin 2/Endothelial cells: High, HPA039247; conflicting or uncurated primary profile; Skin 2/Fibrohistiocytic cells: High, HPA039247; conflicting or uncurated primary profile; Skin 2/Langerhans cells: Medium, HPA039247; conflicting or uncurated primary profile; Skin 2/Lymphocytes: High, HPA039247; conflicting or uncurated primary profile; Skin 2/Vascular mural cells: High, HPA039247; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA039247; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA039247; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA039247; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA039247; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA039247; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA039247; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA039247; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA039247; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA043684; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA043684; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA043684; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA043684; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA043684; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA043684; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA043684; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA043684; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA043684; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA043684; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA043684; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA043684; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA043684; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA043684; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA043684; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA043684; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA043684; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA043684; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA043684; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA043684; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA043684; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA043684; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA043684; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA043684; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA043684; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA043684; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA043684; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA063394; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA063394; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA063394; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA063394; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA063394; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA063394; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA063394; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA063394; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA063394; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA063394; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA063394; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA063394; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA063394; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA063394; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA063394; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA063394; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA063394; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA063394; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA063394; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA063394; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA063394; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA063394; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA063394; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA063394; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA063394; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA063394; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA063394; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA063394; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA063394; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA063394; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA063394; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA063394; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA063394; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA063394; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA063394; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA063394; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA063394; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA063394; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA063394; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA063394; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA063394; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA063394; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA063394; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,3.0302476068599997,16.7,,Neither,oncoref.target-sets.2026-10-23.2,3.03 TPM; blood/TH1; dice_th1; vital,16.7 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 17/133 (12.8%); Liver Hepatocellular Carcinoma (TCGA): 33/362 (9.1%); Skin Cuteneous Melanoma (TCGA): 9/99 (9.1%),testis cancer: 7/11 (63.6%); glioma: 5/11 (45.5%),31,20,P0DPH7 | P0DPH8,https://www.uniprot.org/uniprotkb/P0DPH7/entry | https://www.uniprot.org/uniprotkb/P0DPH8/entry,"Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers. Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms. Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin","Expressed in testis | Expressed in the cornea, sclera, and peripheral blood (PubMed:29051577)","Keratoconus 9: An autosomal dominant form of keratoconus, a common degenerative corneal disease characterized by progressive, non-inflammatory thinning of the corneal stroma, corneal ectasia, and cone-shaped corneal protrusion that results in reduced vision.",,"Cytoplasm, cytoskeleton",,29051577,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S1 | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
UBQLNL,ENSG00000175518,Neither,Cellular,False,False,30.9,30.9,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 77/91 values ≥5 TPM, max 14.3742; DICE NK (unstimulated): 5/90 values ≥5 TPM, max 6.45887; DICE TREG_MEM (unstimulated): 14/89 values ≥5 TPM, max 10.0525; DICE CD4_NAIVE (unstimulated): 56/88 values ≥5 TPM, max 16.3348; DICE TREG_NAIVE (unstimulated): 37/89 values ≥5 TPM, max 10.6502; DICE TFH (unstimulated): 28/89 values ≥5 TPM, max 12.6735; DICE TH1 (unstimulated): 14/81 values ≥5 TPM, max 7.68975; DICE THSTAR (unstimulated): 3/88 values ≥5 TPM, max 7.1572; DICE TH17 (unstimulated): 6/89 values ≥5 TPM, max 9.61749; DICE TH2 (unstimulated): 6/89 values ≥5 TPM, max 7.581; DICE CD8_NAIVE (unstimulated): 54/89 values ≥5 TPM, max 16.2955",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,16.3347989733,6.3,,CTA,oncoref.target-sets.2026-10-23.2,16.33 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,6.3 nTPM; heart muscle/endothelial cells; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 14/50 (28.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 5/176 (2.8%); Liver Hepatocellular Carcinoma (validation): 5/231 (2.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IYU4,https://www.uniprot.org/uniprotkb/Q8IYU4/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
UMODL1,ENSG00000177398,Neither,Antibody,False,False,1.0,1.0,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA067245; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA067245; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA067245; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA067245; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA067245; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA067245; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.5007252283700003,3.1,,Neither,oncoref.target-sets.2026-10-23.2,2.501 TPM; blood/M2; dice_m2; vital,3.1 nTPM; lung/endothelial cells; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 5/50 (10.0%); Kidney Chromophobe (TCGA): 3/64 (4.7%); Ovary Serous Cystadenocarcinoma (validation): 1/81 (1.2%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q5DID0,https://www.uniprot.org/uniprotkb/Q5DID0/entry,,"Isoform 4 is expressed at low level in kidney, testis and fetal thymus. Isoform 3 is expressed at low level in prostate, testis and fetal thymus",,,Cell membrane Cytoplasm,,15194491,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination; inclusion depends on TGCT under this study's thresholds,,,,,,,,
USP29,ENSG00000131864,Neither,Cellular,False,False,4.8,4.8,81,1,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_monaco intermediate monocyte: 7.9 TPM,True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,7.9,3.6192,,CTA,oncoref.target-sets.2026-10-23.2,7.9 TPM; blood/intermediate monocyte; hpa_immune_monaco; vital,3.619 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Rectum Adenocarcinoma (validation): 22/207 (10.6%); Colon Adenocarcinoma (validation): 42/486 (8.6%); Testicular Germ Cell Tumor (TCGA): 9/133 (6.8%),urothelial cancer: 1/12 (8.3%); breast cancer: 0/12 (0.0%),31,20,Q9HBJ7,https://www.uniprot.org/uniprotkb/Q9HBJ7/entry,"Deubiquitinase involved in innate antiviral immunity by mediating 'Lys-48'-linked deubiquitination of CGAS, thereby promoting its stabilization",,,,"Cytoplasm, perinuclear region",32457395,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
USP50,ENSG00000170236,Neither,Antibody,False,False,1.5,1.5,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,kidney: 0.6 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA039470; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA039470; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA039470; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA039470; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA039470; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA039470; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA039470; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA039470; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA039470; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA039470; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA039470; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA039470; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA039470; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA039470; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA039470; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA039470; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA039470; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA039470; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA039470; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA039470; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA039470; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA039470; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA039470; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA039470; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA039470; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA039470; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA039470; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA039470; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA039470; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA039470; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA039470; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA039470; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA039470; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA039470; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA039470; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA039470; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA039470; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.57103770674,12.5,,Neither,oncoref.target-sets.2026-10-23.2,1.571 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,12.5 nTPM; brain/oligodendrocytes; hpa_single_cell_tissue; vital,Liver Hepatocellular Carcinoma (validation): 61/231 (26.4%); Uterine Corpus Endometrial Carcinoma (TCGA): 3/176 (1.7%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%),testis cancer: 10/12 (83.3%); liver cancer: 9/12 (75.0%),31,20,Q70EL3,https://www.uniprot.org/uniprotkb/Q70EL3/entry,"Deubiquitinating enzyme that removes conjugated ubiquitin from specific proteins to regulate different cellular processes. Regulates the inflammasome signaling pathway by deubiquitinating 'Lys-63'-linked polyubiquitination of the PYCARD/ASC adapter protein (PubMed:28094437). Regulates the ubiquitination and stability of the ACE2 protein (PubMed:36876523). Acts as a negative regulator of the G2/M checkpoint pathway, by preventing serine/threonine kinase WEE1 degradation, thereby repressing entry into mitosis following activation of the G2/M DNA damage checkpoint (PubMed:20930503)",Weakly expressed in a few tissues,,,"Cytoplasm Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Nucleus",20930503|28094437|36876523,14715245,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
VN1R4,ENSG00000228567,Neither,Antibody,False,False,0.2,0.2,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA027018; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA027018; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA027018; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA027018; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA027018; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA027018; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA027018; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA027018; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA027018; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA027018; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA027018; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA027018; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA027018; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA027018; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA027018; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA027018; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA027018; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA027018; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA027018; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA027018; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA027018; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA027018; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA027018; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA027018; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA027018; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA027018; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA027018; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA027018; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA027018; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA027018; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA027018; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA027018; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA027018; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA027018; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA027018; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA027018; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA027018; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA027018; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA027018; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA027018; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA027018; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA027018; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.6351239017679999,0.2003,,Neither,oncoref.target-sets.2026-10-23.2,0.6351 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,0.2003 nTPM; blood/MAIT T-cell; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),breast cancer: 9/12 (75.0%); stomach cancer: 7/11 (63.6%),30,20,Q7Z5H5,https://www.uniprot.org/uniprotkb/Q7Z5H5/entry,Putative pheromone receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
VN1R5,ENSG00000197617,Neither,Unassessed,False,False,0.0,0.1,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"incomplete routine rna; insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord; incomplete tissue evidence",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.59596513866,0.6741,,Neither,oncoref.target-sets.2026-10-23.2,2.596 TPM; blood/NK; dice_nk; vital,0.6741 nTPM; blood/plasmacytoid DC; hpa_immune_cell_samples; vital,No exact-ID RNA coverage in the HPA cancer snapshot,No exact-ID IHC coverage in the HPA cancer snapshot,0,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
VRTN,ENSG00000133980,Neither,Antibody,False,False,1.6,1.6,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA001460; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA001460; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA001460; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA001460; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA001460; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA001460; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA001460; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA001460; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA001460; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA001460; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA001460; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA001460; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA001460; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA001460; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA001460; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA001460; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA001460; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: High, HPA001460; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA001460; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA001460; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA001460; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA001460; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA001460; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA001460; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA001460; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA001460; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA001460; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA001460; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA001460; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA001460; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA001460; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA001460; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA001460; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA001460; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA001460; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA001460; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA001460; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA001460; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA001460; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA001460; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.465899850861,1.0,,Neither,oncoref.target-sets.2026-10-23.2,0.4659 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1 nTPM; small intestine/undifferentiated cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 121/133 (91.0%); Stomach Adenocarcinoma (TCGA): 9/346 (2.6%); Ovary Serous Cystadenocarcinoma (validation): 1/81 (1.2%),stomach cancer: 12/12 (100.0%); testis cancer: 12/12 (100.0%),30,20,Q9H8Y1,https://www.uniprot.org/uniprotkb/Q9H8Y1/entry,Acts as a transcription factor that regulates development of thoracic vertebrae,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
WDR88,ENSG00000166359,Neither,Antibody,False,False,8.6,8.6,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 38/91 values ≥5 TPM, max 8.15373; DICE NK (unstimulated): 86/90 values ≥5 TPM, max 14.8144; DICE TREG_MEM (unstimulated): 55/89 values ≥5 TPM, max 9.05444; DICE CD4_NAIVE (unstimulated): 57/88 values ≥5 TPM, max 10.5663; DICE TREG_NAIVE (unstimulated): 64/89 values ≥5 TPM, max 9.96676; DICE TFH (unstimulated): 48/89 values ≥5 TPM, max 10.5088; DICE TH1 (unstimulated): 12/81 values ≥5 TPM, max 6.59384; DICE THSTAR (unstimulated): 3/88 values ≥5 TPM, max 5.49196; DICE TH17 (unstimulated): 8/89 values ≥5 TPM, max 7.1227; DICE TH2 (unstimulated): 19/89 values ≥5 TPM, max 6.96959; DICE CD8_NAIVE (unstimulated): 62/89 values ≥5 TPM, max 8.55845",True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA041916; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA041916; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA041916; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA041916; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA041916; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA041916; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA041916; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA041916; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA041916; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA041916; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA041916; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA041916; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA041916; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA041916; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA041916; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA041916; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA041916; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA041916; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA041916; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA041916; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA041916; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA041916; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA041916; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA041916; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA041916; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA041916; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA041916; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA041916; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA041916; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA041916; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA041916; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA041916; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA041916; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA041916; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA041916; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA041916; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA041916; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA041916; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,14.8143629082,5.1,,CTA,oncoref.target-sets.2026-10-23.2,14.81 TPM; blood/NK; dice_nk; vital,5.1 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Skin Cuteneous Melanoma (TCGA): 2/99 (2.0%); Bladder Urothelial Carcinoma (TCGA): 3/169 (1.8%); Kidney Renal Papillary Cell Carcinoma (TCGA): 5/282 (1.8%),colorectal cancer: 11/11 (100.0%); prostate cancer: 9/9 (100.0%),31,20,Q6ZMY6,https://www.uniprot.org/uniprotkb/Q6ZMY6/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Carter2023_CT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene,,,,,,,,
WFDC9,ENSG00000180205,Neither,Screening,False,False,964.7,964.7,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0722,0.5,,Neither,oncoref.target-sets.2026-10-23.2,0.0722 TPM; blood/total PBMC; hpa_immune_cell_samples; vital,0.5 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 2/207 (1.0%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NEX5,https://www.uniprot.org/uniprotkb/Q8NEX5/entry,,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
XAGE5,ENSG00000171405,Neither,Antibody,False,False,1.1,1.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Caudate/Neuronal cells: Medium, HPA052507; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA052507; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA052507; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA052507; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA052507; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA052507; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA052507; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA052507; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA052507; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA052507; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA052507; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA052507; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.2666887504299997,0.4,,Neither,oncoref.target-sets.2026-10-23.2,2.267 TPM; blood/TFH; dice_tfh; vital,0.4 nTPM; salivary gland/plasma cells; hpa_single_cell_tissue; vital,Liver Hepatocellular Carcinoma (validation): 32/231 (13.9%); Liver Hepatocellular Carcinoma (TCGA): 41/362 (11.3%); Lung Squamous Cell Carcinoma (TCGA): 13/489 (2.7%),colorectal cancer: 1/12 (8.3%); liver cancer: 1/12 (8.3%),31,20,Q8WWM1,https://www.uniprot.org/uniprotkb/Q8WWM1/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Chang2019_TGCT | Loriot2025_S1 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
XKR3,ENSG00000172967,Neither,Antibody,False,False,7.9,7.9,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA003379; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA003379; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA003379; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA003379; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA003379; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA003379; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA003379; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA003379; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA003379; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA003379; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA003379; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA003379; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA003379; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA003379; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA003379; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA003379; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA003379; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA003379; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA003379; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA003379; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA003379; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA003379; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA003379; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA003379; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA003379; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA003379; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA003379; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA003379; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA003379; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA003379; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA003379; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA003379; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA003379; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA003379; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA003379; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA003379; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA003379; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA003379; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA003379; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA003379; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: Medium, HPA035081; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA035081; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA035081; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA035081; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA035081; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA035081; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA035081; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA035081; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA035081; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA035081; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA035081; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA035081; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA035081; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA035081; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA035081; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA035081; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA035081; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA035081; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA035081; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA035081; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA035081; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA035081; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA035081; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA035081; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA035081; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA035081; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA035081; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA035081; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: High, HPA035081; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA035081; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA035081; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA035081; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA035081; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA035081; conflicting or uncurated primary profile; Skin 1/Keratinocytes: High, HPA035081; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA035081; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA035081; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA035081; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA035081; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA035081; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA035081; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA035081; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA035081; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA035081; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,3.0,3.7647,,CTA,oncoref.target-sets.2026-10-23.2,3 TPM; blood/neutrophil; hpa_immune_monaco; vital,3.765 nTPM; blood/neutrophil; hpa_immune_cell_samples; vital,Glioblastoma Multiforme (validation): 1/58 (1.7%); Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),prostate cancer: 10/10 (100.0%); melanoma: 11/12 (91.7%),31,20,Q5GH77,https://www.uniprot.org/uniprotkb/Q5GH77/entry,,"Expressed predominantly, if not exclusively, in testis",,,Cell membrane,,16431037,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ZAN,ENSG00000146839,Neither,Low,False,False,0.3,0.3,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.428,1.6,,Neither,oncoref.target-sets.2026-10-23.2,0.428 TPM; blood/plasmacytoid DC; hpa_immune_cell_samples; vital,1.6 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 9/133 (6.8%); Breast Invasive Carcinoma (validation): 2/50 (4.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9Y493,https://www.uniprot.org/uniprotkb/Q9Y493/entry,Binds in a species-specific manner to the zona pellucida of the egg. May be involved in gamete recognition and/or signaling,"In testis, primarily in haploid spermatids",,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ZAR1,ENSG00000182223,Neither,Low,False,False,1.4,1.4,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,midbrain: 0.7 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.92042340976,5.6,,Neither,oncoref.target-sets.2026-10-23.2,0.9204 TPM; blood/NK; dice_nk; vital,5.6 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 4/58 (6.9%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q86SH2,https://www.uniprot.org/uniprotkb/Q86SH2/entry,"mRNA-binding protein that mediates formation of MARDO (mitochondria-associated ribonucleoprotein domain), a membraneless compartment that stores maternal mRNAs in oocytes. MARDO assembly around mitochondria is directed by an increase in mitochondrial membrane potential during oocyte growth. Promotes formation of MARDO phase-separated membraneless compartment by undergoing liquid-liquid phase separation upon binding to maternal mRNAs. Binds to the 3'-UTR of maternal mRNAs. Maternal mRNAs stored in the MARDO are translationally repressed. Essential for female fertility and oocyte-to-embryo transition by coordinating maternal mRNA storage, translation and degradation",Ovary and testis,,,"Cytoplasm, Cytoplasmic ribonucleoprotein granule Cytoplasm",,12539046,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
ZAR1L,ENSG00000189167,Neither,Antibody,False,False,0.7,0.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA041319; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA041319; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA041319; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA041319; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA041319; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA041319; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA041319; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA041319; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA041319; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA041319; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA041319; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA041319; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA041319; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA041319; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA041319; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA041319; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA041319; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA041319; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA041319; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA041319; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA041319; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA041319; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA041319; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA041319; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA041319; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA041319; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA041319; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA041319; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA041319; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA041319; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA041319; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA041319; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA041319; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA041319; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA041319; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA041319; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA041319; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA041319; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA041319; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA041319; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.4677866739399998,4.2,,Neither,oncoref.target-sets.2026-10-23.2,1.468 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,4.2 nTPM; small intestine/undifferentiated cells; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),melanoma: 12/12 (100.0%); liver cancer: 11/11 (100.0%),31,20,A6NP61,https://www.uniprot.org/uniprotkb/A6NP61/entry,"mRNA-binding protein required for maternal mRNA storage, translation and degradation during oocyte maturation (By similarity). Probably promotes formation of some phase-separated membraneless compartment that stores maternal mRNAs in oocytes: acts by undergoing liquid-liquid phase separation upon binding to maternal mRNAs (By similarity). Binds to the 3'-UTR of maternal mRNAs, inhibiting their translation (By similarity)",,,,"Cytoplasm, Cytoplasmic ribonucleoprotein granule",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
ZC3H11B,ENSG00000215817,Neither,Antibody,False,False,4.8,4.8,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA026439; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA026439; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA026439; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA026439; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA026439; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA026439; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA026439; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA026439; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA026439; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: High, HPA026439; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA026439; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA026439; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA026439; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA026439; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA026439; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA026439; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA026439; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA026439; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA026439; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA026439; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA026439; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA026439; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA026439; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA026439; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA026439; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA026439; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA026439; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA026439; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA026439; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA026439; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA026439; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA026439; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA026439; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA026439; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA026439; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA026439; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA026439; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA026439; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: Low, HPA028490; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA028490; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA028490; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA028490; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA028490; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA028490; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA028490; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA028490; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA028490; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA028490; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA028490; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA028490; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA028490; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA028490; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA028490; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA028490; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA028490; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA028490; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA028490; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA028490; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA028490; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA028490; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA028490; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA028490; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA028490; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA028490; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA028490; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA028490; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA028490; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA028490; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA028490; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA028490; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA028490; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA028490; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA028490; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA028490; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA028490; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA028490; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA028526; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA028526; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA028526; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA028526; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA028526; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA028526; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA028526; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA028526; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA028526; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA028526; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA028526; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA028526; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA028526; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA028526; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA028526; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA028526; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA028526; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA028526; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA028526; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA028526; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA028526; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA028526; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA028526; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA028526; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA028526; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA028526; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA028526; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA028526; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA028526; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA028526; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA028526; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA028526; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA028526; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA028526; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA028526; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.38604854386,5.4,,Neither,oncoref.target-sets.2026-10-23.2,2.386 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,5.4 nTPM; eye/rod photoreceptor cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 7/58 (12.1%); Skin Cuteneous Melanoma (TCGA): 2/99 (2.0%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%),colorectal cancer: 11/12 (91.7%); testis cancer: 9/11 (81.8%),29,20,A0A1B0GTU1,https://www.uniprot.org/uniprotkb/A0A1B0GTU1/entry,May play a role in mRNA transport,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Loriot2025_S1,Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
ZFP42,ENSG00000179059,Neither,Antibody,False,False,2.0,2.0,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,skeletal muscle: 0.7 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, CAB025557; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, CAB025557; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, CAB025557; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, CAB025557; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, CAB025557; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, CAB025557; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, CAB025557; conflicting or uncurated primary profile; Colon/Glandular cells: High, CAB025557; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, CAB025557; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, CAB025557; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, CAB025557; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, CAB025557; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, CAB025557; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, CAB025557; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, CAB025557; conflicting or uncurated primary profile; Lung/Alveolar cells: High, CAB025557; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, CAB025557; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, CAB025557; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, CAB025557; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, CAB025557; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, CAB025557; conflicting or uncurated primary profile; Rectum/Glandular cells: High, CAB025557; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, CAB025557; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, CAB025557; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, CAB025557; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, CAB025557; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, CAB025557; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, CAB025557; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, CAB025557; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, CAB025557; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, CAB025557; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, CAB025557; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, CAB025557; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, CAB025557; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, CAB025557; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,2.9915,3.2293,,Neither,oncoref.target-sets.2026-10-23.2,2.991 TPM; blood/NK-cell; hpa_immune_cell_samples; vital,3.229 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 122/133 (91.7%); Uterine Corpus Endometrial Carcinoma (TCGA): 18/176 (10.2%); Ovary Serous Cystadenocarcinoma (validation): 8/81 (9.9%),colorectal cancer: 9/12 (75.0%); skin cancer: 7/12 (58.3%),31,20,Q96MM3,https://www.uniprot.org/uniprotkb/Q96MM3/entry,"Involved in the reprogramming of X-chromosome inactivation during the acquisition of pluripotency. Required for efficient elongation of TSIX, a non-coding RNA antisense to XIST. Binds DXPas34 enhancer within the TSIX promoter. Involved in ES cell self-renewal (By similarity)","Expressed in kidney, epidermal keratinocytes, prostate epithelial cells, bronchial and small airway lung epithelial cells (at protein level). Expressed in malignant kidney and several carcinoma cell lines (at protein level). Expressed in embryonic stem cells, kidney, epidermal keratinocytes, prostate epithelial cells, bronchial and small airway lung epithelial cells. Expressed in embryonal carcinomas, seminomas, malignant kidney and several carcinoma cell lines",,,Nucleus,,12110702|16344273|16424014|16865673,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ZIM3,ENSG00000141946,Neither,Antibody,False,False,0.3,0.3,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,skeletal muscle: 0.2 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA034575; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA034575; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA034575; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA034575; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA034575; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA034575; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA034575; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA034575; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA034575; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA034575; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA034575; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA034575; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA034575; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA034575; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA034575; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA034575; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA034575; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA034575; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA034575; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA034575; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA034575; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA034575; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA034575; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA034575; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA034575; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA034575; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA034575; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA034575; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA034575; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA034575; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA034575; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA034575; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA034575; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA034575; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA034575; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA034575; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA034575; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.4202245731299998,1.2,,Neither,oncoref.target-sets.2026-10-23.2,1.42 TPM; blood/THSTAR; dice_thstar; vital,1.2 nTPM; liver/hepatocytes; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 16/176 (9.1%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%),colorectal cancer: 10/12 (83.3%); ovarian cancer: 6/11 (54.5%),31,20,Q96PE6,https://www.uniprot.org/uniprotkb/Q96PE6/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
ZNF469,ENSG00000225614,Neither,Cellular,False,False,2.2,2.2,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 1.3 nTPM; continuous selectivity; basal ganglia: 1.1 nTPM; continuous selectivity; cerebral cortex: 1.3 nTPM; continuous selectivity; hippocampal formation: 1.4 nTPM; continuous selectivity; hypothalamus: 0.9 nTPM; continuous selectivity; midbrain: 0.9 nTPM; continuous selectivity; smooth muscle: 0.8 nTPM; continuous selectivity; spinal cord: 0.9 nTPM; continuous selectivity; urinary bladder: 0.9 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,True,"pancreas/fibroblasts cluster c-8: 23.4 nTPM, 265 reads; reproductive-cell max 9.9; skin/fibroblasts cluster c-10: 10.9 nTPM, 27 reads; reproductive-cell max 9.9; brain/excitatory neurons cluster c-0: 18.1 nTPM, 2728 reads; reproductive-cell max 9.9; brain/excitatory neurons cluster c-1: 17 nTPM, 2128 reads; reproductive-cell max 9.9; brain/excitatory neurons cluster c-3: 16.2 nTPM, 1866 reads; reproductive-cell max 9.9; brain/excitatory neurons cluster c-7: 11.7 nTPM, 1090 reads; reproductive-cell max 9.9; brain/excitatory neurons cluster c-13: 27.8 nTPM, 1307 reads; reproductive-cell max 9.9; brain/inhibitory neurons cluster c-14: 19.1 nTPM, 758 reads; reproductive-cell max 9.9; brain/inhibitory neurons cluster c-23: 20.6 nTPM, 478 reads; reproductive-cell max 9.9; brain/excitatory neurons cluster c-24: 15.5 nTPM, 360 reads; reproductive-cell max 9.9; brain/inhibitory neurons cluster c-25: 21 nTPM, 393 reads; reproductive-cell max 9.9; brain/oligodendrocyte precursor cells cluster c-42: 15.6 nTPM, 33 reads; reproductive-cell max 9.9; brain/excitatory neurons cluster c-44: 11.6 nTPM, 33 reads; reproductive-cell max 9.9; skeletal muscle/fibroblasts cluster c-3: 10.2 nTPM, 47 reads; reproductive-cell max 9.9; skeletal muscle/fibroblasts cluster c-6: 10.5 nTPM, 40 reads; reproductive-cell max 9.9",True,True,"DICE NK (unstimulated): 9/90 values ≥5 TPM, max 7.05194",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,7.051937316699999,27.8,,Neither,oncoref.target-sets.2026-10-23.2,7.052 TPM; blood/NK; dice_nk; vital,27.8 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 35/50 (70.0%); Colon Adenocarcinoma (validation): 251/486 (51.6%); Pancreatic Adenocarcinoma (validation): 29/80 (36.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96JG9,https://www.uniprot.org/uniprotkb/Q96JG9/entry,May be involved in transcriptional regulation,"Detected in cornea, sclera, skin fibroblasts and striated muscle","Brittle cornea syndrome 1: An autosomal recessive disorder characterized by extreme corneal thinning resulting in corneal rupture after minor trauma, blue sclerae, keratoconus or keratoglobus, hyperelasticity of the skin, and hypermobility of the joints. It shares some features with, but is much less severe than, the ocular form of Ehlers-Danlos syndrome (EDS6).",,Nucleus,,18452888,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF475,ENSG00000250803,Neither,Screening,False,False,98.3,98.3,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.413462049587,16.7,,Neither,oncoref.target-sets.2026-10-23.2,0.4135 TPM; blood/TH2; dice_th2; vital,16.7 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 4/58 (6.9%); Uterine Corpus Endometrial Carcinoma (TCGA): 4/176 (2.3%); Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A0A1B0GTH9,https://www.uniprot.org/uniprotkb/A0A1B0GTH9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ZNF479,ENSG00000185177,Neither,Low,False,False,2.7,2.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.9,0.69,,Neither,oncoref.target-sets.2026-10-23.2,0.9 TPM; blood/basophil; hpa_immune_monaco; vital,0.69 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Colon Adenocarcinoma (TCGA): 2/254 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Colon Adenocarcinoma (validation): 1/486 (0.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96JC4,https://www.uniprot.org/uniprotkb/Q96JC4/entry,May be involved in transcriptional regulation,Expressed primarily in testis and fetal tissues,,,Nucleus,,11410164,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ZNF501,ENSG00000186446,Neither,Antibody,False,False,2.0,2.0,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.6 nTPM; continuous selectivity; amygdala: 1.8 nTPM; continuous selectivity; basal ganglia: 1.6 nTPM; continuous selectivity; cerebellum: 1.9 nTPM; continuous selectivity; cerebral cortex: 1.4 nTPM; continuous selectivity; colon: 1.8 nTPM; continuous selectivity; esophagus: 0.9 nTPM; continuous selectivity; heart muscle: 1.2 nTPM; continuous selectivity; hippocampal formation: 1.5 nTPM; continuous selectivity; hypothalamus: 1.3 nTPM; continuous selectivity; kidney: 1.4 nTPM; continuous selectivity; lung: 0.9 nTPM; continuous selectivity; lymph node: 0.8 nTPM; continuous selectivity; midbrain: 1.6 nTPM; continuous selectivity; pancreas: 1.4 nTPM; continuous selectivity; pituitary gland: 0.7 nTPM; continuous selectivity; retina: 1.9 nTPM; continuous selectivity; salivary gland: 1.1 nTPM; continuous selectivity; skeletal muscle: 1.2 nTPM; continuous selectivity; skin: 1.1 nTPM; continuous selectivity; small intestine: 0.9 nTPM; continuous selectivity; smooth muscle: 1.3 nTPM; continuous selectivity; spinal cord: 1.7 nTPM; continuous selectivity; spleen: 1.1 nTPM; continuous selectivity; stomach: 1.1 nTPM; continuous selectivity; thyroid gland: 1.3 nTPM; continuous selectivity; tongue: 1.1 nTPM; continuous selectivity; urinary bladder: 1.6 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,True,"eye/muller glia cells cluster c-2: 11.9 nTPM, 20 reads; reproductive-cell max 11.8",True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA044161; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA044161; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA044161; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA044161; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA044161; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA044161; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA044161; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA044161; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA044161; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA044161; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA044161; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA044161; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA044161; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA044161; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA044161; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA044161; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA044161; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA044161; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA044161; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA044161; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA044161; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA044161; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA044161; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA044161; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA044161; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA044161; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA044161; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA044161; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA044161; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA044161; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA044161; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,5.70656882635,15.6,,Neither,oncoref.target-sets.2026-10-23.2,5.707 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,15.6 nTPM; esophagus/plasma cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 42/50 (84.0%); Pancreatic Adenocarcinoma (validation): 27/80 (33.8%),colorectal cancer: 12/12 (100.0%); breast cancer: 8/9 (88.9%),31,20,Q96CX3,https://www.uniprot.org/uniprotkb/Q96CX3/entry,May be involved in transcriptional regulation. Essential for Golgi structural integrity (PubMed:29851555),,,,"Nucleus Nucleus, nucleolus",29851555,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF560,ENSG00000198028,Neither,Screening,False,False,6.0,6.0,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,retina: 2 nTPM; continuous selectivity,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.984646643515,3.9,,Neither,oncoref.target-sets.2026-10-23.2,0.9846 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,3.9 nTPM; bronchus/basal respiratory cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 95/133 (71.4%); Glioblastoma Multiforme (validation): 23/58 (39.7%); Glioblastoma Multiforme (TCGA): 12/141 (8.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96MR9,https://www.uniprot.org/uniprotkb/Q96MR9/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Carter2023_CT | Loriot2025_S2 | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
ZNF679,ENSG00000197123,Neither,Low,False,False,1.0,1.0,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.520006113261,0.8,,Neither,oncoref.target-sets.2026-10-23.2,0.52 TPM; blood/THSTAR; dice_thstar; vital,0.8 nTPM; heart muscle/endothelial cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 7/58 (12.1%); Glioblastoma Multiforme (TCGA): 4/141 (2.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 3/176 (1.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IYX0,https://www.uniprot.org/uniprotkb/Q8IYX0/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ZNF705A,ENSG00000196946,Neither,Low,False,False,2.3,2.3,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,cerebral cortex: 1.4 nTPM; continuous selectivity; smooth muscle: 0.8 nTPM; continuous selectivity; thyroid gland: 1.2 nTPM; continuous selectivity,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.4,1.4,,Neither,oncoref.target-sets.2026-10-23.2,1.4 TPM; blood/Terminal effector memory CD4 T-cell; hpa_immune_monaco; vital,1.4 nTPM; cerebral cortex/bulk; hpa_rna_consensus; vital,Glioblastoma Multiforme (TCGA): 15/141 (10.6%); Lung Squamous Cell Carcinoma (validation): 2/68 (2.9%); Ovary Serous Cystadenocarcinoma (TCGA): 10/349 (2.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6ZN79,https://www.uniprot.org/uniprotkb/Q6ZN79/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
ZNF705B,ENSG00000215356,Neither,Low,False,False,0.7,0.7,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.150425725842,0.5,,Neither,oncoref.target-sets.2026-10-23.2,0.1504 TPM; blood/TH1; dice_th1; vital,0.5 nTPM; unsited/Oligodendrocyte precursor cells; hpa_single_cell; unresolved,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 0/283 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P0CI00,https://www.uniprot.org/uniprotkb/P0CI00/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
ZNF705D,ENSG00000215343,Neither,Low,False,False,3.2,3.2,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.3603112140119999,0.6,,Neither,oncoref.target-sets.2026-10-23.2,0.3603 TPM; blood/TH1; dice_th1; vital,0.6 nTPM; kidney/proximal tubular cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 20/133 (15.0%); Kidney Renal Clear Cell Carcinoma (validation): 1/100 (1.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 1/521 (0.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P0CH99,https://www.uniprot.org/uniprotkb/P0CH99/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
ZNF705G,ENSG00000215372,Neither,Low,False,False,0.6,0.6,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.269733113954,2.6,,Neither,oncoref.target-sets.2026-10-23.2,0.2697 TPM; blood/THSTAR; dice_thstar; vital,2.6 nTPM; eye/muller glia cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,A8MUZ8,https://www.uniprot.org/uniprotkb/A8MUZ8/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ZNF716,ENSG00000182111,Neither,Low,False,False,0.4,0.4,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.04091336514,1.1,,Neither,oncoref.target-sets.2026-10-23.2,1.041 TPM; blood/NK; dice_nk; vital,1.1 nTPM; skin/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 51/133 (38.3%); Pancreatic Adenocarcinoma (validation): 2/80 (2.5%); Uterine Corpus Endometrial Carcinoma (TCGA): 4/176 (2.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A6NP11,https://www.uniprot.org/uniprotkb/A6NP11/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds,,,,,,,,
ZNF722,ENSG00000241149,Neither,Low,False,False,1.7,1.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.4,1.2125,,Neither,oncoref.target-sets.2026-10-23.2,1.4 TPM; blood/basophil; hpa_immune_monaco; vital,1.212 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 15/133 (11.3%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Stomach Adenocarcinoma (TCGA): 2/346 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A0A1W2PQL4,https://www.uniprot.org/uniprotkb/A0A1W2PQL4/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Loriot2025_S1 | Gong2021_reproductive_PC,Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ZNF723,ENSG00000268696,Neither,Unassessed,False,False,3.3,3.3,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"incomplete routine rna; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.5674,1.6793,,Neither,oncoref.target-sets.2026-10-23.2,1.567 TPM; blood/basophil; hpa_immune_cell_samples; vital,1.679 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 73/133 (54.9%); Kidney Chromophobe (TCGA): 8/64 (12.5%); Uterine Corpus Endometrial Carcinoma (TCGA): 10/176 (5.7%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P0DPD5,https://www.uniprot.org/uniprotkb/P0DPD5/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Loriot2025_S1,Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
ZNF729,ENSG00000196350,Neither,Low,False,False,1.9,1.9,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.270098453799,1.2,,Neither,oncoref.target-sets.2026-10-23.2,0.2701 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1.2 nTPM; vascular/endothelial cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 71/133 (53.4%); Glioblastoma Multiforme (validation): 3/58 (5.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,A6NN14,https://www.uniprot.org/uniprotkb/A6NN14/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Loriot2025_S1 | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ZNF730,ENSG00000183850,Neither,Cellular,False,False,4.9,4.9,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 1.6 nTPM; continuous selectivity; cerebral cortex: 1.7 nTPM; continuous selectivity; lymph node: 1.8 nTPM; continuous selectivity; thymus: 2.5 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_monaco Progenitor cell: 7 TPM,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,7.0,11.3,,Neither,oncoref.target-sets.2026-10-23.2,7 TPM; blood/Progenitor cell; hpa_immune_monaco; vital,11.3 nTPM; unsited/Oligodendrocyte precursor cells; hpa_single_cell; unresolved,Glioblastoma Multiforme (validation): 50/58 (86.2%); Testicular Germ Cell Tumor (TCGA): 68/133 (51.1%); Rectum Adenocarcinoma (validation): 29/207 (14.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q6ZMV8,https://www.uniprot.org/uniprotkb/Q6ZMV8/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,Does the full normal-cell distribution support reproductive restriction?,Review diffuse RNA and missing reliable protein evidence rather than selecting the largest reproductive value.,A high reproductive maximum does not erase normal-cell expression; no clinical safety conclusion is recorded.,,,,,
ZNF735,ENSG00000223614,Neither,Low,False,False,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.51591539573,0.2,,Neither,oncoref.target-sets.2026-10-23.2,0.5159 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,0.2 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 7/133 (5.3%); Glioblastoma Multiforme (validation): 2/58 (3.4%); Liver Hepatocellular Carcinoma (validation): 4/231 (1.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P0CB33,https://www.uniprot.org/uniprotkb/P0CB33/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
ZNF813,ENSG00000198346,Neither,Antibody,False,False,4.7,4.7,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 1.3 nTPM; continuous selectivity; colon: 1.7 nTPM; continuous selectivity; duodenum: 1.7 nTPM; continuous selectivity; lung: 1.3 nTPM; continuous selectivity; lymph node: 2.1 nTPM; continuous selectivity; parathyroid gland: 2.3 nTPM; continuous selectivity; rectum: 1.7 nTPM; continuous selectivity; small intestine: 1.6 nTPM; continuous selectivity; stomach: 1.9 nTPM; continuous selectivity,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 91/91 values ≥5 TPM, max 16.1016; DICE NK (unstimulated): 41/90 values ≥5 TPM, max 8.29074; DICE CD4_NAIVE (unstimulated): 85/88 values ≥5 TPM, max 12.4636; DICE CD4_STIM (activated): 88/88 values ≥5 TPM, max 11.9336; DICE TREG_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 15.9715; DICE TFH (unstimulated): 20/89 values ≥5 TPM, max 7.02828; DICE TH1 (unstimulated): 25/81 values ≥5 TPM, max 8.40985; DICE THSTAR (unstimulated): 26/88 values ≥5 TPM, max 6.80319; DICE TH17 (unstimulated): 4/89 values ≥5 TPM, max 6.947; DICE TH2 (unstimulated): 32/89 values ≥5 TPM, max 7.30073; DICE CD8_NAIVE (unstimulated): 87/89 values ≥5 TPM, max 11.7429; DICE CD8_STIM (activated): 88/88 values ≥5 TPM, max 13.8942; hpa_immune_monaco Central memory CD8 T-cell: 6.5 TPM; hpa_immune_monaco MAIT T-cell: 5.8 TPM; hpa_immune_monaco Memory CD4 T-cell Th1: 6.6 TPM; hpa_immune_monaco naive B-cell: 5.4 TPM; hpa_immune_monaco naive CD4 T-cell: 6.2 TPM; hpa_immune_monaco naive CD8 T-cell: 7.1 TPM; hpa_immune_monaco NK-cell: 6.1 TPM; hpa_immune_monaco Progenitor cell: 5.9 TPM; hpa_immune_monaco T-reg: 5.1 TPM; hpa_immune_monaco Terminal effector memory CD4 T-cell: 5.1 TPM",True,True,False,,True,True,"Bone marrow/Hematopoietic cells: Medium, HPA056406; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA056406; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA056406; conflicting or uncurated primary profile; Colon/Endothelial cells: High, HPA056406; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA056406; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA056406; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA056406; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA056406; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA056406; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA056406; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA056406; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA056406; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA056406; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA056406; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA056406; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA056406; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA056406; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA056406; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA056406; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,16.1016004317,21.3,,Neither,oncoref.target-sets.2026-10-23.2,16.1 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,21.3 nTPM; liver/fibroblasts; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 46/50 (92.0%); Prostate Adenocarcinoma (TCGA): 283/480 (59.0%),cervical cancer: 10/12 (83.3%); colorectal cancer: 9/12 (75.0%),31,20,Q6ZN06,https://www.uniprot.org/uniprotkb/Q6ZN06/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZPBP2,ENSG00000186075,Neither,Cellular,False,False,92.5,92.5,87,5,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 12/91 values ≥5 TPM, max 6.85542",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,6.85542498686,6.2,,CTA,oncoref.target-sets.2026-10-23.2,6.855 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,6.2 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 6/283 (2.1%); Lung Adenocarcinoma (TCGA): 5/497 (1.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),31,20,Q6X784,https://www.uniprot.org/uniprotkb/Q6X784/entry,Is implicated in sperm-oocyte interaction during fertilization,Expressed specifically in testis,,,"Cytoplasmic vesicle, secretory vesicle, acrosome Secreted",,17664285,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
,ENSG00000259060,Neither,Low,False,False,3.7,3.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,No positive IHC anywhere measured; RNA below 5 nTPM in all measured tissues; normal RNA ceilings also pass,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0814158095491,0.6,,Neither,oncoref.target-sets.2026-10-23.2,0.08142 TPM; blood/MONOCYTES; dice_monocytes; vital,0.6 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
,ENSG00000259316,Neither,Unassessed,False,False,,,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"incomplete routine rna; insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete routine rna; missing normal RNA: adipose tissue, adrenal gland, amygdala, basal ganglia, bone marrow, cerebellum, cerebral cortex, choroid plexus, colon, duodenum, esophagus, heart muscle, hippocampal formation, hypothalamus, kidney, liver, lung, lymph node, midbrain, pancreas, parathyroid gland, pituitary gland, rectum, retina, salivary gland, skeletal muscle, skin, small intestine, smooth muscle, spinal cord, spleen, stomach, thymus, thyroid gland, tongue, urinary bladder; incomplete tissue evidence",Evidence or anatomical coverage is incomplete/unusable; neither target nor default forbidden,,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,False,False,,True,False,False,,False,False,,False,False,True,Neither,Unassessed,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.0696028883700002,,,Neither,oncoref.target-sets.2026-10-23.2,1.07 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,,No exact-ID RNA coverage in the HPA cancer snapshot,No exact-ID IHC coverage in the HPA cancer snapshot,0,0,Q15004,https://www.uniprot.org/uniprotkb/Q15004/entry,"PCNA-binding protein that acts as a regulator of DNA repair during DNA replication. Following DNA damage, the interaction with PCNA is disrupted, facilitating the interaction between monoubiquitinated PCNA and the translesion DNA synthesis DNA polymerase eta (POLH) at stalled replisomes, facilitating the bypass of replication-fork-blocking lesions. Also acts as a regulator of centrosome number","Expressed predominantly in liver, pancreas and placenta. Not detected in heart or brain. Highly expressed in a number of tumors, especially esophageal tumors, in anaplastic thyroid carcinomas, adrenocortical carcinomas, and in non-small-cell lung cancer lines",,,"Nucleus Cytoplasm, perinuclear region",21673012|23000965,11313979|15789362|22096502,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
,ENSG00000283205,Neither,Screening,False,False,5.8,5.8,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Other CTA admission, identity or curation rule fails; not automatically forbidden",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,False,,False,False,True,Neither,Screening,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.7720724113330001,0.5,,Neither,oncoref.target-sets.2026-10-23.2,0.7721 TPM; blood/CD8_STIM; dice_cd8_stim; vital,0.5 nTPM; salivary gland/serous glandular cells; hpa_single_cell_tissue; protected,Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
,ENSG00000283599,Neither,Cellular,False,False,8.0,8.0,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,Normal-cell RNA or uncertain antibody evidence requires review; not labelled proven clinical toxicity or added to forbidden proteins,,,,oncoref.target-sets.2026-10-24.1,True,"brain/oligodendrocytes cluster c-12: 10.3 nTPM, 125 reads; reproductive-cell max 9.4",True,False,,True,True,False,,False,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,1.31969573088,10.3,,CTA,oncoref.target-sets.2026-10-23.2,1.32 TPM; blood/NK; dice_nk; vital,10.3 nTPM; brain/oligodendrocytes; hpa_single_cell_tissue; vital,Liver Hepatocellular Carcinoma (TCGA): 35/362 (9.7%); Bladder Urothelial Carcinoma (TCGA): 9/169 (5.3%); Skin Cuteneous Melanoma (TCGA): 3/99 (3.0%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,A0A1B0GWI6,https://www.uniprot.org/uniprotkb/A0A1B0GWI6/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Carter2023_CT | Gong2021_reproductive_PC,Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,